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Thus far, none of the several factors attributed to the recent global epidemic of obesity 
fully explain the aetiology of obesity. Recently, changes in the gut microbiota composition 
have been causatively related to the aetiology of obesity in adults as well as children via 
several proposed mechanisms such as production of short chain fatty acids. However, it is 
not yet clear whether differences in the gut microbiota composition between lean and 
obese people are a cause of obesity or if it is an effect of different dietary patterns between 
lean and obese individuals.  
The aim of this observational study was to explore the possibility of ―reverse 
causality‖ by comparing the gut microbial composition, metabolic activity, and 
fermentation capacity in children with obesity of different aetiology.  
For this purpose, children/young adults with ―simple‖ obesity (due to an unknown 
cause) and hypothalamic obesity (due to a known cause, such as Prader-Willi syndrome or 
craniopharyngioma), hypothalamic lean children/young adults (with Prader-Willi 
syndrome) from endocrine and dietetic clinics and healthy lean children/young adults from 
the community were recruited (chapter 2). Two faecal samples at interval of 2-3 months 
with anthropometric, body composition, and 24 h dietary data were collected from each 
participant. For each faecal sample, the gut microbial metabolic activity was measured by 
faecal short chain fatty acids (SCFA), hydrogen sulphide, D and L lactate, and ammonia. 
The fermentative capacity or energy harvesting capability of the gut microbiota from each 
subject group was assessed with 24 h in-vitro batch culture fermentations using 5 different 
dietary substrates (apple pectin, raw potato starch, wheat bran, raftilose and maize starch). 
The V4 region of the 16S rRNA gene was sequenced on the illumina® MiSeq platform to 
explore differences in bacterial community taxonomy between the groups.  
Anthropometric and body composition (chapter 3) in the simple and hypothalamic 
obese patients differed from each other in the nature of their obesity; hypothalamic obese 
patients being shorter and with lower fat mass compared to the simple obese. Under-
reporting on behalf of the obese participants and the nature of dietary assessment method 
employed in this study limited the real association of dietary intake with body composition.  
No significant differences in faecal SCFA, hydrogen sulphide, ammonia, and D & 
L lactate concentrations were observed between participants with obesity of different 
aetiology (chapter 4). Obese (―simple‖ & hypothalamic together) participants had 
significantly higher concentration of propionate than lean (healthy lean& lean 
hypothalamic together) participants both at the time of recruitment and after 2-3 months. 
Moreover, SCFA concentrations were positively correlated with BMI z-score. Our results 
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suggested that metabolic activity of the gut microbiota is not different between obesity of 
different aetiology which contradicts the causative role of gut microbiota in the aetiology 
of obesity. Moreover, higher SCFA concentration in obese (simple & hypothalamic obese) 
than lean (healthy & hypothalamic lean) phenotype in our study indicated that previously 
observed differences in the concentration of SCFA are likely to be the result of differences 
in dietary intake. 
SCFA in faecal samples are a net result of production versus absorption in the gut 
and therefore may not accurately reflect the energy harvesting capability of the gut 
microbiota. To address this question, we conducted in-vitro batch culture fermentation 
studies to assess fermentation capacity of the gut microbiota with 5 different dietary fibres 
(chapter 5). Our results suggested that fermentation capacity of the gut microbiota did not 
differ between obesity of different aetiology implicating that factors other than gut 
microbiota energy harvesting capability may be causally related to the aetiology of obesity. 
Obese groups (simple and hypoth. obese together) tended to produce higher SCFA than 
lean groups (healthy and hypoth. lean together). However, small sample size and large 
inter-individual variations particularly in the two obese groups may have obscured any 
significant differences between lean and obese phenotype. Significantly higher rate of 
propionate production in obese vs. lean groups was in confirmation with our findings from 
faecal samples. Furthermore, processing time of the samples negatively affected the 
production of SCFAs independent of phenotype and pathology. 
Whether no differences in the gut microbial metabolic activity and fermentation 
capacity between obesity of different aetiology were extending to the gut microbiota 
composition was further assessed by high-throughput next-generation sequencing (chapter 
6). Although the major bacterial phyla i.e. Firmicutes and Bacteroidetes were similar 
between simple and hypothalamic obesity, hypothalamic obese group had a higher relative 
abundance of Proteobacteria compared to simple obese. Overall, the two obese groups had 
lower rarefied OTU richness and diversity than the two lean groups. Furthermore, there 
was a highly significant correlation of obesity with community structure and a slight 
impact of pathology explaining 5% of total variance. A higher frequency of Dorea and 
Collinsella and a lower frequency of Veillonella and Alistipes were observed in obese 
groups than lean groups. Moreover, a significant relationship between the OTU community 
composition and weight gain was observed. These results indicated that the presence of 
similar bacterial metabolic activity in hypothalamic vs. simple obese is not fully translated 
into their structural diversity at all taxonomic levels. This suggests that composition of the 
gut microbiota may not be related to the similarity in ―functional‖ diversity and similarities 
at phylum level may not indicate absence of differences at lower taxonomic levels. Similar 
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metabolic function may suggest identical or comparable dietary patterns in obese people 
regardless of the aetiology of obesity.  
Overall, these results do not support the role of the gut microbiota in the aetiology of 
obesity but provide strong evidence to suggest that the findings reported in this and 
previous studies are the result of obesity and likely to be due to different dietary patterns 
and intake between lean and obese children (chapter 7). Further studies are needed to 
investigate whether gut microbiota composition and their metabolic products in our cohort 
are related to the expression of functional genes in metabolic pathways. 
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 Chapter 1: Gut Microbiota and Obesity 
1.1 Purpose and outlines 
The chapter discusses the burden of obesity, its risk factors, and consequences as well as a 
discussion of the gut microbiota composition and metabolic activity in the colon and how 
their diversity changes over the course of life. Further critique of the evidence on the 
composition and functionality of gut microbiota in obesity aetiology from different animal 
and human studies and the proposed mechanisms relating gut microbiota and obesity is 
given. Lastly, the rationale for the current study, study group, and study objectives are 
briefly discussed. 
1.2 Obesity 
Historically, an apple shaped body in humans was a sign of wealth, good health and 
availability of resources. However, the past few centuries have seen transitions of human 
behaviour, culture, economy, and health in many perspectives. Gross changes in lifestyle 
over recent decades have resulted in an increasing incidence of obesity in the developed 
world followed by increases in developing nations. Obesity has nearly doubled in the past 
30 years and is growing in pandemic proportions worldwide. It is now considered ―the 
disease of the millennium‖ by the International Obesity Task Force. Obesity is the leading 
cause of many preventable causes of death such as type 2 diabetes, coronary heart disease, 
hypertension, osteoarthritis, and cancer (1). Overall, it is the fifth leading cause of death 
and is associated with many short and long term morbidities. 
Many criteria have been used to define obesity since 1920 in both American and 
British health surveys. In general terms, obesity is defined as the accumulation of 
excessive body fat to an extent that causes harmful effects. For epidemiologic 
convenience, obesity is expressed as body mass index (BMI) rather than total body fat. 
For adults over 18 years of age, BMI is expressed as weight in kilograms divided by 
height in meters squared. A BMI ≥30 kg/m2 in adults is defined as obesity. In children, the 
body mass index is expressed as standard deviation scores (SDS) because median BMI (in 
kg/m
2
) varies substantially with age and the gender based specific growth of the child. 
However, currently there is no single internationally recognized cut off to delineate 
overweight and obesity in children. The World Health Organization (WHO) defines 
obesity as BMI SD scores of >3 SDS from birth to age 5 years and >2 SDS for 5-19 years 
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above WHO growth standards median (2). The Centre for Disease Control and Prevention 
(CDC) in the United States defines a child as obese at ≥95th centile between ages 2-19 
years and ≥97.7th centile for obese children less than 2 years of age which is a modified 
version of the WHO reference criteria (3). The International Obesity task Force (IOTF) 
recommends the use of BMI cut points which converge to the adult BMI cut offs of 30 
kg/m
2
 for obese and 25 kg/m
2
 for overweight. BMI ≥2 SDS is therefore defined as obesity 
for children age 2-18 years (4). 
 
1.3 Epidemiology of obesity 
1.3.1 Obesity in adults 
In 2008, the WHO reported 1.4 billion people, age 20 years or older, as overweight and 
obese globally. Of  these, 500 million (200 million men and nearly 300 million women) 
were obese (5). The Health Survey of England 2011 recorded an increase in obesity from 
13% to 24% in adult male and from 16% to 26% in adult female population between 1993 
and 2011. The proportion of those with normal weight has decreased from 41% to 34% in 
men and from 50% to 39% in women between 1993 and 2011(6). The Scottish Health 
Survey 2012 reported an increase in obesity from 17.2% in 1995 to 26.1% in 2012 in 
adults aged 16-64 years. Overall 64.3% of the Scottish adult population (16 years and over 
and men more likely than women) were overweight or obese (7). 
1.3.2 Obesity in children 
Obesity in childhood has been linked with obesity in adulthood and hence obesity related 
complications (8). The number of children at risk of obesity is also increasing. In 2011, 
over 40 million children aged less than 5 years were reported as overweight worldwide 
(9). The Health Survey of England 2011 recorded obesity in 17% boys and 16% girls and 
overweight and obesity in 31% boys and 28% girls (6). In Scotland, although some reports 
suggested a decrease in obesity in school children from 14.2% in 1997 to 10.2% in 2004 
in Aberdeen (10), overall there has been an upward trend in overweight and obesity 
prevalence. In the Scottish Health Survey 2012, 16.6% children were at risk of obesity (at 
or above 95
th
 centile). There was an increase in obesity from 14.5% in 1998 to 19.7% in 
boys’ age 2-15 years, while 13.7% girls aged 2-15 were obese in 2012. In addition to these 







The risk of obesity was higher in older children aged 12-15 years than younger ones 
(26.1% of boys, 18.3% of girls) (7). Another report published in May 2012 by the Scottish 
Government reported 22% children at age 6 to be overweight (including 9% obese) (11). 
1.3.3 The plateau effect 
The prevalence of obesity pandemic in children and adolescents has now been observed to 
level off, stabilize, or even decrease in some developed countries after extensive 
campaigns to limit obesity including Australia, Europe, USA and Russia (1). A strong 
decrease in the prevalence of obesity was seen in children and adolescents in Japan (1). 
Data from the USA have shown a stabilization plateau phase between 2003-04 and 2009-
10 after an initial rise from 9.1% in 1988 to 16.9% in 2003-2004 in adolescents’ age 12-17 
years (12).  However, it is worth noting that the trend of increasing obesity in adults is 
variable within many of these countries (12).  
1.3.4 Risk factors contributing to childhood obesity 
Obesity is a multifactorial disorder caused by many known (genetic and acquired) and 
unknown factors. Known causes of obesity could include genetic hormone deficiency such 
as genetic deficiency of the leptin gene (whose expression is responsible for the synthesis 
of hormone leptin involved in the regulation of glucose and lipid metabolism) or it can be 
associated with the malfunctioning of the hypothalamic satiety centre. Malfunctioning of 
satiety centre could either be due to a chromosomal abnormality such as Prader-Willi 
Syndrome (PWS) or due to erosion by a tumour such as craniopharyngioma. Obesity due 
to a genetic or acquired malfunction of the hypothalamic satiety centre is referred to as 
―hypothalamic obesity‖ in this thesis.  However, obesity related to a known cause 
contributes only a small proportion to the global obesity epidemic, most of which is not 
attributable to a definitive risk factor. For the purpose of this thesis, such forms of obesity 
are referred to as ―simple‖ or ―classical obesity‖. 
1.3.4.1 Risk factors contributing to simple obesity 
Although genetic factors contribute to the prevalence of obesity in a small proportion of 
children (~5-8%), such as genetic defects in leptin and its receptors, pro-opiomelanocortin 
(POMC), prohormoneconvertase 1, melanocortin receptor-4 (MCR4), and neurotrophin 
TrKB (13, 14), the recent disproportionate boom in the prevalence of obesity is not solely 
explained by these polygenic factors. Childhood obesity by and large is attributed to many 
putative risk factors, some of which are consistently associated with obesity. However, all 
 7 
 
are only potential and not well established (15). Several studies have highlighted risk 
factors contributing to childhood obesity, some of which are summarised in Table 1.1. Out 
of more than 20 potential risk factors, parental obesity, early adiposity-rebound at <5.5 
years age, rapid growth, weight SDS at age 8 and 18 months, more than 8 h television 
watching per week at three years age, weight gain in first year, and sleep deprivation in 
first 3 years of age have been associated with childhood obesity in multiple regression 
models (15). Others have suggested childhood obesity is a consequence of events in three 
phases of life; prenatal phase, phase of adiposity rebound, and adolescence phase (16), all 
of which include similar risk factors as suggested by Reilly et al. (2005) except for 
maternal under or over nutrition during pregnancy. It is interesting to note that both over 
and under-nutrition in early life can lead to obesity via catch-up growth which follows a 
period of deficient nutrient requirement. The relationship of weight with adiposity may 
therefore be J shaped rather than linear (17). 
Association of adult obesity risk factors with mortality and morbidity related 
complications is well studied (18). Freedman et al. (2001) showed in the Bogalusa heart 
study (n=2617, age 2-17 years) that up to 80% of obese children followed for 17 years 
become obese adults; however, the association of childhood obesity with adult coronary 
heart disease risk factors such as plasma lipids, insulin and blood pressure was very weak. 
Furthermore the levels of these risk factors for coronary heart disease did not change with 
childhood weight status or age of obesity onset (19). The link between childhood obesity 
and the predictors of adverse cardiovascular health in adult obese individuals is therefore 
missing. Park et al. (2012) recently conducted a systematic review of 39 studies to explore 
this link. Although several adult diseases or adult disease-related risk factors such as type 
2 diabetes, coronary heart disease, stroke, kidney and colorectal cancers, and all-cause 
mortality were associated with childhood BMI, the association did not exist after 
adjustment for adult BMI (20).  This suggested other unknown factors that could 
potentially contribute to the link between childhood obesity and adult disease risk factors 
independent of adult BMI status. Additionally there are limited long-term studies to give 
any conclusive evidence on association of disease related risk factors in adulthood with 
obesity in childhood while accounting for the adult BMI (21). 
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1.3.5 Hypothalamic obesity (mechanism of obesity in Prader-Willi 
syndrome and craniopharyngioma) 
1.3.5.1 Obesity in Prader-Willi Syndrome 
Prader-Willi Syndrome (PWS) is a genetic neurological disorder due to loss of function in 
the long arm (q11-q13) of paternally derived chromosome 15 occurring in 1 in 16000 live 
births. This disease is characterised prenatally by decreased fetal movements, 
polyhydromnios and post-natally by hypotonia (―floppy child‖), feeding problems, and 
failure to thrive in early infancy. This is followed by general growth delay, low IQ 
(intelligence quotient), severe forms of obesity due to hyperphagia, sleep abnormalities, 
behavioural problems and hypogonadism. There are some phenotypic features peculiar to 
most but not all PWS patients such as short stature, small hands and feet, narrow nasal 
bridge, almond shaped palpebral fissure, thin upper lip, narrow bifrontal diameter, 
scoliosis, eye abnormalities, thick saliva, hypopigmentation, and cat like cry (22). 
Prader Willi syndrome is the most common cause of syndromal obesity and a major cause 
of metabolic complications in this group. Obesity in PWS is hallmarked by the insatiable 
hunger which inculcates behavioural changes in children to get excess food. Ghrelin is a 
gut hormone released from the stomach and found in higher concentration in plasma in the 
fasting state stimulating food intake (hence called orexogenic). Ghrelin is found in plasma 
in an acylated (active) and de-acylated forms. The levels of ghrelin are reduced after food 
intake in healthy people and hence may determine meal size and help in short term control 
of food intake (23). The first evidence regarding persistently increased orexogenic ghrelin 
levels in PWS vs. normal children came from the study of DelParigi and colleagues (24). 
Ghrelin levels remained high even after meals which lead to a delayed sense of fullness 
and persistent drive to eat.  Many other studies have suggested higher plasma ghrelin 
levels in PWS obese patients compared with simple non-PWS obese, healthy lean, leptin 
deficient, and melatonin receptor 4 deficient patients (25, 26) (Figure 1.1). 
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Table 1.1: Summary of studies investigating factors associated with onset of obesity in children 
Reference Study type Country/region studies included 
(n) 
(Range of) No. (n) Factors predicting childhood obesity 
(27) Longitudinal study USA (Hawaii) n/a n= 9,439 
 age 5-7 years 
Strong association with maternal gestational diabetes (OR (95% CI): 
1.82 (1.15-2.88), p<0.0001) (adjusted for maternal age, ethnicity, 
weight gain, parity) 




n/a n= 881, Infants 
and children 2-5 
years 
high energy intake at 4 months was a predictor of weight gain 
between birth and 1, 2, and 3 years of age (p=0.0005, p=0.0004, 
p=0.007) only in formula or mixed fed infants. Each 420kJ/day 
increase in energy associated with overweight at 3 years [OR, 95% 
CI: 1.46 (1.20-1.78)] and 5 years [OR, 95% CI: 1.25 (1.00-1.55)]. 
No association with breast feeding 




n/a n= 8234 children,  
age 7 years 
Parental obesity [OR, 95% CI: 10.44 (5.11-21.32)], very early (by 
43 months) BMI or adiposity rebound [OR, 95% CI: 15.00 (15.32-
42.30],  >8 h watching television [OR, 95% CI: 1.55 (1.13-2.32)], 
catch-up growth [OR, 95% CI: 2.60 (1.09-6.60)], weight SDS at 8 
months [OR, 95% CI: 3.13 (1.43-6.85)] and 18 months [OR, 95% 
CI: 2.65 (1.25-5.59)], birth weight per 100 g [OR, 95% CI: 1.05 
(1.03-1.08)], weight gain per 100 g in first year [OR, 95% CI: 1.06 
(1.02-1.10)], sleep deprivation (<10.5 h) at 3 years [OR, 95% CI: 
1.45 (1.10-1.89)] 
(29) Crossectional survey 
CLASS survey 
Canada n/a n=4298,  Age 
range between 10 
&11 years 
Increased risk for; Lunch bought at school [OR, 95% CI: 1.39 (1.16-
1.67)] 
Decreased risk; supper with family ≥3 times a week [OR, 95% CI: 
0.68 (0.52-0.88)], attending physical education classes [OR, 95% 
CI: 0.63(0.43-0.87)], high income relative to lower income families 
[OR, 95% CI: 0.50 (0.25-0.70)] 
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(20) Systematic review 
 
n/a 39 n=181-1.1 million, 
Studies age range 
at recruitment; 2-
19 years 
Unadjusted; Type-2 diabetes (OR range: 1.22-2.04), hypertension 
(OR range: 1.35-3.75), coronary heart disease (HR range: 1.53-
5.43), all-cause mortality (40-60% increase in risk), stroke (HR 
range: 1.4-3.2), cancer (20-40% increased risk), colorectal cancer 
(RR range: 2.1-9.1), Kidney cancer [RR (%CI): 2.6 (1.5-4.7)] 
Adjusted; no real association 
(30) Systematic review 
and meta-analysis 
n/a >80 for systematic 
reviews, 20 for 
meta-analysis 




Increased risk; Non-Hispanic blacks (≥10% increased risk), low 
education except in black women (≥10% increased risk), urban 
dwelling (obesity prevalence of up to 30% or higher in 2005),  
(31) Systematic review n/a 21 N= 90-19,257 
Age; 4 yrs. up to 
32 yrs. 
Weight gain in infancy  and first 2 years of life [OR (95% CI: 
5.7(4.5-7.1)] 
(17) Systematic review n/a 141 n= up to 0.2 
million, 
adolescents 
Parental fatness, genetic factors, lower socioeconomic status 
(parents occupation, education, and income), birth weight, early 
and rapid maturation, physical inactivity (TV, total activity), 
CLASS; Children’s Lifestyle and School-performance Study, ALSPAC; Avon Longitudinal Study of Parents and Children, HR; hazard ratio, OR; Odds ratio, RR; risk ratio, 
n; number, n/a; not applicable.
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Nevertheless, the role of ghrelin in the aetiology of hyperphagia in PWS is still 
controversial. In a study by Erdie-Lalena et al. (2006), the authors found no significant 
difference in the fasting levels of total  ghrelin (acylated & des-acylated ghrelin) in nine 
normal weight PWS patients less than 5 years age compared to eight healthy children 
matched for age, BMI, and gender (32). Levels of plasma insulin and glucose in PWS 
children were not significantly different than healthy controls. Moreover, levels of ghrelin 
were negatively associated with BMI in controls but not in PWS children (32). These 
findings indicate that levels of ghrelin in PWS patients might increase only in later 
childhood prior to the onset of obesity in the course of the disease which does not happen 
in healthy population. This was also suggested by Feigerlova et al. (2008) who found a 
significantly greater negative correlation of plasma total ghrelin levels in the children age 
<3 years, prior to the onset of obesity (33). However, there was a high inter-individual 
variation in the total plasma ghrelin levels which was even found when a more specific and 
active acylated form was used indicating small sample size. Additionally, plasma ghrelin 
levels were not assessed for other confounding factors such as difference in energy 
expenditure and requirements particularly at young age.  
In healthy people, circulating acylated ghrelin stimulates the secretion of growth 
hormone by acting as a ligand for the growth hormone receptor,  GH scretogogue receptor 
type 1a (GHS type 1a) (34). Moreover, high growth hormone levels down-regulate ghrelin 
levels via negative feedback (34). In contrast, children with PWS suffer from growth 
hormone deficiency despite high circulating levels of ghrelin. This might indicate the 
desensitization of GHS receptor type 1a. Growth hormone (GH) replacement therapy in 
PWS children have been shown to induce lipolysis, reduces fat mass, and increases lean 
mass in PWS children (35), but the levels of ghrelin are higher despite GH treatment and its 
beneficial effects indicating the failure of the negative feedback mechanisms to operate. 
Therapeutic use of acylated and un-acylated ghrelin in correcting this abnormality is still 
under extensive research (Figure 1.1).   
Plasma insulin deficient states or insulin resistance cause diabetes mellitus, and up 
to 20% of PWS children develop type 2 diabetes in the course of the disease (36). 
However, the role of insulin in hypothalamic obesity is controversial. Some authors have 
suggested lower fasting plasma insulin and delayed insulin secretion during an oral glucose 
tolerance test (OGTT) in the presence of intact insulin sensitivity (37), while others have 
suggested increased plasma insulin depicting insulin resistance (38). Obesity in itself is a 
diabetogenic state, therefore it is unclear whether changes in insulin levels are a 
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consequence of severe obesity or the insulin secreting capability of PWS patients is 
abnormal (37). PWS patients have a higher fat to lean mass ratio and a lower bone mineral 
content suggesting a lower lean mass and a higher fat mass resulting in slow body and limb 
movements in PWS patients (39). Reduced physical activity due to poor co-ordination, eye 
abnormalities such as esotropia and myopia, and slow body movements due to poor muscle 
tone leads to reduced energy expenditure (40) which reduces the caloric requirement in 
these patients. This, in addition to lower lean body mass, favours the accumulation of 
excess body fat and hence obesity. Obstructive sleep apnoea leading to day time sleepiness 
is also a contributing factor in hypothalamic obesity in PWS (22). 
Figure 1.1: Mechanism of obesity in Prader Willi Syndrome. Adapted from Mutch and Karine (2006) 
(41). 
 
Decreased plasma leptin and insulin results in loss of stimulatory signals to the POMC neurons in the arcuate 
nucleus which fails to stimulate α and β-MSH to control satiety via activation of MCR4 receptor in the 
Paraventricular nucleus. On the other hand, persistent increase in plasma ghrelin results in stimulation of 
neurons expressing NPY and AGRP which inhibit MCR4 signaling and hence increase drive towards food 
intake. AGRP, agouti-related protein; α-MSH, alpha melanocyte stimulating hormone receptor; NPY, 
neuropeptide Y;  POMC, pro-opiomelanocortin;TRKB, tyrosine kinase receptor. 
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1.3.5.2  Obesity in craniopharyngioma  
Craniopharyngioma represents 1.2-4% of all brain tumours and is the leading cause of 
hypothalamic obesity. Obesity is one of the major causes of morbidity and reduced quality 
of life in children and adolescents with craniopharyngioma (42) leading to premature 
cardiovascular disease, psychosocial problems and failure to achieve academic potential, 
especially in children with hypothalamic involvement of the tumour (43).   
The exact cause of hypothalamic obesity seen in craniopharyngioma is not well 
understood. The literature suggests that obesity may be related to the disruption of 
hormonal signals from leptin and insulin (44) to the arcuate nucleus. The neurons of the 
arcuate nucleus are responsible for secreting Pro-OpioMelanoCortin (POMC), Agouti-
Related Peptide (AGRP), and neuro-peptide Y (45, 46), altered secretion of which result in 
abnormal appetite and hyperphagia. Data also suggest increased parasympathetic and 
reduced sympathetic tone, nocturnal insomnia and day time sleepiness (47, 48), and 
reduced functional capacity due to the higher BMI as factors leading to weight gain (49, 
50). Pituitary hormone deficiencies as a result of both tumour and treatment modalities 
such as radiotherapy are additional factors which contribute to obesity in these patients. 
Hypothalamic involvement, tumour progression and tumour relapse affect long term 
quality of life (50, 51).  
The known risk of obesity in patients with craniopharyngioma exists both at 
diagnosis and in the long term. Hypothalamic involvement has been established as a long 
term predictor of obesity and health related quality of life in these children. Evidence 
suggests that children who are obese at presentation generally have a higher incidence of 
hypothalamic involvement and hydrocephalus even though they have a normal BMI before 
diagnosis.  Patients without hypothalamic involvement have better quality of life scores in 
long term follow up studies (52). Therapeutic interventions immediately after diagnosis in 
craniopharyngioma have therefore been recommended for the prevention of obesity given 
that a significant increase in BMI occurs in the postoperative period, especially during the 
first three years (53). 
 
1.3.6 Complications of obesity 
Both short and long term consequences of obesity are anticipated to increase in the 
population due to the recent surge of global overweight and obesity in childhood as well as 
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adults (Table 1.2). Complications of paediatric obesity encompass diverse aspects of 
health. Of particular concern are the rising psychosocial complications, cardiovascular 
diseases and metabolic disorders, long term morbidity and mortality, and economic burden 
(54). Although obesity in childhood is associated with consequences in the short and 
intermediate term, it is still unclear whether these complications are associated with 
childhood obesity are independent of adult BMI (17). A recent, extensive systematic 
review by Park et al. (2012) showed association between childhood BMI SDS and type 2 
diabetes, cardiovascular disease and hypertension but the effect could not be seen when this 
was adjusted for adult BMI. There are many limitations in reports associating childhood 
obesity with short, intermediate, and long term complications. This is largely due to lack of 
longitudinal data, inadequate sample size, non-uniform measures of obesity, and reliance 
on retrospective cohorts such as from school and military records (21). 
 
Table 1.2: Complications (consequences) of childhood obesity; adopted from Must and Strauss, 1999 
 System 
involved 
Disease/signs and symptoms Risk for  
obese 
Immediate consequences (prior to adulthood) 
 Orthopaedic Slipped femoral epiphysis; leading to permanent femoral head damage 50-70% 
  Blount’s disease (tibia vara); bowing of the tibial bone due to excess 
weight bearing (80% children with tibia vara are obese) 
80% 
  Idiopathic intracranial hypertension (Pseudomotorcerebri); with headache, 
nausea, vomiting, blurred vision, and diplopia 
30-80% 
 Pulmonary Asthma 30% 
  Decrease performance in exercise by at least 15% due to increased 
bronchial hyperactivity 
80% 
  Sleep apnoea with central hypoventilation Up to 94% 
  Memory and learning difficulties due to obstructive sleep apnoea  
  Pickwikian syndrome;  severe obesity associated with hypoventilation, 
somnolence, polycythaemia, right ventricular hypertrophy and failure, 
 
  Sudden death and pulmonary embolism with Pickwikian syndrome  
 Gastrointesti
nal 
Gall stones (cholelithiasis) 8-33% 
  Liver steatosis due to insulin resistance and increased lipolysis 20-25% 
  Fatty liver and Liver fibrosis with severe obesity  
  Steatohepatitis in severe obesity 40-50% 
 Endocrine Insulin resistance with decreased glucose uptake by cells 20-45% 
  Non-insulin dependent diabetes mellitus (BMI >90
th
 centile) 90% 
  Hyperandrogenemia  





  Polycystic ovarian syndrome;  oligomenorrhea or amenorrhea with 
obesity, insulin resistance, hirsuitism, acnes, acanthosisnigricans, and  
40-60% 
 Social and 
economic 
Poor emotional development  
 Low self-esteem and concerns of body image, expectations of rejection 
and subsequent withdrawal 
 
 Fear of fatness; making an attempt to reduce weight while most (83%) of 
the adolescent girls are normal weight  
50% 
  Eating disorder (Bulimia) and smoking in girls; developed as an attempt to 





  Downward social and academic mobility; Lower academic achievement 









Elevated systolic and diastolic blood pressure in children age 7-11 years 20-30% 
 Hypertension 8.5 fold 
 Familial aggregation of hypertension  
 Deleterious effect on cholesterol, LDL, TG, and low high density 
lipoproteins (HDL) in adulthood 
2.4-8 fold  
 Persistence of 
obesity  
Adolescent obesity continuing to adulthood obesity (vary with gender) 25-50%  
Long-term consequences (remote-aftereffects on morbidity and mortality) 
 Adult 
morbidity 
Risk of heart disease and atherosclerosis in both males and females  
 Risk of colon cancer for males  
  Risk of gout for males  
  Arthritis and hip fractures in females  
  Menstrual problems at age 33 years  
  subfertility at age 33 years  
  Gestational hypertension at age 33 years  
 Adult 
mortality 
All-cause mortality (independent of smoking, socioeconomic status, and 





Coronary heart disease mortality (independent of smoking, socioeconomic 
status, and adult weight status) RR; 2.0  
1.3.7 Management of childhood obesity 
Obesity is a multifactorial disorder and therefore needs a multifaceted multi-environmental 
approach towards its management. For an obesity intervention to be successful, the 
intervention strategy should be aimed both at the child and the family and the risk factors 
or behaviours which have been found consistently associated with childhood obesity (54). 
Many randomised control trials and longitudinal studies suggest interventions in 5 different 
directions including lifestyle changes, dietary advice, physical activity, psychological 
therapy, and in some cases; pharmacologic therapy (Table 1.3) (55). However, there are 
Table 1.2 continued 
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several potential barriers to successful management of obesity. These include lack of 
motivation of the child and their family, low compliance, socioeconomic status, and the 
general ―obesogenic‖ environment (lacking recreation facilities and availability of healthy 
food choices). 
Successful life style interventions result in the reduction of cardiovascular disease 
and diabetes risk. However, achieving weight loss and maintaining it over a longer period 
of time are challenging in obese paediatric and adult population. Furthermore, response to 
weight management across paediatric population is not uniform, as some patients respond 
to weight management while others not. Braet (2006) in her study suggested positive 
association of weight loss with the pre-management severity of overweight, age and initial 
weight loss with weight management and negative association with eating disorder 
especially in girls (56).  Although 77.3% paediatric patients (n=122,  age  range 7-17 years) 
have been reported to lose 10% of their initial weight, only 24% of these tend to maintain 
weight loss over 2 years period while the rest (75%) tend to gain weight (56). Furthermore, 
a two-fold risk of weight regain still exists after weight loss due to continued sedentary 
behaviour. Avoiding sedentary behaviour is therefore recommended by lowering TV 
watching, computer, and use of other electronic equipment for leisure purpose to a 
maximum of 1-2 h per day by the European Society of Paediatric Endocrinology (ESPE) 
(55). In this context, making changes in the school dietary regimen, curriculum, and less 
use of own or public transport are also suggested to achieve weight loss in the long term 
(57). However, several established barriers to achieving these goals have been identified 
particularly lack of motivation of the patient and the lack of the parents’ involvement in 
weight management (58). Moreover, despite the awareness and appreciation of the 
community and school based programmes, long term effectiveness is still rather less 
evident (59). 
Successful weight maintenance also requires reduced caloric intake, reduced fat and 
food consumption, less snacking, regular meals especially breakfast, and less fast food 
consumption (55). It is debatable whether aerobic exercises contribute to weight loss, but a 
positive association of exercise with weight maintenance and weight loss in conjunction 
with dietary and lifestyle interventions have been shown (54). Parents’ lack of obesity 
perception in their children has been documented. Education of parents along with the 
children is necessary to encourage healthy rearing patterns such as healthy dieting of the 
child, physical activity, eating behaviours and motivation and psychological support (60). 
Certain pharmacological agents have been suggested for adult obesity but evidence 
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regarding their efficacy and safety in children and adolescence is lacking. Only few drugs 
are approved by FDA, NICE and SIGN guidelines for use in childhood obesity such as 
orlistat in children more than 12 years, but always in conjunction with other diet, exercise 
and lifestyle measures. Although previous meta-analysis favoured the use of Sibutramine 
and orlistat with behavioural therapy as it was shown to reduce BMI by 2.2 kg/m
2
 and 0.8 
kg/m
2
 respectively with some side effects (elevation of systolic and diastolic blood pressure 
with sibutramine and gastrointestinal side effects with orlistat) (61). However, sibutramine 
was withdrawn from the market in 2010 due to its cardiovascular complication and the use 
of orlistat is recommended with very careful consideration by a specialist physician and are 
indicated only in severe obesity where lifestyle, diet and exercise measures have failed to 
improve metabolic health. These drugs carry several detrimental effects on patient 
physiology and drug to drug interactions (such as anticonvulsants) and therefore are rarely 
used in clinical practice (62). 
1.3.8 Summary of evidence on obesity, risk factors and management of 
obesity- “The knowledge gap” 
In summary, several factors have been studied to explain the aetiology of obesity both in 
children and adults.  These encompass genetic, environmental, dietary, and lifestyle factors. 
However, together they do not explain the current epidemic of obesity. Furthermore, 
obesity in childhood continues towards obesity in adulthood, however, the evidence for the 
link between childhood obesity and adult obesity related disease risk factors is missing. 
Different dietary, behavioural, lifestyle and pharmacologic interventions are suggested to 
tackle obesity but the success of these interventions is limited due to low compliance, lack 




Table 1.3: Management of obesity through prevention and treatment strategies (adapted from(54, 55, 
62)). 
 
SIGN; Scottish intercollegiate network, NICE; National institute for health and core excellence, FDA; 
Federal drug agency USA.* No pharmacologic therapeutic agents are approved by FDA, SIGN or NICE 
guidelines for sole use in paediatric populations. Orlistat is recommended in children above 12 years and 
should only be prescribed along with intensive lifestyle, dietary, and physical intervention and very careful 
consideration by a specialist physician. 
 
 
1.4 Gut microbiota 
Gut microbiota located at the interface of host and environment in the gut is a new area of 
research explored in an attempt to explain the excess accumulation of energy in obese 
population and is therefore a new potential target for therapeutic manipulation to reduce 
host energy storage. 





predominantly residing in the proximal part of colon. The intestinal microbiota are thought 
to be composed of approximately 1000 different species, with a total mass of around 1.5 
Intervention Components of intervention 
Lifestyle   Change in dietary habits 
  Family support and education 
  Encouraging weight loss 
  Change in school diet plans, curriculum, activities 
Dietary  Encouraging lower consumption of  energy dense foods, fast 
foods, fats 
  Regular meal plans- not escaping breakfasts, less food at night 
  Discouraging continuous snacking 
  Encouraging dietary fibre intake 
Physical activity  Encouraging 60 minutes of vigorous activity most of the days 
in a week 
  Reducing sedentary activities especially TV watching, video 
games,  computer entertainment limited  to at least 1-2 hours 
Psychosocial   Parents education about healthy eating and activity 
  Motivation and behavioural change 
  Promoting good communication for support 
Pharmacologic*   Orlistat (for >12 years age) (SIGN, NICE & FDA) 
  Metformin (not approved by FDA for children and adolescents) 
  Octreotide (not approved by FDA for children and adolescents) 
  Leptin(not approved by FDA for children and adolescents) 
  Growth Hormone(recommended only for Prader Willi 
Syndrome) 
 Supplements (not recommended) 




kg, constituting approximately 10
11
 bacteria per gram of colonic content. Up to 99% of the 
known cultivable species of gut microbiota are facultative anaerobes (63).  With a total 
bacterial metagenome of 100 times more genes than the  human metagenome, these 
bacteria contribute to various biochemical and metabolic functions such as breaking down 
indigestible dietary polysaccharides, conversion of conjugated bile acids into secondary 
bile acids, synthesis of vitamins, degradation of dietary oxalates and development of 
immunity against a variety of intrinsic and extrinsic allergens (64). 
1.4.1 Diversity of gut microbiota; “the known amongst many unknown” 
The advent of non-culture dependent techniques have made it possible to sequence the 
whole bacterial metagenome from different body sites including the gut (65). The majority 
of bacterial species residing in the gut are still uncharacterized. Two principal factors 
determining the composition of gut microbiota are substrate availability and gut transit 
time. Others include; competition for nutrients and binding sites in the gut and co-operation 
between different species and groups for the breakdown of dietary substrates (66).  
Compositional differences between the gut microbiota are exhibited at various 
taxonomic levels between individuals even in the same family sharing the same food and 
environment. This was elegantly shown by Turnbaugh et al. (2009), who studied gut 
microbiota composition and function in faecal samples of 154 young adult female mono- 
and dizygotic twins concordant for leanness and obesity and their parents (n=46) (67). 
They found marked inter-individual variations between individuals’ gut microbiota 
structure at different taxonomic levels even between members of the same family. 
However, there was a consistent similarity in the core gut microbiome (i.e. aggregate 
functional genes in gut microbiota) between related members of the family compared to 
unrelated participants. These inter-individual variations both in the structure and function 
of the gut microbiota may be determined by various innate host and environmental factors 
to which individual is exposed in his/her early life (65). These factors might include 
expression of cell surface receptors such as toll-like receptors 5 (TLR5) that recognize 
bacterial cell wall components to elicit immunologic response to determine the preferential 
colonization of certain species but not others. Furthermore, the expression of certain factors 
such as the nucleotide oligomerization domain (NOD) which is a ligand for bacterial 
lipopolysaccharide and activates proinflammatory signaling in the gut (68). Moreover, the 
expression of nucleotide-binding domain and leucine-rich-repeat-containing proteins 
(NLRPs) is associated with obesity and altered insulin signaling (69). Hence, the 
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population of the colonic microbiota depends on many environmental, dietary, innate host 
and immune response factors.   
Although members of all three domains of life; Archaea, Eukarya and Bacteria 
reside in human gut, the majority of intestinal microbes (approximately 99%) are bacteria, 
the term microbiota is often therefore used synonymously with bacteria (64). Gut 
microbiota in the human gut are divided into 5 major phyla including Firmicutes, 
Bacteroidetes, Actinobacteria (e.g.  Bifidobacteria and Actinomycetale), Proteobacteria 
(alpha-, beta-, gamma-, and zeta-Proteobacteria), and Verrucomicrobia (including 
Akkermansia spp.) (65) (Figure 1.2 andFigure 1.3). Firmicutes constitute up to 60% of the 
total bacteria and are represented by Bacilli (Bacilli, Lactobacilli, Lactococci, 
Staphylococci, Streptococci, Leuconostoc), Clostridia (Clostridial cluster, Eubacteria, 
Roseburia spp., Peptococci, Petptostreptococci), Erysipellotrichia (Erysipelotrichaceae), 
Negativicutes (such as Veillonella), Thermolithobacteria, and some unclassified Firmicutes. 
Phylum Bacteroidetes constitute approx. 10-20% of total bacteria and include Bacteroides 
(Bacteroides, Prevotella, Porphyromonasspp.), Cytophagia, Flavobacteria, 
Sphingobacteria, and some unclassified Bacteroidetes (70). To date, approximately 64-70% 
of the detected sequences have not been assigned to any group and the functions associated 
to these sequences are still unknown (64).  
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Figure 1.2: Major gut bacterial phyla and their predominant sub-groups. Adapted from (66). 
 
Methanogens, members of the Archaea, are other distinct microbes which have recently been discovered and 
are under extensive research. The structural and functional organization of gut microbiota varies between 
individuals despite similarities in the broad population of gut microbes in the gut. This is determined by 
various factors such as diet (type and amount of fibre), gut transit time, and other environmental and innate 
host immune response factors. 
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Figure 1.3: Summarised phylogenetic tree and proportion of major gut microbial phyla in the human 
gut. The proportion varies between individuals. Re-printed with permission from Diament et al. 2011 
(71). 
 
The size of the bar represents phylogenetic distance 
 
1.4.2 Gut microbiota and human health 
1.4.2.1 Production of SCFA 
The gut microbiota degrade fermentable dietary carbohydrates (and some proteins) to 1-6 
carbon organic compounds; the short chain fatty acids (SCFA). SCFA are the most 
abundant anions produced in the gut (72). The most important of these are acetate (C2), 
propionate (C3), and butyrate (C4) in a mean ratio of 60:20:20 respectively (73, 74). 
However, the proportion of SCFA may vary between individuals, type of diet, gut transit 
time, and gastrointestinal diseases such as inflammatory bowel disease. The amount and 
proportion of these SCFA may vary with the type of substrate available for fermentation. 
The exact amount of SCFA produced by the gut microbiota in humans is unknown 
due to practical issues related to the lack of access to the proximal colon and therefore 
measurement of the whole fermentation process. Faecal SCFA which are often measured 
are the result of both production and absorption in the colon and do not reflect true 
production rates.  Nevertheless, the rate of production of SCFA varies considerably with 
the amount and type of substrate available for fermentation and also with the gut transit 
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time (75). Although the extent of fermentation is quantified in the ruminants, the amount of 
SCFA produced as a result of fermentation in humans is derived from the equation for 
fermentation based on the known concentration of faecal SCFA, CO2, and methane.  
            34.5C6H12O6→64 SCFA + 23.75CH4 + 34.23 CO2 + 10.5 H2O 
Based on this equation, with daily average intake of 15-20 g fibre per day from a typical 
Western diet, the average production of SCFA varies between 100-200 mmol/day, of which 
approximately 15-20 mmol/day are excreted in faeces (76). However, this predictive 
equation does not take into account those people who do not produce methane. 
Additionally, it also underestimates SCFA production if the consumption of fibre is more 
than 20 g/day or if there are other carbohydrates also available for fermentation. The exact 
amount of SCFA produced per day is therefore still unknown.   
All hexose sugars are essentially converted to pyruvate in the Embden-Myeroff 
pathway (Figure 1.4). Acetate is formed by the oxidative de-carboxylation of pyruvate or 
by the conversion of formate to acetate with the help of formate lyase in Wood-Ljungdahl 
pathway catalysed by Escherichia coli and other Enterobacteriaceae (77).  Propionate is 
formed by two major routes; the de-carboxylation pathway which involves carbon dioxide 
fixation to succinate, followed by the formation of propionate. The second pathway 
involves conversion of lactate and acrylate to propionate in acrylate pathway. The third and 
less common pathway is propanediol pathway for the conversion of fucose and manose to 
propionate (78). Butyrate is formed when acetoacetate is first formed from acetate and then 
reduced to butyrate (79). Additionally, butyrate can also be formed by the utilization of 
lactate by lactate-utilizing butyrate-producing bacteria such as Eubacterium halii and 
Anaerostipes caccae via acetyl CoA at a slightly lower pH (such as pH 5.9) (80).  Although 
lactate (D & L form) is not a major faecal metabolite of the gut microbiota, it is formed in 
large quantities in the colon as an overflow in glycolytic pathways especially from readily 
fermentable carbohydrates. Lactate formation is also favoured when colonic pH is reduced 
after excessive fermentation. This occurs through the inhibition of metabolism of the gut 
microbiota that metabolise lactate. Colonic lactate production is also favoured in 
malabsorption states such as diarrhoea.  
Belenguer et al. (2007) in their study of 4 volunteers reported that lactate is 
primarily produced by Bifidobacterium spp. and lactic acid bacteria such as Lactobacilli 
and Enterococci but it can be produced by other species in the gut. Propionate producing 
bacteria such as Veillonella and Megasphaera elsdenii convert lactate to propionate mainly 
by acrylate pathway at a higher pH (such as pH 6.4) while certain butyrate producing 
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bacteria such as Eubacterium halii and Anaerostipes caccae utilise lactate to produce 
butyrate via acetyl CoA at a slightly lower pH (such as pH 5.9) (80). 
Other metabolites such as formic acid, ethanol, methane, and hydrogen are produced in 
small amounts. The production of these compounds varies between humans and animals 
and also between regions with low and high fibre intake (75-80% methane producers in 
Africa compared to 40-60% methane producers in the UK and USA) (79). 
 
Figure 1.4: Simplified diagram of the different metabolic pathways of production of SCFA in the colon.  
Adapted from (77) 
 
Most of the SCFA are produced by more than one pathway; the pathways represented here are the common 
routes of production. Acetate is produced by oxidative decarboxylation or from formate via Wood Ljungdhal 
pathway. Butyrate is formed from Butyryl CoA or through the conversion of acetate to butyrate. Propionate is 
formed mainly by succinate pathway, however it is also formed via acrylate pathway from lactate or via 
propanediol pathway from fucose and rhamnose. 
1.4.3 Metabolism of SCFA 
A substantial amount of the absorbed SCFA are metabolised in the mucosa. This ratio of 
metabolism increases with increase in chain length (Acetate<propionate<butyrate) and the 
amount available in blood decreases in the same order. About 30% of acetate is converted 
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to ketone bodies (acetoacetate and β-hydroxybutyrate) and 75% of butyrate is metabolised 
in the mucosal cells. It is suggested that 50% of propionate and 90% butyrate are absorbed 
by the colonic epithelial cells (81). The remaining SCFA absorbed into the portal blood are 
transported to the liver for further metabolism. 
1.4.4 Acetate 
Acetate is the major SCFA (approx. 60%) produced in the gut by a diverse range of gut 
microbiota belonging to phylum Firmicutes. Acetate is generated in the gut to feed the need 
to regenerate NAD
+ 
and co-enzyme A (CoASH) in the cells which are utilised in the 
process of glycolysis to generate pyruvate. Overall, acetate contributes 6-8% to the overall 
energy expenditure as reported in stable isotope study by Pouteau et al.(82). Acetate 
significantly contributes towards the formation of butyrate and propionate as it is consumed 
by the butyrate and propionate producing bacteria in the gut. Butyrate producing - acetate 
consumers primarily include Faecalibacterium prausnitzii, Roseburia intestinalis, and 
Eubacterium rectale (83, 84). Schwiertz et al.(2002) identified Anaerostipes caccae as 
another acetate utilizing butyrate producing Clostridial bacteria in 2002 (85). The 
proportion of acetate utilization in an individual depends on the type of butyrate producers 
in the gut and the type of fibre available for fermentation (86). In their study, the amount of 
butyrate formed from acetate varied from 56% in pectin to 90% in xylan in  continuous 
cultures and 72% to 91% in batch cultures (86). 
Being the most abundant SCFA, acetate concentration is associated with several 
important metabolic functions critical for health of the host. First; it contributes to daily 
energy requirement as SCFA may make up to 10% of total energy used (87). This is 
however debated as the daily intake of dietary fibre in European diet is 15-20 g per day.  
The amount of energy gained from the fermentation of non-digestible carbohydrates (e.g. 
oligofructose) is about 25-35% of what would be gained if fructose was absorbed in the 
small intestine which is about 15.7 kJ/g. Assuming daily intake of 40 g fermentable 
carbohydrates (20 g of non-starch polysaccharides and 20 g of resistant starch), the net 
contribution of SCFA to the total energy requirements would be approximately 2.2% of the 
average 2000 Kcal intake (calculated as; 15.7 kJ/g x 40 g x 30%) (88). Secondly; acetate 
has been shown to increase hepatic de novo lipogenesis by stimulating acetyl co-enzyme A 
and fatty acid synthase which are key to lipogenesis (89). Thirdly; acetate is a substrate for 
hepatic cholesterol synthesis by stimulating carbohydrate response element binding 
proteins (ChREBP) (90) (Figure 1.5). Fourthly; acetate and propionate are thought to 
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reduce triglyceride hydrolysis by activation of GPR43 (89). Thus the overall effect of 
acetate is increased hepatic lipogenesis and systemic hypercholesterolemia which might 
suggest an inverse relationship with cardiovascular health. The role of acetate in hepatic 
lipogenesis is however controversial as oral administration of 5.2 mg/kg body weight 
acetate every day for 6 months in obese and diabetic rats were shown to improve glucose 
tolerance, reduce accumulation of fats in adipose tissue and liver by inhibiting the 
expression of genes for lipogenic enzymes such as acetyl CoA carboxylase, malic enzyme, 
fatty acid synthase, and glucose-6-phosphate dehydrogenase (91). 
Acetate is a ligand for G protein coupled receptor 43 and 41 (GPR43 & 41), now 
called free-fatty acid receptor 2 and 3 (FFAR2 & 3), which have been shown to reduce the 
intake of food by GPR43 stimulation and stimulation of satiety hormones such as PYY and 
GLP-1 by GPR41 (92). However, Lin et al. (2012) have suggested that these effects are 
independent of GPR41 receptors (93). In their study, intake of high-fat diet supplemented 
with sodium salt of acetate (3.7%) in C57BL/6J mice reduced weight gain in lean high fat 
fed mice by up to 40% but did not improve glucose concentration and insulin sensitivity, 
while butyrate and propionate reduced food intake and weight gain independent of GPR41 
and GLP-1 (93). Frost et al. (2014) have recently reported a possible direct effect of acetate 
on the suppression of appetite by inducing the expression of pro-opiomelanocortin via 
maloyl co-enzyme A and regulatory neuropeptides (glutamate-glutamine and GABA 
neuroglial cycles) favouring appetite suppression. Interestingly, 
13
C stable isotope labelled 
acetate produced by carbohydrate fermentation was shown to be correlated with 
13
C acetate 
in the hypothalamus (94).   
1.4.5 Propionate 
Gut microbiota involved in the production of propionate are taxonomically less diverse 
than butyrate producing bacteria. Reichardt et al.(78) have described 3 pathways for the 
production of propionate in the descending order of utilization; succinate > acrylate > 
propanediol pathway. Succinate pathway was the most common route of hexose conversion 
to propionate by the Gram-negative Bacteroides and many other Negativicutes as shown by 
an abundant expression of mmdA gene encoding methylmalonyl-CoA decarboxylase. 
Acrylate pathway was restricted to a few members of Lachnospiraceae such as 
Coprococcus catus and Negativicutes to convert lactate to propionate (as shown by 
expression of IcdA gene for lactoyl CoA dehydratase). However, butyrate, but not 
propionate, is the predominant route of utilisation of lactate by butyrate producing bacteria 
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(95). Expression of PduP gene encoding propionealdehyde dehydrogenase in propanediol 
pathway was shown to be used for the conversion of deoxysugars such as fucose and 
rhamnose by Ruminococcus obeum and Roseburia inulinivorans, members of 
Lachnospiraceae (78). 
Higher levels of propionate have been associated with hypocholesterolemia, reverse 
cholesterol transport, anti-lipogenesis (96), improved satiety through hormone PYY, 
appetite suppression through leptin (97), and antiproliferative effect on colonic cancer cells 
(98) (Figure 1.5). SCFA especially propionate also act as a ligand for G protein coupled 
receptor GPR41. These receptors are expressed in adipose tissue, pancreas, spleen, liver, 
enteroendocrine L cells, and mononuclear cells. These receptors have been shown to 
improve insulin sensitivity and secretion via stimulation of GLP-1 from L-cells (99). 
However, other studies have found a reduction in insulin sensitivity with activation of 
GPR41 which indicate other mechanisms involved which are poorly known (99). 
Propionate and acetate added to a culture medium containing adipocytes and pre-
adipocytes reduced lipolysis by 50% and the same effect was seen in C57BL/6 mice (100). 
This anti-lipolytic effect was abolished when GPR41deficient knock-out mice were used, 
suggesting that propionate and acetate exert this effect through GPR41 (100). Propionate 
has been shown to down-regulate hepatic de-novo lipogenesis through reduced expression 
of fatty acid synthase. It also inhibits hepatic cholesterol synthesis by inhibiting the rate 
limiting enzyme in cholesterol synthesis, 3-hydroxy, 3-mehtylglutaryl Co-enzyme A 
(HMG-CoA) (96). 
1.4.6 Butyrate 
Butyrate is one of the main SCFA whose production is increased by the fermentation of 
indigestible complex polysaccharides such as resistant starch from wheat bran and maize. 
Approximately 70% of the energy required by the colonocytes for cellular respiration is 
obtained from butyrate (87) (Figure 1.5). Although a diverse range of gut microbiota are 
attributed to the production of butyrate, Faecalibacterium prausnitzii, Eubacterium rectale, 
and Roseburia intestinalis are the main producers at species level corresponding to 
Clostridial cluster IV and XIV within the phylum Firmicutes (101). Recently, a new 
butyrate (and acetate) producing bacterium Intestinimonas butyriciproducens has been 
identified in mouse intestines by Klaring et al. (2013) in cultures with reduced agar 
medium containing yeast extract, rumen fluid and lactic acid (102). Several cross-feeding 
metabolic pathways are also suggested to be involved in the production of butyrate from 
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other substrates such as lactate and acetate which are produced by the Lactobacilli and 
Bifidobacteria (103). 
Butyrate has been shown to have anti-inflammatory effects by regulating the 
chemotaxis and cellular adhesion processes (104). It increases the chemotactic response of 
neutrophils in the absence of a chemotactic stimulator and decreases the LPS induced 
migration of macrophages by reducing non-receptor tyrosine kinases (105) and monocyte 
chemoattractant protein 1 (MCP-1). Butyrate also increases Helper T-cell (TH2) response 
(106), reduces the levels of ICAM-1 adhesion molecules and lymphocyte function 
associated antigen-3 (104), reduces NFkB induced expression of proinflammatory 
cytokines, reduces LPS-induced  IkB degradation (107). However, the response of butyrate 
is dose dependent and a lower response is seen when higher concentrations of butyrate are 
used. Butyrate also reduces the activation of mitogen activated protein kinase pathways 
which respond to stress and other extracellular stimuli. Some genes involved in these 
cascades are; ERK ½, JNK, and P38 (108).  
Butyrate is a known histone deacetylase inhibitor. Histone deacetylase inhibits gene 
transcription by keeping the chromatin network in a compact form (109). Butyrate 
therefore regulates gene expression for cellular growth and proliferation by 
hyperacetylation. This effect may be important for the prevention of colorectal carcinoma. 
Butyrate has been shown to have an antiproliferative effect on colon cancer HT29 cells 
coupled with increased rate of differentiation and apoptosis (by activating caspases-3/7) 
(110). However, this effect is dependent on the type of cells used for experiments and the 
proliferative state of the cells (111). Other studies have shown that butyrate inhibits pro-
inflammatory cyclooxygenase 2 (Cox-2) induced expression of TNF-α and Cox-2 induced 
angiogenesis in experimental colon cancer cells, which in turn may reduce cancer cell 
proliferation, survival, and growth (112). Interestingly, this antiproliferative and apoptotic 
effect is not seen in the normally differentiating cells (110). Butyrate had anti-obesity effect 
by maintaining β-cell function and reducing inflammatory response in pregnant obese mice 
without increasing risks of fetus toxicity (113).  
1.4.7 Branched chain fatty acids (BCFAs) 
BCFA, iso-butyric acid and iso-valeric acid, are produced as a result of protein 
fermentation particularly from branched amino acids such as valine and leucine 
respectively (114) and also from endogenous sources of proteins in the form of sloughed 
cells. The concentration and proportion of BCFA are generally increased when fermentable 
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carbohydrate is limited in the colon. Although earlier studies by Croft and colleagues 
reported that approximately 300 g of sloughed cells per day from the mucosa of the entire 
gastrointestinal tract are available for degradation (115, 116). However, the calculations 
were based on human DNA from intestinal washings from a small length of human 
intestine and all samples were from patients with gastrointestinal disorders (such as 
inflammatory bowel disease and coeliac disease) which might have affected their results. 
The production of BCFA seems to be correlated consistently in different diets and 
across different animal species. A study on faecal samples of 4 different species (humans, 
horses, rats, and pegs) have shown a consistently strong correlation between percentage of 
iso-butyric and iso-valeric acid in these species fed on different diets, irrespective of the 
amount of SCFA, age, diet, and living conditions (114). There is not much evidence of 
whether the production of BCFAs varies between obese and lean people. A crossectional 
study by Payne et al.(2012) found a higher concentration of iso-butyric acid in faeces of 
simple obese Swiss children than from lean children (95).  
Figure 1.5: Functions of major SCFA in host metabolic homeostasis. Concept adapted from (91, 97, 98, 
110) 
 




Lactate is a metabolic intermediate during the production of butyrate, propionate, and 
acetate. As indicated above, lactate is primarily produced by Bifidobacterium spp. and 
lactic acid bacteria such as Lactobacilli and Enterococci but it can be produced by many 
other species such as propionate producing Veillonella and Megasphaera elsdenii which 
convert lactate to propionate mainly by acrylate pathway at a higher pH (such as pH 6.4) 
while butyrate producing Eubacterium halii and Anaerostipes caccae utilise lactate to 
produce butyrate via acetyl CoA at a slightly lower pH (such as pH 5.9) (80).  
Levels of faecal lactate depend on a) the rate of production by lactate producing 
bacteria, b) absorption from the gut lumen, c) net utilization by lactate utilising-butyrate or 
propionate-producing bacteria, d) status of mal-absorption (faster transit), e) luminal pH, 
and f) dietary complex polysaccharides. Generally, a more acidic  pH (<5.5) in the colon 
inhibits the utilization of lactate by lactate utilizing bacteria while production is still 
maintained (80). The levels of faecal lactate are therefore very low (<3 mmol/L) under 
physiological conditions as physiological gut transit and status of absorption does not allow 
the drop of pH below 5.5. However, concentrations of ≥80 mmol/L in faeces have been 
reported in an acidic gut luminal environment in conditions associated with mal-absorption 
and faster transit either due to inflammation such as ulcerative colitis (116) or due to short 
bowel (short-bowel syndrome) (117). The metabolism of lactate is also partly dependent on 
the presence or absence of polysaccharides and is also subject to inter-individual variations 
(80). Sato et al. (2008) showed that administration of galacto-oligosaccharide (GOS) to the 
Sprague-Dawley rats alone increased both butyrate and lactate in caeca of the rats. 
However, administration of GOS along with a lactate utilising bacterium Anaerostipes 
caccae isolated from human faeces resulted in further acceleration of butyrate but reduced 
the levels of lactate (118). Study by Mayeur et al. (2013) identified lactate accumulators 
and non-lactate accumulators in a group of patients with short bowel syndrome based on 
the presence of D and L lactate in the faecal samples. They found that lactate accumulators 
with higher D/L ratio and plasma bicarbonate ions were at a higher risk of developing D-
lactate induced encephalopathy (117). 
1.4.9 Hydrogen Sulphide 
Faecal hydrogen sulphide is a metabolic degradation product of gut microbiota from 
sulphur related to dietary carbohydrates, proteins, excess supplemental sulphates, mucins, 
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and dead epithelial cells in the colon (119). It is usually difficult to measure the proportion 
of faecal sulphide contributed by the microbial production from the available luminal 
substrates (prokaryotic contribution) and that contributed by the host mucin peptidoglycans 
and peptides (eukaryotic contribution) (120). 
Sulphate reducing bacteria (SRBs), particularly Desulfovibrio spp.(D. desulfurican 
and D. piger) utilise sulphate or sulphite as a terminal electron acceptors for the 
dissimilation of reduced SCFA or molecular hydrogen (121). This results in the generation 
of sulphide ion (HS
-
) that is converted to free H2S in the acidic distal gut lumen. SRBs 
compete with methanogenic bacteria for hydrogen as higher SRBs level is associated with a 
negligible or extremely low methanogens in the distal gut (122). E.coli, Salmonella 
enterica, Clostridium, and Enterobacter aerogenes in the colon can also produce hydrogen 
sulphide by the metabolism of cysteine(123). Whereas physiological concentrations of H2S 
have beneficial effects on gut health as it promotes healing of gut ulcers and resolve 
mucosal inflammation through its angiogenic (cyclo-oxygenase-2 and nitric oxide) and 
anti-inflammatory properties (124), a number of potentially adverse effects of excess 
hydrogen sulphide have been suggested. It is thought to reversibly inhibit the β-oxidation 
of butyrate, increase intestinal permeability, induce abnormal cellular proliferation, goblet 
cell death, crypt cell loss, reduce opsonisation potential of polymorphonuclear leukocytes, 
and mucosal ulceration (119). However, the rise in hydrogen sulphide with tissue injury 
such as mucosal ulceration in experimental colitis is seen as a protective response to 
promote ulcer healing which suggests a protective role of hydrogen sulphide in a dose 
dependent manner as a protective effect against inflammation (125). 
Although extensively studied in relation to inflammatory bowel disease (126); 
faecal hydrogen sulphide in obese humans , including children, has not been studied 
greatly. Most research has focussed on the differential colonisation of SRBs in the colon of 
obese children and adults as the presence of SRBs in faeces is a surrogate marker for the 
utilization of sulphate as an electron acceptor to maintain the redox potential in gut. Most 
studies have looked at the changes in sulphide with changes in diet in both animal and 
human studies. The association of  excretion of sulphide in faecal samples with the 
presence of SRBs is debated as some studies have found no difference in the excretion of 
sulphide between SRBs positive and SRBs negative participants (127). Furthermore, 
evidence also suggests that the production of colonic tissue-produced hydrogen sulphide 
may be independent of the microbiota-produced faecal hydrogen sulphide since rise in 
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elevated colonic tissue-produced H2S was observed in the absence of a rise in faecal H2S in 
mouse models (125). 
Levels of faecal sulphide differ between healthy lean people and people with altered 
function or physiology of the gut such as colonic motility. Chassard et al.(2012) reported 
significantly lower faecal sulphide, molecular hydrogen, and significantly higher methane 
in healthy lean women than women with constipated irritable bowel syndrome (IBS) (128). 
This was coupled with significantly higher lactate utilizing and methanogenic bacteria, and 
significantly lower sulphate reducing bacteria in healthy lean women than in constipated 
IBS women. Although total SCFA, acetate and propionate were similar between the two 
groups; levels of butyrate were significantly lower in the constipated IBS group signifying 
that H2S may have inhibited oxidation of butyrate (128).  
Faecal sulphide has also been shown to be associated with changes in faecal 
consistency and dietary interventions. A recent study using a gnotobiotic mouse model 
showed an increase in caecal sulphide, increase in a prominent SRB; Desulfovibrio piger, 
and a decrease in acetate and propionate on high fat and low complex polysaccharide diet. 
This was in addition to increased gene expression  of sulfatase; an enzyme produced by 
Bacteroidetes (such as B. thetaiotaomicron) with capability to liberate sulphate moiety 
from sulphated oligosaccharide chains of the mucosal glycosaminoglycans(121). Liberated 
sulphate is then utilised by D. piger for the production of hydrogen sulphide (121). Preter et 
al.(2010) showed a significant reduction of sulphide in in vitro faecal incubations with 
oligofructose-inulin (129). In another study, volunteers who had SRBs in their faeces, 
showed a reduction in faecal sulphide with oligofructose along with an increase in total 
SCFA although the population of SRBs did not change after the intervention (130). 
However, reduction in faecal hydrogen sulphide with high intake of dietary fibre is 
controversial, as a recent study by Ou et al. (2013) reported higher sulphate reducing 
bacteria in African population consuming high fibre diet than in African-Americans 
consuming low fibre diet (131). 
Systemic hydrogen sulphide is a gasotransmitter vasodilator and hence may mediate 
several beneficial cardiovascular and anti-obesity effects (120, 124). Little is known about 
the effect of microbiota produced hydrogen sulphide in the gut on the bioavailability of 
hydrogen sulphide in systemic circulation and different organs such as adipose tissue and 
lungs. To address this issue, Shen et al.(2008) have shown that gut microbiota may play a 
key role in regulating the bioavailability of hydrogen sulphide in the systemic circulation as 
they found significantly lower free and bound form of H2S in plasma of germ free vs. 
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conventionally housed animals (132). However, the levels of tissue or organ sulphide was 
inconsistently correlated with caecal and colonic tissue free sulphide as they found lower 
amount of free H2S in lungs and kidneys while a higher amount of free-H2S in heart tissue 
in germ free mice compared to conventionally raised mice (132). The discrepancy between 
the colonic and caecal versus organs free H2S might be due to the fact that the authors used 
caecal and colonic tissue H2S as a marker of microbiota produced sulphide which may 
actually be the endogenously produced sulphide independent of the presence of gut 
microbiota. Furthermore, Flannigan et al.(2011) showed that faecal sulphide in Swiss 
Webster mice were not significantly different between germ free and conventional mice 
(120) which suggests that other as yet unknown mechanisms might be important in the 
production and bioavailability of sulphide. The differences seen between studies may be 
attributed to different mouse models, experimental conditions and sample size between the 
two studies. It will be interesting to correlate gut luminal H2S, which is being considered as 
harmful metabolite, with H2S in systemic circulation with its aforementioned beneficial 
actions and whether gut microbiota or obesity plays any role in determining this balance. 
 
1.4.10 Ammonia 
Ammonia in the colon is produced from endogenous and exogenous sources of proteins; 
however, the predominant route is from the endogenous mucin and epithelial cell proteins 
especially in the absence of carbohydrates as a substrate. This may lead to the formation of 
hazardous metabolic products that may be of particular relevance to colorectal cancer 
(133). In ruminants, gut microbiota producing ammonia are asaccharolytic hyper-ammonia-
producing bacteria to retain nitrogen for nutrition, but in the hind gut fermenters like 
humans they are mostly potential pathogens such as Clostridium spp. (including C. 
perfringens), Enterococcus, Shigella and Escherichia coli, Enterococcus faecalis, 
Staphylococcus spp., Eggerthellalenta. and some Gram positive cocci(134).  
Smith and McFarlane (135) showed that faecal pH and carbohydrate availability 
were the major determinants of peptides and amino acids fermentations in the large 
intestine; carbohydrate availability being stronger factor than faecal pH. Lower pH (pH 5.5 
vs. 6.8) inhibited the fermentation of amino acid to produce ammonia while high starch 
content in the amino acid fermentation culture reduced the production of ammonia from 
peptides by routing the nitrogen towards the production of bacterial proteins independent of 
pH (135). Increased carbohydrate availability seems to divert the action of gut microbiota 
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from endogenous sources towards fermentation of dietary fibre (136). Birkett et al.(1996) 
showed a reduction in faecal ammonia and phenols with increased intake of resistant starch 
although there was no change in the urinary ammonia, phenol, urea, and total nitrogen 
(136). 
The role of exogenous dietary proteins in the production of ammonia in the gut is 
controversial as endogenous sources and availability of carbohydrates are stronger 
determinants of faecal ammonia. Some authors have found an association of increased  
intake of meat protein with increased levels of faecal ammonia and production of SCFA in 
human volunteers (73). In contrast, Russell et al. (2011) found no difference in faecal 
ammonia concentration between obese human volunteers on diets with different protein 
concentration (such as high-protein medium-carbohydrate, high-protein low-carbohydrate, 
and weight-maintenance diets for 8 weeks (137). 
1.5 Gut microbiota and early life 
In utero, the fetus is dependent on maternal physiology and metabolism for its survival and 
growth. The impact of maternal physiology and the changing metabolism during pregnancy 
on ―priming‖ the development of fetal gut microbiota is highly anticipated (138). However, 
the impact of maternal metabolic profiles and gut microbiota on the fetal gut microbiota 
development is scarcely studied in the literature. There are indications that certain maternal 
gut microbial metabolic signatures are associated with preterm labour and childhood 
obesity in later life (139). Pregnancy is associated with a decrease in maternal gut barrier 
integrity which may affect nutrient supply to the fetus. Children born by caesarean section 
harbour different gut microbiota than those born vaginally (140;141). Furthermore, data 
from large population based studies such as ALSPAC study (n=10,219) indicate that mode 
of delivery have a significant impact on the development of overweight and obesity in 
children starting as early as age 6 weeks even after the adjustment for parental weight, 
feeding patterns, parental socioeconomic status, gestational factors (such as parity, 
maternal age, and first trimester smoking, and gestational weight gain) (140). Additionally 
the differences in gut microbial population in gut of breast-fed infants versus formula fed 
infants due to maternal breast milk composition support the notion of significant impact of 
maternal physiology, gut microbiota, and metabolism on the development of gut microbiota 
in the infant. This may subsequently affect the development of lean and obese phenotype 
predisposition of infant in later life. 
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1.5.1 Gut microbiota before and at the time of birth 
The concept of sterile fetal gut was presented more than 100 years ago in a French journal 
by Tissier (141) and has been considered the case since then. The idea that the preliminary 
gut microbiota are acquired during passage through maternal vaginal tract in case of normal 
delivery or from the immediate environment in case of caesarean section is generally 
accepted in the literature (142). However, Esther Gimenez and colleagues were able to 
isolate Lactobacilli from meconium of healthy new-born infants delivered by caesarean 
section (143). It is not clear if these bacteria were from maternal blood through the 
placental barrier or of vaginal origin. The same group tested for the presence of microbiota 
in the umbilical cord of healthy children born by elective caesarean section (144). Several 
bacterial genera commonly isolated from breast milk were detected in the umbilical cord 
blood by PCR after incubation and growth in selective media. All the isolates were Gram 
positive cocci and were the inhabitants of neonatal gut from day one of life. These included 
bacteria related to genus Enterococcus, Streptococcus, Staphylococcus, or 
Propionibacterium. Interestingly, bacteria related to oral mucosa such as Staphylococcus 
epidermidis, Propionibacterium acnes, Enterococcus faecium, and Streptococcus sanguinis 
were also detected in small quantities suggesting that oral microbiota could also enter the 
uterus through blood stream. Furthermore, oral inoculation of a genetically labelled E. 
faecium, a breast milk commensal, into pregnant mice was isolated from amniotic fluid of 
the same mice while no bacteria could be isolated from the non-inoculated group (144). 
This suggested that maternally derived bacteria from different body sites could cross 
placental barrier into the amniotic fluid.  
Whether bacteria isolated from umbilical cord blood could also be seen in the 
meconium of the new-born was further investigated by the same group in 2008 (145). 
Bacteria belonging to the genus Enterococcus (Enterococcus faecalis) and Staphylococci 
(Staphylococcus epidermidis) were isolated from meconium of 17 out of 21 healthy 
neonates born by normal vaginal delivery or elective caesarean section, while E.coli and 
Enterobacter were isolated from some samples (six and five respectively). This 
transmissibility was confirmed in animal model in which labelled E. faecium was 
inoculated orally in pregnant mice. This inoculated E. faecium was then detected in the 
meconium of the new-born delivered one day before the expected date by caesarean section 
suggesting that the microbiota are potentially transferred from the mother to the fetal gut. 
(145). This study was however limited as similar but significantly higher counts of 
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bacterial colonies in agar plates were observed in samples incubated immediately compared 
to those which were incubated after four days of storage. 
1.5.2 Gut microbiota in early infancy and childhood 
Undoubtedly, neonatal gut maturation and colonisation by gut microbiota is affected by 
maternal gut health. These effects are mediated in pre and peri-natal period by 4 major 
routes 1) trans-placental transfer of maternal blood and growth factors, 2) ingestion of 
amniotic fluid by the fetus, 3) colonisation of the gut microbiota, and 4) maternal breast 
milk (146). The presence of gut microbiota in the amniotic fluids and the umbilical cord 
blood in the absence of any clinical infections or signs of inflammation suggests that 
maternal factors might play a crucial role to help in maturation of fetal immune system for 
the external world.  
In a Norwegian cohort of 86 infants and their mothers, faecal samples were shown 
to exhibit all major components of the commensal gut microbiota within 3 days of life in 
full term infants represented by Escherichia, Bacteroides, Bifidobacteria, other 
Actinobacteria, Faecalibacterium, Lachnospiraceae, Streptococcus, and Lactobacillales. 
The population of gut microbiota shifted in relative abundance in subsequent months up to 
one year of life such as an increase in Bifidobacteria by up to 60% and a reduction in 
Lactobacillales and Streptococci at 4 months of age (147). This study also suggested that  
faecal microbiota of children at first year of life had some resemblance with maternal 
microbiota during early and late pregnancy except that infants at 1
st
 year of life exhibited 
higher amounts of Bifidobacteria and Actinobacteria and lower Faecalibacterium and 
Bacteroides compared to their mothers (147). Although this study gave a global picture of 
the gut microbiota using next generation sequencing, the cohort used was only from 
Norway where feeding patterns are significantly different from the Southern Europe and 
the UK and hence these findings may not translate to the rest of the Europe.  
In the INFABIO study, a large (n=606) multicentre European study, infants at 6 
weeks of age were shown to harbour predominantly Bifidobacteria, followed by 
Bacteroides, Enterobacteria, Clostridium coccoides, Clostridium perfringens, and 
Clostridium difficile measured by FISH and flow-cytometry (148). The proportion of gut 
microbiota differed according to the geographic location (more Bifidobacteria in northern 
Europeans and Bacteroides in Southern Europeans), mode of feeding (more Bifidobacteria 
in breast fed while more Bacteroides, Clostridium coccoides, and Lactobacilli in formula 
fed), and mode of delivery and antibiotic treatment (More Bacteroides and Atopobium 
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cluster in caesarean section and antibiotic treated infants). The same infant cohort followed 
4 weeks after the start of weaning (~17-23 weeks age) showed predominance of 
Bifidobacterium followed by Clostridium coccoides, and Bacteroides. Differences 
according to geography, feeding and delivery mode were observed similar to those 
observed during pre-weaning period (149). In the Dutch KOALA birth Cohort study, by 
Pender et al.(2006) reported detection of Bifidobacteria in all, E. coli and Bacteroides 
fragilis in most, and Lactobacilli and C. difficile in less infants at 1 month of age (150). 
In contrast to findings of Avershina et al.(2013), qPCR based study by Johansson et 
al.(2012) on faecal samples of 13 full term infants at one week and 2 months of age 
suggested an increase in the frequency of Lactobacilli (L. casei, L. paracasei, and L. 
rhamnosus) from ~20% at 1
st
 week to ~50% at two months, Staphylococcus aureus from 
50% to 70%, Bifidobacterium bifidum increased to approximately 55%, while the 
Bifidobacterium breve and B. adolescentis remained stable throughout the 2 months period 
(151). Despite giving a narrow picture of the bacterial frequency, colonisation of S. aureus 
with peripheral blood mononuclear cells resulted in the increased expression of IL-10 and 
IFN-Ɣ which are markers of allergic response. This was decreased in the presence of 
Lactobacillus alone or co-colonisation with Staphylococcus aureus (151). Whether 
Lactobacilli could have a potential beneficial effect in the prevention of allergic disorders 
in earlier life is not known. However, there are reports that non-allergic 5 year old children 
acquired Lactobacilli (Lactobacillus (L. rhamnosus, L. paracasei, L. casei) 
and Bifidobacterium (B. bifidum) in first few weeks of life more often than allergic 5 year 
olds, whereas the opposite tendency was seen for Staphylococcus aureus colonization 
(152). The conclusions from these studies are limited due to differences in the methodology 
and technique of analysis (pyrosequencing vs. qPCR). 
The gut microbiota of the child undergoes modifications to reach adult type at least 
until the age of 4 years with all major gut microbial phyla being represented. Gut 
microbiota communities of children age 4 years resemble those of their mothers at first 
trimester and are over represented by butyrate producing Faecalibacterium and 
Eubacterium, members of Clostridiales and Lachnospiraceae, Ruminococci, Blautia, and 
Bifidobacteria (138). Additionally, similarities have been observed between microbiome of 




1.5.3 Factors determining the colonisation of gut microbiota in human 
colon 
The structure and function of gut microbiota in early life is ―plastic‖ i.e. subject to change 
with a variety of environmental stimuli. Additionally, the gut of new-born, although fully 
formed, is still in the process of maturation to develop immunity against external 
pathogenic stimuli and acquire gut microbiota population that suits the changing gut 
environment of the host (146). Since gut microbiota developed in early life become 
resilient in later life, it is essential to underline factors that affect its colonisation in early 
infancy. Several factors related to mother and the infant are therefore suggested that could 
affect the development of gut microbiota (148, 150) (Table 1.4). However, the evidence is 
inconsistent due to the use of different study designs, methodologies, differences in faecal 
sampling techniques and laboratory analyses which are not accounted for in many studies 
while comparing results with other studies. The actual contribution of these factors 
therefore remains unclear and requires further investigation (148). 
Table 1.4: Factors affecting colonization of gut microbiota in early infancy and childhood 
Factors Changes in the gut microbiota induced in the infant Reference 
Maternal factors 
Pregnancy Increased intestinal permeability, inflammatory markers in faeces, faecal 
energy loss, reduced insulin sensitivity, increased intestinal permeability 
(138) 
Maternal allergy Allergic mother breast milk low in Bifidobacteria. Lower counts of 
Bifidobacterium adolescentis and Bifidobacterium bifidum in maternal 
faeces at 35 weeks gestation associated with lower counts of B. 
adolescentis and B. bifidum in infant at one month age.  
(153) 
Caesarean section Lower Bifidobacteria and Bacteroides and higher C. difficile (150) 
 Delayed detection of Bacteroides fragilis (154) 
 Higher Clostridium coccoides and Streptococcus group (140;141) 
 Delayed colonization of Bifidobacteria and Lactobacilli (154) 
Infant factors 
Gestational age Higher rate of colonisation of C. difficile in premature babies (150) 
Country of birth Higher Bacteroidetes and Actinobacteria in African while higher 
Firmicutes and Proteobacteria, Xylanibacter, Butyrovibrio, and 
Treponema in European children 
(155) 
Place of birth 
(Hospital/home) 
Higher Clostridium difficile in hospital born (155) 
Nutritional status Diminished OTUs in malnourished children, delayed maturity of gut 




Lower Bifidobacteria and Bacteroides with amoxicillin (155) 
 Higher Enterobacteria in antibiotic exposed pre-weaned infants (148) 
Breast or formula 
feeding 
Lower Clostridium difficile and E.coli in breast fed (157) 
 Higher rate of colonisation of E.coli, Clostridium difficile, Bacteroides, 
and Lactobacilli in exclusive formula fed and higher Bifidobacteria in 
breast fed 
(158) 
 Higher Bifidobacteria and lower Bacteroides, C.coccoides, and 




1.5.4 Gut microbiota in adulthood 
Predominant gut microbiota in adults are discussed in section 1.4.1 above. Although gut 
microbiota of individuals are established by the age of 4 years, changes in the community 
structure are observed with variations in conditions such as change of diet, antibiotics, and 
pregnancy. The greatest variability observed in the phylogenetic analysis of gut microbial 
ecology is explained by the inter-individual variation and the sampling site (65).This 
adaptation of gut microbiota to the changing environment on individual basis suggests 
―awareness‖ and capability of gut microbiota to sustain its existence in their hosts in a new 
set threshold. However, changes in the metabolic pathways might affect the host 
physiology and metabolism in either direction (beneficial or harmful to the host). One such 




 trimester of 
pregnancy. Pregnancy is associated with decrease in richness and diversity of gut 
microbiota regardless of pre-pregnancy BMI and health status and an increase in relative 
abundance of Proteobacteria and Actinobacteria from 1
st
 trimester to 3
rd
 trimester by 69.5% 
and 57% respectively (138). This is coupled with significant variation in the relative 
abundance of Bacteroidetes and Firmicutes between individuals. Furthermore, gut 
microbiota in first trimester resemble that of normal healthy non-pregnant adults being 
overrepresented by butyrate producing bacteria such as Faecalibacterium prausnitzii, 
Eubacterium, Blautia, Clostridia and members of Lachnospiraceae. On the other hand, gut 
microbiota in 3
rd
 trimester are aberrant; being overrepresented by Enterococcus faecalis, 
Propionibacterium and Streptococcus genus, Streptococcus faecalis and Tenericutes (138). 
Interestingly these changes in gut microbiota were shown to be driven by pregnancy and 
not by health status as no correlation was found between the relative abundance of specific 
groups with BMI, use of probiotics, antibiotics and diet in the pregnant mothers. 
Whether changes in the gut microbiota are associated with changes in the 
functionality assessed by metagenomics is controversial as studies have shown no 
association of structural differences with changes in expression of genes for 
metabolism(138) while others have shown changes in functionality with differences in gut 
microbiota in aberrant health states such as obesity (159). A comprehensive metagenomic 
analysis of 39 individuals from 6 nationalities by Arumugam et al.(2010) revealed that gut 
microbiota of individuals formed three distinct clusters termed as ―enterotypes‖(160). 
Individual metagenome could be identified as one of the three enterotypes based on the 
variations in one of the three genera: Bacteroides (enterotype 1), Prevotella (enterotype 2), 
 40 
 
and Ruminococcus (enterotype 3). These three enterotypes strongly correlated with the 
presence or absence of many other genera suggesting that each enterotype is driven by 
groups of bacterial species to determine the predominant community structure in an 
individual (160). Additionally, this aggregation was more or less similar when the samples 
were clustered using a functional metric, as enterotype 1 was associated with 
overrepresentation of enzymes in carbohydrate and protein fermentation and biotin 
synthesis, enterotype 2 in mucus  glycoprotein degradation and thiamine synthesis, and 
enterotype 3 in mucus degradation and haem synthesis. A further study by Wu et al. (2011) 
has linked these enterotypes with long term dietary patterns in individuals such that 
enterotype 1 (Bacteroides) were associated with diets rich in protein and fats while 
enterotype 2 (Prevotella) was associated with carbohydrate intake (161). 
1.6 Gut microbiota and obesity 
1.6.1 Initial evidence of the role of gut microbiota in obesity 
The worldwide increase in obesity has prompted researchers to investigate the aetiology of 
obesity which is multifactorial, involving environmental, dietary, life style, genetic and 
pathological factors. Although the gut microbiota were already established as a metabolic 
organ that could ferment indigestible dietary components (particularly complex 
polysaccharides) to generate SCFA, their role as one of the environmental factors that 
could affect host adiposity through an integrated host signalling pathway was explored in 
2004 by Backhed and colleagues (162). 
Male C57BL/6J germ free mice (GF) were conventionalised with unfractionated gut 
microbiota from the caecum of conventionally raised mice (CONV). After 14 days of 
colonisation, conventionalised GF mice had a 57% increase in total body fat content, 61% 
increase in epididymal fat weight, elevated fasting plasma glucose and insulin levels and 
insulin resistance compared to non-conventionalised GF mice. This was in the presence of 
a reduced chow intake, reduced lean mass, and normal fasting triglyceride levels in the 
blood (162). The gut microbiota were shown to stimulate hepatic de novo lipogenesis by 
activating acetyl Co-enzyme A carboxylase and fatty acid synthase via expression of 
carbohydrate response element binding protein (ChREBP) and sterol response element 
binding protein 1 (SREBP1). Lipoprotein lipase is the key enzyme involved in triglycerides 
storage in adipose tissue, liver, and muscles. Conventionalisation of GF mice also resulted 
in an increase in triglycerides storage in the liver by suppressing fasting induced adipocyte 
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factor (fiaf) which is an inhibitor of adipocyte lipoprotein lipase. This inhibition of fiaf was 
not dependent on lymphocytes and PPARγ which are one of the key regulators of 
peripheral triglyceride storage. Together, this break-through evidence suggested that the 
gut microbiota induced adiposity by stimulating hepatic de novo lipogenesis and 
triglyceride storage. Further reviews from the same group proposed that this intestinal 
―high-efficiency bioreactor‖ in certain individuals might promote energy storage (obesity), 
whereas a low-efficiency reactor would promote leanness due to lesser energy harvest from 
complex polysaccharides (64). Differences in the gut microbiota between obese and lean 
people could therefore be one of the aspects for further exploration. 
Differences in the gut microbial ecology and host energy homeostasis between 
obese and lean animals were reported by the same group in another study. Ley et al. (2005) 
analysed 5,088 bacterial 16S rRNA gene sequences in genetically obese leptin-deficient 
C57BL/6J ob/ob mice and lean mice (ob/+ and +/+ wild-type siblings) fed similar 
polysaccharide rich diets (163). Intake of a polysaccharide rich diet was significantly 
higher (40% - 44% higher) in obese ob/ob mice resulting in a significantly greater weight 
gain. Although the gut microbiota communities were shared between mothers and offspring 
regardless of the ob genotype, obese ob/ob mice had a reduction in the relative abundance 
of Bacteroidetes by 50% and a proportional increase in Firmicutes regardless of the kinship 
(163). A higher Firmicutes to Bacteroidetes ratio was therefore suggested to be associated 
with increased energy harvest from food facilitated by the microbiota. However, no 
evidence was presented to show an increased expression of genes related to bacterial 
metabolic activity and how this could be affected by the diverse environmental factors such 
as diet and lifestyle nor whether these changes could also be seen in humans. These 
questions were explored first in an animal model of obesity (159) followed by an 
interventional study for the first time in 12 obese humans subjected to a low- caloric diet 
(164). 
The first part of the question as to whether changes in gut bacterial diversity are 
associated with changes in metabolic potential were addressed by Turnbaugh et al. (2006) 
by whole metagenome shotgun metagenomic and microbiota transplantation studies (159). 
They observed a high Firmicutes rich microbiome in ob/ob mice clustered together (in non-
metric multidimensional scale plot) compared to low a Firmicutes to Bacteroidetes in lean 
mice. The microbiome of ob/ob mice was richer in enzymes for degradation of complex 
polysaccharides including starch compared to lean mice. Ob/ob mice exhibited higher 
faecal concentrations of fermentation end products (high acetate and butyrate) and less 
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stool energy loss as measured by bomb calorimetry. These traits were transmissible, as the 
transplantation of gut microbiota from ob/ob mice or lean mice to germ free mice resulted 
in obese (high Firmicutes) or lean (high Bacteroidetes) gut microbiome in the recipients. 
Obese-microbiome recipients had higher percentage body fat despite similar quantity of 
chow consumption.  
The second; whether these changes could also be seen in humans was investigated 
in another study (164). Obese adults were randomised into fat restricted or carbohydrate 
restricted diet and were followed for a period of one year. Despite the presence of marked 
interpersonal variations at species level diversity of gut microbiota, Firmicutes and 
Bacteroidetes were the predominant divisions representing 92.6% of the known 16S rRNA 
sequences (164). Obese people had a lower relative abundance of Bacteroidetes and a 
higher relative abundance of Firmicutes before the onset of diet therapy. However, over the 
period of follow-up, the relative abundance of Bacteroidetes significantly increased while 
those of Firmicutes significantly reduced. Increased Bacteroidetes was significantly 
positively correlated with percentage loss of body weight and not with the caloric content 
of diet over time (164). This suggested that the gut microbiota restructured by changing 
their metabolic priorities to support co-existence in a changed environment. However, this 
study did not explore the same relationship in a parallel lean group to see whether lean 
phenotype exhibit the same response to dietary intervention. 
Further evidence suggested that the presence of gut microbiota was necessary to 
develop obesity as germ free mice were resistant to obesity even though these animals 
consumed more calories from a normal chow or after the consumption of high fat Western-
type diet as compared to CONV mice (89). Compared to wild-type littermates, high-fat fed 
conventionalised GF mice showed a higher phosphorylated AMP kinase (AMPK-P), 
phosphorylated acetyl coenzyme-A carboxylase  and carnitine palmitoyltransferase 1 
activity, all of which are involved in muscle fatty acid oxidation. Increased peripheral fatty 
acid oxidation results in reduction in triglycerides levels in the tissues protecting GF mice 
against obesity. Additionally, GF mice exhibited higher expression of fiaf in the intestine 
and low serum level of leptin and insulin compared to wild type littermates which is a 
strong inhibitor of lipoprotein lipase activity thus preventing fat storage in adipose tissue 
(89).  
However, the idea of GF mice being resistant to obesity and that gut microbiota 
were a causative factor in obesity was challenged in a later study by Fleissner et al.(2010) 
(165). GF and CONV mice were fed with low fat (LF), high fat (HF) or high-fat Western 
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(WD) ad-libitum diet. Over the period of follow-up, germ free mice on high fat diet gained 
significantly more weight and body fat and had less energy expenditure compared to lean 
CONV mice. Additionally, intestinal fiaf increased in HF and WD fed GF mice compared 
to CONV mice but not in systemic circulation (165). Importantly, both HF and WD diets 
increased the proportions of Firmicutes (especially Erysipelotrichaceae) at the expense of 
Bacteroidetes in CONV mice. This was one of the important evidence to suggest diet as 
one of the factor in affecting gut microbiota diversity. 
In summary, this initial evidence spanning a period of 3 years indicated the role of 
gut microbiota in shaping host energy balance. Several possible mechanisms were 
proposed to explain the impact of structural and functional differences in gut microbiota 
between lean and obese that may contribute to host adiposity and whether an obese 
phenotype is transmissible by transplantation of gut microbiota. However, most of these 
studies were conducted in experimental animals which exhibit anatomical, physiological 
and bacterial colonisation pattern differences in the gut from that of humans. Several 
human and animal based studies have now revealed controversial evidence attributing 
differences in gut microbiota to the differences in diet while others suggested no such 
association. This is discussed further in proceeding sections1.7 and 1.8.  
1.6.2 Proposed mechanisms for the role of gut microbiota in obesity 
The gut microbiota can be regarded as a ―microbial organ‖ contributing to a variety of host 
metabolic processes from digestion to modulation of gene expression. The differences in 
gut microbiota between lean and obese animals or human subjects suggest a role of gut 
microbiota in energy homeostasis. Evidence regarding various mechanisms linking gut 
microbiota to the pathogenesis of obesity and metabolic disorders mainly stem from 
experimental animal studies and some human studies (71). Various mechanisms have been 
suggested to link gut microbiota with obesity-genesis and other metabolic disorders (Table 
1.5). However, it is still unclear how these mechanisms interact with each other to 
influence the overall metabolic status of an individual. 
 
1.6.2.1 Short chain fatty acid production 
As discussed earlier, complex dietary polysaccharides and proteins that escape digestion in 
small intestine are fermented in the colon through glycosyl hydrolases produced by the gut 
microbiota into short chain fatty acids (SCFA) mainly acetate propionate, and butyrate. The 
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amount of energy harvested from this important portion of our diet is hypothesised to be 
determined by the type of microbiota in the gut (64). Up to 10% of our energy needs and up 
to 70% of energy for cellular respiration for the colonic epithelium may be derived from 
short chain fatty acids. A chronic excess energy harvest may therefore impact the long term 
increase in energy accumulation in the body (95).  
By and large there is a general agreement from many studies that the obese 
phenotype is associated with excess SCFA in the caecal and faecal samples in animal and 
human studies compared with the non-obese (Table 1.6). Furthermore, there is a 
considerable disagreement and controversy over the population of the gut microbiota that 
may be associated with increased SCFA measured in the caecum or faeces (Table 1.6). 
Whether increased SCFA result in increased energy harvest from the diet in obese 
phenotype depends on several factors such as substrate availability, gut transit, mucosal 
absorption, general gut health, production by the gut microbiota and symbiotic 
relationships between different groups of gut microbiota (166). 
As mentioned above, the obese phenotype is associated with higher total caecal 
SCFA, acetate, and butyrate and higher expression of genes responsible for polysaccharide 
metabolism (159). Increased efficiency in the production of SCFA in obesity might also 
result from cross-talk between different species and genera to maintain their growth and 
population. A classic example of these cross-feeding pathways is between methanogenic 
archaea (hydrogen consuming bacteria) and members of Prevotellaceae (hydrogen gas 
producing bacteria) harboured in excess by obese subjects (167). Hydrogen is constantly 
generated as a result of fermentation process and the excess of residual hydrogen in the 
colon inhibits the fermentation process if accumulated in excess. This excess residual 
hydrogen is removed by three routes; mainly by the reduction of CO2 to generate acetate, 
or in some cases utilization by the sulphate reducing bacteria (SRBs) to generate sulphide, 
or utilization by methanogenic archaea to generate methane. Methanogenic bacteria in 
some obese individuals have been shown to hydrolyse this residual hydrogen produced by 
the action of Prevotellaceae to accelerate the fermentation of plant polysaccharides causing 
increased energy harvest from the diet (167). Absorption of these excess SCFA, coupled 
with other lifestyle and environmental factors may result from excess energy storage and 
obesity. It is not clear whether this is an effect of substrate (i.e. carbohydrates) or the 
population of specific gut microbiota that is associated with increased SCFA production, 
absorption, and storage in adipose tissues and liver. The results are largely confounded by 
the study settings, lifestyle, and environmental factors of the study subjects. 
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Table 1.5: Suggested mechanisms for the role of gut microbiota in the aetiology of obesity. 
AMP; Adinosine monophosphate, ChREBP; carbohydrate response element binding protein, SREBP; Sterol response element binding protein, PYY; peptide YY
 Proposed mechanism Agents involved Site of 
Production  
Site of action  Outcomes for the host  
Metabolic 
(162) 
Increased production of 







↑energy harvest  
Energy for colonocytes. 
Alteration in cholesterol 
metabolism 
 Muscle fatty acid oxidation ↓AMP kinase Small intestine Muscle, liver ↓Muscle fatty acid oxidation 
 Bile acid circulation Secondary bile acid 
production 
Colon Colon Reverse cholesterol transport 
 Expression of liver 
ChREBP/SREBP-1 
↑glucose absorption  Liver Liver ↑Hepatic lipogenesis 
Inflammatory 
(168) 
Chronic low grade 
inflammation 
LPS, NF-kappaB and 
TNFα mRNA  
Colon, ileum Endothelium, 
hypothalamus? 
Metabolic endotoxemia and 
hyperphagia 
 ↑Endocannabinoid (eCB) 
system tone 
Bacterial LPS Ileum, colon Stomach, small 
and large 
intestine 
↑ Gut permeability and ↓Apelin 
and APJ mRNA expression 
Hormonal 
(162) 
Suppression of Fiaf Colonic L-cells Colon Adipose tissue ↑Lipolysis, ↓ muscle fatty acids 
oxidation 
 ↑PYY Satiety centre Ileum, colon Hypothalamus ↓ Appetite, ↓ gastric motility, ↓ 
gut emptying 
 Expression of G-Protein 
coupled receptors 41 & 
43(GPRs 41 &43) 








Table 1.6: Studies looking at differences in SCFA in faecal or caecal samples in obese versus lean phenotypes in animal and human studies 
Reference Technique Used SCFA Differences Gut microbiota differences 
Turnbaugh et al 2006 
(159) 
GC-MS, Pyrosequencing  ↑caecal acetate and ↑ butyrate in obese ob/ob 
mice compared to lean 
↑ Firmicutes and lower Bacteroidetes in obese than lean 
mice. No differences in genera level diversity 
Duncan SH et al 2007 
(166) 
GC and FISH ↓total SCFA and↓ butyrate in obese adults on 
high protein medium CHO or high protein-low 
CHO diet 
↓ in close relatives of Roseburia intestinalis and 
Eubacterium rectale. 
Zhang et al 2009 
(167) 
GC, qPCR, and 
Pyrosequencing  
↑ acetate in obese than lean and gastric bypass 
group 
↑ M. smithi and Prevotellaceae in obese than lean and gastric 
bypass 
Schwiertz et al 2010 
(175) 
GC and qPCR with SYBR 
Green 
↑ total SCFA and Propionate (conc. & %) in 
obese than lean 
↑ Bacteroides and ↓ Firmicutes,↓ Ruminococcus flavifaciens, 
↓Bifidobacterium, ↓Methanobrevibacter in obese than lean 
De Fillipo et al 2010  
(155) 
454 FLX pyrosequencing 
and SPME-GCMS 
↑ total SCFA and ↑ Propionate and ↑ butyrate in 
African children than EU children. Acetic and 
valeric acids were comparable (conc. & %) in 
obese than lean 
↑Actinobacteria and ↑ Bacteroidetes in high fibre African 
children. 
↑ Firmicutes and ↑ Proteobacteria in EU children. 
Prevotella, Xylanibacter, Butyrovibrio,  and Treponema 
exclusively found in African children 
Payne et al 2011  
(169) 
qPCR, TGGE, and HPLC ↑ Butyrate, propionate, and iso-butyrate in obese 
than lean. 
↑ Lactate and valerate in Lean than obese 
No difference in acetate and total SCFA 
No difference in Firmicutes and Bacteroidetes, 
Firmicutes/Bacteroides ratio, Bifidobacteria, 
Enterobacteriaceae, Sulphate reducing bacteria between lean 
and obese children 
↑ Roseburia/E.rectale in obese 
Highly variable banding pattern on TGGE for both obese and 
healthy 
Kim et al 2013 
(170) 
SPME-GCMS and 454 
pyrosequencing of v1-v2 
regions 
↓total SCFA, ↓ acetate, ↓ propionate, ↓ butyrate 
in obese adults on strict vegetarian diet for 28 
days  
After 28 days; ↓Firmicutes, ↑ Bacteroidetes, 
↓Firmicutes/Bacteroidetes ratio, ↓Escherichia, ↓Klebsiella, ↓ 
Veillonella parvula, ↓ C. Clostredioforme, ↓Lactobacillus 
ruminis, ↓ L. mucosae, ↓ Strept. lutetiensis 
Larsen et al 2013 
(171) 
qPCR and capillary gas 
chromatography 
No difference in SCFA between placebo group 
and lactobacillus salivarius intervention group 
(12 weeks) 
No significant difference in bacterial cell numbers with 
intervention. 
 ↑ ratio of Bacteroides-Prevotella-Porphyromonas vs. 
Clostridium cluster XIV-C.coccoides-E.rectale group  
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Yang et al 2013 
(172) 
GC ↑ ratio of molar propionate: total SCFA and  ↓ 
actate:SCFA ratio in obese vs. lean 
Not measured 
Taxairia et al 2013 
(173) 
GC ↑ acetate, propionate, and butyrate in obese vs. 
lean women 
SCFA correlated with body fat, blood pressure, 
waist circumference, insulin and HOMA index 
Not studied 
Belobradjic et al 2013 
(174) 
GC Increase in total SCFA pool and stool energy 
irrespective of obese or lean phenotype  
Not studied 
Rahat et al 2014 
(175) 
GC ↑ total SCFA, acetate, butyrate in obese than 
lean 
No differences in iso-butyrate, iso-valerate, and 
valerate 
↑ Firmicutes: Bacteroidetes ratio in obese. Firmicutes 
correlated with SCFA in obese 
Fernandes et al 2014 
(176) 
GC, qPCR Significantly ↑ propionate and valerate 
Marginally ↑ acetate and butyrate 
Escherichia coli higher in lean than obese 
No difference in Bacteroides/Prevotella, Clostridium 
coccoides and C. leptum group, Bifidobacteria and total 
bacteria, F/B ratio 
Li et al 2013  
(113) 
GC Higher SCFA in obese than lean ↑ Firmicutes and lower Bacteroidetes in obese 
GC; gas chromatography, GC-MS; gas chromatography-mass spectrometry, SPME-GCMS; solid phase microextraction-gas chromatography mass spectrometry, v1-v2; 
variable region 1 and 2, HPLC; high performance liquid chromatography, TGGE; temperature gradient gel electrophoresis, CHO; carbohydrate, EU; European Union, qPCR; 




1.6.2.2 Gut microbiota and G protein coupled receptors 
SCFAs including acetate, propionate, and butyrate act as ligands for the expression of G 
protein coupled receptors 43 and 41 (GPR41 &43). GPR41 &43 are expressed by the gut 
epithelial cells, endocrine cells, and adipocytes. GPR43 receptors in white adipose tissue 
have been shown to act as sensors of post-prandial energy excess and regulate energy 
expenditure and hence, body energy homeostasis. GPR43 and GPR41 enhance insulin 
sensitivity and activate the sympathetic nervous system at the level of ganglion to prevent 
excess energy deposition in adipose tissue and enhance energy expenditure in other tissues 
such as liver and muscles (177). GPR43 deficient mice have metabolic abnormalities 
including excess fat accumulation. When treated with antibiotics or under germ free 
conditions, these metabolic abnormalities have been shown to reverse which suggests that 
the gut microbiota are key players in the expression of these receptors (177). Samuel et 
al.(2008) demonstrated that GF mice deficient in GPR-41 genes remain lean compared 
with their wild type counterparts, although their body composition was not different(178).  
SCFAs bind to GPRs to stimulate leptin expression in mouse-cultured adipocytes. 
Propionate and butyrate act specifically on GPR41. In a mouse model of GPR41-/- and 
GPR41+/+ mice compared with wild type conventionalised and wild type germ free mice, 
Samuel et al. (2008) showed that GPR-41 stimulates the expression of the gut anorexigenic 
hormone, Peptide YY (PYY), which in turn causes inhibition of gastric emptying, reduced 
intestinal transit time (measured by flourescin isothiocynate labelled dextran), increased 
energy harvest (in the form of caecal acetate and propionate), and increased hepatic 
lipogenesis (178). The gut microbiota also convert primary bile acids into secondary bile 
acids which stimulate the secretion of another incretin hormone from intestinal K cells,  
called glucagon like peptide-1 (GLP-1), which regulate satiety through gastric vagal 
afferent signals to the satiety centre, reduce gastric emptying, and also acts on the pancreas 
and stimulates secretion of insulin (179).  
However, in vivo studies have reported several controversies regarding the role of 
GPR43 in energy homeostasis. Some studies showed GPR43 mediated increased 
expression of GLP-1 from intestinal L-cells enhancing insulin sensitivity (180), while 
others suggested enhanced insulin sensitivity and reduction in metabolic dysfunction 
associated with GPR43 deficiency through unknown mechanisms (181). The differences 
between studies might be attributed to the differences in the colonisation of gut microbiota 
influenced by the genetic background of the mouse models, different environmental 
conditions (conventional versus specific) and strains of animals used in the study (177). 
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Overall, this evidence suggests that a selective increase in the gut microbiota may affect 
hormonal status of individual via G-protein coupled receptors. These hormonal changes 
bring a change in satiety, food intake, metabolic inflammatory markers, and ultimately 
metabolic endotoxemia that are a hallmark of the metabolic syndrome including obesity. 
1.6.2.3  Gut microbiota and fasting induced adipocyte factor 
Fasting induced adipocyte factor or angiopoitein-like protein 4 (Fiaf/ANGPTL4) is a target 
gene for peroxisome receptor activated proteins (PPARs) and is produced by large 
intestinal epithelial cells and liver. Fiaf/ANGPTL 4 inhibits lipoprotein lipase (LPL) which 
causes the accumulation of fat in peripheral tissues. Inhibition of fiaf by the gut microbiota 
with a resultant increase in LPL may be one of the mechanisms of gut bacterial induced 
host adiposity (162). This is further supported by studies on GF mice, genetically deficient 
in Fiaf genes (fiaf -/-). Lack of the fiaf gene causes dis-inhibition of LPL which leads to the 
deposition of up to 60% higher epididymal fat compared to germ free wild type littermates 
expressing fiaf genes (fiaf +/+). Fiaf/ANGPTL4 is therefore involved in the regulation of 
fat storage mediated by the gut microbiota. Controlled manipulation of the gut microbiota 
may alter the expression of this hormone as shown in a study by Aaronson et al. (2010) 
(182). Normal weight SPF C57B/6J mice were fed either with high fat (20%) diet or high-
fat diet supplemented with probiotic Lactobacillus paracasei F19 for 10 weeks. Compared 
to non-supplemented group, plasma fiaf/ANGPTL4 was found to be up-regulated in 
Lactobacillus paracasei F19 supplemented group with significantly elevated plasma VLDL 
lipoprotein and no change in cholesterol levels (TG, VLDL, LDL and HDL). In another 
study, Lactobacillus paracasei F19 and Bifidobacterium lactis BB12 was found to up-
regulate ANGPTL4 in colon carcinoma HCT116 cell line in a dose and time dependent 
manner while Bacteroides thetaiotaomicron did not have any effect (182). In another 
experiment in the same study, the authors fed germ free (GF) NMRI mice with normal 
chow and exposed them to F19. They found an increasing trend of ANGPTL4 in the serum 
after 2 weeks of colonization, while the effect could not be observed with heat killed F19 
(182). This study suggested that manipulation in the expression of fiaf/ANGPTL4 is 
dependent on the presence of gut microbiota and that future interventional studies on 
weight management can be based on modification of ANGPTL4 by manipulating gut 
microbiota. 
Whether the increase in levels of fiaf in systemic circulation and the subsequent 
suppression of LPL and fat storage is associated with a change in gut microbiota has been 
questioned in some studies as the authors found no difference in fiaf in serum of both GF 
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and conventionally-raised mice (165). Germ-free (GF) and conventional (CV) mice were 
fed on low fat diet (LFD), high fat diet (HFD), and commercial high-fat Western diet 
(WD). GF mice gained more weight and body fat than CV mice on HFD and vice-versa on 
WD. Although Intestinal Fiaf/ANGPTL4 was high both in GF mice on HFD and WD, 
circulating levels of fiaf did not change significantly as compared to CV mice. Gut 
microbiota changed differently with HFD and WD in CV mice. These observations 
suggested that diet affects the type of gut microbiota population in the gut, and that fiaf 
does not play a major role in peripheral fat storage as mentioned by other studies. 
In summary gut microbiota-dependent-production of fiaf/ANGPTL4 inhibits 
lipoprotein lipase which is responsible for storage of lipids in peripheral tissues. The 
evidence however remains controversial. 
1.6.2.4  Gut microbiota and fatty acid oxidation 
Gut microbiota are thought to reduce muscle and liver fatty acid oxidation by suppressing 
adenosine monophosphate kinase (AMPk), an enzyme in the liver and muscle cells, that 
acts as a fuel gauge monitoring cellular energy status. Inhibition of AMPk results in a 
reduction in muscle and liver fatty acid oxidation ultimately leading to excess fatty acids 
storage in these tissues (162). 
Phosphorylated AMPk inhibits the formation of malonyl Co-A via acetyl Co-A 
carboxylase. Inhibition of malonyl Co-A causes dis-inhibition of Carnitine Palmitoyl 
transferase-1 (Cpt-1) which in turn catalyses the rate limiting step in the entry of long chain 
fatty acyl-CoA into the mitochondria for fatty acid oxidation(183). Increased fatty acid 
oxidation is associated with enhanced cellular energy status coupled with glycogen level 
reduction, and increase insulin sensitivity (183). 
Germ free mice lacking gut microbiota have a consistently raised level of 
phosphorylated Acetyl Co-A carboxylase (Acc) and carnitine palmitoyl transferase-1 (Cpt-
1) activity in gastrocnemius muscles and raised AMPk in liver and skeletal tissue compared 
to CONV mice (89, 184). This effect has also been observed with high calorie diet 
suggesting that enhanced or suppressed muscle fatty acid oxidation is dependent on the 
presence or absence of gut microbiota. Gut microbiota may therefore impact the storage of 
peripheral adipose tissue and hence affect host adiposity by inhibiting fatty acid oxidation. 
1.6.2.5 Gut microbiota and bile acids circulation 
Bile acids secreted by the liver are one of the important contributors to the digestion and 
absorption of fats as they cause emulsification of dietary fat consumed. Bile acids, 
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cholicand chenodeoxycholic acids are conjugated by glucuronosyl-hydrolases in the small 
intestine to deoxycholic and lithocholic acids respectively. Primary bile acids (cholic and 
chenodeoxycholic acids) are ligands for Fernesoid x receptor (FXR) which has been shown 
to play a key role in the control of hepatic de novo lipogenesis, very-low-density 
lipoprotein-triglyceride (VLDL) export and plasma triglyceride turnover leading to 
improved lipid and glucose metabolism(185). By binding to FXR in ileal cells, bile acids 
are able to stimulate the expression of genes (Asbt, IBABP, and Ost α/β) which help in 
absorption, intracellular transport, and systemic transport of bile acids into the liver by 
enterohepatic circulation (Figure 1.6). Studies on germ-free and FXR deficient mice have 
shown that the expression of genes responsible for the uptake, transport and export of bile 
acids into circulation after ileo-caecal resection is dependent on gut microbiota (186). 
Primary bile acids are converted to secondary bile acids in the distal ileum and large gut by 
gut microbiota into secondary bile acids. Secondary bile acids are ligands for G protein 
coupled receptor-5 (TGR5) which helps in glucose homeostasis by stimulating the 
expression of Glucagon Like pettide-1 (GLP-1) (187, 188). Studies in animal models using 
TGR5 agonist have shown a reduction in serum and hepatic triglyceride levels. Gut 
microbiota may therefore affect host hepatic adiposity by altering bile acid circulation via 
FXR and TGR5 mechanisms. However, it is also suggested that bile acids may reciprocally 
affect the gut microbiota through its bactericidal activity as it can damage the microbial cell 
membrane phospholipid (189). High fat diet induced stimulation of bile acids into the gut 
may therefore alter the normal gut microbial population causing dysbiosis (190). 
1.6.2.6 Gut microbiota and changes in satiety (gut-neural axis) 
Gut microbiota, through the production of SCFA, may affect host energy metabolism and 
the development of obesity by changing the hormonal milieu in the intestine and other 
visceral organs (Figure 1.7). Glucagon like peptide-1 (GLP-1) plays a key role in regulating 
communication between the nutritional load in the gut lumen and peripheral organs such as 
brain, liver, muscle and adipose tissue by post-prandial  increases in satiety, increasing gut 
transit time, and incretin induced  insulin secretion (191). Secretion of GLP 1 is decreased 
in obesity secondary to weight gain which causes insulin resistance independent of 
circulating level of fatty acids (191). Gut microbiota regulate GLP-1 by influencing the 
expression of its precursor, pro-glucagon and increasing GLP-1 positive entero-endocrine 
L-cell in the gut (192). GF mice in this study expressed a higher GLP-1 secretion in the 




Figure 1.6: Modulation of bile acid circulation by gut microbiota and its effect on glucose metabolism. 




GPCR- TGR5; G protein coupled receptor TGR5, VLDL; very low density lipoprotein, TG; triglycerides, 
GLP-1; glucogon like peptide 1, FXR; fernesoid x receptor 
 
Conventionalization of the GF mice with gut microbiota resulted in a significant decrease 
in both pro-glucagon and L-cell number after 24 to 72 h. These effects were induced by 
SCFA (independent of the type of SCFA) which are fermentation products of the gut 
microbiota(192). 
Certain groups of gut bacteria such as Bifidobacteria have been reported to be 
inversely related to the development of fat mass, glucose intolerance, and bacterial 
lipopolysaccharide (LPS) level in the blood. Intervention with prebiotics such as dietary 
fructans stimulates the growth of Bifidobacteria species (184). These effects are mediated 
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by the stimulation of hormones PYY and ghrelin. High Intake of prebiotics oligofructose 
(21 g/day) has been shown to reduce weight accompanied by increased PYY and reduced 
Ghrelin consistent with a reduced food intake in the prebiotics group (193). A randomized 
double-blind placebo-controlled trial on 10 healthy adults (5 male, and 5 females) 
randomized into 16 g fructose/day or 16 g dextrin maltose/day group for 2 weeks, showed 
an increase in breath hydrogen (a marker of colonic bacterial fermentation) and increased 
production of satiety hormones PYY and GLP-1 (179). Similar results were observed in 
experimental studies where feeding ob/ob mice with oligofructose resulted in increased 
Lactobacillus species, Bifidobacteria species and Clostridium coccoides-Eubacterium 
rectale cluster in association with reduced intestinal permeability as shown by increased 
Zonula Occludin-1 expression and reduced inflammatory markers (194).  
Figure 1.7: Proposed mechanism of the changes in gut hormonal axis by gut microbiota. 
 
 
TG; Triglycerides, LPL; lipoprotein lipase, Fiaf; fasting induced adipocyte factor, ANGPTL-4; angiopoitein 
like protein-4, GLP-1; glucagon like peptide 1, GPR43 & 41; G-protein coupled receptor 43 & 41, PYY; 
peptide YY, SCFA; short chain fatty acids. Minus sign indicate inhibitory effect, plus sign indicate 
stimulatory effect. 
1.6.2.7  Gut microbiota and intestinal permeability –chronic low grade inflammation 
Emerging evidence suggests close ties between metabolic and immune systems 
(195).Obesity contributes to immune dysfunction by secretion of inflammatory adipokines 
from adipose tissues such as TNFα, IL-6, and leptin (196). The inflammatory adipokines 
induce carcinogenic mechanisms such as increased cellular proliferation and/or 
dedifferentiation that are potential risk factors for various cancers such as colonic, 
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oesophageal and hepatocellular cancers. An example of this is the association of high levels 
of leptin with hepatocellular carcinoma (196). Intra-abdominal adipose tissue secretes 
adipokines with atherogenic properties (IL-1, IL-6, TNF-α, IFN-α) which increase the risk 
of cardiovascular diseases (197). These proinflammatory cytokines also activate certain 
kinases, which in turn initiate the expression of inflammatory and lipogenic genes, 
ultimately increasing inflammation and adipogenesis in a loop fashion (Figure 1.8).  
Bacterial lipopolysaccharide (LPS) and inflammation 
Gut microbiota have been suggested to contribute to chronic low grade inflammation and 
obesity via the absorption of bacterial lipopolysaccharide (LPS). LPS is an outer membrane 
protein of Gram negative bacteria, and is increasingly recognized as a player in chronic low 
grade inflammation, a hallmark of obesity. 
Cani et al. (2007) demonstrated the link between LPS and metabolic disease by infusing 
bacterial LPS subcutaneously into germ free mice for 4 weeks which produced the same 
level of metabolic endotoxemia as by high fat diet (168). Furthermore, mice lacking 
functional LPS receptors were resistant to these changes. Feeding high fat diet to mice with 
mucosal immune dysfunction (Toll-Like Receptor-4 knockout mice) for 4 weeks resulted 
in two to three times increased systemic LPS levels in liver, adipose tissue and muscles, 
and higher body fat mass, termed as ―metabolic endotoxemia‖ (168). This inflammatory 
status was associated with lower Bacteroides, Bifidobacterium species, Eubacterium 
rectale-Clostridium coccoides group (168). Additionally, LPS stimulated markers of 
inflammation (e.g. plasminogen activator inhibitor 1 & tumour necrosis factor alpha) and 
oxidative stress (e.g. lipid peroxidation) in visceral adipose tissue via CD14 receptor. 
Absence of CD14 in CD14 deficient ob/ob (CD14 -/-) mice has been shown to protect 




Figure 1.8: Proposed model for the role of LPS in generating inflammation and its relationship with 
obesity. Concept adapted from(168, 194, 195, 198). 
 
 
Altered mucosal barrier function due to reduced expression of Glucagon like peptide- 1 &2 (GLP- 1&2) leads 
to altered mucosal function and reduced synthesis of tight junction proteins, Zonula Occludin-1&2 (ZO-
1,ZO-2) increasing gut permeability. This allows LPS to enter the systemic circulation inducing the release of 
pro-inflammatory cytokines. Proinflammatory cytokines result in activation of a family of kinases JNK and 
IKK (Inhibitor of NFkB Kinase) that increase the expression of inflammatory and lipid metabolism genes. 
Subcutaneous administration of LPS, hyperglycaemia and insulin resistance induces the same pathway by 
increasing the Endoplasmic reticulum and mitochondrial stress. Type-2 diabetes, hyperglycaemia, and insulin 
resistance also cause macrophage infiltration and inflammatory cytokine release leading to the same process. 




Gut Barrier integrity and inflammation 
The gut lumen is separated from the blood by a gut epithelial barrier that is composed of 
the series of layers starting from mucosal epithelium to basement membrane, submucosal 
tissue, lamina propria, muscularis propria, and the endothelium of blood vessels or central 
lacteals. Tight junctions between epithelial cells act as a barrier to the paracellular transport 
of nutrients and other biomolecules including the microbes into the circulatory system, 
limiting the transport based on charge and size of the molecules. These tight junctions are 
formed by complex network of proteins including Occludin and Zonula Occludin-1 (ZO-1).  
Alteration in gut microbiota is linked to an altered gut barrier function (194) and may 
promote the release of bacterial endotoxins through the damaged and leaky gut. Cani et 
al.(2007) showed a significant reduction in the population of Bifidobacteria with high fat 
diet in male C57BL/6J mice (184). Supplementation with prebiotic oligofructose was 
shown to restore the Bifidobacteria population with improvement in the gut barrier 
function evidenced by the expression of precursors of GLP1, proglucagon mRNA and 
decrease in endotoxemia (184). No correlation was found between endotoxemia and other 
bacteria (Lactobacilli/Enterococci, E. rectale/C.coccoides, Bacteroides, and sulphate 
reducing bacteria) measured in their study (184). GLP-1 helps in the differentiation of 
mucosal cells into enteroendocrine L-cells, while GLP-2 helps in increased expression of 
mRNA for synthesis of tight junction proteins. These changes are associated with lower 
LPS levels in the blood suggesting increased integrity of the gut barrier function. In 
contrast treatment with antibiotics has been shown to reduce inflammation by reducing the 
LPS-producing gut microbiota population, further elucidating the relationship between gut 
microbiota, LPS levels, and inflammation (194). 
High fat diet and inflammation 
As mentioned earlier, obesity is a state of chronic low-grade inflammation and generally 
obese people consume a high-fat diet. The association of high fat-diet with sub-clinical or 
clinical inflammation in obesity has been investigated in several studies and there is a clear 
evidence to suggest that consumption of high fat diet is associated with metabolic 
endotoxemia and 2-3 fold increase in bacterial LPS levels in the blood. This was shown in 
experimental animals by Cani et al.(2007) (168). However, it is controversial whether this 
chronic low-grade inflammation is dependent on the gut microbiota. Cani et al.(2007) 
found a dramatic change in gut microbiota (reduced Lactobacillus, Bacteroides Prevotella 
and Bifidobacteria species) of obese ob/ob mice fed high-fat diet (184). This was 
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associated with an increase in gut permeability indicated by a reduced expression of 
Occludin and ZO-1 tight junction proteins. 
In contrast, de La Serre et al.(2010) suggested that high fat diet induced intestinal 
inflammation in obese Sprague- Dawley rats may cause hyperphagia and obesity by 
impairing the regulation of food intake. However, changes observed in the gut microbiota 
were independent of lean and obese phenotype (199). On ingestion of a high-fat diet for 8 
or 12 weeks, Sprague-Dawley rats emerged in two genetically distinct groups, diet induced 
obesity resistant rats (DIO-R) which were resistant to diet induced obesity, and diet 
induced obesity prone (DIO-P) rats, which were prone to diet induced obesity on feeding 
high fat diet. DIO-P rats had significantly increased gut permeability, increased LPS levels, 
lower intestinal alkaline phosphatase (iAP) levels (which detoxifies LPS),and systemic 
inflammation (high Toll-Like Receptor-4/Mitogen Detector-2 protein immunoreactivity) 
compared to DIO-R rats(199). Activation of TLR4 by LPS via MD-2 results in the 
production of an inflammatory cascade (IL6 and TNF alpha) (200)ensuing metabolic 
endotoxemia. Mice with genetic deficiency of TLR4 do not develop diet induced 
obesity(201). This series of changes associated with high fat diet inducing inflammation 
may alter food intake regulation and trigger hyperphagia, the mechanism of which is yet to 
be fully understood (212). 
In summary, changes in the gut microbiota are associated with changes in the 
expression of GLP-2 which in turn leads to altered permeability of the gut epithelium, 
higher level of LPS in the blood, chronic low-grade inflammation, and metabolic 
endotoxemia. The association of obese or lean gut microbiota with inflammation is 
however controversial (168, 198, 202-209) (Figure 1.8). 
1.6.2.8  Gut microbiota and endocannabinoid receptor system 
Cannabinoid receptor 1 and 2 (CB1 & CB2) are G proteins activated by the 
endocannabinoid (eCB) system. The eCB system is composed of endogenous lipids and 
plays an important role in adipogenesis, as studied in genetically obese mouse models. Two 
of the most widely studied lipids in the eCB system are; N-arachidonoylethanolamine, and 
2-Arachidonoylglycerol. Obesity and type-2 diabetes are associated with a higher tone of 
eCB system. Furthermore, the expression of CB1 and CB2 degrading enzymes (Fatty acid 
amide hydrolase) is increased in adipose tissue of obese ob/ob mice as compared to lean 
mice (194). 
Bacterial LPS regulates the expression of cannabinoid receptors via the LPS 
receptor signalling system shown in both in vitro and in vivo studies (209). This increased 
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tone is represented by increased levels of the precursor enzymes N-
acylphosphatidylethanolamine-selective phospholipase-D, CB1 mRNA and increased eCB 
components in plasma or adipose tissue(209). Using CB1 receptor antagonists in ob/ob 
obese mice with disrupted gut barrier and metabolic endotoxemia has been shown to 
improve gut permeability and reduce body weight, compared with lean littermates(209). 
The gut microbiota therefore regulate the activity of the eCB system and play an important 
role in host energy regulation. 
 A study by Geurts et al. (2011) in obese leptin resistant db/db mice suggested that 
the abundance of several taxa of Gram negative bacteria, higher Firmicutes, higher 
Proteobacteria, and lower Bacteroidetes were correlated with up-regulation of apelin and 
APJ expression. This was shown to be the result of direct action of bacterial LPS on the 
expression of apelin and APJ mRNA in obese diabetic mice through chronic low-grade 
inflammation (204).These newly discovered adipokines are widely expressed in 
mammalian tissues. Apelin is a ligand for APJ, a G-protein coupled receptor. Apelin/APJ 
system plays a key role in the cardiovascular system by acting on heart contractility, blood 
pressure, fluid homeostasis, vessel formation, and cell proliferation. Apelin also affects 
glucose homeostasis by acting through AMP kinase and nitric oxide (NO) dependant 
mechanisms (210). Endocannabinoid system down-regulates the expression of apelin and 
APJ mRNA in physiological conditions. In contrast, higher levels of apelin and APJ 
mRNA have been found in pathological conditions such as obesity and diabetes (204). 
In summary, bacterial LPS increase the tone of eCB system, and increase the expression of 
Apelin/RPJ system in adipose tissue. However, how far gut microbiota population 
contribute to the actions of eCB and apelin/APJ and eCB in obesity is unknown. This has 
opened yet another area of interest about the role of gut microbiota in obesity. 
1.7 Review of animal studies relating gut microbiota with 
obesity 
The evidence from animal studies has thus far concentrated on studies which looked at the 
interplay of diet, gut microbiota and metabolic changes (changes in energy balance, 
lipoproteins, cholesterol etc.) in different animal models such as wild type mice, leptin 
deficient ob/ob mice, and Sprague-Dawley rats. These studies have concentrated on how 
changes in diet and differences in gut microbiota composition affect the efficacy of gut 
bacteria to extract energy from various carbohydrates, changes in hormonal status, changes 
in the levels of hepatic enzymes, expression of obesity-related genes and local and systemic 
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levels of inflammatory mediators. Some of the proposed mechanisms were discussed in the 
section above. However, several animal and human studies found conflicting evidence for 
the causative role of the gut microbiota in obesity.  
1.7.1 Evidence from animal studies; Gut microbiota as a cause of obesity 
Initial evidence suggesting the role of gut microbiota in the aetiology of obesity was 
explored in a series of studies using germ free and CONV mice. This was discussed in 
detail in section 1.6.1. The role of the gut microbiota in the aetiology of obesity was also 
explained through mechanisms that are only partly understood (Table 1.5). Differences in 
gut microbiota are therefore anticipated between lean and obese phenotype at three distinct 
levels as suggested by several animals models of obesity.  These include 1) compositional 
differences, 2) functional differences in the expression of genes for metabolic pathways, 
and 3) the property of transmissibility of the phenotype.  
Phylum level compositional differences in the relative proportions of the gut 
microbiota were seen in initial studies suggesting higher Firmicutes and lower 
Bacteroidetes in obese vs. lean mice (Table 1.7) (159, 162, 163).Although differences 
between lean and obese animals at species and genera level vary between studies, there is a 
general agreement on reduced diversity and richness of gut microbiome in obese vs. lean 
animals.  
TLR5 knockout mice have been shown to develop hyperphagia and features of 
metabolic syndrome due to lack of an immune response to the bacterial flagellin. TLR5 is a 
ligand for bacterial flagellin which then activates an immune response to these bacteria. 
This lack of immune response in TLR5 knockout mice allows bacterial endotoxin to 
destroy tight junction proteins which may lead to metabolic endotoxemia, hyperphagia, and 
metabolic syndrome. Germ free mice did not exhibit these changes due to lack of gut 
bacteria but developed the same features after they were transplanted with faecal material 
from the TLR-5 deficient mice. Interestingly, 16SrRNA sequencing of bacterial diversity in 
TLR5 knock-out mice revealed a significantly reduced ratio of Bacteroidetes vs. Firmicutes 
against wild-type littermates (217). These observations show that components of gut 
microbiota may act as triggering factors to the development of metabolic syndromes 
including obesity. Diet-induced obesity-prone mice (DIO-P) develop obesity on a high fat 
diet and have also been shown to harbour higher Firmicutes and lower Bacteroidetes than 
mice which are resistant to developing obesity (DIO-R) on high-fat diets. This is coupled 
with capability of DIO-P mice to absorb carbohydrates more efficiently than lean DIO-R 
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mice (211) suggesting that the peculiar compositional differences alter the host response to 
prioritise its metabolism towards increased energy harvest. 
Compositional differences in the gut microbiota between obese and lean phenotypes 
extend to the functional differences in the expression of genes capable of maintaining an 
obese or lean state. For example, gut microbiota of obese twins transplanted to lean mice 
not only caused obesity but also exhibited higher expression of genes involved in 
detoxification and stress response, biosynthesis of cobalamin, essential and non-essential 
amino acids and gluconeogenic pathways. In contrast, animals with lean- transplanted 
microbiota exhibited genes capable of fermenting plant polysaccharides and producing 
butyrate, and propionate (212). Additionally, the mere presence of the gut microbiota in 
conventionally raised mice compared to the amicrobiotic environment in germ-free mice 
has been shown to result in higher levels of energy metabolites such as pyruvic acid, citric 
acid, fumaric acid, malic acid, and higher rate of clearance of cholesterol and triglycerides 
(213). These studies suggest that the presence of the gut microbiota is essential for the 
characteristic metabolic outlook of a species. Won et al. (2013) found significant 
differences in urinary and serum metabolites between lean and obese C57BL/6J mice 
(214). Of many metabolites measured by H-NMR spectroscopy, 48 urinary and 22 serum 
metabolites were significantly up-regulated in obese compared with lean mice. These 
metabolites were involved in amino acid metabolism (particularly branched amino acids), 
tricarbolic acid and glucose metabolism (pyruvate, citrate, acetoacetate, glycolate, and 
acetone), lipid metabolism (cholesterol and creatinine), creatine metabolism (creatine and 
creatinine), and gut microbiome-derived metabolism (choline, trimethylamine N-oxide, 
hippurate, p-cresol, isobutyrate, 2-hydroxybutyrate, methylamine, and trigonelline). 
However, these differences were influenced by gender as obese male mice were associated 
with insulin signalling while female obese mice were associated with lipid metabolism 
(214). 
Transmissibility of these characteristic compositional and functional differences has 
been observed (215). Colonisation of GF mice with the gut microbiota from obese animals 
favoured the development of compositional and metabolic features of the obese 
microbiome. Similarly, gastric bypass surgery in mouse models has been shown to affect 
the composition of the gut microbiota (increase in Proteobacteria, decrease in Firmicutes 
and Bacteroidetes compared to sham operated mice) for reasons partially explained; post-
surgical dietary modification being the most important (215). However, the causative role 
of the gut microbiota in affecting the host physiology is supported by the finding that gut 
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microbiota transplanted from a post-gastric bypass animals who lost weight after surgery to 
other obese mice which had no surgery experienced reduction in weight and other 
metabolic aberrations in the recipient animals (215). However, the response of lean animals 
(by developing adiposity) to co-housing with obese cage mates is controversial. Some 
authors report the development of obesity and obesity related microbiota and metabolism in 
the lean animals (170). In contrast, others report successful acquisition of lean microbiota 
by obese animals characterised by the invasion of species from Bacteroidetes (including B. 
cellulocyliticus, B. uniformis, B. vulgatus, B. thetaiotaomicron, B. caccae), 
Parabacteroides merdae, and Alistipes putridinis. Lean animals on the other hand were not 
colonised by the members of the obese microbiome when they were caged together. As a 
consequence of invasion of lean microbiota, the metatranscriptome of the transformed-
obese phenotype became similar to the lean phenotype (increased expression of genes 
related to branched chain amino acid degradation) suggesting a ―functional transformation‖ 
(212).  
In summary, despite similar caloric intake and amount of food ingested by lean and 
obese animals, characteristic differences in composition, function, and transmissibility of 
microbiome between obese and lean phenotype suggests that gut microbiota and its 
components might play a causative role in the aetiology of obesity. How far the obese vs. 
lean differences are dependent on the genetic make-up of the animals, physiology of GF 
and CONV animals, environment, gender, and experimental methodology is scarcely 
studied and needs further investigation.  
1.7.2 Evidence from animal studies: Diet as a cause of obesity 
Gut microbiota are located at the interface of the environment (from the luminal side of the 
gut) and host (from the epithelial side of the gut). The effect of environmental factors 
particularly diet is therefore highly significant and may contribute to the changes in the gut 
microbiota composition and function and ultimately their phenotype (obese or lean 
microbiome) (216). 
Ingestion of high fat Western diet may play an important role in modifying the gut 
bacterial population which in turn alters the energy harvesting capability. This has been 
studied in various animal models such as GF/CONV mice and Sprague Dawley rats(199, 
217), leptin deficient ob/ob mouse models (218), and immune deficient mouse models 
(Toll-Like Receptor proteins deficient mice) (203) showing a tendency towards an increase 
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in population of Firmicutes and reduction in Bacteroidetes after feeding with high fat 
Western diet.  
Ingestion of high fat diet correlates with changes in the level of inflammatory 
markers and oxidative stress (194) such as Tumour Necrosis Factor alpha (TNF-α) and 
Nuclear Factor-kappaB (NF-kappaB), which play a major role in promoting 
inflammation(219), immune response, cellular proliferation and apoptosis. In CONV mice, 
but not in germ free mice, changes in the expression of these inflammatory markers in the 
intestine preceded weight changes and carried a strong positive correlation with high fat 
diet induced adiposity and markers of insulin resistance (202). This suggests an interaction 
of high fat diet and enteric bacteria promoting intestinal inflammation and insulin 
resistance prior to weight gain which is driven by the high fat diet. 
In a study using GF and CONV mice, a significant surge in the Mollicutes class of 
Firmicutes was seen with reduced bacterial diversity and reduced number of Gram positive 
Bacteroides as a result of switch over from standard chow diet to a high fat Western diet 
(217). In contrast, reduction of fat and carbohydrates in the diet significantly decreased the 
consumption of calories, weight gain, and body fat than those on high fat Western diet 
(217). In another study, Sprague Dawley rats fed with milk-based high fat diet in addition 
to standard chow diet, had increased adiposity, lower jejunal Bacteroides, higher 
Firmicutes, higher Firmicutes to Bacteroidetes ratio, and higher jejunal Alkaline 
Phosphatase activity than those fed with standard chow diet (218). Observations from these 
studies suggest that a high fat diet, especially HF Western diet, is associated with a relative 
increase in the gut microbiota population in favour of Firmicutes. Increase in Firmicutes 
may in turn contribute to the chronic low-grade inflammation by production of LPS, and 
increased energy salvage by increased SCFA production.   
Studies in mice indicated that although the obese phenotype is characterised by a 
particular set of gut microbiota, change in caloric load and type of diet changes and 
redistributes the equilibrium that may be independent of the genotype or phenotype (obese 
or lean) of the animal. Leptin deficient ob/ob mice are genetically prone to obesity due to 
the absence of the appetite regulating hormone leptin. Murphy and colleagues showed that 
leptin deficient ob/ob mice when fed low fat diet for 7 weeks show increased weight, 
increased fat mass and reduced muscle mass in association with significantly increased 
Firmicutes and reduced Bacteroides. However, similar changes were also observed in wild 
type lean mice fed the same high fat diet, although the caloric intake was similar amongst 
the two groups (220). These changes were however dissociated from markers of increased 
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energy harvest i.e. caecal SCFA and energy excreted in faeces. Caecal SCFAs were 
increased (acetate by ~16 µmol/g, propionate by ~4 µmol/g, and butyrate by ~3 µmol/g 
caecal content) and faecal energy excretion decreased (by ~0.4 kJ/g faeces) in ob/ob mice 
but the effect diminished after 7 weeks in both HF-fed CONV mice and ob/ob mice. These 
data suggest that the association of the gut microbiota with energy harvest from the diet is 
complex. Changes in gut microbiota composition may be attributed to the high fat diet 
rather than the genetic propensity of the animals to obesity. Furthermore, shift in 
microbiota towards higher Firmicutes to Bacteroidetes, or the absence of gut microbiota 
may not be associated with the development of obesity (165). The assertion that germ free 
mice having no gut microbiota are protected from obesity was contradicted in a study by 
Fleissner et al. (2010) where they found a significantly higher body weight gain in GF than 
CONV mice on high fat diet although the composition of gut microbiota in CONV mice 
increased in favour of Firmicutes (specifically, Erysipelotrichaceae) at the expense of 
Bacteroidetes on a high fat diet and Western diet (165). 
As discussed above, the functional association of metabolic endotoxemia with gut 
microbiota was dependent on the intake of high fat diet in the obese ob/ob animal model 
(184, 194). However, these effects were later shown to be independent of obesity 
phenotype, as a high energy intake in lean C57BL/6J mice fed a high fat diet showed a 2-3 
fold increase in plasma LPS compared to normal chow diet. Furthermore, the increase was 
blunted when the percentage intake of energy contributed by fat was reduced (221). 
Additionally, capability to harvest increased energy from the diet has also been shown to be 
independent of the phenotype or the peculiar pattern of gut microbiota. Murphy et al. 
(2010) reported that both wild type and leptin deficient ob/ob mice fed HF diet had a 
significant increase in Firmicutes and Bacteroidetes compared to lean controls after eight 
weeks but these changes were not associated with markers of increased energy harvest. 
Although energy harvesting capability initially increased (higher caecal SCFA and lower 
stool energy) with change in gut microbiota, this effect diminished over the period of 
follow up from 7 weeks to 15 weeks of age (222). 
In a study by de Wit et al.(2012) a high fat diet composed of palm oil (with more 
saturated fat) was shown to distinctly increase the Firmicutes ( particularly Bacilli, 
Clostridial cluster XI, XVII,XVIII) to Bacteroidetes ratio in the gut compared to a diet 
high in fat-olive oil, high fat-safflower oil, and low fat-palm oil (223). Additionally, high 
fat palm oil also stimulated the expression of 69 genes related to lipid metabolism in the 
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distal intestine which suggested that an overflow of lipids to the distal small intestine 
resulted in enhanced lipid metabolism and changes in gut microbiota.   
Several other recent studies suggested similar changes in gut microbiota and the 
expression of genes for the metabolism of lipids in animal models using different dietary 
regimens (224-226) (table 1.6). Daniel et al.(2013) investigated composition and function 
of gut microbial ecology after 12 weeks dietary intervention with high fat (HF) (60% fat, 
21% carbohydrates) or high carbohydrate (CARB) diet (with 66% carbohydrate and 11% 
fats) in male C57 BL6/N mice (n=6 per group) (227). Diets, and not the gut microbiota, 
were shown to affect not only the distribution of the gut microbiota communities (decrease 
in Ruminococcaceae and increase in Rikenellaceae with HF compared to CARB) but also 
the metabolome and proteome of the individual groups. CARB group had proteome related 
to energy production, carbohydrate metabolism, post translational modifications, and 
protein turnover while HF group had proteome related to amino acid and simple sugars 
metabolism, translation and other unknown functions (227). Although this study used two 
functional approaches (LC-MS/MS for metaproteome and Fourier-transform ion cyclotron 
resonance mass spectrometry for metabolome) to explore gut microbiota function, the 
study numbers available for these techniques were very low (n=3) which might have 
contributed to the variation within the groups.  
1.7.3 Conclusion from animal studies 
In conclusion, the relationship of gut microbiota with diet and metabolic disorders has been 
studied in a variety of animal models. Various mechanisms have been suggested in an 
attempt to probe the relationship between the gut microbiota and energy harvest and 
subsequent development of obesity. Some of these mechanisms include the production of 
short chain fatty acids, regulation of liver lipogenic enzymes, regulation of metabolic and 
satiety hormones, and inflammation. With the onset of increase in weight, there is good 
evidence of a reduction in overall diversity of the gut microbiota, reduction in 
Bacteroidetes, and an increase in Firmicutes. Increase in the endotoxin-producing gut 
microbiota may increase gut permeability that helps in the systemic absorption of bacterial 
LPS. LPS in turn induces inflammatory cytokines, metabolic endotoxemia, and metabolic 
syndrome. However, there is controversy as to whether these changes are attributable to the 
diet itself or that they are caused by the gut microbiota (199, 224) as the increase in 
Firmicutes is not always associated with increased weight. Some authors suggest changes 
in the gut microbiota occur due to the change in diet and they observed similar changes of 
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gut microbiota and energy harvesting capability in genetically obese low-fat fed and wild 
type CONV high-fat fed mice (224). On the other hand, studies in GF mice suggest the gut 
microbiota is the critical player in inflammation, development of immunity, and host 
metabolic regulation (194). Diet is also considered as a confounding factor that determines 
a change in gut microbiota and obesity because the diversity of gut microbiota has not been 
found to be different between wild-type and certain genetic models of obese mice (224).  
Discrepancies between and within studies could be attributed to the selection of 
animals (rats vs. mice) each study using different strains for reasons partially explained. A 
recent study by Walker et al. (2014) observed a distinct microbiome and metabolome in 
two strains of C57BL/6J and C57BL/6N mice (228) . Some differences in the metabolome 
might also be attributed to the gender of the experimental animals as suggested by Won et 
al. (2013) (214) and described above. This, in addition to other methodological, host, and 
environmental differences in experimental conditions add to the complexity of the 
relationship. The exact mechanism of how these changes lead to an obesity phenotype is 
still not known. Large humans based interventional studies are therefore required to 
establish the true association between diet and gut microbiota and obesity. 
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Table 1.7: Evidence from animal studies about the role of gut microbiota in obesity 
Reference Study model Aim of the study Study design and outcomes measures Results Conclusion  
Fleissner 
CK et al. 
2010 
(165) 
Male adult C3H 





To study the influence of 
different diets on the body 
composition of GF and CV 
mice. 
Ad libitum intake of low fat (LF), high fat 
(HF) and commercial Western diet (WD) for 
GF and CV mice. Real time PCR, FISH and 
fiaf/angplt4 in gut and blood 
GF mice gained more weight and body fat and had less energy 
expenditure than CV mice on HFD. Higher Firmicutes (especially 
Erysipellobacteriacae) and lower Bacteroides in CV mice on HF 
and WD.   Intestinal Fiaf increased in GF mice but no change in 
plasma fiaf levels as compared to CV mice.  
GF mice are not protected from 
diet induced obesity. Diet 
affects gut microbiota 
composition and fiaf does not 
play a role in fat storage 
mediated by gut microbiota. 
Ajslev TA 
et al. 2011 
(229) 
28 354 mother-
child dyads, age 
7 years 
To assess the influence of 
delivery mode, maternal pre-
pregnancy BMI, and child’s 
early exposure to antibiotics on 
the child’s risk of  overweight  
Maternal pre-pregnancy BMI, delivery mode 
and antibiotic administration in infancy. 
Children followed at 7 years of age 
No significant association of delivery mode with overweight. 
Increased risk of overweight and obese in children, born to 
normal weight mothers, given antibiotics in first 6 months of life 
and decreased risk in children born to overweight mothers.  
Antibiotics use in early infancy 
and pre-pregnancy weight of 
mother affect tendency of child 
to become overweight and 
obese. 
Sefcikova Z 
et al. 2010 
(218) 
8-10 pups per 
nest, Sprague-
Dawley rats, 
from day 21-40.  
To evaluate the effect of normal 
and over-nutrition on the 
development of gut microbiota, 
intestinal Alkaline Phosphatase 
and occurrence of obesity 
Standard laboratory diet for control group 
and additional milk based liquid diet for 
study group. Epididymal and peri-renal fat 
pads  and bacterial enumeration via FISH, 
Alkaline phosphatase activity via 
immunocytochemistry 
Obese rats gained more energy (25%) and higher body fat (27%) 
than lean rats. Alkaline phosphatase increased in obese rats. 
Lactobacilli increased while Bacteroides decreased in obese rats 
significantly.  
 
Due to early changes in diet and 
the intestinal environment, this 
study may provide a baseline for 
further insight into the ways of 
involvement in programming of 
a sustained intake and digestion 







To test the hypothesis that 
Intestinal inflammation is 
promoted by the interaction of 
gut bacteria and high fat diet, 
which contributes to the 
progression of insulin resistance 
and obesity. 
High and low fat diets for 2, 6 or 16 
weeks.GF mice fed with diet after exposure 
to faecal slurries of CONV mice. Blood 
glucose and ELISA for insulin. TNF- α 
mRNA expression by qPCR. Intestinal EGFP 
expression of NF kB mice by fluorescent 
light microscopy. 
CONV mice gained more weight than GF. Increased expression 
of TNF-α mRNA and NFkB in CONV HF diet mice. TNF- α 
changes precedes weight changes. Enhanced NFkB in GF NFkB 
mice on feeding CONV NFkB faecal slurry. 
HF diet and enteric bacteria 
interact to promote 
inflammation and insulin 
resistance prior to the 
development of weight gain, 
adiposity and insulin resistance. 
Turnbaugh 
et al. 2008 
(217) 
8-9 weeks old 
GF/CONV mice  
To study the inter-relationship 
between diet, energy balance 
and gut microbiota using mouse 
model of obesity. 
Conventionalization of GF mice with HF 
Western diet followed by introduction of 
Western or CHO diet in CONV mice. 
CARB-Reduced or FAT-Reduced diets in 
another subset. qPCR, DEXA scan and 
weight measurements done 
Western diet-associated caecal community had a significantly 
higher relative abundance of the Firmicutes (specifically 
Mollicutes) and lower Bacteroidetes. Mice on the Western diet 
gained more weight than mice maintained on the CHO diet and 
had significantly more epididymal fat. Mice on CARB-R and 
FAT-R diet consumed fewer calories, gained less weight and had 
less fat. 
There is restructuring of gut 
microbiota with Western diet, 
specifically reduction of 
Bacteroides and surge in 
Mollicutes class of Firmicutes 
with increased capacity to 
harvest energy from diet. 
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de La Serre 





To evaluate whether changes in 
gut bacteria and gut epithelial 
function are diet or obese 
associated. 
Measurement of intestinal permeability, 
intestinal alkaline phosphatase, plasma LPS, 
tissue Myeloperoxidase activity, 
Immunochemical localization of TLR4/MD2 
complex and Occludin, Sequence analysis of 
the microbial 16S rRNA gene. body fat 
composition and measures of adiposity from 
fat tissue samples 
Appearance of two distinct groups; Diet induced obesity Prone 
and Resistant groups. DIO-P rats had more features of adiposity, 
higher MPO activity, TLR4 MD2 immunoreactivity and higher 
plasma LPS levels, increased gut permeability, immunoreactivity 
of Occludin and lower alkaline Phosphatase levels than LF and 
DIO-R group. HF diet was associated with an increase in 
Clostridiales regardless of propensity for obesity.  A marked 
difference in Enterobacteriales in DIO-P animals compared with 
either DIO-R or LF-fed animals. 
Changes in gut bacteria are 
independent of obese status. Gut 
inflammation marked by 
increased LPS may be a 
triggering mechanism for 






mice (n=6, per 
group) 
To investigate changes in 
function and activity of the gut 
ecosystem in response to 
dietary change 
LC-MS/MS for metaproteome, Fourier-
transform ion cyclotron resonance mass 
spectrometry (FT-ICR-MS) for 
metabolome, Miseq illumina 
pyrosequencing for gut microbial 
composition. Intervention with high fat 
(HF) and control (carbohydrate) diet for 
12 weeks  
HF diet did not affect caecal taxa richness. Bacterial communities 
clustered according to diet. Significantly lower Ruminococcaceae 
(Firmicutes) and higher Rikenellaceae (phylum Bacteroidetes), 
Lactobacilli, and Erysipelotrichiales in HF fed vs. carbohydrate 
fed diet. 19 OTUs affected by HF diet. Carbohydrate group had 
proteome related to energy production, carbohydrate and post 
translational modifications, protein turnover while HF group had 
proteome related to amino acid and simple sugars metabolism, 
translation and other unknown functions. Caecal metabolome 
clustered distinctly based on diet. 
High fat diet affects gut 
microbial ecology both in terms 
of composition and function 
Backhed F 





To evaluate the effect of gut 
microbiota on the host energy 
metabolism using animal model 
Conventionalization of GF mice with murine 
gut microbiota or β-thetaiotaomicron, 
intestinal fiaf, liver metabolism, total body 
fat, LPL activity in adipose tissue, faecal 
microbiota composition by Sybr-Green qPCR  
Conventionalized GF mice showed 57% increase in body fat, 
increased energy expenditure, suppressed intestinal fiaf, 
increased LPL activity and increased expression of ChREBP and 
SREBP-1 in liver. Firmicutes to Bacteroides ratio similar in GF 
and CONV. 
Gut microbiota alters  host 
energy storage by affecting fiaf 
and LPL activity. It may be 
regarded as an environmental 
factor that affects host energy 
storage 
Backhed F 




mice (n=5) and 
CONV mice 
(n=5) 
To assess whether GF mice are 
protected against obesity on 
high fat Western diet 
Dietary intervention with low fat followed by 
high fat Western diet for 8 weeks 
CONV mice gained more weight on HF diet while 
Conventionalised GF mice didn’t. Stool energy was similar to the 
LF fed GF mice. Persistent elevated TG in HF fed GF mice. GF 
mice had high Acc-p, AMPK-P and Cpt-1 activity depicting 
increased fatty acid oxidation. GF mice had reduced hepatic 
glycogen and glycogen-synthase activity. High fiaf in HF fed GF 
mice  
GF mice are protected against 
diet induced obesity by two 
mechanisms; 1. Increased 
phosphorylated AMPK 2. 
Increased fiaf 
Vijay-






Wild type  mice 
(WT) 
To show that mice deficient in 
TLR-5 exhibit hyperphagia, 
which is a principal factor in 
the development of obesity and 
metabolic syndrome? 
Introduction of broad spectrum antibiotics to 
assess the role of altered microbiota resulting 
from loss of TLR5. Pyrosequencing of 16S 
rRNA genes in the caecum to find out the 
extent of alterations in microbiota due to loss 
of TLR5. Transplantation of T5KO mice 
microbiota  into WT germ free hosts 
Antibiotic treatment lowered the bacterial load by 90%, 
correction of metabolic syndrome similar to the wild type mice. 
Relative abundance of bacterial phyla was similar in both; with 
54% Firmicutes, 39.8% Bacteroides. 116 phyla observed to be 
enriched or reduced in R5KO relative to WT mice.  Microbiota of 
WT mice transplanted to the R5KO mice resulted in all features 
of metabolic syndrome in the R5KO group 
Loss of TLR-5 results in 
metabolic syndrome and 
alteration in gut microbiota. 
Acquired microbiota from 
mother can be an important 
means by which environmental 
factors can exert long lasting 










lean ob/+, and 
+/+ mice 
(n=19) 
To study differences in 
bacterial diversity between 
obese genetic model of obesity 
and its relationship with kinship 
16S rRNA gene amplification of caecal 
bacteria followed by analysis using PHRED 
and PHRAP software. All mice fed the same 
polysaccharide rich chow. 
ob/ob mice consumed 42% more chow, gained significantly 
higher weight. Mothers and offspring shared bacterial 
community. Obese ob/ob had 50% reduction in Bacteroidetes and 
a proportional increase in Firmicutes as compared to lean 
regardless of the kinship and gender 
Obesity is associated with 
altered bacterial ecology. This 
however needs to be correlated 
with the metabolic attributes of 
gut microbial diversity in obese 
and lean 
Turnbaugh 





(n=13) and lean 
ob/+, and +/+ 
mice (n=10) 
Whether gut microbial gene 
content correlates with 
characteristic distal gut 
microbiome of leptin deficient 
ob/ob mice and their lean 
counterparts and whether this 
trait is transmissible 
1S rRNA whole metagenome Shotgun 
Metagenomics, GC-MS for SCFA analysis, 
bomb calorimetry for stool energy, gut 
microbiota transplantation, DEXA for fat 
mass 
Firmicutes-enriched obese microbiome clustered together while 
lean phenotype with Low Firmicutes to Bacteroidetes ratio 
clustered together. Obese microbiome was rich in enzymes 
involved in the breakdown of dietary polysaccharides particularly 
glycoside hydrolases. Ob/ob had higher acetate and butyrate and 
significantly less stool energy 
Obese microbiome is associated 
with increased energy harvest 







To evaluate the influence of gut 
microbiota on the development 
of metabolic endotoxemia 
Metabolic, inflammatory and 
microbiological differences 
(FISH) between high-fat-fed 
obese or rodent lean chow-fed 
mice 
High-fat feeding and obesity 
decimates intestinal microbiota– Bacteroides-mouse intestinal 
bacteria, Bifidobacterium, and Eubacterium rectale–Clostridium 
coccoides groups all significantly lower than in control animals 
High-fat diet-induce changes in 
gut microbiota that leads to 
elevated plasma LPS leading to 
metabolic endotoxemia, by 
altering the gut barrier function 





Manipulating gut microbes 
through antibiotics to 
demonstrate whether changes in 
gut microbiota control the 
occurrence of metabolic 
syndromes  
Caecal microbiota of mice under 
High-fat low-fibre diet and antibiotics. qPCR 
and DGGE 
Antibiotic reduced LPS caecal content and metabolic 
endotoxemia in both ob/ob and high fat. High-fat diet increased 
intestinal permeability and LPS uptake leading to metabolic 
endotoxemia. Absence of CD14 mimicked the metabolic and 
inflammatory effects of antibiotics 
High fat diet modifies gut 
microbiota which induce 
inflammation and metabolic 
endotoxemia. Antibiotics can 










Whether gut microbiota 
especially LPS promote 
inflammation in white adipose 
tissue (WAT) and impair 
glucose metabolism  
DEXA, insulin and glucose tolerance, 
Macrophage isolation, 
immunohistochemistry, and flowcytometry 
and immunoblot  in WAT, LPS analysis, RT-
qPCR 
Monocolonisation of GF mice with E.coli W3110 or isogenic 
strain MLK1067 with low immunogenic LPS had impaired 
glucose tolerance. However, only  GF mice with E.coli W3110, 
and not MLK1067, showed increased  pro-inflammatory 
macrophage infiltration in WAT 
Macrophage accumulation is 
microbiota dependent but 






mice (TLR2 -/-) 
and wild-type 
mice (n=8 per 
group) 
Influence of gut microbiota on 
metabolic parameters, glucose 
intolerance, insulin sensitivity, 
and insulin signaling in TLR2 
Knockout mice 
454 pyrosequencing Higher Firmicutes (47.92% vs. 13.95%), Bacteroidetes (47.92% 
vs. 42.63%), and lower Proteobacteria (1.04% vs. 39.53%) in 
TLR2 -/-. Higher LPS absorption, insulin resistance, impaired 
insulin signalling and glucose intolerance in TLR2 -/-compared 
to controls. 
Alteration in gut microbiota in 
non-germ free conditions links 






obese, HF fed, 
type 2 diabetic) 
To ascertain the role of 
Akkermansia muciniphila in 
obesity and type 2 diabetes 
Real time qPCR, MITChip analysis, 
LTO- Orbitrap mass spectrometer, ELISA for 
insulin and faecal IgA 
Akkermansia muciniphila decreased obesity and type-2 diabetes 
which was normalised by oligofructose. Administration of A. 
muciniphila reversed markers of metabolic disorders. These 
effects needed viable A. muciniphila 
This microbe could be used as 
part of a potential strategy for 
the treatment of obesity 
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Enterobacter cloacae B29 
isolated from obese human gut 
could induce obesity and 
insulin resistance in GF mice 
16S rRNA gene sequencing for bacteria and 
Limulus amebocyte lysate test for endotoxin 
measurement 
Mono-colonisation of GF mice with E.cloacae induced obesity 
and insulin resistance on HF diet while GF control mice only on 
HF diet didn’t. Enterobacter-colonised GF obese mice had higher 
plasma endotoxin levels and inflammatory markers  
Gut microbiota-produced 
endotoxin  may be causatively 







To investigate the gut 
microbiota composition in 
obese and diabetic leptin 
resistant mice vs. lean mice 
Combined pyrosequencing and phylogenetic 
microarray analysis of 16S rRNA gene 
Higher Firmicutes, Proteobacteria, and Fibrobacters phyla in 
db/db mice compared to lean mice. Odoribacter, Prevotella, and 
Rikenella were exclusively present in db/db mice while 
enterorhabdus was identified exclusively in lean mice. Db/db 
mice had a higher tone of eCB, and higher Apelin and APJ 
mRNA levels. Gut  microbiota were significantly correlated with 
Apelin/mRNA tone 
Gut microbiota varies with 
genotype and play a significant 
role in the regulation of eCB 





type mice, and 
leptin deficient 
ob/ob mice 
(n=8 per group) 
To investigate the effect of high 
fat diet and genetically 
determined obesity for changes 
in gut microbiota and energy 
harvesting capability over time. 
GC, metagenomic pyrosequencing 
High fat or normal chow diet fed to ob/ob 
mice and wild type mice for 8 weeks.  
Increase in Firmicutes and Bacteroidetes in HF fed and obese 
mice but not in lean. Changes in microbiota were not associated 
with markers of energy harvest initial increase in caecal SCFA 
(acetate) and decrease in stool energy with HF diet did not remain 
significant over time. No correlation of bacterial phyla with 
energy harvest 
Changes in bacterial phyla is a 
function of high fat diet and 
these changes are not related to 
the markers of energy harvest 





To study the effect of dietary 
fat type (polyunsaturated and 
saturated fatty acids ratio) on 
the development of obesity 
Phylogenetic microarray (MITChip) analysis, 
bomb calorimetry, measurement of 
triglycerides, plasma insulin 
HF diet with high saturated fatty acids (palm oil) induced higher 
weight gain and liver triglycerides compared to high fat diet with 
olive oil and safflower oil. HF diet with palm oil reduced 
microbial diversity and increased Firmicutes (Bacilli, Clostridium 
cluster XI, XVII, and XVIII) Bacteroidetes ratio. Up-regulation 
of 69 lipid metabolism genes in distal small intestine and increase 
fat in stool suggest overflow of fats to distal small intestine 
Type of dietary fat influences 






mice (n=10 per 
group) 
Changes in 10 model gut 
communities species abundance 
and microbial genes with 
changes in peculiar diet 
ingredient were studied  
Shotgun sequencing of faecal DNA 
Diets used for each community; casein (for 
protein), corn oil (for fat), starch (for 
polysaccharides), and sucrose (for simple 
sugars) 
61% variance in abundance of the community members was 
explained by diet particularly casein. Absolute abundance of 
E.rectale, Desulphovibrio piger and M. formatixegens decrease 
by 25-50% while Bacteroides caccae increase with increase in 
casein, although the total community biomass increases. 
Host diet explains configuration 
of gut microbiota both for 
refined diets and complex 
polysaccharides 
Hildebrandt 
et al. 2009 
(224) 
RELM-B knock 
out female mice 
and wild type 
mice 
To assess the influence of host 
phenotype, genotype, immune 
function, and diet on gut 
microbiota  
16S rDNA 454 FLX pyrosequencing, 
metagenomic sequencing 
Switching to high fat diet resulted in decreased Bacteroidetes and 
increased Firmicutes and Proteobacteria in both wild type and 
RELM B knockout mice irrespective of the genotype. Genetic 
makeup (RELM B KO) only modestly influenced the gut 
microbiome composition. Changes in gene content were seen 
with high fat diet 









To assess the relationship of 
diet content and source on gut 
microbiota, and adiposity 
16S rRNA analysis vi terminal restriction 
fragment length polymorphism and V3-V4 
sequence tag analysis via next generation 
sequencing. Mesenteric fat and gonadal fat 
tissue analysis. 
Milk, lard, or safflower based diets for 4 
weeks. 
Higher weight gain and caloric intake with high fat than low fat 
diet. Milk based and PUFA based diets animals had higher 
adipose tissue inflammation than lard based or low fat diet. Milk 
based and PUFA diet had significantly higher Proteobacteria and 
lower Tenericutes. PUFA based fed animals had higher 
expression of adipose tissue inflammation genes (MCP1, CD192, 
resistin) 
Dietary fat components reshape 
gut microbiota and alter 
adiposity and inflammatory 






To investigate the effect of 
dietary fibre on metabolic risk 
markers in low and high fat 
diets at 2, 4, and 6 weeks 
Gas liquid chromatography, liver fat content, 
cholesterol and triglycerides analysis, 
terminal fragment length polymorphism. 
Diets were supplemented with guar gum, or a 
mixture 
Decrease in weight gain, liver fat, cholesterol, triglycerides with 
fibre. Change in formation of SCFA. Reduction in serum SCFA 
with high fat diet followed by recovery after 4 weeks. Succinic 
acid increased with high fat consumption. Dietary fibre reduced 
this effect and also reduced inflammation. Bacteroides were 
higher with guar gum and Akkermansia was higher with fibre-
free diet. 
High fat diet increase metabolic 
risk factors which are partly 
reversed by high fibre diet. 
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1.8 Review of human studies relating gut microbiota with 
obesity 
1.8.1 Gut microbiota as a cause of obesity 
Evidence linking the gut microbiota with obesity in humans is thus far inconclusive and 
controversial. This may be partly due to marked inter-individual variations in the gut 
microbiota and metabolic activity in humans with age, diet, use of antibiotics, genetics and 
other environmental factors (234). Apart from the inter-individual variation in faecal 
microbiome and diversity, re-analysis of large datasets such as human microbiome project 
(HMP) and MetaHIT has shown large inter-study variability which was far greater than the 
actual differences between the lean and obese phenotypes (235). A refined statistical 
modelling therefore led to the loss of some correlations previously found, such as 
correlation of BMI with Firmicutes to Bacteroides ratio (235). Bridging these gaps in 
analysis and accounting for these technical and clinical factors is therefore important to 
elucidate differences between normal and altered host microbiome and metagenome.   
Although 16S-rRNA sequencing based studies revealed differences in the gut 
microbiota between and within individuals, the general concept about predominant phyla is 
emerging. Firmicutes, Bacteroidetes and Actinobacteria in descending order of abundance, 
form the major groups of gut bacteria constituting about 92.6% of all the known gut 
microbes (164). Differences in these groups may drive the difference of energy harvest 
from food in individuals.  
The first evidence regarding aberrant relative abundance of the gut microbiota in 
human faeces was presented by Ley et al.(2006) who found higher Firmicutes and lower 
Bacteroidetes in obese vs. lean adults before the onset of dietary intervention (164). This 
was followed by a number of studies reviewed in Table 1.10. Moreover, several gut 
microbes have been associated with obesity (such as Lactobacillus reuteri) or leanness 
(such as Bifidobacteria) (236, 237) (Table 1.8). The type of gut microbiota and their exact 
hierarchy at which they exhibit differences is still under investigation. 
The energy harvesting capability of the gut microbiota in obese subjects is thought 
to be set at a higher threshold than in lean phenotype with or without differences in the 
relative abundance of the gut microbiota.   
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Table 1.8: Association of gut microbial species/genera with obesity or leanness in human studies 
Bacteria Association 
with obesity 
Group Level Other associations Reference 
Lactobacillus 
reuteri 




+ve Firmicutes group Anti-inflammatory (170) 





+ve Firmicutes Genus Energy intake (239) 
Bacteroides -ve/+ve Bacteroidetes Genus Controversial  (164) 
Akkermansia 
muciniphila 
-ve Verrucomicrobia Species Mucus degradation (231) 
Methanobrevib
acter smithi 
-ve Archaea Species Increase in anorexia (240) 
Clostridium 
cluster IV; F. 
prausnitzii 
-ve Firmicutes Species Anti-inflammatory (241) 
Bifidobacteria -ve Actinobacteria Genus -ve association with 
allergy 
(236) 
+ve: positive association, -ve; negative association, +ve/-ve; controversial. 
 
In a crossectional study by Fernandes et al. (2014), significantly higher faecal acetate, 
propionate, butyrate, valerate, and total SCFA were found in obese vs. lean adults(176). 
Although relative abundance of Firmicutes, Bacteroides/Prevotella, and Firmicutes to 
Bacteroides ratio were not significantly different between the lean and obese phenotype, 
faecal total and major individual SCFA (acetate, propionate, butyrate) were negatively 
correlated with Bacteroides and positively correlated with Firmicutes/Bacteroides ratio 
(176). Additionally, the anti-obesity effect of polyunsaturated fatty acid (PUFA) derived 
conjugated linoleic and linolenic acid in obese women has been shown to be produced by 
the action of Bifidobacteria, F. prausnitzii, and Lactobacilli. The production of these 
compounds from dietary PUFA is unaffected by intervention with prebiotics which suggest 
that indigenous gut microbiota might be determining this potential (242). A recent study by 
Bergstorm et al.(2014) found no significant correlation of gut microbiota at 9, 18, or 36 
months of age with dietary intake (measured by 7 days food diary), body composition 
(measured by DEXA), gender, and mode of delivery (243). Furthermore, positive 
correlation of BMI SDS with Firmicutes particularly butyrate producing C. leptum, E.halii, 
and Roseburia indicated that changes in the gut microbiota at these developmental stages 
may not depend on the dietary factors. Bervoets et al. (2013) also found a higher 
Firmicutes to Bacteroides ratio, lower Bacteroides fragilis, higher Lactobacillus spp. and 
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no correlation of major colonic bacterial groups with dietary intake in obese and healthy 
children (age 6-16 years) (239). The only exception was S. aureus which was positively 
correlated with energy intake (239). However, this study was crossectional and the dietary 
intake of obese and lean children was similar (~2200 Kcal/day in obese vs. ~2100 Kcal/day 
in lean) which might indicate underreporting by the obese children. Karlsson et al. (2012) 
found significantly higher Enterobacteriaceae and significantly lower Desulfovibrio and 
Faecalibacterium prausnitzii in obese vs. lean children (n=20 each, age 4-6 years)(244). 
However, no differences in the counts of Lactobacillus, Bacteroides fragilis, and 
Bifidobacterium were found between lean and obese (244). Moreover, concentration of 
Bifidobacterium was negatively correlated with serum alanine aminotransferase in obese 
and overweight children while faecal calprotectin was not different between lean and obese 
indicating the absence of inflammation at the early age of overweight and obese (244).  
In this context, differences in gut microbiota have been observed distinctly in obese 
compared to lean phenotype before pregnancy (such as higher counts of Bacteroides in 
obese vs. lean women) and during pregnancy in obese and lean women (such as increase in 




 trimester in obese vs. lean women). However, 
these have not been studied in relation to the changes in diet that occur over the period of 
pregnancy thereby limiting its implications. 
Modulation of gut microbiota with the use of antibiotics have been shown to affect 
the gut microbiota development in early infancy and childhood and hence bacterial 
metabolic activity (150, 245). In the context of obesity, population based studies suggest 
that the use of antibiotics may affect weight gain in early childhood (Table 2.3) and the 
maturation/ stabilisation of gut microbiota in the long term. Long term changes in gut 
microbiota composition (such as lower counts of Bifidobacteria and higher Bacteroides) 
have been observed in children who were exposed to antibiotics in early childhood (150, 
245). Modulation of gut microbiota with antibiotics (e.g. norfloxacin and ampicillin) have 
been shown to alter the expression of hepatic and intestinal genes involved in inflammation 
and metabolism thereby changing the hormonal, inflammatory, and metabolic milieu of the 
host (246). These antibiotic-induced changes may predispose children to overweight and 
obesity by a selective ―obesogenic-bacterial-growth‖ promoting effect. This is confirmed in 
a large population based study of the Danish National Birth Cohort (229). This study found 
a higher tendency of overweight at 7 years in children who had a history of antibiotics use 
in their early infancy born to normal weight mothers. Interestingly, mode of delivery 
(vaginal vs. caesarean section) had no impact on the rate of antibiotic use in first 6 months 
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of life of infant (Odds ratio 1.02, 95% CI; 0.88-1.19) suggesting that the effect of 
antibiotics on overweight is independent of this confounder (264). 
The development of gut microbiota in infants and their tendency towards 
overweight and obesity in later childhood are linked to mother’s pre-pregnancy BMI and 
gut microbiota. In a study by Santacruz et al. (2010), obese pregnant women revealed 
significantly lower numbers of faecal Bifidobacteria and Bacteroides and significantly 
higher E coli and S.aureus compared to normal weight pregnant women (247). 
Furthermore, Staphylococcus aureus was positively correlated with high cholesterol levels 
in obese women (247). These gut microbiota were transferred to the infants as infants born 
to mothers who gained excessive weight during initial periods of pregnancy or were 
overweight and obese prior to pregnancy were found to have lower number of Bacteroides 
and higher number of Clostridia in first month of birth and the relationship reduced at 6 
months of age (248). Interestingly, higher Staphylococcus and lower number of 
Bifidobacteria have been associated with the presence of obesity in later childhood. 
 In addition to the relative higher abundance of Bacteroides than Firmicutes in lean 
vs. obese subjects (164), functional differences in the metabolome of the obese and lean 
phenotype may be more important. Calvani et al. (2010) in their preliminary study of 15 
morbidly obese and 10 age matched controls found distinct gut microbial co-metabolites in 
urine of obese versus lean participants, including lower levels of hippuric acid (benzoic 
acid derivative), trigonelline (niacin metabolite), and xanthine (purine metabolism) and a 
higher levels of 2-hydroxybutyrate (metabolite of dietary protein) (241). The metabolic or 
functional representation of gut microbiota might be proportional to each other despite 
differences in the relative abundance of gut microbiota in the gut. Disturbance of this 
equilibrium is a hallmark of the obese phenotype as suggested by Ferrer et al. (2013) in a 
comparative metagenomic and metatranscriptomic analysis of faecal samples from obese 
and lean adolescents (249). Faecal samples of obese adolescents had higher relative 
abundance of Firmicutes (~95%) and lower Bacteroidetes (~4%) compared to lean 
(Firmicutes ~79%, Bacteroidetes ~18%). However, up to 81% of the expressed proteins 
were contributed by Bacteroidetes despite a low compositional representation.  
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Table 1.9: Population based studies to investigate the risk of obesity and overweight in children who were given antibiotics for treatment of infections in early 
infancy 




Tools Primary outcome Factors considered Findings 
ISAAC study 
(International Study of 








Antibiotics use in first 
12 months of life 
Ht., Wt., BMI, age, gender, antibiotics, 
paracetamol, breast feeding, Maternal 
smoking, gross national income, Asthma 
Association of antibiotics use and 
BMI in Boys (+0.107 kg/m
2
 
p<0.0001), not in girls even after 
adjustment for the other variables 
DNBC study (Danish 
National Birth Cohort) 
(229) 





Antibiotics use in <6 
months of life 
Socioeconomic status, maternal age and 
smoking, gestational weight gain, parity, 
delivery mode, breastfeeding, paternal 
BMI, birth weight and age at 7-year 
follow-up. 
Increased risk of overweight in 
children born to normal weight 
mothers (adjusted OR: 1.54, 95% 
CI: 1.09–2.17). and especially in 
boys when adjusted for maternal 
age, smoking, SE status, birth 
weight and breast feeding 
 
ALSPAC study (Avon 
Longitudinal Study of 
Parents and Children) 
(251) 
n= 11, 532 
Longitudinal  





Antibiotic exposure at 
<6 months, 6-14 
months, and 15-23 
months and BMI at 6 
weeks, 10 months, 20 
months, 38 months and 
7 years 
Maternal parity, social class, education, 
parental BMI, parental smoking, 
breastfeeding, lifestyle and dietary 
patterns  
Increased risk of overweight at 38 
months (OR 1.22, P=0.029) but not 
at 7 years in children exposed to 




Furthermore, obese metagenome showed higher aerobic and anaerobic vitamin B12 and 1, 
2- propanediol metabolism genes compared to lean which expressed genes related to 
vitamin B6 metabolism (249). A recent study by Cottilard et al. (2013) has shown a 
reduced bacterial richness, reduced diversity and higher dys-metabolism and low-grade 
inflammation in obese vs. lean humans (252). Although dietary intervention partially 
improved gene richness, reduced measures of adiposity such as waist circumference and 
fat mas and reduced plasma cholesterol, it was less efficient in improving low grade 
inflammation (levels of hsCRP) (252). Furthermore, the tendency of the changes in gene 
clusters to return to the pre-dietary restriction phase suggests that gut microbiota tend to 
remain stable in individuals after the dietary stimulus is removed. 
1.8.2 Gut microbiota as a consequence of dietary differences in obesity 
Diet seems to play an important role in altering the proportion of gut microbiota in 
individuals because the amount and type of bacteria change significantly with change of 
diet (247, 253). This change varies between individuals and may be due to the distinct 
microbiota colonising the colon during early life, altering the capacity for energy harvest 
from the diet. Composition and caloric content of the diet significantly alters the relative 
abundance of the gut microbiota (253). An increased intake of resistant starch was shown 
to be associated with an increase in population boom of Eubacterium rectale (a butyrate 
producing bacteria) to ~10% and Ruminococcus bromii (an acetate producer) to ~17% 
compared to ~4% in volunteers consuming non-starch polysaccharides (253). These 
changes were seen to be reversed with weight loss diets along with a decrease in 
Collinsella aerofaciens, a member of Actinobacteria. This shows the substantial effect of 
the nature of diet on gut microbiota population and its energy harvesting capability in the 
form of short chain fatty acids (247, 253).  
Compositional differences in the gut microbiota have been a subject of controversy 
driven by dietary and environmental factors. Zhang et al.(2009) showed an association 
between methanogenic archaea and obesity in lean, obese, and post-gastric bypass patients 
as they found more Prevotellaceae (hydrogen producing bacteria) and methanogenic 
archaea (hydrogen consuming bacteria) in obese people than lean subjects (167). In 
contrast, Schwiertz et al. (2010) (254) found low methanogenic bacteria in obese and 
overweight individuals along with a low Bacteroides and Firmicutes/Bacteroides ratio. 
SCFA production is affected by the nutrient load and amount of dietary carbohydrates 
available for fermentation. Weight loss diets usually have low carbohydrate and high 
protein content and have been shown to reduce the population of butyrate producing 
Roseburia and Eubacterium rectale (166). Human subjects on high protein/medium 
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carbohydrate (HP/MC) and high protein/low carbohydrate (HP/LC) diet had lower total 
SCFA while faecal butyrate was significantly lower on HP/LC diet than the HP/MC and 
maintenance diet. These carbohydrate-reduced diets may therefore help in reducing weight 
by reducing the substrate availability for the amount of energy extracted from the diet 
available for fermentation in the colon (166). In another study, faecal propionate was found 
to be significantly higher in obese than lean volunteers from the general population (254).  
Changes in the anatomy (such as removal of part of the stomach in Roux-n-Y 
gastric bypass surgery) and as a consequence physiology (changes in pH, nutrient 
availability) of the gut have been shown to have an impact on gut microbiota composition 
(such as increase in Proteobacteria, Bacteroidetes and Alistipes and a decrease in Blautia, 
Dorea, Lactobacilli, and Bifidobacteria ) and its relationship with change in the expression 
of genes related to host metabolism (such as those expressed in white adipose tissue) 
within 3 months after surgery (238). Whereas these changes are associated with post-
surgical modifications in the dietary behaviour, about 50% of the associations were found 
to be independent of caloric intake. However, post-surgical changes in gut microbiota and 
the expression of genes between 0-3 months did not change in the long term between 3 
months and 6 months which suggested restructuring of the gut microbiota and plateau of 
the response to changes in gut physiology.  
It is argued that probiotics (such as Lactobacillus paracasei species paracasei 
strain F19) may beneficially affect host metabolic parameters when used as probiotics, 
which have been shown to beneficially affect energy homeostasis in weaning infants (4-13 
months age)  by reducing mono-unsaturated fatty acids (palmitoleic acid) associated with 
triglyceridemia in the short term (255). However, no differences in the serum lipids, 
glucose, insulin, and anthropometric measurements were seen in F19 intervention group 
compared to placebo group when the same cohort of children were followed at age 8-9 
years (256).  Another study by Weickert et al. (2011) found no significant difference in the 
total and individual faecal SCFA and gut microbiota relative abundance after 18 weeks 
intervention with diet supplemented with either high (43 g/day), moderate (26 g/day), or 
low (14 g/day) in cereal fibre (257). This indicates that several other factors including diet 
play their role in determining the overall health and energy homeostasis rather than gut 
microbiota and that the nature of the gut microbiota already established in the colon may 
be resisting ―foreign microbiota‖ even though declared as beneficial to the energy 
homeostasis of the host.  
In this context, factors affecting colonisation of the gut microbiota in the new-born 
from before birth to early and late childhood might play an important role. These were 
discussed in section 1.5.3. However, the role of these factors in determining the 
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colonisation of gut microbiota with tendency towards obesity or allergic disorders in later 
life is controversial. For example; higher numbers of Bifidobacteria and lower numbers of 
Staphylococci in breast fed children age 6 and 12 months had a negative correlation with 
overweight and obesity at 7 years (258). Similarly, the mode of delivery through caesarean 
section has been studied in relation to the development of overweight and obesity in male 
children in a population based cohort study of a Danish National birth Cohort(229). 
However, despite a larger cohort involving more than 10,000 children, the data was not 
adjusted for other confounding factors such as socioeconomic status, anthropometric and 
behavioural factors. In contrast, a recent Brazilian study following children born by 
caesarean section (n=5914) at age 4, 7, 15, and 23 years showed that although children 
born with caesarean section had ~50% higher prevalence ratio of obesity, this effect was 
no more significant when mode of delivery was adjusted for socioeconomic, demographic, 
maternal, anthropometric, and behavioural factors (259). This suggests that other factors 
play role in the genesis of obesity in children born with caesarean section. 
In summary, an overall increase in the metabolic potential of the gut microbiota 
may be due to a change in the amount and nature of the diet which results in changes in the 
structural and functional distribution of the gut microbiota. The association is however 
complex as it is affected by many other factors such as colonisation of the gut microbiota 
in early infancy, maternal factors, and use of antibiotics. 
1.8.3 Conclusion from human studies 
Controversies exist as to whether or not obese and non-obese individuals differ in hosting a 
particular type of bacterial phyla or enterotype and whether the response of the gut 
microbiota to the nature of diet or a change in dietary habits differs between obese and 
non-obese individuals. Correlation of BMI with Bacteroides in obese and non-obese 
subjects on different dietary regimens (260) is unclear as an inverse relationship has also 
been observed (254), adding to the complexity of the relationship of diet, gut microbiota, 
and obesity. The population of gut microbes in the human intestines is affected by a variety 
of factors from birth till adulthood; of which some are known and others are largely 
unknown. Additionally, inter-individual variations have been observed almost universally 
in all human studies suggesting peculiar host-diet interaction at individual level that may 
affect the metabolic activities to contribute towards obesity, diabetes, and cardiovascular 
disease risks.  
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Table 1.10: Evidence from human studies about the role of gut microbiota in obesity 
Reference Study model Aim of the study Study design and outcomes 
measures 
Results Conclusion  
Santacruz 




and 34 normal 
weight Pregnant 
women 
To investigate the 
relationship between gut 
microbes,  body weight, 
weight gain, and various 
biochemical parameters in 
pregnancy 
Faeces by  qPCR and blood samples 
for glucose, total cholesterol, HDL, 
TAG, LDL, urea, creatinine, uric acid, 
bilirubin, Iron, Ferritin, transferrin, 
folate, food 24-72 h food diaries for 
caloric intake. Weight of the babies at 
birth. 
Bifidobacteria and Bacteroides significantly higher while E 
coli and S.aureus lower in normal weight. Total bacteria 
especially S.aureus positively correlated with cholesterol. 
Lactobacillus group negatively correlated with infant birth 
weight in women with excessive weight gain. Normal 
weight women had higher HDL, iron and folate 
Bifidobacteria and Bacteroides 
may play a positive role in weight 
management of pregnant women 
and in their metabolic regulation. 
Kalliomak
i M. et al. 
2008(258) 
Children, 25 
obese and 24 
normal weight at 
7 years age 
To evaluate whether 
differences in gut microbiota 
at an early age precedes the 
development of atopy. 
 Subjects examined at 3, 6, 12, 24 
months and 7 years. Gut microbiota 
composition at age 6 and 12 months by 
FISH, FISH with flowcytometry and 
qPCR. 
Higher Bifidobacteria numbers and lower S. aureus at 6 
and 12 months age in children remaining normal weight.  
More Bacteroides in obese and overweight children during 
6 and 12 months than in normal weight children. 
Bifidobacteria constitute an internal link between 
breastfeeding and weight development 
Higher numbers of Bifidobacteria 
and low numbers of S. aureus in 
infancy may provide protection 
against overweight and obesity 
development. 
Zhang HS 
et al. 2009 
(167) 
3 Obese (OB), 3 
normal weight 
(NW) and 3 post-
gastric bypass 
(GB) patients 
To compare the gut microbial 
community of normal weight, 
morbidly obese and post-
gastric bypass surgery 
patients 
DNA pyrosequencing and 
amplification by real time PCR. 
GB group had a marked increase in Gammaproteobacteria, 
Enterobacteriaceae, and Fusobacteriaceae and fewer 
Clostridia. Prevotellaceae (H2 producing) enriched in the 
OB group compared with the NW group.  Methanobacteria 
(H2 consuming bacteria of the group Archaea) were found 
more in obese group. 
Confirm an association between 
methanogenic Archaea and 
obesity. H2 uptake by 
methanogens accelerates 
fermentation by H2-producing 
Prevotellaceae, which leads to 
increased production of acetate. 
Duncan 
SH et al. 
2008 
(260) 
33 obese and 24 
non-obese 
subjects 
To examine the relationships 
between BMI, weight loss 
and the major gut microbial 
groups 
16S rRNA sequencing using FISH, 
quantitative PCR. Dietary intervention 
with high protein low carbohydrate 
ketogenic diet and high protein 
moderate carbohydrate non-ketogenic 
diet 
No difference in total bacteria and Bacteroides between 
obese and non-obese. No significant relation between BMI 
and Bacteroides. Bacteroides were not affected either by 
diet or by diet order, and no significant relationship 
between number of Bacteroides and weight loss. Reduction 
in Roseburia-Eubacterium rectale. Reduction in 
Bifidobacteria after 4 weeks of low carbohydrate weight 
loss diets. 
No relationship of Bacteroides 
and Firmicutes ratio at phylum 
level with obesity. Low 
carbohydrate weight loss diets 
results in reduction in butyrate 
producing bacteria Roseburia-
Eubacterium rectale, together 
with Bifidobacteria 
Duncan 
SH. et al. 
2007 
(166) 
20 obese healthy 
volunteers 
To evaluate the effect of high 
protein and low fermentable 
carbohydrate diet on gut 
microbiota activity and 
population. 
Dietary intervention with maintenance, 
high protein medium carbohydrate and 
high protein low carbohydrate diets. 
Bacterial enumeration with FISH and 
butyrate with GC  
Total SCFA were lower during consumption of the HPMC 
and HPLC diets.  Butyrate was lower for the HPLC than for 
the HPMC diet. Butyrate proportion decreased as 
carbohydrate supply was lowered. Most abundant bacterial 
group was Cytophaga-Flavibacterium-Bacteroides group 
butyrate production and counts of 
certain bacteria are largely 
determined by the content of 




and Clostridial cluster IV. Bacterial count reduced 
significantly with reduction in carbohydrate including close 
relatives of Roseburia intestinalis and Eubacterium rectale. 
Faecalibacterium prausnitzii had fewer roles in 
fermentation. 





Effect of weight loss 
intervention on the faecal gut 
microbial composition and 
immunoglobulin coating 
bacteria and its relationship 
to weight loss.  
Restricted calories diet and increased 
physical activity for 10 weeks. BMI, 
BMI z-scores before and after 
intervention. Microbiota by FISH and 
immunoglobulin coating bacteria by 
fluorescent-labelled F(ab')2 antihuman 
IgA, IgG and IgM 
Clostridium histolyticum, Eubacterium rectale-Clostridium 
coccoides groups’ decreased count with weight loss. 
Bacteroides Prevotella increased and total faecal energy 
decreased upon weight loss of >4 kg. IgA coating bacteria 
decreased with weight loss of >6 kg. 
Changes in adolescents’ body 
weight is linked to specific gut 
microbiota and an associated IgA 
response in obesity after lifestyle 
interventions 
Walker 
AW et al. 
2010 
(253) 
16 obese stable 
weight subjects 
To examine the influence of 
the precisely controlled diet 
on the human colonic 
microbiota population and 
composition 
Intervention with maintenance diet, 
resistant starch, non-starch 
polysaccharide, low carbohydrate diet, 
and wheat bran. Chemical analysis of 
diet composition and digestibility.  
Real time qPCR, denaturing gradient 
gel electrophoresis (DGGE). 
Marked Inter-individual variation was noted. 
Ruminococcus bromii increased with RS diet. Oscillibacter 
group increased on the RS and WL diets. Relatives of 
Eubacterium rectale increased on but decreased, along with 
Collinsella aerofaciens, on WL. 
Depending on the initial 
composition of gut microbiota of 
an individual, different dietary 
carbohydrates can produce 
substantial changes in gut 
bacterial diversity. 
Tihonen K 
et al. 2010 
40 obese and 
non-obese adults 
To compare obese and lean 
individuals’ gut bacterial and 
immunological biomarkers 
with blood glucose, lipids, 
satiety related hormones and 
inflammatory markers.  
Interview for dietary fibre, 
anthropometry, faecal sample for 
microbiota diversity using PCR and 
inflammatory markers. Blood 
biochemistry for hormones and 
inflammatory markers 
IL6, CRP, Insulin, TAG and leptin rose in obese. BCFA 
and phenolics increase in obese faecal samples indicate 
increased bacterial fermentation due to protein rather than 
carbohydrates. waist circumference and Bacteroides were 
inversely correlated while positively correlated with IL6 
Increased phenolics and lactic 
acid in intestine of obese subjects 
most probably have an effect on 
the physiology of systemic 
inflammatory condition. 
Larsen N 






To assess the differences 
between gut microbiota of 
diabetic and non-diabetic 
persons 
Bacterial composition of faecal 
samples by real time PCR and by tag-
encoded amplicon pyrosequencing of 
V4 region of 16S rRNA gene 
Bacteroides, Proteobacteria and lactobacilli more in 
diabetics, Firmicutes (clostridium group) were higher in 
non-diabetics. Ratio of Bacteroides Prevotella group to 
C.coccoides-E. rectale group positively correlated with 
glucose level and negatively correlated with BMI. Β-
Proteobacteria highly enriched in diabetics and positively 
correlated with plasma glucose levels. 
Reverse Firmicutes to 
Bacteroides ratio in diabetic 
patients indicate a different 
Bacterial composition in this 
group. Increased number of Gram 
negative bacteria may explain the 
chronic low grade inflammation 




A et al. 
2009 
(263) 





The evaluate the influence of 
weight loss intervention on 
the gut microbiota  and body 
weight of overweight 
adolescents  
Energy restricted diet and increased 
physical activity to all participants. 
Anthropometric measurements, food 
diaries and faecal sample for qPCR 
Two distinct groups emerged with high (>4 kg) and low 
(<2 kg) weight loss groups. In Overall groups and in high 
weight loss group; increase in Bacteroides fragilis, 
Lactobacillus group and decrease in C.coccoides, 
Bifidobacterium longum and Bifidobacterium adolescentis.  
In high vs. low weight loss groups. Total bacteria, B. 
fragilis group and Clostridium leptum group, and 
Bifidobacterium catenulatum group counts significantly 
higher while levels of C. coccoides group, Lactobacillus 
group, Bifidobacterium, Bifidobacterium breve, and 
Bifidobacterium bifidum significantly lower in high vs. low 
weight loss groups 
Correlation of gut microbiota 
with body weight may be 
sensitive to the life style 
intervention such as weight loss 
to a different extent depending on 
the composition of gut microbiota 
of an individual 
Schwiertz 






33 obese adults 
To evaluate the differences in 
gut bacteria and faecal Short 
chain fatty acids between 
lean and obese individuals 
Faecal samples for quantitative PCR 
and SCFA analysis 
>20% higher SCFA in stools of obese than lean, with 
higher propionate and butyrate. Significantly higher 
Bacteroides in overweight than lean but not obese. 
Overweight and obese had higher Bacteroides and lower 
Ruminococcus flavifaciens and Methanobrevibacter. 
C.leptum and Bifidobacteria significantly lower in obese 
only. Positive correlation between BMI and propionate, % 
propionate, Bifidobacteria and Methanobrevibacter even 
after correction for the influence of age and gender. 
Because of controversial results, 
no specific bacterial group can be 
attributed to obesity at this stage. 
Armougo








To determine the role of 
Methanobrevibacter smithii 
and Lactobacilli in patients 
with abnormal weights using 
real time PCR 
Real time PCR Reduction in the Bacteroidetes community and higher 
Lactobacillus species in obese patients than in lean controls 
or anorexic patients. M. smithii much higher in anorexic 
patients than in the lean population.  
Lactobacilli used as probiotics 
may be linked to obesity. M. 
smithii in Anorexia Nervosa 
patients may represent an 
adaptive response to the disease. 
Turnbaugh 
PJ et al. 
2009 
(264) 
31 Adult Mono- 
and 23 Di-
zygotic (MZ & 
DZ) female twins 
and their mothers 
(n=46) 
To assess how gut 
microbiome is influenced by 
the host genotype, external 
environment, and the extent 
of host adiposity  
UniFrac analysis, and gut microbiota 
assessed by 16SrRNA pyrosequencing 
No significant difference in the degree of similarity in the 
gut microbiota of adult MZ versus DZ twin-pairs. 
Decreased Bacteroides and increased Actinobacteria in 
obese. Difference in Firmicutes was not significant. 
Glucosyltranferases were similar in all individuals while 
glycoside hydrolases were variable. Phosphotransferases 
involved in microbial processing of carbohydrates were 
rich in obese. 
Genomic profile of microbiota 
exists at a level of metabolic 










(n=16) with their 
infants and non-
obese mothers 
(n=26) with their 
infants  
To evaluate the faecal 
microbiota of infant born to 
overweight and normal 
weight mothers and to find 
out their relationship with the 
weight and weight gain of 
mothers during pregnancy. 
Faecal sampling of infants, weight of 
mothers before and during pregnancy. 
Real time PCR and FISH with 
flowcytometry for bacterial 
composition 
Bacteroides and S.aureus higher in infants of overweight 
mothers. Higher weights and maternal BMI related to 
higher concentrations of Bacteroides, Clostridium, and 
Staphylococcus and lower concentrations of the 
Bifidobacterium group. Lower counts of Akkermansia 
muciniphila, Staphylococcus, and Clostridium dificile 
groups and higher no. of Bifidobacteria in infants of normal 
weight mothers and those with normal pregnancy weight 
gains. 
Lower Bifidobacteria and higher 
S.aureus associated with obesity 
in children. BMI, weight and 
weight gain of mothers before 
and during pregnancy affects the 
gut microbiota composition in 
infants 
Ley et al. 
2006 
(164) 
12 obese Human 
adults, followed 
over a period of 
1 year  
To show that the relative 
proportion of Bacteroidetes 
group of bacteria in the gut of 
obese people are more as 
compared to lean individuals 
16S rRNA gene sequence library of 
gut microbiota in obese subjects 
on weight reduction diets (low 
carbohydrate or low fat, n = 12) 
Gut bacteria are remarkably constant in individuals. 
Relative proportion of Bacteroidetes increased compared 
with Firmicutes and correlated with percentage of weight 
loss 
The gut in obesity exerts 
ecological 
pressure promoting a higher 
relative abundance of Firmicutes 
Jumpertz 
R et al. 
2011 
(265) 
12 lean and 9 
obese adults 
To assess the influence of 
change in nutrient load on the 
gut microbiota of lean and 
obese individuals and 
correlation of microbiota 
with energy harvest from the 
diet 
Stool and urine energy content with 
change in caloric content of diet, 
culture independent metagenomic 
studies of microbiota  
Nutrient load caused 20% increase in Firmicutes  and 
corresponding decrease in Bacteroides in lean subjects with 
approximately 150 kcal increase in energy harvest from 
diet 
Nutrient load affects gut 
microbiota composition which is 
also associated with increased 





infants  (n=330) 
at 9, 18, and 36 
months of age 
Characterization of gut 
microbiota of infants at 
different ages 
qPCR, DEXA and bio-electrical 
impedance analysis for body 
composition, barcoded food diary for 7 
days for dietary analysis 
At 9 months: higher Lactobacilli, Bifidobacteria, and 
Enterobacteria. At 18 months; Firmicutes (particularly 
C.leptum, E.halii, and Roseburia) and Bacteroidetes 
increase while Bifidobacteria, lactobacilli, and 
Enterobacteria decrease except B. adolescentis. At 36 
months; high Firmicutes, Bacteroidetes, and small fraction 
of Actinobacteria, Proteobacteria, and Verrucomicrobia. No 
correlation of specific bacteria with mode of delivery, 
dietary or anthropometric parameters. Increase in BMI 
between 9-18 months was associated with higher 
Firmicutes 
Significant differences occur 
between 9 and 18 months, and 
changes at 36 months are 
independent of breast feeding at 
early age. Butyrate producers 
positively correlated with BMI 
might indicate increased 










(n=27) age 6-16 
years, 
To assess differences in gut 
microbiota between lean and 
obese children 
Selective plating and qPCR, MALDI-
TOF-MS for detailed study of 
Bacteroides fragilis group. Dietary 
records for dietary intake 
High Firmicutes to Bacteroides ratio in obese vs. lean. Low 
B. vulgatus and high Lactobacillus spp. in obese vs. lean. In 
all groups, S. aureus positively associated with energy 
intake. Lactobacilli in obese children positively associated 
with plasma CRP.  
Obese microbiota are different 









To assess differences in gut 
microbiota-associated urinary 
metabolites between obese 
and lean and how these 
differences are affected by 
biliopancreatic or Roux-en-Y 
surgery 
high-resolution proton NMR (1H 
NMR) spectroscopy 
Baseline: Lower levels of hippurate, xanthine, and 
trigonelline and higher levels of 2-hydroxybutyrate in 
obese vs. lean. Inverse relationship of xanthine with plasma 
uric acids levels 
3 months after surgery: reversal of the above metabolites 
with weight loss 
Obese phenotype is associated 
with a peculiar metabotype 
compared to lean. These 
metabolic changes are reversed 
with bariatric surgery 
Cotillard 





To investigate temporal 
relationship between food 
intake, gut microbiota, and 
metabolic and inflammatory 
phenotype 
6 week energy restricted, high protein 
diet followed by 8 weeks weight 
maintenance period, food diaries, 
quantitative metagenomics 
Gene counts showed bimodal distribution. Patients with 
low gene count (<480,000 genes) had a tendency towards 
higher LDL, dys-metabolism, insulin resistance, 
inflammation and obesity and vice versa for high gene 
count. Weight loss diet partially reduce inflammation and 
improve dys-metabolism but not to full extent 
Obesity is associated with lower 
gene richness which is partially 






To investigate the effect of 
prebiotic induced  gut 
microbiota modulation on 
PUFA derived bacterial 
metabolites production 
Inulin type fructans (oligofructose 
50/50) supplementation (16g/day) for 
3 months, qPCR, Human intestinal 
tract chip analysis, circulating fatty 
acids levels (UFA derived bacterial 
metabolites) 
Treatment with prebiotics did not affect levels of PUFA 
derived conjugated linoleic and linolenic acids. PUFA 
derived bacterial metabolites were negatively correlated 
with total cholesterol, LDL, and HDL, while positively 
correlated with Bifidobacterium spp., Eubacterium 
ventriosum, and Lactobacillus spp. 
 
Fernandes 





60 years), lean 
adults (n=52, age 
18-67 years) 
To investigate dietary 
intakes, faecal SCFA, gut 
microbiota composition and 
physical activity levels in 
simple obese vs. healthy lean 
adults 
3 day food diary, breath methane and 
hydrogen, faecal SCFA, qPCR 
Higher acetate, propionate, butyrate, valerate, and total 
SCFA in obese vs. Lean. No difference in Firmicutes to 
Bacteroides/Prevotella ratio between lean and obese. 
Higher E.coli in lean compared to obese. Irrespective of the 
group, total faecal SCFA were negatively correlated with 
Bacteroides/Prevotella and positively correlated with 
Firmicutes/Bacteroides ratio 
Obese phenotype carries distinct 
energy harvesting capability than 
lean. However, the evidence is 
not conclusive due to limitations 
such as small differences, age 
differences between participants, 










To perform a holistic 
phylogenetic and functional 
analysis of the gut microbial 
communities of the lean and 
obese microbiome 
454 FLX pyrosequencing, Orbitrap 
MS/MS 
Lean microbiome more diverse than obese. High 
Firmicutes (~95% vs. 78%) and low Bacteroidetes (~4% 
vs. ~18%) in obese vs. lean. Obese metagenome associated 
with vitamin B12 and 1, 2-propandiol metabolism while 
lean metagenome with B6 metabolism. High butyrate 
production in obese than lean 
Lean and obese metagenome and 
microbiome differ from each 
other however; both shows 
functional redundancies in terms 
of proteins expression 
Karlsson 






To investigate differences in 
faecal gut microbiota 
between lean and obese 
children  
qPCR and RFLP, liver function tests Significantly higher Enterobacteriaceae and significantly 
lower Desulfovibrio and Akkermansia muciniphila in obese 
than lean. No difference in Lactobacillus, Bifidobacterium, 
and Bacteroides fragilis between lean and obese. Serum 
alanine aminotransferase negatively correlated with 
Bifidobacterium. No difference in faecal calprotectin 
between lean and obese. 
Differences in gut microbiota 
composition exist at an early age 
between lean and obese. The 
study is however crossectional. 






women  (n=30) 
To assess the impact of  Roux 
en Y gastric bypass surgery 
(RYGB) on the gut microbial 
population and its effect on 
the genes expression in white 
adipose tissue (WAT) 
454 GS-FLX Pyrosequencing of faecal 
samples at 0, 3, and 6 months after 
RYGB, dietary assessment,  
Increase in Proteobacteria after RYGB by 37%, increase in 
association between 102 genera and 562 WAT genes. 
Bifidobacteria and Firmicutes such as Dorea, Lactobacilli, 
and Blautia decreased while Bacteroides such as 
Bacteroidetes and Alistipes and Proteobacteria such as 
E.coli increased after 3 months. About 50% of changes in 
genes expression were independent of caloric intake. No 
difference seen between 3 and 6 months 
Gut microbiota richness increase 
after RYGB with changes in 
associations with genes 
expression in WAT. Further 
exploration of gut microbiota 
with weight loss is needed 
Weickert 




(n=69, age 24-70 
years)  
To investigate mechanisms 
for the effect of high cereal 
fibre on insulin sensitivity by 
exploring gut microbiota 
composition and colonic 
fermentation  
18 weeks intervention with cereals. 
Gas chromatography for SCFA. In-
vitro fermentation on healthy 
volunteer faeces with fibres, FISH and 
flowcytometry. Euglycemic clamp for 
insulin sensitivity 
No difference in faecal SCFA at 0, 6, and 18 weeks. No 
differences in SCFA with In vitro fermentation. Roseburia 
tended to decrease, Clostridium cluster IX decreased after 6 
weeks but not at 18 weeks, Atopobium increased after 18 
weeks. Insulin sensitivity improved after 18 weeks 
Improvement in insulin 
sensitivity is not associated with 
colonic microbiota metabolism 
and fermentation  
Brignardel
lo Jet al. 
2010 
(266) 
13 obese and 11 
normal weight 
adults 
Evaluation of gut 
permeability in asymptomatic 
obese and its relationship 
with plasma and faecal 
markers of inflammation and 
alteration in gut microbiota  
Lactulose- mannitol sucralose test for 
intestinal permeability, blood CRP and 
fatty acids. Faecal G+C profiling, 
calprotectin and leptin 
CRP levels were significantly higher in obese than non-
obese individuals. Faecal fat, calprotectin and leptin and 
ARA/EPA were not significantly different in both groups. 
Obese subjects had significant increase in relative 
abundance bacteria with 23-37% G+C contents in their 
DNA and significant decrease in the relative abundance of 
those with 40–47% and 57–61% of G+C content. G+C 
peak values negatively correlated with CRP values. 
Gut microbiota differ between 
obese asymptomatic and non-
obese. High CRP levels in 
asymptomatic obese individuals 




1.9 Conclusion and proposed area of research 
Recent decades have witnessed an increase in prevalence of obesity in pandemic 
proportions both in adults as well as children. Several factors have been identified in the 
literature to explain the aetiology and pathogenesis of obesity such as factors related to 
diet, life style, environmental factors, and host genetic factors. However, as discussed in 
detail in this chapter, none of these factors fully explain the aetiology of obesity and the 
search for possible causes of obesity is still under exploration. The gut microbiota have 
recently been advocated as one of the factors affecting host energy homeostasis through 
several putative mechanisms investigated in mouse models and some human studies (Table 
1.5). However, several studies in animal and humans have suggested a profound effect of 
diet on the changes in the gut microbiota to influence host metabolism towards a lean and 
obese phenotype.  
When taken together, evidence linking gut microbiota to the increasing epidemic of 
obesity in animal and human studies is inconclusive and controversial to suggest a ―cause 
or effect‖ relationship. There are limitations in exploring this relationship partly due to 
differences in methodology, study designs, lack of control over the diet, genetic propensity 
of individuals to obesity, and other life-style factors. Moreover, faecal samples are the 
usual source of gut microbiota used in human studies which may not represent the true 
picture of the gut microbial population. Access to the full length of the gut is restricted for 
medical or ethical reasons. In addition; differences between animals and human beings 
such as differences in intestinal microbiota, metabolic rate, and length of intestine, caecal 
fermentation, coprophagy (habit of rodents eating their own faecal matter) and genetic 
variability limit the extrapolation of results from animal studies to humans.  
Whether gut microbiota are causally related to the aetiology of obesity or it is an 
effect of differences in dietary intakes between lean and obese people is a question 
unanswered and less well explained. Most of the studies thus far have studied obesity only 
in relation to lean phenotype and have therefore been unable to establish reverse causality. 
Furthermore, obesity in childhood is linked to obesity in adulthood and gut microbiota 
metabolic activity and composition is a subject of great controversy in this age group 
similar to that in adults. To help unravel this conundrum, we designed this observational 
study comparing obesity of known versus unknown aetiology to investigate differences in 
the gut microbiota metabolic activity and composition using high throughput sequencing 
technology. A difference in the gut microbial composition and metabolic activity between 
known and unknown cause of obesity would implicate a causal relationship of gut 
microbiota with obesity. 
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Out of thousands of bacterial species in the gut, very few have been cultured so far. 
Therefore new culture independent molecular microbiology techniques have been 
developed (267) of which most high throughput analysis techniques used are barcoded 
pyrosequencing and phylogenetic microarrays (268, 269). Most recent advances in 
molecular microbiology focus on functional studies with suffix ―-omics‖: including 
metabolomics, proteomics, and metatranscriptomics. This has resulted in an extensive 
catalogue of 3 million non-redundant bacterial genes which has been derived from 124 
European subjects and 178 intestinal bacterial species metagenome (270, 271) including 
healthy volunteers, obese subjects and patients with Inflammatory Bowel Disease (IBD). 
Development of these techniques has further enhanced our understanding of the diet-host-
gut microbiota relationship.  
Many studies report faecal SCFA in relation to specific gut microbiota as a 
surrogate marker of colonic fermentation capacity (table 1.5). Since, faecal gut bacterial 
metabolites (such as SCFAs) might be the result of either an increased production in the 
colon or malabsorption in the gut, the actual colonic fermentation capacity might be over 
or under-estimated. Incubating faecal samples in batch cultures with a range of dietary 
fibres mimicking gastrointestinal condition might therefore be a practical and reliable way 
to establish the energy harvesting capability of the gut microbiota. To date only 4 studies 
have measured fermentation capacity of gut microbiota of obese and lean individuals and 
none in children. To establish the energy harvesting capability of the gut microbiota in 
obesity of different aetiology, we therefore incubated faecal samples in in-vitro batch 
culture fermentation using 5 dietary fibres. 
By and large the evidence to prove reverse causality is still missing. The aim of this 
PhD journey was therefore to investigate the relationship of gut microbiota diversity, 
metabolic activity, and fermentation capacity in a set of patients with known of cause of 
obesity (pathological or hypothalamic obesity) and compared them with an unknown cause 





Figure 1.9: Schematic representation of the study question for this PhD 
 
 




 Chapter 2: Subjects and Methods 
This chapter describes the study design, eligible participant characteristics, research 
methodology, data handling, statistical analysis and process of ethics approval. 
2.1 Study design 
This was a prospective observational study, carried out as a joint collaboration of the Unit 
of Human Nutrition, University of Glasgow and the Departments of Paediatric 
Endocrinology and Paediatric Dietetics, Royal Hospital for Sick Children Yorkhill, 
Glasgow. The study was approved by the West of Scotland research Ethics committee 
(WoREC) and Research and Development department of National Health Service (R&D 
NHS) Greater Glasgow and Clyde on 14
th
 of September 2011 for a period of 4 years under 
the study reference number WS/11/032 and title ―Diet, gut microbiota, and energy from 
colonic fermentation of dietary carbohydrates in children with simple and pathological 
obesity; cause or effect?‖ (appendix 1). 
2.2 Recruitment 
2.2.1 Definition of obesity and study participants 
For the purposes of this study ―obesity‖ was defined in those under 24 years as a BMI SDS 
more than or equal to 2 standard deviations (≥2 SD). Those with a BMI SDS less than 2 
SD were classed as lean. Participants aged more than or equal to 24 years were classed as 
obese if their body mass index was ≥30 kg/m2 based on the International Obesity Task 
Force criteria for obesity in adults (4). Eligible participants for this study were: 
A. Children and young adults with classical/simple obesity: This group included children 
and young adults who were classified as obese in the presence of unknown aetiology of 
obesity. This group of children were recruited from the weekly dietetic outpatient 
clinics in Royal Hospital for Sick Children Yorkhill Glasgow. The dietetic clinics 
manage obese patients who are either referrals from GP surgeries or the community 
weight management programs for the dietetic management of obesity. 
B. Hypothalamic/pathological obesity: These were those whose obesity was related to a 
known medical cause, usually related to malfunctioning hypothalamic control of 




dietary intake (e.g. craniopharyngioma or due to a genetic syndrome such as Prader-
Willi Syndrome (PWS)).  
C. Lean hypothalamic group: As not all of the PWS children were obese, those with 
normal BMI were assigned to a separate subgroup (lean hypothalamic group) who 
would act as a ―control‖ for the obese children with the same pathology. 
D. Healthy lean children and young adults with normal weight were recruited as a control 
group (healthy participants with no chronic disease or other illness: Normal weight 
participants had a BMI within 2 standard deviations of the mean for that particular age 
and sex or between 18-25 kg/m
2
 in the case of adults).  
E. Parents of the above four groups (simple obese, hypothalamic obese, hypothalamic 
lean and healthy lean control): The aim of their optional recruitment was to analyse 
their gut microbiota for assessment of similarity and differences of bacterial 
community structure and metabolic activity with their children. This group included 
adult parents only of the recruited participants. However, data generated as a result of 
parents’ recruitment, body composition, and collected faecal samples were not included 
in this thesis. 
2.2.2 Exclusion criteria 
Each patient was screened using a health check questionnaire to rule out conditions related 
to changes in physiology of the gut which can alter gut microbiota composition and 
metabolic activity such as gut surgeries, immune disorders of the gut, systemic use of 
probiotics and prebiotics, or medications. Specifically exclusion criteria were:  
A. Participants who had an active gastrointestinal condition or any surgical procedure 
involving removal of part or the whole gut. 
B. Use of antibiotics in the past 4 weeks.  
C. Systemic use of pre- or probiotics, defined as a daily use of prebiotics or probiotics. 
The use of certain complex polysaccharides (prebiotics) or live cultures of bacteria 
(probiotics) have also been shown to alter the metabolic activity and gut microbial 
diversity. Therefore children who were prescribed with or using probiotic drinks as 
daily food component were excluded from the study. 




2.2.3 Recruitment of subjects 
2.2.3.1 Recruitment of hypothalamic obese subjects and their parents 
Participants in this group were recruited from the 4-monthly endocrine PWS or 
craniopharyngioma clinics. This clinic manages patients from the West of Scotland and 
some parts of Northern England. Potential participants were first identified by the 
consultant endocrinologist from the hospital database. The age range of these participants 
varied between 2-25 years. Information sheets about the study were sent to all identified 
patients under the age of 25 years, 7 days prior to their regular clinical appointment. These 
information sheets aimed to inform the eligible participants and their parents about the 
study, and that a researcher would approach them to ask if they were willing to participate. 
On the day of visit to the hospital, these patients were introduced to the study by 
the clinician. If the participants were willing to know more about the study, the researcher 
would discuss the study with them. The participants were then given enough time to ask 
any questions about the project. If the participants and their parent/carer agreed to 
participate, the researcher would ask them to sign a consent form in triplicate; one for the 
patient, the researcher, and the hospital records.  They were then given instructions by the 
researcher about sample collection, a food frequency questionnaire and 24 hour food diary 
for dietary records. They were also given contact information for mail, email or phone if 
they had any queries in future. 
2.2.3.2 Recruitment of simple obese subjects and their parents 
Participants in this group were recruited through weekly dietetic clinics. Participants 
attending these clinics were recruited in the same way as hypothalamic obese patients.  
2.2.3.3 Recruitment of control group and their parents 
Participants in the control group and their siblings were recruited through advertisements 
and by word of mouth. We tried to match their age (2-16 years and above) and 
demographic characteristics with those of simple obese and pathological obese groups; 
however, this was not successful. The advertisements were posted in and around the 
hospital, the University, and different parts of Glasgow. Interested individuals were 
requested to contact the researcher through e-mails or phone. All interested responders 
were sent information sheets through the post or electronically via email. If they were 
happy to participate in the study, they were requested to arrange a meeting with the 
researcher either at the hospital, or a place of their own convenience, or at their home if 




they were happy for the researcher to come. To check for their eligibility for the study, the 
participant were asked questions regarding any chronic disease, use of medication, use of 
antibiotics over the last 4 weeks, and regular use of probiotics. Participants who met the 
eligibility criteria and were happy to participate gave written informed consent. Dietary 
information was collected as described below. They were instructed by the researcher 
about collection of faecal samples. Contact information was given to the participants for 
queries they might have.  
2.2.3.4 Follow-up assessments 
The process of health check, sample collection, and 24 hour food diary was repeated after 
2-3 months for the participants only. Parents were asked to give only one sample, if they 
were happy to participate. 
2.2.4 Collection of dietary information 
Dietary information was collected by a 24 hour food diary. The participants or their parents 
on the participant’s behalf were asked to record all food intakes throughout 24 h starting 
from one time of the day chosen by the participants at their own convenience. Questions 
were asked about the time when food was taken (e.g. 8 am), details of the food (e.g. 
cornflakes, semi-skimmed milk and sugar), quantity of the food consumed (e.g. a bowl of 
cereal in one cup of semi-skimmed milk and half teaspoon white sugar), method of 
preparation (e.g. un-cooked, cooked, boiled, grilled etc.), and method of food serving (e.g. 
cold or hot, refrigerated, frozen etc.) 
Participants were asked to fill in the food diary prior to the day they were intending 
to provide a faecal sample to match the faecal metabolites with the diet being consumed. 
They were also encouraged to fill the food diary prospectively, starting from early 
morning, to reduce the chance of memory-recall bias or insufficient (<24 h) food entry. 
However, some participants filled the diary in retrospect (n=10).  
The food diaries were collected at the same time as faecal samples or were handed in by 
the participants in the clinic at the time of recruitment or in some cases, were posted after 
the sample was collected. 
2.2.5 Sample collection and processing 
At the time of signing the consent, every participant was given a faecal sample collection 
kit. Each kit had a pre-weighed stool collection pot, a plastic bag to enclose the pot along 




with an anaerobic gas production kit(Anaerocult® A Merck KGaA 62471 Darmstadt, 
Germany or Anaerogen
TM
 Compact Oxoid limited Hampshire, England), a cool pack (to 
keep the sample cold), a pair of gloves (for sample handling), a paper bed pan (for use on 
the toilet seat to facilitate sample collection), and an instruction sheet (for sample 
collection and handling at home and contact details of the researcher). A ―possible‖ sample 
collection day was agreed between the parents and the researcher. Courtesy calls and 
reminders were made every two weeks in cases where the sample was not available on the 
agreed day. When the sample was ready for collection, the participant or parent would call 
the researcher immediately. The participants in most cases asked the researcher to come 
and collect the sample or brought the sample themselves, or rarely, sent it via a taxi. Any 
expenses incurred by the participant in relation to the study participation were reimbursed. 
The radius of the distance from which the samples were collected is shown in Figure 2.1. 
Figure 2.1: Approximate radius for sample collection. 
 
Outer circle represent approximately 120 miles radius. About 15% participants fall in the outer circle. The 
public transport time from the farthest point on this radius would take at least 5 h to and from the lab. This 
has been a major limitation in processing the sample within 4h period 
2.2.6 Progress of recruitment 
2.2.6.1 Recruitment of PWS and craniopharyngioma patients 
Recruitment of this group began from the first available clinic on the 28
th
 of October 2011 
and ended at the January 2013 clinic. In total 5 clinics (each after every 4 months) were 




attended during this period for recruitment purposes. Forty eight PWS patients including 
adults more than 25 years attending the Yorkhill endocrine clinics were approached. 
Participants with age >25 years (n=7) or having severe co-morbidities (n=2) or using 
regular probiotic drinks (n=1) were excluded from the study. Amongst patients attending 
craniopharyngioma clinics (n=12), one patient age >25 years was excluded from the study, 
5 patients declined to participate, while one patient did not respond after giving written 
informed consent. Response rate of the participants in this group after consent was 63% 
(Figure 2.2).  
Parents/carers of the recruited participant in this group were also requested to take 
part in the study by giving single faecal sample. Thirteen of the 25 parents managed to give 
a faecal sample while others refused after giving consent (n=10) or did not respond after 
consent (lost to follow up) (n=2). 
Figure 2.2: Progress of recruitment for PWS & Craniopharyngioma group 
 
Missed; those participants who did not attend the clinics during this period and were not available on phone 
or did not reply to the information sheets sent at the address, n; number of participants 





2.2.6.2 Recruitment of simple obese group 
Despite more regular clinics than the PWS and craniopharyngioma clinics, this group was 
the least successful among all the three groups to recruit due to a high refusal and a low 
attendance rate. A summary of the participants recruited in this group is given in Figure 
2.3. On average, weekly clinics were scheduled for 2-3 simple obese patients who were 
eligible for participating in the study, in addition to other obese or non-obese children with 
other diseases and who were not eligible for the study. Response rate of the participants in 
this group after consent was 72.7%. Of 17 parents of children in this group who initially 
consented to give a faecal sample; 9 were able to give one sample, 1 parent refused after 
giving consent, and 7 parents did not respond after consent.  
Figure 2.3: Summary of progress of recruitment of simple obese group 
 
2.2.6.3 Recruitment of control group 
A summary of recruitment of this group is given in Figure 2.4. A total of 45 potential 
participants were approached, of which 25 participants completed the study. Response rate 
of participants after consent was 80.6%. Although attempts were made to match 
participants in this group by age, ethnicity, demography, and gender with the other two 
groups, this was not fully achieved. 




Fourteen parents agreed to take part along with their children in this group; only 8 
of whom gave one faecal sample, one parent dropped out after consent, and 5 parents did 
not respond after consent. 
Figure 2.4: Summary of recruitment progress for lean healthy participants 
 
 
N; total number of participants approached, n; number of participants 
 
2.3 Laboratory Methods 
2.3.1 Sample analysis time 
It was aimed to process every faecal sample within 4 h after collection. The median (IQR) 
time elapsed between sample production (telephone call for sample collection taken as the 
time of sample production) and storage of the sample (after being processed) was 4 (1.1) h 
for healthy lean group, 5.1 (3.75) h for hypothalamic lean group, 4 (1.9) h for 
hypothalamic obese group, and 3.7 (2.9) h for simple obese group. It should be noted that 
some samples took longer than 4 h to be transported to the laboratory for processing either 
due to the longer distance for sample collection or because more than 3 faecal samples 
were unexpectedly received from different participants at the same time which made it 
difficult to be processed all at once. Some of these faecal samples (n=4, one from hypoth. 




Lean, 2 from simple obese, one from hypoth. obese) were immediately frozen at -20
o
C for 
few hours to stop any bacterial activity, and then processed as soon as possible. However, 
analysis of faecal short chain fatty acids (SCFA) and SCFA from the incubated samples 
from in vitro fermentation did not reveal any significant difference from other samples of 
the same group. 
2.3.2 Initial processing of the sample 
Each sample collected in cold anaerobic conditions was weighed along with the stool 
collection pot and then manually homogenized with sterilized wooden spatulas under a 
laminar flow cabinet. Any large undigested food pieces were removed whenever possible. 
A summary of the initial processing of the sample is given in Figure 2.5. 
Figure 2.5: Flow chart for initial sample processing in the lab 
 
 
Approximately 200 mg faecal sample was weighed in 2mlscrew-cap tubes in quadruplicate 
and immediately stored in -80
o
C.  About 1 g faecal sample was weighed in 5 ml bijoux 




tubes containing 3-5 glass beads in triplicate. To this was added equal volumes (1:1 w/v) of 
1 M NaOH to help retain the volatile fatty acids and stored in -20
o
C. 
To store sample for free and total faecal sulphide, about 1-1.5 g sample was 
weighed in 2 universal 25 ml tubes containing 3-5 glass beads. For free sulphide; 10 ml of 
1.25 M NaOH (sonicated on a sonicator (Sonomatic® Langford, Jencons Scientific ltd) for 
15 minutes) was added to one of these tubes and vortexed well. The diluted sample was 
then centrifuged at 15,000 g for 30 minutes in a centrifuge (Sorvall legend RT+, Thermo 
Scientific®, UK) in quadruplicate. The supernatant was then aliquoted in separate 2 ml 
safe-lock eppendorf tubes and stored in -20 
o
C until for further analysis. For total sulphide, 
10 ml of 0.11 M zinc acetate was added to one of the universal tube and vortexed to mix. 
The tube was then stored in -20 
o
C until analysed. Approximately 1 gram faecal sample 
was stored in 5 ml bijoux tubes for faecal calprotectin and faecal phenol and cresol and 
stored in -20 
o
C.   Any spare sample was stored in a 5 ml bijoux and/or 25 ml universal 
tube. 
2.3.3 Faecal pH 
Approximately 1 g of well homogenized fresh faecal sample was weighed on a digital 
scale. To this was added equal volumes of sterilized distilled water (1:3 v/v), vortexed 
thoroughly, and the pH measured on a portable bench-top pH meter (HANNAH®). 
2.3.4 Faecal Ammonia 
Faecal ammonia was measured using the same 1:3 v/v faecal slurry used for the 
measurement of pH. This slurry was diluted down by 1:500 by mixing 100 µl 1:3 v/v 
faecal slurry in 49.9 ml distilled water in a 50 ml universal tube. Ten millilitres of this 
1:500 slurry was filtered through 0.22 µl green Millipore filter (Millex®GP, Millipore, 
USA catalogue number; SLGP033RB) into a clear glass bottle. After adjusting the 
ammonia meter to zero with this clear filtrate, 4 drops each of the proprietary solution 1 
and 2 were added, gently inverted to mix, and then measured on the automated ammonia 
analyser (Hannah Electrical HI93715).    
 




2.3.5 In-Vitro Batch Culture Fermentation 
2.3.5.1 In vitro batch culture fermentation  
In vitro batch culture fermentation is a commonly applied method to determine the 
fermentation capacity for dietary fibres. This system does not remove fermentation 
products from the incubated inoculum, in contrast to the continuous and semi continuous in 
vitro systems that remove the fermentation products either continuously or intermittently. 
Many methods have been developed in different studies (Table 2.3). Most, if not all of 
them, have used different methods for reasons partially explained. Also, few of these 
studies have been validated by inter-laboratory validation studies and there is lack of in 
vivo validation data (272). Two of the validated methods are those of Barry et al. (1989) 
(273) and Edwards et al. (1996) (274). The method of Barry et al. (1989) is different in 
some aspects from that of Edwards et al. (1996) (Table 2.1). However, Barry et al. (1989) 
found different results in different laboratories for the same individuals after fermentation, 
despite similar conditions provided.  
Table 2.1: Salient features of method from Barry et al. (1989) that makes it different from methods by 
other authors 
Features of in vitro batch culture fermentation model used by Barry et al. (1989) 
 Different carbohydrates in addition to the resistant starch 
 Low inoculum size 
 Faecal samples from three volunteers whose samples were used in all the labs to 
maintain uniformity 
 Use of trace elements and urea in the medium for nutrition 
 Complementary experiments for investigating their ring test 
 
2.3.5.2 Rationale for fermentation method used in this chapter 
 
The in vitro batch culture fermentation technique used in this thesis is adopted from the 
study of Edwards et al. (1996) (274). This method differs from other methods in various 
aspects. It considers the physiology of the colon; therefore Edwards et al. have attempted 
to mimic human colon by using shaking water bath at a rate of 50 strokes per minute to 
mimic peristalsis. The medium is not required to be bubbled continuously with CO2 
because phosphate buffer is used to prepare the faecal slurry. A higher concentration of the 
faecal slurry is used that has been shown to provide suitable nutritive environment for the 
faecal microbiota thus reducing the need for excess fermentation medium. The use of 
carbonate and phosphate buffer does not allow a drop of pH due to SCFA production 
before the sample is being incubated in the fermentation bottles. The method has been 
validated in 8 laboratories on 40 healthy volunteers from different geographical regions, all 




with similar laboratory settings. Although the method has only been validated for starch, it 
has been used for other fibres in later studies based on the same method for different types 
of carbohydrates (295;296). 
2.3.5.3 Protocol for in vitro batch culture fermentation used in this thesis (Figure 2.6) 
Faecal samples were collected from study participants of all three groups, and brought to 
the laboratory as soon as possible [time between sample collection and taking the 0 h 
fermentation sample; median (IQR) 4 (2.0) h minimum 1.6 h and maximum 13.6 h]. The 
composition and preparation protocol for the solutions used are shown in Table 2.2 and the 
entire procedure is summarised in Figure 2.6. Sodium phosphate buffer [0.06 M KH2PO4 
(9.078 g/L) and 0.06 M Na2HPO4 (11.876 g/L mixed in a ratio of 1:4] was boiled on a hot 
plate and then cooled to 37 
o
C under Oxygen-Free nitrogen (OFN). A 32% w/v faecal 
slurry was prepared by adding sodium phosphate buffer (pH 7) and homogenizing it with 
the help of blender (Braun™) to maintain a constant pH before the samples are incubated 
in the fermentation bottles. Fermentation medium was freshly prepared using tryptone, 
carbonate buffer (ammonium bicarbonate and sodium bicarbonate buffer), macromineral 
solution (di-sodium hydrogen sulphate, potassium dihydrogenortho-phosphate, and 
magnesium sulphate), micromineral solution (containing cobalt chloride , manganese 
chloride, calcium chloride, and iron chloride), and a colouring reagent (0.1 M resazurin). 
The pH of the medium was adjusted before boiling on a hot plate for 5 minutes. 
Boiled medium was then cooled under Oxygen-Free Nitrogen (OFN) to 37 
o
C, and the pH 
was adjusted to pH 7 using 6 M HCl. Forty-two ml fermentation medium was added to 
each 100 ml pre-sterilized fermentation vessels. One gram each of five different substrates; 
pectin, Raw potato Starch, Maize starch, raftilose, and wheat bran were added to the 
bottles, except for the blank. Raw potato starch (starch from potato, cat. No. S2004) and 
Pectin (pectin from apple) were obtained from Sigma Aldrich (catalogue number; 76282), 
wheat bran from Infinity foods Co.(Product no.; BRAN3), Raftilose (Orafti® P95, 
BENEO, Tienen, Belgium ) was kindly provided by BeneoOrafti® Belgium, and maize 
starch (Hi-maize® 260) was kindly provided by the National Starch Food Innovation 
Manchester. Two ml of freshly prepared reducing solution (cysteine hydrochloride, sodium 
sulphide and 1 M sodium hydroxide) was then added to the bottles. All fermentation 
vessels were crimped and sealed with self-sealing silicon rubber-crimp tops to provide 
airtight anaerobic environment. The contents were mixed by shaking manually and then 
purged with OFN for two minutes each. The faecal slurry was strained through a nylon 
mesh to remove any particulate material and 5 ml of this final slurry was added into each 




bottle with the help of a 10 ml syringe. The final concentration of the faecal slurry in the 
42 ml medium and 1 g substrate obtained was 8.04%. All faecal samples from participants 
with initial weight sufficient to give the required amount of slurry for fermentation were 
incubated in duplicate for substrate as well as the blank.  
The bottles were incubated in a shaking water bath for 24 h at a speed of 60 strokes 
per minute. Three ml of fermentation supernatant was taken in 5 ml bijoux tubes from each 
incubated sample at 0, 4, and 24 h of incubation, their pH measured, and 1ml of 1 M 
NaOH added to stabilise faecal short chain fatty acids. These samples obtained were 
immediately stored at a temperature of -20 
o
C. 
Table 2.2: composition and preparation of the solutions used for in vitrofermentation studies 
Solution Volume Composition  Preparation  
Buffer Solution 
 
500 ml NH4HCO3 
NaHCO3 
Distilled water  





up to 500 ml 
Macromineral 
Solution  
500 ml Na2HPO4 or Na2HPO4.2H2O 
KH2PO4 or KH2PO4.2H2O 
MgSO4.7H2O 
Distilled water  
Store at 4 
o
C 
2.85 g or 3.57 g 
3.1 g or 3.92 g 
0.3 g 


















Tryptone in 450 ml of distilled water  
Micromineral solution 





Adjust the medium pH to 7, using 6 M 
HCl 













200 ml KH2PO4 0.06 M (9.078 g/L): 1.82 
g/200ml 
Na2HPO4 0.06 M (11.876 g/L): 2.38 
g/200ml 
Maintain pH of 7 & at 20
o




C up to 1 week max. 
78 ml Of KH2PO4 
0.06 M to 122 ml Of 




50 ml Cysteine hydrochloride 
NaOH 1 M 
Na2S.9H2O 




up to 50 ml 





Figure 2.6: Flow chart summarizing the in-vitro fermentation procedure (adopted from Edwards et al. 
1996) 
 
SBP; Sodium phosphate buffer, OFN; Oxygen-free nitrogen,  
2.3.5.4 Considerations  
The procedure was performed in aseptic environment, using sterilized containers, bottles, 
pipette tips etc. to avoid any external contamination. The medium was prepared fresh using 
sterilized distilled water and stock solutions were stored at an appropriate temperature up 
to a maximum of one week.  




Keeping in view the distance to travel and the variable timings of habits of the 
participating children, there was a difficulty in managing early processing of some faecal 
samples in the laboratory. However, the participants and their parents were provided with 
stool collection kits which would keep the samples cold with the help of ice packs and in 
an anaerobic environment with anaerocult® A, which produces gas that removes all the 
oxygen around the sample. 
Raw potato starch and maize starch would partly settle down in the medium even in 
shaking water bath at 60 strokes per minute, which might have affected the fermentibility 
of the dietary fibre due to insufficient exposure to the faecal slurry. This was minimized by 
constant monitoring and manual shaking during incubation and that the incubation period 
of 24 h was considered sufficient to reduce the overall effect of insufficient contact.  
Evidence from the literature suggests that the rate of fermentation is not affected by the 
mixing rate (272). Also many researchers did not use a shaking water bath during their 
fermentation experiments (275). 
The pattern of fermentation of the true fibre fraction of certain polymeric substrates 
(e.g. wheat bran) is masked by some starch content. Enzymatic pre-digestion is therefore 
applied in some studies to facilitate fermentation of the substrates (276, 277). Raw potato 
starch and wheat bran had no enzymatic pre-digestion in our study and no overnight 
hydration which might have affected the overall in vitro fermentibility of dietary fibre and 
the concentration of colonic SCFA because of protein contents of the cells. This however 
was thought unlikely in our experiments.  




Table 2.3: Various in vitro models of fermentation used in studies. 





(274) 40 healthy 
individuals in 
total, 4-7 in each 
of the 8 
laboratories  
Pregelatinized potato starch (RS1), 
raw potato starch (RS2), semi 
purified retrogradated amylase 
(RS3), Glassy pea starch (RS3) 




Carbonate buffer, mineral 
salts, at pH 6.5 
Phosphate buffer 24 h 50 strokes/min or 50 
rev/min, in a shaking  
water bath for 24 h,  
(273) 3 Healthy 
volunteers  for 
all the labs 
Solca-floc Cellulose, sugar beet, 
soybean fibre, maize bran, apple 
pectin, 100 mg each 
10 g/L Human 
faecal inoculum  
Carbonate-phosphate 
buffer  solution, Trace 
elements, urea, medium 





24 h Shaking Water bath 
(speed not given) at 37 
o
C,  
(278) Healthy adults 0.5 g each of Guar, pectin, gum 
tragacanth, gum Arabic, Karaya, 
course wheat bran, 
carboxymethylcellulose, Xanthan, 
Gellan 
200 g/L fresh 
human faecal 
inoculum. 10 ml 
into each bottle 
Trypticase (pancreatic 
digest of casein), minerals 








oligosaccharides in 5 g/L 
concentration 
10 g/L faecal 
inoculum  in 
degassed 
PBS(prepared from 
stored  faeces in 
50% glycerol ) 
Minimal Basal Medium ( 
containing peptone water, 
yeast, salts, bicarbonates, 
vitamins, reducing agents) 
Phosphate buffer 24 h Anaerobic cabinet at 37 
o
C 
(276) 3 healthy  
volunteers 
100 mg each of commercial rye, 
wheat, and oat bran,commercial 
inulin, raftilin P95. Starch and 
protein content removed after 
enzymatic digestion  process 
208 g/kg of faecal 
inoculum;  
Culture medium with 
carbonate phosphate buffer 
and trace elements.  
Culture medium 24 h Anaerobic chamber at 
30 
o
C for 2 h before 
adding the slurry, and 
then in the shaking 
water bath at 37 
o
C 
(275) 6 healthy 
volunteers (24-
45 years age) 
Oligofructose, inulin, other 
carbohydrates (glucose, arabinose, 
galactose, fructose, lactose, 
sucrose, lactulose, cellobiose, 
sorbitol, lactitol, Linter's starch, 
polydextrose, pectin, maltitol, 
arabinogalactan) 
5% w/v faecal 
slurry in anaerobic 
Sodium Phosphate 
buffer 0.1 M/L, pH 
7.0 
Batch culture fermenters 
(70 ml working volume) 




0.1M/L, pH 7.0 
48 h Incubation at 37
o
C. 
(No details given). 
Medium was flushed 
with high purity argon 
for 10 minutes 
 104 
 
2.3.6 Short chain fatty acids (SCFA) analysis 
Short chain fatty acids, including short, medium, and branched chain fatty acids, were 
extracted using diethyl ether and then analysed using Gas Chromatography TRACE GC 
2000 series Gas Chromatograph (GC) (Thermo Quest CE Instruments, Manchester, UK). 
The method is adopted from Laurentin and Edwards (126, 280). The methods have been 
used in the same research facility and elsewhere with or without modifications.  
2.3.6.1 Principles of gas chromatography 
Gas chromatography is a technique for separation of compounds in a sample mixture 
(Figure 2.7, Figure 2.8). The samples are injected into the ―gas chromatograph‖ through an 
injection port, where the sample is separated at a high temperature and pressure and 
converted into a gaseous phase.  The vaporized sample is then allowed to flow through a 
column by a carrier gas also called as ―mobile‖ phase. The carrier gas is an inert gas, 
usually helium, nitrogen, or sometimes hydrogen. In the column; the samples are separated 
into its components with the help of a liquid or ―static‖ phase which has a high partition 
coefficient and a high solubility for the samples. Through the process of repeated 
absorption and desorption; the vaporized sample is separated at different speed and time 
interval and elute at the distal end of the column where the molecules are detected by a 
flame ionization detector. Electrical signals are generated by the detector, which are 
recorded in the form of peaks, ―the chromatogram‖, at intervals depending on their 
molecular weight. The time from the point of injection to the appearance of the peak is 
called as the ―retention time‖ which identifies the peak. The area that is covered by the 
peak is called as the ―area under the curve‖, which is proportional to the concentration of 
the SCFA. Gas chromatography is a useful technique for SCFA extractions as it is a 
sensitive, accurate, speedy technique, relatively cheap and has a high resolution. However, 
it is limited in certain aspects such as the samples must be volatile and clean, as dirty 
samples can destroy the columns.   








The sample is injected into the injection port (b) and is vaporised by a high temperature (about 250
o
C) and 
pressure, the vaporised sample then flows through the column (c) with the help of a carrier gas (a). The 
sample separates into its components through absorption and desorption by mobile and static phase. The 
eluted components are detected by a detector (d) and peaks are generated on a chromatogram (e) which is 
used to identify and quantify the fatty acids. 
Figure 2.8: Series of temperature changes occurring in the oven to facilitate sample disintegration and 
subsequent elution at the detector end of the column. 
 
Note that the temperature of the injection chamber reaches 250 
oC at the ―initial temperature‖ stage when the 
column temperature is still 80 
o
C (the baseline temperature of the oven). This corresponds to the initial 
solvent peak visible on the chromatogram. As the temperature in the oven starts increasing at ―ramp‖ stage, 
the peaks for SCFAs start to appear on the chromatogram. The ―ramp‖, ―final temp post run‖, and ―cool‖ 
stage lasts for 5 minutes each. The vertical indicators with their labels are part of the self-check system that 
goes through every time the GC is switched on. 




2.3.6.2 Preparation of samples for gas chromatography  
All collected samples were homogenised thoroughly with a wooden disposable spatula 
under laminar flow in a biological cabinet. Approximately 1 gram homogenised faecal 
sample was weighed in 5 ml bijoux tubes with glass beads in triplicate, and equal volumes 
of 1M NaOH was added to preserve and stabilize short chain fatty acids. A high alkaline 
environment allows the substitution of free carboxylic hydroxyl group by divalent ions 
which decrease their volatility and further metabolic activity of the faecal microbiota. The 
sample was then vortexed thoroughly and saved in -20 
o
C until analysed. As mentioned 
earlier, samples for fermentation were also stored with 1 ml 1M NaOH and stored at -20 
o
C 
immediately after collection from the fermentation vessels and pH measurement. 
2.3.6.3 Freeze drying  
Faecal samples for SCFA measurement stored in -20 
o
C were taken out, holes were created 
in the lids of the sample tubes through syringe needles, then placed in -80 
o
C overnight and 
finally freeze dried (Edwards apparatus Micro Modulyo, Thermo Scientific®) for 24 h. 
The freeze dried samples were then homogenized thoroughly with sterile wooden spatulas, 
and kept in sealed tubes away from moisture at room temperature until analysed. 
2.3.6.4 Extraction of short chain fatty acids from the faecal samples using diethyl 
ether 
Various methods have been used to extract faecal SCFA. Some of these include; 
ultrafiltration with a membrane (281), vacuum distillation (282), derivatization using 
propylchloroformate (283), and steam distillation (284). However, extraction using organic 
solvents such as diethyl ether is widely used (284-287). This method takes into account the 
property of diethyl ether to form two phases in a mixture of the extract after a strong acid 
(such as ortho-phosphoric acid) is added to increase the dissociation constant (pKa value) 
of SCFA in the sample. These two phases include; (a) an upper ether phase which has 
diethyl ether and SCFA released out of the (b) lower faecal sample phase which includes 
faecal sample and orthophosphoric acid. 
For freeze dried faecal material; 100 mg of freeze dried faecal samples was 
weighed in duplicates in 15 ml polypropylene centrifugation tubes (Corning®, Mexico, 
USA). The sample was mixed with 300 µl of distilled water and vortexed to homogenise. 
To this mixture was added 100 µl orthophosphoric acid and 100 µl 2-ethyl butyric acid (as 
internal standard). Di-ethyl ether (1.5 ml) was added to the tube and vortexed on a shaker 
(IKA® VIBRAX VXR basic) at 1200 shakes/min for 1 minute. The upper clear phase was 




aliquoted in separate 15 ml polypropylene tubes and the process repeated 3 times (1.5 ml 
diethyl ether + vortex for 1 min). The clear supernatant was then immediately transferred 
to 1.5 ml glass vials (Agilent technologies®, USA, cat. No. 5181-3375) and crimped with 
silicone rubber seal crimp tops (Fisher scientific®, UK, cat. No. 11588150) for GC 
analysis to avoid evaporation. 
For samples from in vitro batch culture fermentation, the same procedure was used 
to extract SCFA except that 800 µl of supernatant from fermentation was used instead of 
freeze dried faecal sample and 3 ml diethyl ether was used instead of 1.5 ml diethyl ether. 
To ensure correct calibration of the machine, external standard was run after every 
12th sample measured and two quality controls at the beginning and the end of the whole. 
Some samples were re-extracted and re-analysed after about 1 year of storage to see the 
repeatability of the procedure and it showed no difference in the calculated concentrations 
of SCFA. 
2.3.6.5 Preparation and extraction of external standards  
Since the gas chromatograph does not give an equimolar response to the sample, we used 
external standard to quantify SCFA in our samples. An external standard with a total of 11 
short, medium and branched chain fatty acids (Table 2.4) was extracted with 6 dilutions 
(10, 25, 50,100, 200, and 300) using the same protocol as for the unknown samples to 
obtain the retention times and draw quantification calibration curves. The molarities of the 
individual acids to be used in the standard were optimized previously by Laurentin and 
Edwards (2004). 








2 Acetic acid 60.05 183.50 
3 Propionic acid 74.08 134.52 
4 Butyric acid 88.11 111.74 
5 Valeric acid 102.13 89.92 
6 Caproic acid 116.16 80.12 
7 Enanthic acid 130.18 68.53 
8 Caprylic acid 144.21 57.59 
9 Iso-butyric acid 88.11 104.22 
10 Iso-valeric acid 102.13 85.51 
11 Iso-Caproic acid 116.16 52.41 
All chemicals were supplied by Sigma Aldrich (Dorset, UK) except acetic acid which was supplied by Fisher 
scientific (Loughborough, UK) 





To account for the losses of the short chain fatty acids due to handling and processing, 2-
ethyl butyric acid (73.6 mmol) was used as an internal standard with each extraction. On 
the gas chromatogram, internal standard gives a peak that can be related to the mass of an 
analyte, so it is used to find the area ratios (see below in calculation). Internal standard 
extracted alone (with water, orthophosphoric acid and ether) was analysed after every 12 
sample to estimate the consistency of the analysis.  
2.3.6.6 Conditions of the column and gas chromatograph machine for sample 
analysis;  
All the extracted samples along with standards were loaded onto the AS2000 Autosampler 
(Thermo Quest CE® instruments, Manchester, UK) and were allowed to run on the GC in 
splitless mode, at base temperature of 250 
o
C, oven temperature of 260 
o
C (max) (Table 
2.5). The samples analysed on the GC were using 32 bit Chrom-card data-system software 
(version 2.2 (April 2003) Thermo-Scientific®, Milan Italy). The parameters of the gas 
chromatograph method are summarised in Table 2.5. Individual peaks were identified 
based on the component table from the analysis of external standards. To ensure that the 
column is clean prior to the start of the analysis; two injections of ether (only) were 
allowed to run and this was shown by only one peak for solvent on the chromatogram. The 
needle was washed with ether and absolute methanol (100%) each time between two 
injections by the Autosampler. 
2.3.6.7 Calculations;  
Calculations for the measurement of concentration of sample were based on the area under 
the curve obtained from the peaks in chromatogram. For SCFA concentration measured in 
freeze dried faecal material, the concentration was expressed as µg/g of freeze dried faecal 
material, while in case of samples from fermentation, the same was expressed as µmol/ml.  
First; the area ratio was calculated by the following formula: 
Area ratio of individual SCFA= Area under the curve for individual acid/Area under the 
curve for Internal Standard 
Relative response factor measures area ratios between two points. It was calculated for 
each short and branched chain fatty acid in external and internal standard by the formula; 




Area ratio of individual SCFA in 100 µl ext. standard/ (conc. of that SCFA in the final 
vial/concentration of internal Standard in the final vial) 
Finally the concentration of SCFA in µmol/ml was calculated by the formula 
(Area ratio of individual acid/Relative Response factor) x Concentration of internal 
standard 
Table 2.5: Parameters of the gas chromatograph for the analysis of samples 
Program Parameter Value 
Oven Ramp rate 15 
o
C/min 
 Initial temperature 80 
o
C 
 Ramp temperature 210 
o
C 
 Oven maximum temperature 260 
o
C 
 Prep run time out 10 min 
 Equilibration time 0.25 min 
 Acquisition time 10.67 min 
Right inlet Inlet temperature 230
o
C 
 Mode Splitless 
 Purge Constant septum purge 
Right Carrier Ramps; Flow 12 ml/min 
 Flow mode Constant flow 
Autosampler Sample volume 1µl 
 Sample Speed 100 µl/sec 
Column parameters Length 15 M 
 Internal diameter 0.53 mm 
 Temperature 100 
o
C 
 Inlet pressure gauge 70kPa 
 Outlet absolute pressure 10kPa 
Carrier gas parameters Carrier gas Nitrogen (N2) 
 Flow standard 1.89 cc/min 
 Velocity 35.14 cm/sec 
 Hold up time 85.38 sec. 
Right detect Base temperature 250 
o
C 
 Hydrogen Pressure 25 PSi 
 Nitrogen Pressure 30 kPa 
 Air 350 kPa 
 





Extraction of SCFA using diethyl ether is a robust method and can measure SCFA 
concentration with a confident level of precision however; it has got several limitations 
which include: 
Faecal sample used in the extraction may have freeze dried material that is not 
actual faecal sample but undigested food material. This was prevented by the through 
homogenization and separating the gross unfermented food material like seed coats etc.  
Diethyl ether used for extraction is a volatile compound and may facilitate the loss of the 
volatile SCFA during handling and analysis after they are extracted from the sample. 
However, this is accounted for by the internal standard to a greater extent.  
The final concentration of SCFA may vary due to intrapersonal variation with 
extractions. This is true in both the fermentation and freeze dried samples. This has been 
overcome with meticulous practice and re-extraction of the samples that were analysed in 
the beginning of the project. To quote as an example; median (IQR) %CVs for major 
SCFAs such as acetate, propionate, butyrate, and for total SCFA compared were 
2.08(2.91)%, 1.02(0.60)%, 1.40(1.04)%, and 1.48(1.65)% respectively.  
2.3.7 Faecal hydrogen sulphide 
Butyrate is the primary source of energy for colonic epithelium (81). Sulphur compounds 
have been shown to inhibit fatty acid oxidation especially, butyrate, in the distal and 
ascending colonic epithelium (119). This mechanism was thought to explain, at least in 
part, the aetiology of ulcerative colitis (119); an inflammatory bowel disease. Sulphate and 
sulphite ions are utilized by the sulphate reducing bacteria as electron acceptors for the 
dissimilation of reduced butyrate and molecular hydrogen. This causes the release of 
sulphide (HS
-
) into the luminal mucosa which is converted to free hydrogen sulphide (H2S) 
in the acidic environment (pKa 7.04). Total and free hydrogen sulphide from faecal 
samples in this study were measured by a modified methylene blue method (288). Under 
the oxidative effect of ferric chloride, H2S reacts with n, n-dimethyl-p-phenylenediamine 
to form methylene blue (288), which absorbs visible light at 670 nm region of the 
electromagnetic spectrum  (Figure 2.9). This method was originally developed for the 
measurement of hydrogen sulphide in water by Cline in 1969(289) and modified for 
hydrogen sulphide in faeces by Strocchi et al. (1992) (290) and Gerasimidis et al.(2014) 
(126). 




Figure 2.9: Mechanism of methylene blue reaction. 
 
DPD; n, n-dimethyl-p-phenylenediamine, H2S; Hydrogen sulphide (total and free), FeCl3 Ferric Chloride. 
Source; (314) 
2.3.7.1 Reagents and samples preparation  
Typically; 1-1.5 g of well homogenised fresh faecal sample was weighed in a pre-sterilized 
25 or 50 ml polypropylene tubes for free and total sulphide. To prevent oxidation of 
sulphide in the faecal samples, 10 ml of NaOH 1.25 M (for free sulphide) or 10 ml of Zinc 
acetate 0.11 M (for total sulphide) were mixed with the faecal sample. Glass beads (3-5 in 
each tube) were added to the tubes to ensure thorough mixing of the sample with the 
solutions. To remove oxygen, both the solutions were ultra-sonicated in a sonicator bath 
(Jencons® Scientific ltd, Sonomatic® Longford) for 15 minutes before mixing with the 
sample. Preparation and use of all the reagents in this protocol are presented in Table 2.6. 
Zinc acetate-diluted sample for total sulphide was immediately stored in -20 
o
C until 
further analysis, while NaOH-diluted free sulphide sample was centrifuged at 15,000 g for 
30 minutes. The supernatant, containing a rich free sulphide fraction was transferred to 2 
ml eppendorf tubes and stored in -20 
o
C until further analysis.  
2.3.7.2 Dilution 
The already processed frozen faecal samples were thawed at room temperature and 
measured immediately to minimize sulphide losses due to oxidation. Samples for total 
sulphide were diluted by 1:20 (v/v) with zinc acetate 0.11 M by mixing 0.5 ml of total-H2S 
faecal slurry with 9.5ml zinc acetate 0.11 M and stored at 4 
o
C or kept on ice racks until 
measured. The eppendorfs for free-H2S were centrifuged at 15,000 g for 5 minutes and the 
clear supernatant recovered in new eppendorf. This supernatant was diluted by 1:5 (v/v) 
with distilled water. This step significantly reduces turbidity and increases sensitivity of 
the assay as was observed during optimization phase.  
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Table 2.6: Reagents and their composition used in the spectrophotometric assay for free and total 
sulphide 
Chemical Preparation Use 
NaOH 1.25 
M  
10 g NaOH mixed with 200 ml distilled water  
Stored in glass McCartney tubes with metallic rubber 
stopper caps.  
Sonicated for 15 minutes to remove oxygen. Stable in 
room temperature. This was done prior to measurement. 
Prevent hydrogen sulphide 
oxidation in initial 
processing of free sulphide 
samples.  
Zn-acetate 
0.11 M  
3.62 g of zinc acetate dihydrate (Sigma Aldrich, 383058-
500G) mixed with 150 ml distilled water 
Stored under the same conditions as NaOH 1.25 M.  
Stabilize sulphide (free 
and total) by forming 
insoluble zinc sulphide 
salts. 
HCl 6 M  1:1 (v/v) dilution of HCl 12 M (Sigma Aldrich, 07102) 
with distilled water  
Part of the reaction 
reagents and to drive off 
all the hydrogen sulphide 
from blank samples. 
Reaction 
Reagent  
Concentrated Reagent: 500 ml ice cold HCl 6 M mixed 
with 2 g n, n-dimethyl-p-phenylenediamine (DPD, 
Sigma Aldrich, Fluka, 0775025G) and 3 g iron chloride 
hexahydrate (FeCl3, Sigma Aldrich).  
Diluted Reagent: 1:1 (v/v) concentrated reagent mixed 
with ice cold HCl 6 M.  
Both reagents are stable for a week when kept in dark 
and at -20 
o
C. 
Reaction components for 





48 mg crystal sodium sulphide nonahydrate (Na2S 
9H2O), Sigma Aldrich, 208043-100G); rinsed and dried 
with lint-free cellulose tissue and then mixed with 100ml 
zinc-acetate 0.11 M.  
Storage at 4 
o
C in glass McCartney tubes with metallic 
rubber stopper caps after flashing with nitrogen for 10 
minutes.  
Used for the preparation of 
spike sulphide and 
standard working dilution 





Sulphide standard 2 mmol, 200 μl mixed with 600 μl of 
zinc acetate 0.11 M.  
Prepared fresh every day 
Measure the recovery of 
this assay in spiked 
samples and Corrected 
absorbance in all samples 
NaOH; Sodium hydroxide, HCl; hydrogen chloride, M; Moles 
 
2.3.7.3 Colorimetric reaction  
Each sample for free and total hydrogen sulphide was measured in duplicate and different 
samples from the same participant were measured on the same day, using the same 
calibration curve, to reduce the intra-assay variability. As a standard practice, equal 




number of samples from all the groups were analysed on the same day to reduce inter-
assay variability.   
For the measurement of each sample in duplicate, 6 eppendorf tubes and cuvettes 
were prepared; 2 each for the sample, the blank, and the spiked sample (Table 2.7).  Equal 
amount of diluted faecal sample was added to each of the 6 tubes. Hydrogen sulphide was 
driven off the blank sample using 80 µl concentrated HCl, while spiked sample had 15μl of 
spike-standard sulphide 0.5 mmol in addition to the other reaction components. 
Concentrated hydrochloric acid was used to drive off sulphide out of the blanks, while 
spiked samples were used to estimate the recovery of the method and to correct the 
sample’s absorbance.  
Table 2.7: composition of the colorimetric reaction of the methylene blue protocol. 





Diluted sample 900 900 900 - - 
Zinc acetate - - - 900 900 
Spiked standard - - 15 15 15 
HCl Concentrated 80 - - 80 - 
Reaction reagent (concentrated) 80 - - 80 - 
Reaction reagent (Diluted) - 160 160 - 160 
All values are expressed in µl. 
The reaction reagent (both diluted and concentrated) was always added cold, and was 
followed by vortex and 45 minutes incubation in dark (15 minutes at room temperature and 
30 minutes at 37 
o
C) which allows the colorimetric reaction to take place. Subsequently, all 
samples were centrifuged at 14,000 g for 6 minutes and the supernatant was measured in a 
spectrophotometer (Biomate 3, Thermo Electron Corporation) at 670 nm.  
2.3.7.4 Calibration Curve and calculations  
Standards were prepared and a calibration curve plotted each day with the sample 
measurements. Eleven serial dilutions (Table 2.8) of working standard sulphide solution 
0.05 M (200 μl 2 mmol sulphide standard mixed with 7.8 ml of zinc-acetate 0.11 M) were 
measured.  
Table 2.8: Composition of the calibration curve used in the methylene blue reaction. 
Chemical 1 2 3 4 5 6 7 8 9 10 11 
Sulphide (µmol) 0 0.7 1.4 2.3 3.7 4.7 7 9.3 18.7 28 37.4 
Zn- Acetate 910 895 880 860 830 810 760 710 510 310 110 
Standard 0 15 30 50 80 100 150 200 400 600 800 
Reaction reagent 160 160 160 160 160 160 160 160 160 160 160 
All values are expressed in µl 




Absorbance at 670 nm was plotted against sulphide concentrations to obtain a linear curve. 
An equation was drawn based on the linear curve to calculate the faecal sulphide in the 
samples. The values of free and total sulphide, expressed in μmol/g of wet and dry faeces, 
were adjusted for the recovery of the assay and the corrected absorbance.  
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Where: Abs: absorbance, CorAbs: corrected absorbance, a: slope of the calibration curve, b: intercept of the 
calibration curve, W: weight of the stool sample, %WC: percentage of sample’s water content  
2.3.7.5 Optimization of the assay; testing the sensitivity and specificity  
The protocol used for these measurements was previously established in the laboratory by 
M.Sc. student (Svolos V, masters’ dissertation). The same student also measured the 
samples for hydrogen sulphide concentrations in faeces from our participants. However, 
the dilutions were further investigated to achieve a higher recovery values. The dilutions 
eventually decided to be used were 1:20 (dilution with zinc acetate) for total sulphide and 
1:5 (dilution with distilled water) for free sulphide with a recovery varying between 70-
120%. As the absorption values for these dilution rates were relatively low despite a 
satisfactory recovery; we used both less (1:10 and 1:3, or 1:5 and 1:1 respectively) and 
high diluted slurries to achieve a higher absorbance values. However, the absorbance did 
not improve and the recovery values decreased even further. This might indicate that more 
diluted or concentrated faecal samples inhibit methylene blue reaction. In order to increase 
the method’s sensitivity around the low absorptions area, three more standard sulphide 
points of low concentration were plotted in the calibration curve.  
Dilutions of various inorganic sulphate salts including ferrous sulphate, calcium 
sulphate, ammonium peroxodisulphate, ammonium iron sulphate, potassium persulphate, 
magnesium sulphate were used to test the specificity of the assay and to measure the 
interference of non-bacterial sulphate compounds. This was found to be negligible. 




2.3.8 Measurement of D- & L- Lactate 
Lactate is an important fermentation product of gut microbiota, especially, the lactic acid 
bacteria. Although total faecal lactate can be measured by gas chromatography (291); 
measurement of the isomers, D & L Lactate, can effectively be measured by an enzymatic 
colorimetric assay. Different brands of kits for measurement of lactate in faecal samples 
based on enzyme action have been used in the literature (117, 292, 293). The kit used for 
the measurement of faecal D and L lactate in this study was D & L-lactic acid, UV method, 
R-Boehringer/Biopharm AG, Roche (Cat. No. 11112821025), actually designed for the 
measurement of lactate in food material. However, the method was previously optimized in 
our laboratory for faecal samples, after applying a series of different lactate extractions and 
enzymatic reaction conditions (126).   
This method is based on the oxidation of D & L lactate (in the freeze dried faecal 
sample) to pyruvate and NADH (Nicotinamide Adenine Dinucleotide Hydrate) by D & L 
lactate dehydrogenases. Since the reaction is reversible in favour of lactate; pyruvate is 
trapped in another reaction catalysed by glutamate pyruvate transaminase (GPT) in the 
presence of L-glutamate to displace the equilibrium in favour of pyruvate and NADH 
(figure 2.10). The amount of NADH thus generated is stoichiometrically related to the 
concentration of D or L lactate in the sample. NADH absorbs light at 340 nm which is 
measured spectrophotometrically on a 96 well plate. 
 
Figure 2.10:Principle of enzymatic determination of D & L-lactate in freeze dried faecal samples 
 
D/L Lactate + NAD
+ 
    Pyruvate + NADH + H
+ 
Pyruvate + L- Glutamate   L-Alanine + 2 - Oxoglutarate 
 
NAD; nicotinamide Adenine Dinucleotide, LDH; lactate Dehydrogenase, NADH; nicotinamide Adenine 
Dinucleotide Hydrate, H
+
; Hydrogen ion, GPT; Glutamate Pyruvate Transaminase 
 
Measurement of lactate from freeze dried faecal material involves extraction of lactate 
from the freeze dried samples and spectrophotometric determination of lactate in the 
extract. Different chemicals used in this procedure, and their function is given in Table 2.9.  
D/L-LDH 
GPT 




Table 2.9: Components of lactate extraction. 
Chemical Preparation Function  
Carrez 1 (potassium 
hexacyanoferrate(II) trihydrate 
(K4[Fe(CN)6] x 3H2O) 
Ready-made 15 mg/100ml Together with Carrez 2; 
Precipitate proteins, eliminate 
turbidity, break emulsions 
Carrez 2 (zinc sulphate 
heptahydrate (ZnSO4x 7H2O)  
Readymade 30 g/100ml Together with Carrez 1; 
Precipitate proteins, eliminate 
turbidity, break emulsions 
NAD (Nicotinamide Adenine 
Dinucleotide) 46.4 mg/ml 
232 mg NAD in 5 ml double 
distilled H2O  
Required for oxidation of 
lactate to pyruvate by 
accepting H+ 
GPT (Glutamate Pyruvate 
Transaminase) 207.36 units/ml 
0.8 ml GPT in 4.2 ml double 
distilled H2O 
Catalyse reaction of L-
glutamate with pyruvate 
Glycylglycine buffer 4.75 g Glycylglycine and 0.88 
g L-glutamic acid in 50 ml 
double distilled H2O. Adjust 
pH to 10 with 10 M NaOH, 
make up to 60 ml.  
Buffer to facilitate reaction 
L-LDH (L- Lactate 
Dehydrogenase) 107.92 
units/ml 
38 mg L-lactase in 5 ml double 
distilled H2O 
Catalyse the oxidation of L-
lactate to pyruvate  
D-LDH (D- Lactate 
Dehydrogenase) 107.879 
units/ml 
4.63 mg D-lactase in 5 ml 
double distilled H2O 
Catalyse the oxidation of D-
lactate to pyruvate  
Glycylglycine buffer is stable for 12 weeks at 4
o
C, can be stored in bottles after filtration with 0.22µl filter. 
2.3.8.1 Extraction of D & L-lactate from the faecal sample 
Faecal samples (with 1:1 NaOH 1 M) stored at -20 
o
C were freeze dried and 60 mg of this 
material was weighed in pre-sterilized 2 ml eppendorf tubes in duplicate. To this was 
added 800 µl sterilized distilled water and vortexed for 1 minute. The samples were 
incubated at 65 
o
C for 20 minutes in a water bath (Grant GLS400, Grant®); vortexed and 
inverted after every 10 minutes. To precipitate proteins, eliminate turbidity, and to break 
emulsions (which can interfere with the analysis in subsequent steps), 100 µl each of 
Carrez 1 (potassium hexacyanoferrate(II) trihydrate (K4[Fe(CN)6] x 3H2O) 15 g/100 ml) 
and Carrez 2 (zinc sulphate heptahydrate (ZnSO4x 7H2O) 30 g/100 ml) were added, and 
the samples vortexed each time after adding the solutions. Carrez 1 and 2 (BIOQUANT 
Carrez clarification reagent kit for sample preparation in food analysis, Merck) form a 
sparingly soluble precipitate that adsorbs and also binds high molecular weight substances. 
To separate this precipitate from the aqueous portion, the samples were centrifuged 
for 8 minutes at 14,000 g and then 500 µl of this supernatant recovered in separate 2 ml 
safe-lock eppendorf tubes. For further purification, 50 µl each of Carrez 1 and 2 were 




added and then centrifuged for 8 minutes at 14,000 g. The supernatant thus obtained was 
aliquoted into a separate set of 2 ml eppendorf tubes and centrifuged again for 8 minutes at 
14000 g before being stored in the freezer at -20 
o
C for further analysis. 
2.3.8.2 Spectrophotometric determination of D & L lactate 
The clear supernatant obtained from extraction was centrifuged after being defrosted at 
room temperature. D and L- Lactate were measured on separate 96 well reaction plates 
(Sero-Wel, Sterilin, UK). To carry out enzymatic reaction, 30µlsample was added to each 
well followed by 15 µl NAD, 15 µl GPT, 100 µl glycyl-glycine buffer, and 45 µl water, as 
given in table 2.10.  Equal volumes of standard, quality control, and water were added 
instead of sample in their respective allocated wells (Table 2.10). 
Table 2.10: Proportions of different components in the blank, samples, and the quality control 
 GPT Buffer NAD H2O Sample QC D-LDH L-LDH 
Blank (µl) 15 100 15 75 0 0 10 10 
Control (µl) 15 100 15 45 0 30 10 10 
Sample (µl) 15 100 15 45 30 0 10 10 
GPT; Glutamate Pyruvate Transaminase, NAD; Nicotinamide Adenine Dinucleotide, QC; quality control, D-
LDH; D- Lactate Dehydrogenase, L-LDH; L- Lactate Dehydrogenase, Sample; faecal sample. 
 
Nine standard dilutions (Table 2.11) prepared from working solution of 0.454 g/L D- 
Lactate (Lithium D-lactate, Sigma-Aldrich, cat. no. L1000-100MG) & 0.63 g/L L-lactate 
(Lithium L-lactate, Sigma-Aldrich, L2250-10G) were analysed with each 96 well plate 
(Sero-Wel, Sterilin, UK) to create a calibration curve which was then used for calculation 
of D & L-lactate in a polynomial equation. The standard dilutions and the time of 
incubation (2 h) were optimized prior to the start of the sample extractions. 
Each plate was sealed with a membrane sealer (Thermo® scientific, USA). The 
plates were gently vortexed on orbital shaker (IKA® VIBRAX VXR basic) for 10 minutes 
and the absorbance was measured at 340 nm. The membrane was gently removed from the 
plate and the enzymes D and L- LDH were added to their respective plates to initiate the 
enzymatic reaction. Each plate was incubated for 2 h with continuous shaking on the 
shaker and the absorbance was measured at 340 nm at the end of 2 h. Each sample was 
extracted in duplicate and each of this duplicate was analysed in triplicate. The triplicates 
were compared at the end of the analysis, averaged, and any value with a higher variance 
was excluded from calculation.  




Table 2.11: Standard dilutions of D & L Lactate used for the calibration curve 
Standard D-lactate (0.454 g/L) L-Lactate (0.63 g/L) 
 D-Lactate (ml) ddH2O(ml) L-Lactate (ml) ddH2O (ml) 
1 0.025 1.975 0.03 1.97 
2 0.05 1.950 0.06 1.94 
3 0.10 1.90 0.09 1.91 
4 0.15 1.85 0.15 1.85 
5 0.20 1.80 0.30 1.70 
6 0.30 1.70 0.45 1.55 
7 0.50 1.50 0.65 1.25 
8 0.70 1.30 1.00 0.00 
9 1.16 0.90 1.30 0.70 
ddH2O; double distilled water 
2.3.9 DNA extraction by chaotropic method 
Increasing knowledge about the role of the gut microbiota in host energy metabolism and 
the advent of various culture independent techniques necessitates good quality and yield of 
genomic bacterial DNA to ensure reliability of the results obtained. For DNA to be 
extracted from the faecal samples; there are two major obstructions to achieve a good 
quality and quantity. Firstly; faecal samples are a mixture of undigested food material 
along with sloughed mucosa, dead cells, mucus secretions, bile, enzymes, bacteria, and 
other secreted and excreted substances. Secondly; bacterial DNA is intra-cellular and needs 
to be recovered by removing these physical barriers to access. Choice of an efficient DNA 
extraction method is therefore of utmost importance in extracting genomic bacterial DNA. 
There are a variety of commercially available kits used for extraction of faecal bacterial 
DNA (Table 2.12), and although they are considered equally efficient in extracting DNA 
of bacterial species, studies have found variation in the quantity and purity of DNA 
between the kits which might partially explain the differences in the relative abundance of 
gut microbiota between lean and obese individuals in the literature (294). In addition, there 
is a controversy whether freezing and various storage conditions may (295, 296) or may 
not (297, 298) affect the population of gut bacteria.   
Table 2.12: Some kits commercially available for extracting bacterial DNA 
Full name of the kit Manufacturer details 
QIAsymphony® Virus/Bacteria Midi Kit Qiagen, Hilden Germany 
ZR Faecal DNA MiniPrep Zymo Research Corp. Irvine USA 
QIAamp® DNA Stool Mini Kit Qiagen, Valencia CA USA 
Ultraclean® Faecal DNA Isolation Kit MoBio Laboratories Inc. Carlsbad, USA 
PowerSoil® DNA Isolation Kit MoBio Laboratories Inc. Carlsbad, USA 
 




The chaotropic DNA extraction method used in this dissertation was adapted from Godon 
1997 (299) and has already been used by previous researchers in the same lab(126). This 
method was chosen because it involves extensive cleaning and purification steps in an 
attempt to remove the impurities and inhibitors present in the faecal samples while keeping 
the gut microbiota composition and the quality of the obtained DNA intact. Previous work 
in the same department has shown that this method gives the highest yield and purity of 
genomic bacterial DNA (on spectrophotometry and agarose gel electrophoresis) as 
compared to other methods such as the QIAamp® DNA Stool Mini Kit, and phenol 
chloroform method. A summary of different chemicals/materials used in the bacterial DNA 
extraction process along with their concentrations and functions are given in Table 2.13. 
Faecal samples were collected and homogenised as previously described. 
Approximately 200 mg faecal sample was stored in 1.5 ml screw cap tubes in 
quadruplicate and immediately stored in -80 
o
C. Before starting DNA extraction, each 
sample was thawed at room temperature. To avoid variability of extraction between the 
samples and to maintain efficiency of the researcher, DNA was extracted from a set of 12 
samples each time with all samples from the same patient included in the same run.  Each 
set of DNA extractions needed 2 days to complete. A summary of the steps involved in the 
DNA extractions using chaotropic method is given in the flowchart (Figure 2.11). 
To lyse cells and virus particles in the samples, 250 μl of 4M Guanidine 
Thiocyanate 0.1 M Tris-Cl (pH7.5) (Sigma Aldrich®) and 40 μl of 10% N-
Lauroylsarcosine (Sigma Aldrich®)  was added to each sample and homogenised by 
vortexing followed by centrifugation for three seconds at 15,000 g in Thermoscientific 
ultracentrifuge (Thermo Electron corporation, UK). The sample was then incubated at 
room temperature for 10 minutes.  
Anionic surfactant, N-Lauroylsarcosine (5%) and 500 μL, already prepared in 0.1 
M Phosphate buffer (pH8.0), was added to the sample. The sample was then homogenised 
thoroughly by vortexing and centrifuged for three seconds before being incubated for one 
hour at 70 °C in a dry bath (Dri-Block Teche, UK). The sample was vortexed at 20 minute 
intervals, then centrifuged for three seconds before adding 750 mg of sterile 0.1 mm 
zirconia glass beads (Biospec Products. USA) to disrupt cells. 
After vortexing briefly; further cell disruption was achieved using an MP 
FastPrep®-24 benchtop homogenizer for 3x30 seconds at 6 m/s, resting between each 
burst for 15 seconds to allow cells to cool down. Samples were then placed on ice for 5 
minutes before homogenizing again for 3x30 sec at 6 m/s. The samples were again placed 
in ice for five minutes; centrifuged for three seconds before adding 15 mg of PVPP powder 
(Sigma Aldrich® Co) and vortexed upside down to dissolve the pellet.  




Table 2.13: Chemicals used in bacterial DNA extraction with their method of preparation and 
respective functions 




4 M GTC [Mw = 118.16] 12.37 g 
Double distilled water (ddH2O) 13.5 ml 
Tris-Cl 1 M (pH 7.5) 2.6 ml 
Filter-sterilise (Heat to dissolve) 
Filter into 5 ml bijoux tubes 
Cover with foil (light sensitive) 
Store in fridge 
 
Lyse cells and virus 
particles in RNA and 
DNA extractions 
Prevent activity of 
RNase enzymes and 




5 % N-Lauroylsarcosine 1 g 
Fill up to 20 ml with Phosphate buffer 0.1 M (pH 
8) 




10 % NLS  1.1g + 8 ml sterile H2O  
Fill up to 11 ml with ddH2O 





5 M NaCl [Mw = 58.44 g/mol] 14.61 g 
Fill up to 50 ml with ddH2O  
Autoclave 
 
Used in TENP buffer 
Phosphate buffer 
(pH 8.0) 
0.1 M  Na2HPO4 1M 9.32 ml mix with NaH2PO4 1M 
0.68 ml 
sterile H2O  90 ml 
Autoclave 
Adjust pH with 37% HCl 





Potassium Acetate (Mw = 98.15 g/mol) 4.9075 g 
ddH2O fill up to 10 ml  
Filter-sterilise 
Used as a salt for the 
ethanol/isopropanol 
precipitation of DNA 
Ethanol 70 & 
100% 
For 70%; Absolute ethanol mixed with dH2O in 
70:30 ratio 
For 100%; Absolute ethanol used as such 
Precipitation and 





NA PVPP 15mg in a cheap 1.5 ml microcentrifuge 
tube (1 tube = 1 sample) 
Centrifuge for 10 seconds at high speed 
 
dispersion enhancing 
agent and ensure 
removal of polyphenol 
contamination that could 
inhibit subsequent qPCR 
reactions 
Tris-Cl 
(pH 7.5 and pH 
8) 
1 M Trizma base [Mw = 121.1 g/mol] 12.11 g 
ddH2O Fill up to 100ml  
Autoclave 
Split into 2x 50ml and adjust pH with 
concentrated HCl 
Mixed with EDTA, 
NaCl, and PVPP as 




RNAase 10 mg 
Tris-Cl 1 M (pH 7.5) (= 10 mM) 10 μL 
NaCl 5 M (= 15 mM) 3 μL 
ddH2O fill up to 1 ml 
Keep in freezer 
Removes RNA from 
DNA preparations by 
cleaving phosphodiester 




3 M Sodium acetate [Mw = 82.03 g/mol] 2.4609 g 
ddH2O Fill up to 10 ml 
filter-sterilise 
 
Acts as a buffer and 
added before ethanolic 
precipitation of DNA as 




- Tris-Cl 1M (pH 8) 1 ml 
EDTA 0.5 M (pH 8) 0.8 ml 
NaCl 5 M, 0.4 ml 
ddH2O Fill up to 20 ml 
PVPP (= 1 %) 0.2 g (just before using) 
 
Mixture used as 
dispersion agent to clean 
DNA 




Proteinase K - - serine protease 
Activated by calcium 









10% SDS 10 mg dissolved in 90 ml of ddH2O strong anionic detergent. 
Works by disrupting 
non-covalent bonds in 
proteins, denaturing 
them, and causing the 
molecules to lose their 
native shape 
 
Samples were then placed on an orbital shaker (IKA® VIBRAX VXR basic) for 5 
minutes, at low speed to avoid damaging DNA and then centrifuged for 3 minutes at 15000 
g and 4 °C. The supernatant was carefully recovered in sterile 2ml eppendorf tubes and the 
pellet washed with 500 μl TENP buffer which had been vigorously shaken immediately 
before use to disperse the PPVP. The sample was vortexed upside down until the pellet 
dissolved and then centrifuged for 3 minutes at 15000 g and 4 °C. The supernatant was 
recovered in the same 2 ml eppendorf and this step of washing, centrifuging and recovery 
repeated twice.  
The final 2 ml supernatant was centrifuged for 10 minutes at 15,000 g (4 °C) and 
then split into 3 eppendorf tubes (2 x 750 μl and 1 x 500 μl) .Proportionate amount of 
isopropanol (1:1, v/v) was added to each sample to precipitate nucleic acids and gently 
mixed by hand before being incubated for 10 minutes on the bench.  
Each sample was centrifuged for 5 minutes at 15000 g and 4 °C and the supernatant 
was discarded. Each inverted eppendorf was tapped onto absorbent paper until the paper 
was dry and then left to air dry with the lid open for 15 minutes. To precipitate DNA, 225 
μl of phosphate buffer 0.1 M (pH 8) was added to each sample before adding 25 μl 
potassium acetate 5 M. The 2 ml eppendorf tubes were vortexed shortly and put on an 
orbital shaker for 5 minutes to break down the pellet. All the samples were then left 
overnight in the fridge at 4 
o
C. 
The following day (Figure 2.11); samples were shaken on an orbital shaker for 10 
minutes. Each sample split previously into three eppendorf tubes were combined together 
in one of the 2 ml tubes. Samples were then centrifuged for 30 minutes at 15000 g (4 °C) 
and the supernatant was recovered in a new 2ml eppendorf tube. To remove any potentially 
present RNA in the sample, 5 μl of RNAase (RNAse ONE, M426A, Promega®) 10 mg/ml 
added to each sample. Samples were vortexed shortly thereafter, centrifuged for 3 seconds 




to bring the contents down, and then incubated for 45 minutes in dry bath at 37 °C. Each 
sample was intermittently vortexed after every 15 minutes to homogenise the contents. 
An additional step involving the addition of 25 µl of SDS 10% (Sigma Aldrich® 
Co), and 12.5 μl of Proteinase K 800 units/ml (Sigma Aldrich® Co) to the sample was 
used to break down proteins in order to reduce potential inhibition of the PCR reaction. 
The samples were vortexed for 3 seconds and then incubated at 45 °C for 2 h. Each sample 
was vortexed briefly after every 30 minutes to mix the components.  
After incubation; each sample was centrifuged for 3 seconds and 54 μl of 3 M 
sodium acetate buffer (S2889, Sigma Aldrich®) was added to precipitate the DNA. This 
was followed by 1 ml 100% ethanol (-20°C) which was mixed by inverting. The sample 
was then frozen at -20 °C for 1 h, shaken on an orbital shaker for 10 minutes and then 
centrifuged for 10 minutes at 15000 g and 4 °C.  
The supernatant was discarded and 800 μl of ice cold 70% ethanol 
(Fisherscientific®, UK) (-20 °C) was added to the pellet, vortexed, and then shaken at 
medium speed on an orbital shaker for 5 minutes. The pellet was then broken up by 
pipetting with a wide tipped 1ml pipette and shaken on an orbital shaker at medium speed 
for 10 minutes followed by centrifugation for 10 minutes at 15000 g and 4 °C. The 
supernatant was discarded and these steps (washing-breaking the pellet - vortexing for 10 
min - centrifugation for 10 min - discarding the supernatant) were repeated 3 times in total. 
The pellet was then dried on a lint-free paper and then air dried under the biological 
cabinet (name) for one hour. Each sample was then re-suspended in 300 μl of RNAase-free 
water (Fisherscientific®, UK). Each sample was aliquoted equally in 5 flat cap thin-walled 
0.2 ml PCR tubes and stored at -20 °C until further analysis. 




Figure 2.11: Day 1 (2.11a) and day 2 (2.11b) of the chaotropic method used for genomic bacterial DNA 
extraction. 
 
GTCN; Guanidine thiocynate, NLS; N-LauroylSarcosin, PVPP; Poly vinyl Pyrolidine, SDS; Sodium 
Dodecyl Sulphate, Na-acetate; Sodium acetate 
 
2.3.10 Preparing amplicon pools for pyrosequencing 
Genome wide sequencing is becoming more popular in current research on gut microbiota 
due to its ability to generate sequences for a large number of bacterial groups applying an 
untargeted approach. This enables the researcher to have a global view of the data in terms 
of relative abundance of gut microbiota rather than absolute quantities of a specific set of 
gut microbiota. Pyrosequencing involves sequencing of nucleotide bases along the length 
of DNA by the release of pyrophosphate after the incorporation of each nucleotide base 
along the complementary DNA strand (Figure 2.12). This is ―sequencing by synthesis‖ 
unlike Sanger sequencing; which is ―sequencing by chain termination‖ with di-
deoxynucleotides.  




Figure 2.12: Summary of reactions involved in Pyrosequencing. 
 
 
16S RNA gene of the double stranded DNA (dsDNA) is amplified by PCR reactions in the presence of 
degenerate forward primers (F), bar coded reverse primers (R) specific for each amplicon, and 
deoxynucleotides triphosphate (dNTPs). This library of Amplicons is then resized into small fragments. Each 
amplicon is then attached to a bead in a water-oil emulsion with solutions for emulsion PCR to give several 
millions copy numbers per bead. DNA polymerase attaches the nucleotide into the template. The 
pyrophosphate (PPi) released with each amplification process reacts with adenosine 5’ phosphosulphate to 
generate Adenosine triphosphate (ATP) with the help of enzyme ATP Sulfurylase. This ATP is used for 
converting Luciferin to oxy-Luciferin with the help of enzyme luciferase. Oxyluciferin gives visible light that 
is detected by the detector to give a pyrogram. All unreacted nucleotides and ATPs in this reaction are 
degraded by the enzyme apyrase into adenosine monophosphates (AMP) in a wash cycle. This process is 
repeated with the attachment of every nucleotide and subsequent release of PPi. 
 
As shown in Figure 2.12; the process of pyrosequencing involves preparation of amplicon 
library of 16S RNA using degenerate forward, and bar coded reverse primers prior to an 
emulsion PCR and pyrosequencing. This preliminary step was done in our laboratory and 
is therefore included in this dissertation. 
The process of preparing 16S RNA gene amplicons involves a) PCR; using forward 
primers, reverse primers (Golay, barcoded), hotstart PCR mastermix and di-
methylsulphoxide (DMSO), b) agarose gel electrophoresis to extract the bands and c) band 
extraction d) measuring the concentration using flourometer e) adjustment of the 
amplicons concentration to the desired concentration, and pooling of the amplicons. 
2.3.10.1 PCR amplification; 
A day before PCR amplification of the double stranded DNA, bar coded fusion reverse 
primers (Golay barcoded primers) specific for each sample were diluted to 1 ng/µl from 
their original concentration and aliquoted into separate thin walled 200 µl PCR tubes from 
the 96 well plate. The list of reverse primers used for all 150 samples is given in appendix 
(appendix-3). Sequence of nucleotides used in the forward primer obtained from Eurofins 




MWG Operon (Ebersberg, Germany) was 5´-GTGNCAGCMGCCGCGGTAA-3´, where 
―N‖ represents ―any base‖ (A, C, T, G) and ―M‖ represents ―amino (A & C)‖. This is an 
example of a degenerate forward primer, which are often used if the same gene (such as 
16S rRNA) is to be amplified from different microorganisms. It is commonly used in 
molecular microbiology because it allows the amplification of genes from organisms that 
have not yet been cultivated, thus increasing the recovery of more and more genetic 
information. 
 Although this combination reduces the specificity of the PCR reaction by 
mishybridizations and primer dimers but this can be reduced by using modified PCR cycle 
conditions. In addition to dilution of the primers, a set of 4 PCR 200 µl tubes were 
sterilized for each sample (3 tubes for PCR in triplicate and one tube for non-template 
control labelled as ―N‖). Molecular biology grade, nuclease free water (Fisher scientific) 
was aliquoted into eppendorf tubes (Eppendorf®, USA, cat. No. 022363352) and UV 
sterilized under the biological laminar flow cabinet.  
On the day of PCR; the biological cabinet was cleaned with 70% ethanol. All the 
pipettes to be used were given a clean wipe with alcohol. UV light was switched on for 15 
minutes to ensure clean non-contaminated working space. Components for PCR reaction 
were mixed in the order given in Table 2.14. Nuclease free water was obtained from fisher 
scientific (Fisher Scientific® UK), PCR mastermix used was KAPA HiFi HotStart Ready 
Mix (KR-03070-v4.13) from KAPABIOSYSTEMS®, USA, and DMSO (cat. No. D1970-
5VL) from SIGMA-Aldrich to improve the efficiency of the reaction.  The PCR kit 
contained a hotstart DNA polymerase (which has the ability to amplify long and GC & AT 
rich targets), KAPA HiFi buffer, magnesium chloride 2.5nM (1x), and dNTPs (specifically 
treated for each kit). Additionally the enzyme is inactivated by a proprietary antibody until 
first denaturation step to reduce non-specific amplification.  
All components for 4 reactions (3 for sample, 1 for non-template control) except 
template DNA were mixed in the tube ―N‖, vortexed, and then added to the PCR tubes in 
triplicate (23 µl in each tube). DNA template (2 µl) was added to the 3 PCR tubes for the 
sample, and same volume of water was added to the tube ―N‖ instead of the template 
DNA. A set of 10 samples were amplified at one time as a standard practice.  




Table 2.14: Components of PCR reaction 
Component of PCR reaction Volume per reaction 
Nuclease Free water 7.51 µl 
KAPA hifireadymix (2x) 12.5 µl 
forward Primer (same for all samples) 0.87 µl (0.35 µM) 
Reverse Primer (different for each sample) 0.87 µl (0.35 µM) 
DMSO(Di-Methyl Sulfo-Oxide) 1.25 µl 
Template DNA 2 µl 
Total volume of one reaction 25 µl 
 
Within each set; equal number of samples from all the groups (lean, obese, hypothalamic 
obese/lean) were used to eliminate a possible variation with time and conditions. All the 
tubes were vortexed again and then placed in the PCR thermal cycler machine (PCR 
Engine, MJ Research USA). The samples were amplified in the following cycle 
temperatures to aim for the amplicon band size of 378-400 bp; 
95 
o
Cfor 5 min 
98 
o
Cfor 20 sec 
60 
o
Cfor 15 sec  
72 
o
Cfor 1 min 
Repeat step b to step d for 25 cycles. 
4 
o
C (until the samples were taken out of the PCR machine). 
2.3.10.2 Agarose gel electrophoresis 
While the PCR reaction was in progress, the casting base of the agarose gel tank was 
cleaned and prepared for agarose gel electrophoresis. 2 g agarose was weighed out and 
mixed with 200 ml 1X TAE buffer. 1X TAE buffer was prepared by diluting 1 part 50X 
TAE buffer in 49 parts dH2O. This solution was then heated in the microwave to boil until 
the solution was clear. The solution was cooled for 2-3 minutes at 60 
o
C in a water bath. 
SYBR® safe DNA gel stain 10,000X in DMSO (Invitrogen®, USA) in a ratio of 1 µl/10ml 
was mixed in this solution. This DNA staining dye is safe and less toxic as compared to the 




more popular ethidium bromide. The dye is light sensitive; hence, it was always stored in 
the dark and wrapped in aluminium foil. The 1% agarose gel in solution was emptied into 
the gel casting base and allowed to cool for 50 minutes in the dark (by covering the gel 
with aluminium foil). The tank was filled with 1X TAE buffer. This buffer was replaced 
after every three gels to avoid contamination of the samples.  
After 50 minutes, the combs were vertically lifted and carefully removed from the 
gel. The gel was then placed in the tank. One of the three amplified sample tube was 
equally distributed between the other two amplified samples. To each of the amplified 
sample and the non-template control was added 3 µl blue/orange loading dye 6X (Promega 
Corporation, USA). This dye has xylene cyanol, bromophenol blue, and orange G to 
facilitate optimization of the gel run time and to track the gel to prevent the smaller 
fragments migrating too far in the gel. A 100 bp DNA ladder was used to quantify the 
base-pair size of the DNA templates. The wells were loaded in the order; 2 samples 
followed by a non-template control. The total volume added in each well was 40.5 µl for 
the samples (37.5 µl PCR amplicons + 3 µl loading dye 6x) and 28 µl for the non-template 
control (25 µl un-reacted PCR amplicons + 3 µl Loading dye 6x). Tanks and gels of 
different sizes were tried before the actual samples were applied to ensure that the entire 
sample from the tube is electrophoresed without leakage and cross contamination. The 
samples were then allowed to run for 45 minutes at 125 volt. The gel was visualized using 
Gel Doc 2000 (Bio Rad) with ethidium bromide filter. 
Each sample typically gave two bands (Figure 2.13); a proximal band with the 
amplified sample and a distal band with the residual primers, primer dimers, and other 
degraded nuclear material. The non-template control gave only one distal band at the end 
of the gel signifying that the reaction did not amplify any external DNA and was not 
contaminated. Samples which showed extensive smearing, indistinct bands, absent bands, 
or multiple bands were re-amplified.  
2.3.10.3 Extraction of gel bands using QIAquick gel extraction kit 
Samples that gave a distinct band were extracted using QIAquick gel extraction kit (Cat. 
no. 28705 QIAGEN® Germany) (Table 2.15). This is a silica membrane assembly based 
on the binding of DNA to a high salt buffer and eluting DNA with a low-salt buffer or 
water. The membrane allows the elution of the DNA free of enzymes, primers, salts, 
nucleotides, mineral oils, agarose, staining dyes, and other impurities while ensuring 
approximately 80% DNA recovery. 




Figure 2.13: Example of a typical gel scan from the gel doc. 
 
The amplified sample (in duplicate) gives two bands with proximal amplified sample band of about 400 bp 
and a distal more diffuse residual primers, primer dimers. The non-template control (in singlicate) with each 
duplicate sample gives only one band 
 
Table 2.15: Components of the QIAquick gel extraction kit with their functions 
No. Component Proportion used Function  
1 QIAquick spin column One column for  each sample Elution of impurities-free 
DNA 
2 Buffer QG (guanidine 
isothiocynate with a pH 
indicator) 
3 volumes( 3x w/v in µl) the 
weight of the band excised and 
500 µl in another step  
High salt buffer to bind 
DNA 
3 Isopropanol (100%) One volume( 1x w/v in µl) the 
weight of the excised band 
For precipitation of 
amplicons 
4 Buffer PE 300 µl Washing the spin column 
5 Buffer EB(10 M Tris.Cl, 
pH 8.5) 
30 µl Low salt buffer to elute 
amplicons 
    
6 Gel Loading dye 3 µl in each PCR amplified 
sample  
Stains the amplicons and 
holds DNA in the wells 
 
Amplicons were carefully excised from the gel in square shape bands into a 2 ml DNA 
low-bind Eppendorf tube (Eppendorf®, USA) under the UV light and then weighed on 
electronic scale. Care was taken not to expose bare skin to the UV light by using a UV 
protection board, full body cover, and UV gargles. The maximum weight of excised band 
was kept below 400 mg as the subsequent process of purification involves addition of 
proportionate volumes of buffers (given below) that would not accommodate the entire 
sample in a single eppendorf tube. Three volumes (3x w/v) of buffer QG were added to the 
eppendorf tubes having DNA fragment. Yellow colour of Buffer QG indicates a pH ≤7.5 
and DNA adsorption to the membrane in spin column is only efficient at this range of pH. 




The mixture was then incubated at 50 
o
C for 10 min in a dry bath and vortexed every 2-3 
minutes to dissolve the gel slice. The colour of the mixture was observed after the gel slice 
had dissolved completely (it should be similar to the buffer QG). A change in colour to 
orange or violet shows an increase in pH. If so, 10 µl, 3 M sodium acetate, pH 5.0, was 
added and mixed. The mixture would turn yellow. Equal volume of 100% isopropanol 
(equal to the weight of DNA fragment excised) was then added to the sample and mixed 
shortly. 
QIAquick spin columns labelled for each sample were placed in the provided 2 ml 
tubes. The sample was applied to the QIAquick column and centrifuged for 1 min at 
17,900 g. The flow-through in the 2 ml tube was discarded, and the column placed back 
into the same tube. For sample volumes of >800 µl, the sample was loaded onto the 
column, spun again, and the flow-through discarded. 500 µl Buffer QG was added to the 
QIAquick column and centrifuged for 1 minute at 17900 g and the effluent was discarded 
again. To wash the sample, 300 µl Buffer PE was added to the QIAquick column, allowed 
to stand for 2-5 minutes, and centrifuged for 1 min at 17,900 g. The flow-through was 
discarded and the QIAquick column was placed back into the same tube. The remaining 
sample in the QIAquick column was centrifuged again for 1 min at 17,900 g to remove any 
residual wash buffer. 
The column was then placed into a clean 1.5 ml DNA Lowbind eppendorf tube. To 
elute DNA, 30 µl Buffer EB (10M Tris.Cl, pH 8.5) was carefully pipetted on the middle of 
the membrane so that amplicons up to 30 µl can elute. The buffer was allowed to stand for 
up to 8 minutes. The column was centrifuged for 1 min at 17,900 g to precipitate DNA into 
the DNA Lowbind eppendorf tube and then aliquoted into 200 µl thin walled PCR tubes 
and stored in -20 
o
C. 
2.3.10.4 Measuring the concentration of amplicons using Qubit® 2.0 flourometer 
(life® technologies, USA) 
This is a 2
nd
 generation flourometer to measure the concentration of DNA by high 
sensitivity fluorometric probe that emits light only when it specifically attach to the target 
molecules, thus giving more accurate results. It has the additional advantage of measuring 
of broad range DNA quantities using separate broad-range assay reagents.  
To measure the concentration of amplicons in each samples, working solution was 
prepared by adding 1 µl dsDNA HS assay reagent (life® technologies, USA) in 199 µl 
buffer (life® technologies, USA). One µl of amplicon was mixed with 199 µl of this 
working solution in special 500 µl PCR tubes (life® technologies, USA) supplied with this 
equipment. The flourometer was calibrated before these measurements every day, using 




two standard reagents S1 and S2 (Cat. No. life® technologies, USA) supplied with the kit. 
Working solution was prepared as mentioned above, but instead of adding 1 µl sample, 10 
µl of Standard S1 and S2 were added to 190 µl of working solution in separate tubes, 
vortexed briefly, and then measured on the Qubit®. 
Samples with concentration less than 2.5 ng/µl were re-amplified (using the same 
reverse primers) and then purified after gel electrophoresis until this minimum 
concentration was achieved. 
2.3.10.5 Adjusting the concentration of the amplicons and preparing amplicons pool 
The final concentration of the amplicons for each sample was standardised to 2.5 ng/µl so 
as to standardise the quantity of the DNA used for emulsion PCR and sequencing. 
Proportionate amount of sample and nuclease free water were mixed in separate 200 µl 
thin walled PCR tubes to make a final volume of 30 µl. 
From each of these samples (n=150); 2 µl sample was pipetted into a single 0.5 ml 
DNA lowbind eppendorf tube (Eppendorf®, USA) to make a total of 300 µl amplicon pool 
and stored in -20 
o
C. DNA concentration of 5 samples measured by Qubit®, selected in 
random, showed a median concentration of 2.45 ng/µl. From this 300 µl pool, 100 µl was 
aliquoted into another 0.5 ml DNA lowbind tube and transported to the laboratory for 




 Chapter 3: Subject Characteristics 
3.1 Chapter Outline 
This chapter discusses the basic anthropometric, demographic, and dietary characteristics 
of the participants recruited in this study. It further explores changes in weight, body 
composition and dietary intake during the observational period of the study. These results 
will further be related to the gut microbial metabolic activity and diversity in chapters 4 
and 6.   
3.2 Patients and methods 
Study subjects 
Detailed description of the recruitment process is given in chapter 2 (subjects and 
methods). Briefly, simple obese (total n=16, young adults, n=2, children & adolescents, 
n=14), hypothalamic obese (total n=10, young adults, n=3, children & adolescents, n=7), 
and hypothalamic lean children/young adults (total n=12, young adult, n=1, children & 
adolescents, n=11), age 2-25 years, were recruited from the endocrine and dietetic clinics 
at the Royal Hospital for Sick Children Yorkhill Glasgow. Healthy lean children and 
young adults (total n=27, young adults, n=4, children & adolescents, n=23) were recruited 
from the local community.  
Methods 
Height was measured using a Seca® Leicester stadiometer (Seca213, Birmingham, United 
Kingdom) to the nearest 1 mm by the researcher. Body weight and body composition were 
measured with a TANITA® (TBF300, TANITA, Japan) body composition weighing scale. 
This scale measures single frequency foot-to-foot bioelectrical impedance and two 
compartment body composition analyses. Since the 1980’s, impedance analysis has been 
widely accepted as a valid but mostly practical method to measure body fat and lean mass 
(300). Height measured in centimetres, age (in years), and gender was entered into the 
analyser prior to the measurement of body composition. The device uses 50 kHz, 500µA 
insensible current to measure impedance. The analysis of body composition, calculated by 
the in-built equations in the machine, was printed. Each of the body composition 
measurements was taken at baseline and after 2-3 months. Body composition with this 
method was not measured for some participants (n=19) because the feet of the children 
were too small to fit on both anterior and posterior electrodes in order to allow the 
measurement of impedance analysis (n=10/19), or the child was unwilling to have their 
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weight measured (n=3/19), or we were unable to arrange time with the participants 
(n=6/19). 
The body composition data (including fat mass, fat free mass, and %fat) of children 
less than 6 years of age were excluded from the analysis due to lack of equations to 
calculate body fatness for this age. Bioelectrical impedance was adjusted for the height of 
each participant by dividing height squared in centimetres over resistance in ohms (Ht
2 
cm/Ω) and then used for analysis as this is a measure of the resistance of the body to 
electrical current corrected for height(301). Fat index was expressed as fat mass in kg 
divided by height squared in metres. Lean index was expressed as fat-free mass in kg 
divided by height squared in metres. Weight velocity was expressed as weight gained in 
grams per kg body weight in 24 h. 
Since,  physiological weight gain, growth pattern, and body composition varies 
with age and gender, the UK 1990 reference growth standards were used to classify 
children as obese or non-obese. Standard deviation scores (SDS) were calculated using 
LMS growth software which is also based on the UK 1990 reference growth standards 
data(302). Children with BMI at or above 2 SDS were classed as obese and those below 2 
SDS as non-obese. Height, weight, and BMI were expressed as standard deviation scores. 
Change in BMI SDS per month (∆BMI SDS/month= BMI SDS at recruitment - BMI SDS 
after 2-3 months/ period between the two assessments in months) was calculated. Change 
in weight (g/kg body weight/day) in all participants during the period of the study was 
expressed by calculating growth weight velocity.  
 
To obtain an estimate of socioeconomic status, the Scottish Index of Multiple Deprivation 
(SIMD) score was calculated (http://www.scotland.gov.uk/Topics/Statistics/SIMD). SIMD 
scores is a system of identifying small areas of multiple deprivations across the whole of 
Scotland. All areas are identified based on 7 different criteria including current income, 
employment, housing, health, education, geographic access, and crime. Each area is ranked 
from the most deprived (SIMD rank of 1) to a least deprived (SIMD rank 6505) area. 
SIMD ranks are also represented as quintiles from 1 to 5. The first quintile includes 
population range  between rank 1-1301, 2
nd
 quintile from 1302-2602, 3
rd
 quintile from 
2603-3903, 4
th
 quintile from 3904 to 5204, and 5
th
 quintile ranges from 5205-6505. 
The food diaries were analysed using Windiet® 2005 software (Robert Gordon 
University Aberdeen UK). All foods inserted in the software were recorded as total caloric 
intake and major macronutrients per day. The amounts of macronutrients were then 
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expressed as proportion of total energy intake. The intake as a proportion of the daily 
recommended nutritional intake of protein was calculated using Department of Healthy 
recommendations 1991 (DoH 1991) while intake of dietary fibre as a percentage of 
recommendations was calculated using the UK Scientific Advisory Committee on 
Nutrition (SACN) 2011 report (303). Portion sizes for all unspecified foods were estimated 
from the information based on published data from National Diet and Nutrition Survey 
(NDNS). Foods not mentioned in the Windiet® software were added as per 100 grams 
dietary values to the software from the information given by the manufacturer such as 
Tesco and ASDA stores in the UK. A total of 99 new foods were added. 
Ethical considerations 
The study was approved by the West of Scotland Research Ethics committee and Research 
and Development (R&D) NHS Greater Glasgow and Clyde under the study number 
WS/11/032 (appendix 1), for a period of 4 years. Each participant (when age appropriate) 
and their carer gave informed written consent.   
3.3 Data handling and cleaning 
All the data collected during the course of the study were organised in a single Microsoft 
Office, Excel spreadsheet. The dietary data was first analysed by two independent 
researchers using Windiet® 2005 software for the macronutrients (carbohydrates, fats, 
proteins), dietary fibre, percent estimated average requirements (%EAR) and 
recommended nutritional intake of proteins (%RNI). These data were then compared 
between the two researchers, and the coefficient of variation (%CV) calculated. All 
macronutrients and dietary fibre with %CV of more than 25% were re-analysed and 
compared again for any differences in the diet plans (in terms of their food amount, 
proportion, and composition). These data from two researchers were averaged before being 
used for further analysis. 
All other data collected from the analysis of the faecal samples (discussed in chapter 
4) were first organised in individual Excel spreadsheets and then pulled together in a large 
dataset. All data for each participant were individually checked for any random, user-
specific, or systematic error. The data were then copied onto a statistical package for 
summarized descriptive statistics and distribution to identify any abnormal values. 
3.4 Statistics 
The Anderson-Darling test of normality was applied to evaluate the normal distribution of 
continuous variables (i.e. BMI SDS). Probability plots showed a highly significant 
deviation of the anthropometric and dietary variables from normality hence non-parametric 
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statistics were used. All data were expressed as median and inter-quartile range (IQR). 
Kruskal-Wallis test was used to explore the differences between more than two 
independent variables. Mann-Whitney U test was applied to measure the differences in 
independent variables between simple obese and hypothalamic obese, hypothalamic lean 
and hypothalamic obese, healthy lean and hypothalamic lean, and healthy lean and simple 
obese children/young adults. Spearman Rank correlation was used to determine rank 
correlations between different continuous variables. No adjustment for multiple testing or 
false discovery rate was done for these tests. All significant p-values mentioned in this 
chapter should therefore be considered as nominally significant. 
Univariate analysis followed by multivariate regression analysis was used to assess the 
associations of BMI SDS and changes in BMI SDS with demographic variables (i.e. SIMD 
rank scores) and with dietary macronutrients (fats, carbohydrates, proteins as grams and 
percentage) and energy intake expressed as %EAR. P-values of 0.05 were considered 
significant. All the data were analysed by Minitab Version 16 (Minitab® V. 16 Inc. USA). 
3.5 Results 
3.5.1 Demographic characteristics 
The hospital records showed 83 patients with Prader Willi Syndrome diagnosed between 
1950 and 2013 (Table 3.1). Over the past few decades, increasing numbers of female 
patients were diagnosed as the number of female children diagnosed with PWS increased 
from 27.27% (n=6) between 1950 &1980 to 46.43% (n=13) between 2001 and January 
2013. During our study period (2011-2013), 48 patients with PWS were attending the 
Yorkhill endocrine clinics. Patients aged more than 25 years (n=7, 14.5%), or having 
severe co-morbidities (n=2, 4.2%) or using a regular probiotic drink (n=1, 4.2%) were 
excluded. Of the participants eligible for this study (n=38), 22 (57.8%) PWS patients were 
recruited into the study. Of these 22 patients, 10 (45.45%) were hypothalamic obese 
patients while the remaining 54.54% (n=12) were hypothalamic lean patients. 
Table 3.1: Distribution of PWS patients on the Royal Hospital for Sick Children database from 1950 
till January 2013 
Time Period 
Total PWS patients 
 (n) Male (n) Female (n) 
1950-1980 22 16 (72.72%) 6 (27.27%) 
1981-2000 33 21 (63.63%) 12 (36.37%) 
2001-2013 28 15 (54%) 13 (46%) 
1950-2013 83 52 (62.65%) 31 (37.35%) 
n; number of patients 
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Although there were 26 craniopharyngioma patients on the hospital record since 
1976, 12 patients were attending the clinic in Yorkhill hospital during the study period. Of 
these, patients age >25 years (8%, n=1) were excluded, five patients (41%) declined to 
participate, and one patient (8%) did not respond after giving written consent. Five 
craniopharyngioma patients (41 %) took part in our study.  
Overall, we were able to recruit 65 participants (34 females and 31 males); 16 
simple obese, 10 hypothalamic obese, 12 hypothalamic lean, and 27 healthy lean 
children/young adults. Although the number of participants attending the endocrine and 
dietetic clinics in hypothalamic and simple obese group was more than the number we 
aimed at, we were not able to recruit a number of them because of their age, disease related 
co-morbidities, distance of residence from the hospital, decline to participate, and multiple 
admissions in the hospital. 
3.5.2 Anthropometric characteristics of participants at baseline 
Height and weight SDS of simple obese patients were significantly higher than 
hypothalamic obese group (p=0.01) (Table 3.2, Figure 3.1); however, BMI SDS was not 
significantly different (simple vs. hypoth. obese, p=0.1). As expected, the two obese 
groups (hypothalamic and simple obese groups) had a significantly higher BMI SDS than 
the two lean groups (healthy lean and hypothalamic lean) (Table 3.2, Figure 3.1). Height 
SDS was similar between hypothalamic lean and hypothalamic obese participants, 
however, both were significantly shorter [median (IQR): hypoth. Lean; -0.88(1.47), 
hypoth. obese; -1.09(1.85)] than the healthy lean [median (IQR); 0.67(2.22)] and simple 
obese participants [median (IQR); 0.74(2.58)] (Table 3.2, Figure 3.1). This indicated a 
strong influence of pathology on height SDS. Therefore, when participants were grouped 
together based on the presence or absence of pathology, pathological group (hypothalamic 
lean and hypothalamic obese) showed a significantly lower height SDS than healthy group 
(healthy lean and simple obese) [Median (IQR), pathological group; -0.998(1.622) vs. 
healthy group; 0.704(2.458), p=0.0002] (Figure 3.2).    
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Variable Median IQR Median IQR Median IQR Median IQR 
Age (Years) 6.31 9.14 9.84 13.13 9.47 7.67 11.38 6.76 
Ht.(cm)a 111.5 61.15 136.1 45.98 143 51 150.5 23.05 
Wt.(kg)a 23.25 33.92 55.5 61.8 30.8 39 79.95 59.55 
BMI (kg/m2)a 18.17 3.34 29.04 15.27 16.28 5.30 36.15 12.63 
Ht. SDS -0.88¥ 1.47 -1.09‡ 1.85 0.67¥ 2.22 0.74‡ 2.58 
Wt. SDS 0.31† 1.37 2.21‡† 1.713 0.43* 1.70 3.55‡* 1.27 
BMI SDS 1.01† 0.68 2.91† 1.161 -0.28* 1.114 3.74* 0.91 
Hypoth.; hypothalamic (lean or obese), N; total number, SDS; Standard Deviation Scores. 
All values are expressed as median (Interquartile range).  
a
 Ht. (cm), Wt. (kg), and BMI (kg/m
2
) were not used in the analysis. Age and gender adjusted SD scores were 
used instead. 
† indicate significant differences between hypoth. lean and hypoth. obese  
* indicate significant differences between healthy lean and simple obese  
‡ indicate significant differences between hypothalamic obese and simple obese  
¥ indicate significant differences between hypothalamic lean and healthy lean  
 
 
Figure 3.1a, b, c: Boxplots showing height SDS (a), weight SDS (b), and BMI SDS (c) of all participants 














Hypoth.; hypothalamic (lean or obese), Ht. height, Wt. Weight. Significant differences are based on Mann-
Whitney U test. 
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Figure 3.2: Boxplot showing height SDS at the time of recruitment based on the presence of pathology. 
 
Healthy; Healthy lean and simple obese, pathological; hypothalamic lean and obese. P-value based on Mann-
Whitney U test 
 
3.5.3 Social deprivation status of the study participants 
Generally, participants in simple obese group were from a lower socioeconomic group 
with low SIMD rank score compared with all other three groups. However, this difference 
was only significant between simple obese and healthy lean group (p=0.01) (Table 3.3). 
Considering all groups together, Spearman rank correlation showed a significant 
negative correlation of SIMD rank score with BMI SDS (p=0.006, R=-0.34) (Figure 3.3), 
height SDS (p=0.03, R=-0.26), and a trend towards weight SDS (p=0.08, R=0.28). 
Similarly, BMI SDS was significantly negatively associated with SIMD rank with the 
latter explaining 64.2% of the BMI SDS variation in general linear model analysis 
(p=0.005, R
2
=64.16%), considering all groups together. 
When participants were grouped based on the presence of pathology into healthy 
(healthy lean & simple obese) and pathological groups (hypoth. lean & obese), SIMD rank 
score was significantly negatively correlated with BMI SDS in healthy group (R= -0.47 
p=0.002) and weight SDS (R=-0.32, p=0.039), but not in the pathological group (BMI 
SDS; R=0.92, p=0.701 & Wt. SDS; R=0.041, p=0.863) (figure 3.4). Height SDS was 
significantly positively correlated with SIMD rank scores in healthy group (R=0.400, 
p=0.008) but not in pathological group (R=0.02, p=0.935). Furthermore, general regression 
analysis adjusted for pathology showed a significant association of SIMD rank scores with 
height SDS (β-coefficient=5.625, R2-adjusted=9.45%, p=0.005). 
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Table 3.3: SIMD rank scores and quintiles of all the study participants. 







Control (N=27)  
Simple Obese  
 
 (N=16) 
1n(%) 1(8.33) 2(20) 5(18.52) 5(31.25) 
2n(%) 2(16.67) 0(00) 1(3.70) 5(31.25) 
3n(%) 4(33.33) 1(10) 4(14.81) 3(18.75) 
4n(%) 4(33.33) 6(60) 8(29.63) 0(00) 
5n(%) 0(00) 1(10) 9(33.33) 3(18.75) 
SIMD Rank 3127 (3806) 4160(2022) 4513 (2700)* 2193 (2732) * 
† One hypothalamic lean child was from Northern England. His deprivation score was therefore not included. 
* shows significant difference (p=0.01) between healthy lean and simple obese (Mann-Whitney U test). 





Figure 3.3: Scatter-plot showing correlation of SIMD rank scores with BMI SDS of all participants at 




R; Spearman rank correlation, Hypoth.; hypothalamic (lean or obese) 
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Figure 3.4: Scatter-plot showing correlation of SIMD rank scores with BMI SDS based on the presence 
or absence of pathology. 
 
Healthy; healthy lean & simple obese, pathological; hypothalamic lean & obese, R; Spearman-rank 
correlation, hypoth.; hypothalamic (lean or obese) 
 
3.5.4 Differences in body composition measurements 
Body composition measurements were not available for all participants (especially <7 
years) as explained above. Data for participants was available for 5/12 hypothalamic lean, 
4/10 hypothalamic obese, 23/27 healthy lean, and 13/16 participants in simple obese 
groups at the time of recruitment. Body composition analysis of simple obese participants 
showed significantly higher fat mass (kg) compared with the hypothalamic obese group 
(median (IQR): simple obese; 40.7(25.28) kg vs. hypoth. obese; 26.85(20.25) kg, p=0.031) 
(Table 3.4, Figure 3.5b). However, no differences were seen between simple and 
hypothalamic obese participants when fat mass and fat-free mass was expressed as fat 
index (fat mass in kg/m
2
) or lean index (FFM in kg/m
2
)  (Table 3.4).Both simple obese and 
hypothalamic obese groups had significantly higher fat mass, percentage body fat, and fat 
index (fat mass in kg/height
2
 in meters) when separately compared with the two lean 
groups at the time of recruitment and after 2-3 months (Table 3.4, Figure 3.5a, b, c, and e). 
There was a striking similarity in the composition of fat-free mass between hypothalamic 
lean, hypothalamic obese and healthy lean participants (Table 3.4, Figure 3.5d).  
Bioelectrical impedance expressed as height squared in centimetres divided by the 
resistance in Ohms (Ht2/ Ω) was not significantly different between any of the groups except 
between healthy lean and hypothalamic lean participants after 2-3 months (p=0.011, Figure 
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3.6) When participants were grouped either into a pathological group (hypoth. Lean & 
obese) or healthy group (simple obese & healthy lean), the former showed significantly 
lower impedance compared to healthy group only at the time of final assessment 
(p=0.0096, Figure 3.7b).  
Additionally, fat mass (p<0.0001, R=0.87), percentage fat (p=0.0001, R=0.88), fat 
index (p=<0.0001, R=0.91) and fat-free mass (p=0.003, R=0.46) were positively and 
significantly correlated with BMI SDS. 
 
Table 3.4: Body composition measurements of the participants at the time of recruitment and after 2-3 
months. 
 Hypoth. lean Hypoth. obese Healthy lean Simple obese 
Variable Median IQR Median IQR Median IQR Median IQR 
At recruitment n=5 n=4 n=23 n=13 
Resistance (Ω) 623 126 568‡ 108.8 631* 89 495*‡ 156 
Impedance  Ht
2 / Ω 32.57 22.67 36.71 20.48 36.15 28.76 46.35 28.42 
Fat% 16.85† 12.9 44.8† 6.25 18.7* 14.65 46.2* 6.8 
Fat Mass (kg) 6.3† 4.33 26.85†‡ 20.25 8.95* 14.23 40.7*‡ 25.28 
FFM (kg) 38.4 21.7 37.55 26.32 37.65 22.38 45.2 25.5 
Fat Index (kg/m
2
) 3.351† 2.628 13.02† 3.9 3.377* 4.085 18.19* 8.29 
Lean Index(kg/m
2
) 16.205 2.732 17.37 7.31 14.276 3.526 19.44 5.59 
After 2-3 months n=7 n=7 n=20 n=12 
Resistance (Ω) 718†≦ 163 607† 159 600.5*¥ 67.5 499* 139.5 
Impedance  Ht
2 / Ω 14.7¥ 26.71 34.17 17.64 41.63¥ 29.05 48.67 23.51 
Fat% 24.3† 8.9 42.4† 11.2 14.8* 14.7 47.7* 10.1 
Fat Mass (kg) 16.2† 6.3 28.5†‡ 28.2 6.9* 13.8 43.6*‡ 26 
FFM (kg) 35.6 16.6 40.9 28.9 40.2 20.9 44.6 18.2 
Fat Index (kg/m
2
) 5.677† 2.767 13.37† 6.87 2.572* 3.617 18.47* 6.77 
Lean Index (kg/m
2
) 15.2 3.3 18.75 10.95 14.345 2.3 18.21 4.88 
† indicate significant differences between hypoth. lean and hypoth. obese (p<0.01) 
* indicate significant differences between healthy lean and simple obese (p<0.001) 
‡ indicate significant differences between hypoth obese and simple obese (p<0.05) 




Figure 3.5: Boxplot showing bioelectrical impedance (a), fat mass (b), percentage body fat (c), fat-free mass (d), fat index (e), and lean index (f) of all groups at the time of 
recruitment. 




Figure 3.6: Boxplot showing bioelectrical impedance expressed as Height in cm
2
/resistance in Ω at 
recruitment and after 2-3 months. 
 
*indicate p=0.011 (Mann-Whitney U test) 
Figure 3.7: Boxplot showing Bioelectrical impedance expressed as Height in cm
2/resistance in Ω in all 
groups according to pathology at recruitment (a) and after 2-3 months (b). 
 
Healthy: Healthy lean and simple obese, Pathological: Hypothalamic lean and obese 
 
3.5.5 Changes in body composition and anthropometric parameters 
between baseline and after 2-3 months 
The second assessment of participants from all the groups was carried out in median (IQR), 
2.92(1.28) months (range: 1.25-7.56 months) and the time interval was not significantly 
different between any of the groups (Figure 3.8).  
Changes in all other body composition measurements including impedance (Ht
2 
cm/Ω), fat mass (kg), percentage body fat (%), fat-free mass (kg), fat index (fat mass as 
kg/m
2
), and lean index (FFM expressed as kg/m
2
) were not significantly different between the 




Change in weight SDS, height SDS, and BMI SDS (∆) were not significantly different 
between any of the groups (Table 3.5). When expressed as change in BMI SDS per month 
(ΔBMI SDS/month), no significant differences were observed between any of the groups 
(Figure 3.8). Interestingly, the variation in Δ BMI SDS/month in simple obese participants 
was lower compared to all other groups. Δ BMI SDS/month increased in significantly higher 
proportion (%) of healthy lean than simple obese participants over the study period (n (%): 
healthy lean; 11(40.74) vs. simple obese; 3(18.75), p<0.05) (Figure 3.9, Table 3.6) while no 
differences were found between the hypothalamic lean and hypothalamic obese groups or 
hypothalamic obese and simple obese group. 
Figure 3.8: Individual value plots of time (in months) elapsed between two body composition assessments. 
 
Blank circle in each row represents median time in months. 
Figure 3.9: Boxplot showing change in BMI SDS/month in all groups. 
 
Blank Circles represent individual ΔBMISDS/month 
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Table 3.5: Changes in anthropometric and body composition measurements between baseline and after 2-3 months. 
 
FFM; fat-free mass, Hypoth.; Hypothalamic (Lean or obese). 
Delta represents the difference between the two measurements (follow-up – baseline).  
All values are expressed as medians and (minimum-maximum).  
Participants in each group above 6 years of age for whom body composition data was available at both time points were included.  
Hypothalamus lean group is not compared in this table with healthy lean or hypothalamic obese due to small sample size 
* Delta BMI SDS changes to 0.1(0.61) when one of the participant in this group, who lost weight, is excluded 
‡ indicate significant difference between healthy lean and simple obese. 









Variable Median (Min Max) Median (Min Max) Median (Min Max) Median (Min Max) 
Changes in anthropometric measurements 
Number (n) n=24 n=10 n=9 n=13 
 Δ Ht (cm) 1.15 (0.00 4.00) 1.45 (0.00 7.10) 1.30 (0.00 8.30) 1.50 (0.00 3.10) 
 Δ Wt (kg) 0.60 (-2.20 2.40) 0.95 (-1.20 1.74) 0.90 (-4.00 6.00) 0.70 (-1.90 4.70) 
 Δ Ht SDS 0.03 (-0.36 0.60) -0.15 (-0.35 2.63) 0.03 (-0.27 2.15) 0.04 (-0.41 0.50) 
 Δ Wt SDS 0.00 (-0.32 0.73) 0.26 (-0.43 1.99) 0.01 (-0.51 1.14) -0.03 (-0.19 0.16) 
 Δ BMI SDS -0.03 (-0.40 0.78) -0.02* (-1.30 0.57) -0.06 (-0.62 0.22) -0.07 (-0.18 0.10) 
Changes in body composition  
Number (n) n=17 n=1 n=3 n=9 
 Δ Resistance (Ω) -26.0‡ (-47.0 93.0) -40.0 (40.0 40.0) 53.0 (-57.0 -43.0) 2.50‡ (-108.0 34.0) 
Δ Impedance (Ht2/Ω) 1.87 (-3.58 3.90) 1.92 (1.92 1.92) -2.97† (-3.55 -0.69) 0.45† (-5.44 5.38) 
 Δ fat% -1.00 (-4.10 1.60) 11.1 (11.1 11.1) 1.20 (-2.60 3.40) 0.00 (-6.50 4.10) 
Δ fat mass (kg) -0.30 (-2.30 1.40) 5.00 (5.00 5.00) 1.00 (-1.30 3.30) -0.10 (-5.70 3.70) 
 Δ FFM (kg) 0.90 (-1.40 1.90) -5.70 (-5.70 -5.70) -0.70 (-1.10 0.00) -0.60 (-2.70 5.40) 
 Δ fat index -0.22 (-1.02 0.43) 2.03 (2.03 2.03) 0.36 (-1.42 1.89) -0.09 (-3.24 1.26) 
 Δ lean index 0.15 (-0.65 1.01) -2.36 (-2.36 -2.36) -0.47 (-0.49 -0.06) -0.45 (-1.36 1.54) 
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  n (%) Median Q1 Q3 n (%) Median Q1 Q3 
Healthy Lean (N=24) 11(40.74)* 0.08 0.03 0.12 13(48.15) -0.05 -0.08 -0.03 
Hypothalamic lean (N=9) 4(33.33) 0.11 0.08 0.11 5(41.67) -0.03 -0.16 -0.01 
Hypothalamic obese (N=9) 3(30.00) 0.06 0.03 0.06 6(60.00) -0.05 -0.11 -0.02 
Simple obese (N=13) 3(18.75)* 0.03 0.02 0.03 10(62.50) -0.02 -0.04 -0.01 
Data for 3 healthy lean, 3 hypothalamic lean, 1 hypothalamic obese, and 3 simple obese participant were not 
available at follow-up. * indicate significant difference between healthy lean and simple obese, p<0.05. 
 
3.5.6 Differences in weight velocities observed over the period of follow 
up 
Median weight velocities calculated as g/kg/day showed variations within the groups; 
however, the differences were not statistically significant between any of the groups 
(Figure 3.10).  
Figure 3.10: Weight velocity (as g/kg/day) of study subjects expressed as median (IQR). 
 
Blank circles represent individual values 
3.5.7 Differences in dietary macronutrients and energy intake over the 
period of recruitment 
To estimate the extent of under reporting, the reported energy intake was compared with 
the predicted energy requirement of each participant calculated using the Schofield 
equation (304) which is also used by the FAO (Food and Agricultural Organization) and 
WHO (World Health Organisation) in their expert reports (305). This equation estimates 
basal metabolic rate (BMR) in kilojoules/day considering body mass (in kg), age, and 
gender of an individual. Estimated BMR from the Schofield equation was multiplied by a 
physical activity level (PAL) value of 1.2 to calculate predicted or estimated energy 
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requirement per day. PAL value of 1.2 corresponds to the value to be multiplied with the 
BMR of a bed bound or chair bound person with no strenuous or leisure activity. Although 
our participants were not bed-bound, and Goldberg cut-offs (minimum suggested 
PAL=1.35) are the commonly used cut-offs (306), we applied this value as it was likely 
that some of our participants were on a weight loss diet. The actual energy intake reported 
by the participant was compared with the predicted energy requirement per day to estimate 
the proportion of actual energy intake (%AEI) of the participant. Based on these 
calculations, ~62% (40/65) participants under-reported, half (48%) of which was 
contributed by simple obese group. 
The %AEI was significantly higher in healthy lean group compared to simple obese 
group, both at the time of recruitment [%median (IQR): healthy lean; 142.5(69.0) vs. 
simple obese; 67.4(39.1), p=0.0003] and after 2-3 months [%median (IQR): healthy lean; 
157.7(71.0) vs. simple obese; 65.4(51.8) p=0.0005] (Table 3.7).  Similarly, healthy lean 
participants also showed a significantly higher %EAR compared to hypothalamic lean 
group after 2-3 months (median (IQR) %: healthy lean; 97.88(43.89) vs. hypoth. lean; 
64.78(27.39), p= 0.014 (Figure 3.11, Table 3.7).  
In terms of the intake of individual macronutrients, no significant differences were 
observed between simple and hypothalamic obese participants (Figure 3.12&Figure 3.13). 
Compared to healthy lean participants, simple obese group reported significantly lower 
intake of carbohydrates in grams [median (IQR) g: simple obese; 136.8(57.6) vs. healthy 
lean; 235.7(85.0), p=0.0009] as well as proportion of carbohydrates [median (IQR) %: 
simple obese; 46.02(4.48) vs. healthy lean; 53.22(7.53), p=0.0013] only after 2-3 months 
(Figure 3.12, Table 3.7). On the contrary, the proportional intake of protein was 
significantly higher in simple obese than healthy lean participants [median (IQR) %: 
simple obese; 20.06(5.94) vs. healthy lean; 13.75(3.14), p=0.0013] only after 2-3 months 
(Figure 3.13, Table 3.7).  
Although a general tendency of a lower dietary fibre intake was observed in obese 
groups compared to the lean groups (Figure 3.15), the intake of dietary fibre expressed as 
% DF recommended intake was significantly lower only in simple obese compared to 
healthy lean group after 2-3 months [median (IQR) %: healthy lean; 88.3(39.6 vs. simple 
obese; 40.8(33.5), p=0.0003] (Figure 3.16). 
3.5.8 Changes in dietary macronutrients intake between two assessments 
within the groups 
No significant differences in the dietary macronutrient intake were observed within the 
group over the period of study except that there was a significant increase in percentage 
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intake of daily protein in simple obese group [(median (IQR) %: 20.06 (5.94) vs. 18.91 
(4.5), p=0.05] and in percentage intake of recommended dietary fibre in healthy lean group 
[median (IQR) %: 88.33 (39.5) vs. 77.78 (36.68), p=0.05]. 
Table 3.7: Intake of dietary macronutrients as measured by 24 hour food diary at the time of 
recruitment and after 2-3 months 
Dietary variables Hypoth. Lean  Hypoth. Obese  Healthy Lean  Simple Obese 
Energy intake and macronutrients at recruitment 
 Number (n) (n=10) (n=8) (n=17) (n=15) 
Predicted energy req. 
(Kcal) 
997(653) 1545(902)‡ 1198.3(535.5)† 1917(684)†‡ 
% of actual Energy 
intake 
138.6(71.5) 87(485) 142.5(69.0)† 67.4(39.1)† 
Energy (kcal) 1369(509) 1064(1227) 1438.0(585.6) 1318(735) 
Energy % EAR 86.36(40.05) 74.84(37.83) 86.98(29.50) 62.56(42.89) 
Fat (g) 37.02(19.74) 32.6(47.5) 46.75(37.55) 50.00(29.95) 
Prot (g) 47.38(40.49) 46.2(44.6) 61.65(36.30) 53.90(41.45) 
CHO (g) 208.1(61.9) 177.8 (137.6) 194.4(88.9) 157.9(56.9) 
DF (g) 12.52(11.16) 11.82 (10.65) 13.40(7.25) 10.40(3.20) 
Fat % 25.25(8.92) 30.23(19.53) 32.08(11.37) 35.27(10.52) 
Prot % 13.84(6.95) 17.23(4.14) 15.61(7.48) 17.02(4.50) 
CHO % 62.67(8.96) 58.30(19.83) 54.70(17.63) 49.86 (8.49) 
DF % intake 73.9(93.3) 67.2(47.9) 77.78(36.67) 59.44(16.12) 
Prot %RNI 179.4(154.3) 192.1(142.0) 158.1(100.9) 167.8(106.3) 
Energy intake and macronutrients after 2-3 months 
 Number (n) (n=9) (n=9) (n=22) (n=12) 
Predicted energy req. 
(Kcal) 
936(560) 1514(1152)‡ 1218.1(563.5)† 1864(557)‡† 
% of actual Energy 
intake 
105.00(34.32)* 77.4(270.8) 157.7(71.0)*† 65.4(51.8)† 
Energy (kcal) 942(595)* 1014(573) 1734.9(514.9)* 1213(378) 
Energy % EAR 64.78(27.39)* 73.42(46.44) 97.88(43.89)* 63.1(49.4) 
Fat (g) 28.75(38.52)* 39.90(29.78) 65.90(34.05)* 50.05(33.96) 
Prot (g) 38.95(27.05)* 42.65(27.45) 61.00(28.57)* 59.80(24.85) 
CHO (g) 148.4(32.1)* 159.8(86.7) 235.7(85.0)*† 136.8(57.6† 
DF (g) 12.10(12.27) 10.30(4.97) 16.00(7.16) 6.72(6.07) 
Fat % 27.28(17.22) 29.66(15.93) 32.14(7.99) 37.13(8.34) 
Prot % 15.28(2.39) 16.54(2.94) 13.75(3.14)† 20.06(5.94)† 
CHO % 61.91(15.23) 57.38(14.28) 53.22(7.53)† 46.02(4.48)† 
DF % intake 66.7(74.2) 53.89(37.78) 88.33(39.58)† 40.84(33.47)† 
Prot %RNI 186.2(103.0) 147.9(132.1) 201.0(153.3) 179.2(131.6) 
Kcal; kilocalories, Prot; proteins, CHO; carbohydrates, DF; dietary fibre, Prot. %RNI; Percentage 
recommended nutritional intake of proteins, Energy %EAR; percentage estimated average recommended 
intake of energy. 
*Indicate significant differences between healthy lean and hypothalamic lean 
† Indicate significant differences between healthy lean and simple obese 




Figure 3.11: Boxplots showing total caloric intake expressed as estimated average energy requirements 
(%EAR) in all groups at the time of recruitment and after 2-3 months. 
 
*indicate p<0.05, Hypoth; hypothalamic lean or obese 
 
Figure 3.12: Boxplots showing intake of fats, carbohydrates, and proteins in all participants expressed 
in grams at the time of recruitment and after 2-3 months. 
 
*indicate p<0.05, HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, SO; Simple 




Figure 3.13: Boxplots showing proportional intake of fats, carbohydrates, and proteins in all 
participants expressed as percentage at the time of recruitment and after 2-3 months. 
 
*indicate p<0.05, HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, SO; Simple 
obese 
 
Figure 3.14: Boxplots showing proportional intake of recommended nutritional intake of proteins 
(%RNI) in all participants at the time of recruitment and after 2-3 months. 
 




Figure 3.15: Boxplots showing dietary fibre intake (in grams) in all participants at the time of 
recruitment and after 2-3 months. 
 
 
*indicate p<0.05, Hypoth; hypothalamic lean or obese 
 
Figure 3.16: Boxplots showing SACN 2011 recommended proportional intake of dietary fibre (%) in 
all participants expressed as percentage at the time of recruitment and after 2-3 months. 
 
*indicate p<0.05, Hypoth; hypothalamic lean or obese  
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3.5.9 Correlation of dietary macronutrients intake with adiposity 
To assess the relationship of the degree of adiposity with the dietary intake, BMI SDS of 
individual groups were tested for any correlation with the amount and proportion of major 
macronutrients (fats, carbohydrates, proteins and dietary fibre) and energy intake (%EAR) 
both at the time of recruitment and after 2-3 months. 
No characteristic patterns of positive or negative correlations between 
macronutrient intake and adiposity were observed in the groups. Inconsistent negative 
correlation of carbohydrate intake (in grams) (R=-0.506, p=0.038) and %EAR (R=-0.532, 
p=0.028) with BMI SDS were observed in healthy lean participants only at the time of 
recruitment (Table 3.8). Furthermore, inconsistent significant positive correlation of fats 
(g), carbohydrates (g), and protein intake (g) were observed in hypothalamic obese 
participants only after 2-3 months and not at the time of recruitment (fats (g): R=0.483, 
p=0.013, CHO (g): R=0.792, p=0.013, and proteins (g): R=0.753, p=0.019) (Table 3.8). 
When participants were grouped according to their phenotype (lean vs. obese) or 
according to their pathology (pathological vs. healthy), we observed that lean or obese 
phenotypes were not significantly correlated with any of the dietary macronutrient (amount 
and proportion) or energy intake (as %EAR) both at the time of recruitment and also after 
2-3 months (Table 3.9). However, when participants were grouped according to the 
presence or absence of a pathology (pathology vs. healthy), significant negative correlation 
of BMI SDS with energy intake expressed as %EAR and amount of dietary carbohydrate 
was observed in healthy group (healthy lean and simple obese) both at the time of 
recruitment and after 2-3 months (table 9). Moreover, dietary fibre in healthy group was 
significantly negatively correlated with BMI SDS in terms of its amount at recruitment 
(DF (g): R=-0.564, p=0.001) and proportion after 2-3 months (%DF: R=-0.610, 
p<0.001).None of these significant differences were seen in the group of patients with 
pathology (Table 3.9). 
 153 
 
Table 3.8: Spearman rank correlation of dietary macronutrient intake with BMI SDS in each group at 
the time of recruitment and after 2-3 months. 
 Healthy Lean Hypoth. lean Hypoth. Obese Simple Obese 
 R p R p R p R p 
At recruitment 
Fat (g) -0.227 0.381 -0.217 0.575 0.400 0.326 -0.074 0.794 
CHO(g) -0.506 0.038 -0.331 0.385 0.241 0.566 -0.484 0.067 
Prot(g) -0.058 0.825 -0.283 0.461 0.197 0.640 -0.159 0.572 
DF(g) -0.290 0.259 0.247 0.521 0.120 0.777 0.049 0.862 
%Fat -0.042 0.874 0.077 0.844 0.397 0.330 0.159 0.573 
%CHO -0.214 0.409 -0.047 0.905 -0.303 0.466 -0.207 0.460 
%DF -0.239 0.356 0.168 0.665 0.170 0.687 0.093 0.741 
%RNI -0.267 0.301 0.107 0.783 -0.546 0.161 0.083 0.768 
%EAR -0.532 0.028 0.128 0.743 -0.421 0.300 -0.091 0.747 
After 2-3 months 
Fat (g) 0.318 0.160 0.432 0.286 0.783 0.013 -0.266 0.403 
CHO(g) 0.279 0.221 0.435 0.281 0.792 0.011 -0.477 0.117 
Prot(g) 0.065 0.781 0.160 0.704 0.753 0.019 -0.515 0.087 
DF(g) -0.036 0.878 0.059 0.890 0.204 0.599 -0.293 0.356 
%Fat 0.105 0.650 0.300 0.471 0.251 0.514 0.100 0.758 
%CHO -0.066 0.775 -0.253 0.545 -0.066 0.866 -0.253 0.428 
%DF -0.002 0.993 0.006 0.989 0.090 0.817 -0.272 0.393 
%RNI -0.110 0.634 0.490 0.217 -0.206 0.594 -0.031 0.924 
%EAR 0.044 0.849 0.791 0.019 0.259 0.500 -0.18 0.577 
Significant differences or correlation with a tendency are highlighted. Prot; proteins, CHO; carbohydrates, 
DF; dietary fibre, Prot. %RNI; Percentage recommended nutritional intake of proteins, Energy %EAR; 




Table 3.9: Spearman rank correlation of dietary macronutrient intake with BMI SDS based on 
phenotype (lean or obese) and pathology (pathological vs healthy) at the time of recruitment and after 
2-3 months. 
 Obese 
(simple & hypoth. 
obese) 
Lean 
(healthy & hypoth. 
lean) 
Pathology 
(Hypoth. Lean & 
obese) 
Healthy 
(healthy lean & 
simple obese) 
 R p R p R p R p 
At recruitment        
Fat (g) 0.261 0.254 -0.098 0.611 0.474 0.055 -0.157 0.384 
CHO(g) 0.027 0.906 -0.275 0.149 0.487 0.047 -0.595 <0.001 
Proteins (g) 0.253 0.269 -0.281 0.140 0.428 0.087 -0.029 0.874 
DF (g) -0.163 0.480 -0.098 0.613 -0.095 0.716 -0.564 0.001 
%Fat 0.308 0.153 -0.164 0.424 0.348 0.172 0.230 0.200 
%CHO -0.298 0.168 0.078 0.705 -0.320 0.210 -0.215 0.238 
%DF 0.039 0.858 -0.105 0.611 0.104 0.691 -0.322 0.073 
%RNI -0.166 0.448 -0.079 0.700 -0.197 0.448 -0.133 0.467 
%EAR -0.231 0.289 -0.231 0.257 -0.379 0.133 -0.405 0.022 
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After 2-3 months        
Fat (g) 0.197 0.367 -0.292 0.147 0.003 0.990 -0.055 0.766 
CHO(g) -0.161 0.464 -0.279 0.168 -0.257 0.319 -0.432 0.014 
Proteins (g) 0.014 0.948 -0.158 0.441 -0.025 0.924 -0.073 0.690 
DF (g) 0.007 0.975 -0.113 0.582 0.049 0.851 -0.323 0.067 
%Fat 0.267 0.243 -0.049 0.799 0.304 0.235 0.239 0.181 
%CHO -0.354 0.116 0.060 0.755 -0.232 0.370 -0.526 0.002 
%DF -0.185 0.423 -0.120 0.534 -0.168 0.520 -0.610 <0.001 
%RNI -0.006 0.980 -0.085 0.661 -0.122 0.640 -0.093 0.605 
%EAR -0.003 0.991 -0.139 0.471 0.201 0.438 -0.371 0.034 
Significant differences or correlation with a tendency are highlighted. CHO; carbohydrates, DF; dietary fibre, 
Prot. %RNI; Percentage recommended nutritional intake of proteins, Energy %EAR; percentage estimated 
average recommended intake of energy. 
 
3.5.10 Association of dietary macronutrients and energy intake with 
adiposity 
Univariate regression analysis was done to assess the association of BMI SDS with dietary 
macronutrients (the amount and proportion of fats, carbohydrates, and proteins), dietary 
fibre, and energy intake (%EAR), both at the time of recruitment and after 2-3 months. 
Variables showing a significant association (p<0.05) or a tendency (p<0.10) in univariate 
analysis were further analyzed in multivariate regression analysis with and without 
adjustment for pathology. 
Although BMI SDS of individuals was significantly associated with the intake of 
carbohydrates (g), proteins (%), dietary fibre (g and %), and energy (as %EAR) in 
univariate analysis, none of the dietary variables were strongly significantly associated 
with BMI SDS in multivariate regression analysis with and without adjustment for 
pathology except a significant association of proportional intake of fats only at the time of 












Table 3.10: Univariate and multivariate regression analysis of dietary macronutrients intake with BMI 
SDS with and without adjustment for pathology 
 
Β-coef; beta coefficient, R2-adj; R2 adjusted,CHO; carbohydrate intake, %EAR; % intake of    





3.6.1 Anthropometric measurements 
Children with PWS suffer from growth retardation partly due to growth hormone 
deficiency, feeding difficulties in early life, hypotonia and limited activity which 
contribute to short stature in these children (22, 307). This was particularly true in our 
group of PWS patients as their height SDS was significantly lower than the simple obese 
(p=0.01) and healthy lean group (p=0.008). As mentioned earlier, low height for age 
coupled with reduced physical activity due to poor co-ordination, low muscle mass, eye 
abnormalities such as esotropia and myopia, and slow body movements due to poor muscle 
tone leads to reduced energy expenditure which reduces the caloric expenditure in these 
patients. Low caloric requirement, in addition to lower lean body mass and increased 
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appetite favours the accumulation of excess body fat and hence obesity in hypothalamic 
obese patients(22).  
Weight SDS of the hypothalamic obese children was significantly lower than the 
simple obese patients but when corrected for height SDS (i.e. expressed as BMI SDS) no 
differences were observed between simple and hypothalamic obese groups which suggest 
that both obese groups were proportionate to each other. Most of the hypothalamic obese 
children are usually under the GH therapy which has been shown to reduce fat mass, 
increase skeletal muscle mass, and exercise and motor performance after 12 and 24 months 
of start of GH therapy (308). Studies have shown long term GH replacement to induce 
lipolysis, cause reduction in fat mass, and increase lean mass (35, 309). This might be a 
factor accounting for the significant difference in the weight SDS between simple and 
hypothalamic obese children in our study. It has been observed that this effect is reversed 
after cessation of GH therapy as found by Oto et al. (2014) (310). This study on young 
PWS patients found a significant increase in BMI SDS over a period of 24 months after 
GH cessation and a trend towards increase in subcutaneous and visceral body fat 
distribution (310).  
BMI (in kg/m
2 
or SDS) is a good measure of assessing the cardiovascular disease 
risk in general population. Studies have shown a strong association of increased BMI SDS 
scores in childhood as predictors of adulthood obesity and its metabolic complications 
(311). A non-significant but relatively lower BMI SDS in hypothalamic obese children 
than simple obese children may be due to the fact that simple obese children in our study 
may not be a representative sample of the general population, as cases of obesity attending 
the tertiary care centre are severely obese [median BMI SDS 3.91 (0.91)] or resistant to the 
community weight management programs. Additionally, the nature of obesity might 
possibly be different from those of simple obesity because children with Prader Willi 
Syndrome and craniopharyngioma are generally short for their age with more fat and less 
muscle per unit of body weight and so they are likely to become obese even in the presence 
of a normal caloric intake. Weight SDS may therefore be a more sensitive predictor of 
obesity than BMI SDS in these patients. A relatively lower BMI in hypothalamic obese 
group than simple obese group could also be an indication of the effect of treatment in 
addition to the dietetic intervention in these children. Furthermore, waist circumference has 
been suggested as a strong predictor of adiposity in children and adolescents than BMI 
(312) but BMI SDS is more commonly used in population based studies for practical 
reasons. 
Although not all children with Prader Willi syndrome in our study were obese, the 
median BMI SDS of PWS children in lean category was more than 1 SDS as compared to 
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healthy lean controls (median BMI SDS <0 SDS).This may represent the transitional phase 
between the initial changes in metabolism (i.e. reduced energy expenditure and increased 
fat mass) and hyperphagia towards an obese status as suggested by Miller et al. (2011) in 
their study. They followed 79 children with PWS and 84 siblings over a period of 10 years 
(307). This study found a gradual progression of PWS patients in 7 distinct nutritional 
phases as opposed to the previously described traditional 2 stage nutritional phases which 
suggested a switch towards hyperphagia and obesity between 18-36 months of life (313). 
Gathering physical activity data in our group of patients would help determine how much 
of this difference could be explained by physical activity. Published data suggests that 
three month, easy to follow, well accomplished, exercise significantly increases calf 
muscle mass, reduces calf skin-fold, and exercise endurance in PWS children (37). A lower 
bone mineral density suggest lower limb-muscle activity and hence a lower muscle mass 
and muscle power (39). The limb and body movements of hypothalamic obese children are 
therefore slow and less intense even in the presence of a comparable time of activity to 
lean healthy children (40). Adiposity in hypothalamic obese children (PWS) has been 
shown to increase with age, such as in patients age 12 years and above in a study by 
Brambilla et al. (1997) (39). However, we did not observe a significant positive correlation 
of BMI SDS with age in our hypothalamic obese participants. 
3.6.2 Body composition 
In our study, lean index (expressed as kg/m
2
) was significantly higher in simple obese than 
healthy lean group. Given that our simple obese participants were taller, heavier, and had a 
high lean mass might suggest that in fact height and lean mass contribute to a higher BMI 
SDS scores in simple obese, followed by the hypothalamic obese participants. This is in 
line with findings from Metcalf et al.(314), who reported three major findings from the 
Earlybird diabetes cohort of children age 7-12 years, in Plymouth, UK. Firstly; BMI and 
fat mass correlated with height at each annual visit similar to that of height with other 
measures of adiposity (fat%, leptin, and insulin). Secondly; body mass and fat mass were 
more closely correlated with fat%, leptin and insulin rather than their height independent 
formulations and thirdly; children who grew faster gained the most weight(314). Further 
analysis by Wells and Cole suggested that independent of increase in adiposity, height was 
significantly associated with insulin resistance, while lean mass was associated with both 
leptin and insulin resistance in children especially girls measured annually (315). The 
associations of height and lean mass with insulin resistance in their study were never above 
60% which suggested that un-explained variations related to diet, social class, physical 
activity, and other unknown confounding factors might also be playing their role as 
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environmental predictors of cardiovascular risk. Moreover, from our study, we found that 
fat mass, fat%, and fat index (fat mass dependent on height) were significantly higher in 
both of our obese than lean groups. Furthermore, hypothalamic obese children with PWS 
have a reduced visceral to subcutaneous fat ratio on dual energy X-ray absorptiometry and 
visceral adipose tissue is correlated with subcutaneous fat and BMI (316). This suggests 
that subcutaneous fat measurement can possibly be a surrogate measure of the elevated 
risks associated with high BMI in adults. 
The method for the measurements of body composition in our study was based on 
foot-to-foot bioelectrical impedance analysis. Although this has been validated for use in 
children (317) and adults (317, 318), studies have shown that it may overestimate fat-free 
mass and underestimate fat mass (319, 320) and the measurements can vary largely 
between DEXA and foot-to-foot impedance analysis and according to the gender (321). 
Body composition of all participants could not be measured primarily due to age of the 
study participants. Furthermore, the initial plan was to measure only basic anthropometric 
data such as height and weight; however, the ease of use and the nature of body 
composition in hypothalamic obesity encouraged us to also measure the body composition 
data using non-invasive, portable, and validated device. Therefore, body composition 
measures of some of the participants recruited before the start of use of TANITA® were 
not available and the results of body composition should therefore be interpreted with great 
caution due to lower number of readings available for analysis. 
3.6.3 Relationship of obesity with socioeconomic status 
Our data showed significantly lower SIMD scores in the simple obese than healthy lean 
while a trend was observed in the hypothalamic group (lean and obese). SIMD rank and 
quintiles significantly negatively correlated with BMI SDS in healthy group (healthy lean 
and simple obese). Although our participants sample is not representative of general 
population, this finding is in line with the Scottish government reports attributing a high 
prevalence of obesity to areas with low SIMD scores and quintiles (7, 11). This is 
primarily explained by the association between obesity and socioeconomic class or 
possibly by the recruitment of more affluent lean control group. Other studies also found a 
significant negative association  of socioeconomic status with obesity (322). Although 
some countries are in a plateau phase of obesity prevalence but this has been at the expense 
of increasing socioeconomic disparity (323, 324). Parents and families with low 
socioeconomic status are likely to follow unhealthy food choices, have less awareness of 
health benefits of good food choices, live in more deprived areas with limited access to 
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physical exercise and leisure facilities, and have limited access to fresh fruits and 
vegetables. However, some studies have found an upward trend of obesity in highly 
educated  (325) and high socioeconomic group  with long working h. 
3.6.4 Dietary energy and macronutrients intake 
Obesity is a state of positive energy balance occurring as a result of increased energy 
intake against a reduced energy expenditure (326). Population based studies and large 
meta-analyses have mentioned a reduced intake of dietary fibre, increased intake of readily 
available carbohydrates and fats by obese people including children  and this increased 
intake is associated with increased weight (327). Here we show that the proportional intake 
of the dietary fat (fat %) and proteins (protein %) were higher while that of carbohydrate 
was lower in the obese group, particularly simple obese group. Dietary fibre is important 
for colonic health and a lower intake has been reported in obese population (328, 329). Our 
data suggest a clear downward trend in the percentage recommended intake of dietary fibre 
from lean towards obese.  
Simple obese children reported 32.6% and 34.6% lower intake of energy than their 
predicted basal metabolic rate at recruitment and after 2-3 months respectively. Similar 
results have been reported in the literature for obese children with central adiposity in the 
US (329). The lower percentage of average recommended intake of energy in the 
hypothalamic lean, hypothalamic obese and simple obese groups can either be attributed to 
reduced energy requirements, reduced energy expenditure, or due to the actual effect of 
dietetic management, or it may represent under-reporting of dietary habits. We found that 
the healthy group (healthy lean and simple obese) but not the pathological group 
(hypothalamic lean and obese) showed a significant negative correlation of BMI SDS with 
percentage of recommended estimated intake of energy (%EAR), intake of dietary 
carbohydrates, and dietary fibre. This finding suggested that the observed lower dietary 
energy and macronutrient intakes in patients with Prader-Willi syndrome and 
craniopharyngioma irrespective of the lean or obese status were possibly related to the 
reduced energy requirements and reduced energy expenditure rather than under-reporting. 
This is in line with the studies reporting lower energy intake in the hypothalamic obese 
group compared to the reference population (330-334). Moreover, using Schofield 
equation or Goldberg cut offs may not be relevant while considering pathological 
conditions such as PWS or craniopharyngioma as these equations assume stable health 
status. Despite this evidence, we still are cautious to rule out under-reporting in the 
hypothalamic disease group due to large variation and hence less power in our data. 
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Furthermore, our assumption needs confirmation via physical activity and body energy 
metabolism studies in our cohort, although these have been shown to affect obesity in PWS 
as mentioned in chapter 1 section 1.3.5.1(22, 39, 335). On the other hand, disparity of BMI 
SDS scores with energy intake (lower BMI SDS-higher energy intake) in the healthy group 
suggested under-reporting in our simple obese group. Recording a reliable dietary history 
is a challenge as many studies have pointed towards the tendency of the obese population 
to under report(336). This reporting error has been shown to be consistently associated 
with increasing BMI SDS of the participants (337, 338) and increasing age (329). The 
former evidence is supported by our findings.  
None of the dietary macronutrients or energy intake as %EAR was significantly 
associated with BMI SDS in adjusted and un-adjusted multivariate regression analysis 
except an association of proportion of fat intake (p=0.054) at recruitment. Moreover, 
change in BMI SDS (ΔBMI SDS) did not correlate with changes in energy intake over the 
period of study. This further indicated that apart from the above mentioned possible 
factors, limitations related to the dietary assessment method and bias on behalf of the 
patients related to interpretation of portion sizes might also play their role in determining 
this association. The food diaries were not weighed which might have resulted bias in 
portion size interpretation and hence false differences in macronutrients and energy intake. 
The diaries used were for a single day and may not reflect the frequency of foods taken on 
daily or weekly basis. Furthermore, foods taken by the child at school might have not have 
been reported by the parents. We tried to address these potential limitations by explaining 
the food diary in detail to the participant and/or the parent and asking them to 
preferentially choose a weekday to fill the diary.  Use of multiple pass food diaries might 
help address issues related to memory bias and under-reporting by participants (339), and 
is therefore suggested for future studies involving these groups.   
Despite possible under-reporting, we observed that the proportion of recommended 
dietary fibre and carbohydrate intake was lower in the simple obese compared to the 
healthy lean participants and a lower intake of dietary fibre and carbohydrate intake was 
negatively correlated with BMI SDS when both healthy lean and simple obese groups were 
studied together. Population based studies have suggested lower intake of dietary fibre in 
the simple obese population (340). Moreover, the use of more readily available sources of 
energy such as glucose has further contributed to this low fibre intake. Diets with readily 
available sources of energy(such as glucose) have a high glycaemic index which induces 
hormonal changes (such as hyperinsulinemia and hypoglucogonemia) that has been shown 
to promote voluntary food intake by up to 81% compared to 51% in low glycaemic index 
foods (341). The typical Western diet is composed of a higher proportion of fats and it has 
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been reported in longitudinal studies in adolescents that diets high in fat are devoid of 
fruits and vegetables which are important sources of dietary fibre (342). Additionally, the 
dietary choices of obese children may be influenced by the family meal plans and it has 
been observed that obese children usually have obese parents whose diet is rich in fats and 
low in fibre intake (15). Proportional intake of fats was marginally associated with BMI 
SDS in our cohort, and it has been suggested that the consumption of high fat diet is a 
consistent factor for obesity in paediatric population (343). Other factors such as unhealthy 
food choices with low dietary fibre (340), education, socioeconomic status, and awareness 
regarding high fibre diets could also be amongst other contributory factors to low fibre 
intake in simple obese group (17, 344).   
Although the time period between the two assessments was relatively short (median 
2.92 months) it allowed us to investigate changes in anthropometry and dietary intake with 
weight management in short term. Weight management in dietetic clinics for overweight 
and obese patients in Yorkhill hospital has two main goals a) to stop the progression of 
weight gain followed by b) reduction in the current over-weight by no more than 
0.5kg/week. We observed no major significant differences in the anthropometric 
measurements and dietary intake between and within the groups. However, there was 
strikingly lesser variation in the change in BMI SDS/month in the simple obese 
participants compared to the lean groups. This finding can have three probable 
interpretations; firstly, it suggests the resistance of obese people to changes in BMI SDS 
and secondly, it might suggest that the weight management plan are at least successful to 
keep the change in BMI SDS/month close to zero which is also supported by the finding 
that more simple obese patients had ∆BMI SDS/month <0 SDS compared to healthy lean 
participants. Thirdly, the simple obese participants had probably reached their ―limit of 
adiposity‖ to accommodate any further change in BMI SDS. However, long term follow-
up data of these patients would help in confirming any of the three possible interpretations.  
3.7 Conclusions 
In conclusion, simple and hypothalamic obese patients differ from each other in the nature 
of their obesity; hypothalamic obese patients being shorter and with lower fat mass 
compared to simple obese. Correlation of change in BMI SDS with change in energy 
intake as %EAR, dietary fibre and carbohydrates only in the non-pathological group 
suggest that the actual dietary consumption of the hypothalamic obese and lean patients 
might be less and that their energy expenditure and satiety (controlled by hypothalamus) 
might play a more important role in determining their energy intake. Additionally, dietary 
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intervention in the hypothalamic lean or obese groups should take into account this 
reduced energy intake to avoid under or over nutrition. On the other hand, simple obese 
participants seem to under-report which limits the real association of dietary intake with 
body composition. Differences in the ―nature‖ of anthropometry and body composition 
between the simple and hypothalamic obese groups therefore make them better suited for 
comparison to test our main hypothesis. 
In subsequent chapters, this anthropometric and dietary information will be used as the 
basis to investigate the association of the gut microbiota metabolic activity and diversity 
with anthropometric data and dietary intakes to support or refute our hypothesis of gut 
microbiota in relation to obesity.  
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Chapter 4: Differences in Bacterial Metabolites of Gut 
Microbiota in Simple and Hypothalamic Obesity 
 
4.1 Chapter Outlines 
This chapter explores differences in the faecal bacterial metabolites between simple and 
hypothalamic obese groups and their relationship with diet and weight change. 
4.2 Introduction 
4.2.1 Short chain fatty acids and human health 
Gut microbiota may in part affect obesity by degrading complex dietary polysaccharides 
(and some proteins) to 1-6 carbon organic compounds, called short chain fatty acids 
(SCFA). The most important of these SCFA are acetate (C2), propionate (C3), and butyrate 
(C4), the molar ratios of which varies between 48:29:23 and 70:15:15 respectively with a 
mean ratio of 60:20:20 (75). The exact amount of SCFA produced by the gut microbiota in 
humans is difficult to determine due to difficulties in access to the proximal colon (i.e. in-
vivo) and measurement of SCFA both in the lumen and the portal circulation to give an 
estimate of the total amount produced. However, the rate of production of SCFA 
considerably varies with the amount and type of substrate available for bacterial 
fermentation, gastrointestinal tract transit time, and composition of the gut microbiota 
(345, 346). 
There are estimates that SCFA, primarily acetate, propionate, and butyrate may 
contribute to approximately 10% of the daily energy requirements (347). Acetate is 
involved in de novo hepatic lipogenesis (162). Propionate is related to beneficial effects 
such as inhibition of lipogenesis (via 3-hydoxy, 3-methylglutaryl co-enzyme A reductase), 
hypocholesterolemia (via redistribution of cholesterol from plasma to the liver), hepatic 
and intestinal gluconeogenesis (348),  intestinal GPR41- induced induction of satiety via 
hormone Peptide YY (PYY), and eating behaviour through leptin (97). Butyrate is one of 
the main SCFA required by the colonocytes as an energy source for cellular metabolism. It 
exerts anti-proliferative effects on colon cancer cells, stimulates apoptosis and positively 
affects cellular differentiation, and proliferation of normal colonic epithelium (111, 349). 
Studies have shown the potential anti-obesity and anti-inflammatory effect of butyrate by 




4.2.2 Gut bacterial metabolites in relation to obesity 
Pioneering studies in gnotobiotic mouse models (GF mice) suggested a potential causative 
role of the gut microbiota in the development of obesity. GF mice were shown to be 
resistant to obesity despite higher caloric intake compared with their lean wild-type 
counterparts (162). This was attributed to reduced energy harvest in the colon from the diet 
and increased expression of energy sensors such as AMP kinase that stimulate energy 
generation and inhibit anabolic pathways. Transplantation of gut microbiota from 
conventionally raised (CONV) mice resulted in the development of an obese phenotype 
which meant that this ―amicrobiotic‖ environment may have acted as a caloric restrictor for 
protection against obesity in GF mice (66). One study found reduced diversity of gut 
microbiota, reduction in Bacteroidetes, and increase in Firmicutes with development of 
obesity on high fat feeding (258). These differences in gut microbiota may be driving 
differences in the faecal SCFA between lean and obese individuals. However, results from 
human studies have been controversial due to small study samples, inter-individual 
variations, differences in diet, and other confounding factors. A recent study by Rahat et al. 
(2014) has suggested that a higher faecal SCFA in overweight and obese adults than in 
lean adults might be due to an increased production of SCFA and more dietary energy 
indirectly available to the host, by a different pattern of gut microbiota (175). A 
crossectional study by Payne et al. (2011) found significantly higher levels of faecal 
butyrate, propionate, and iso-butyrate in obese than lean children (95). Schwiertz et al. 
(2010) found 20% higher total SCFA and a significantly higher concentration and 
proportion of propionate in the faecal samples of obese than the lean volunteers (350). 
In this context, several controversial differences in gut microbiota between lean and 
obese individuals have been suggested. In children, an increase in Staphylococcus aureus 
and reduction in Bifidobacteria has been associated with development of obesity (258). 
Some studies revealed a reduced diversity of gut microbiota, reduction in Bacteroidetes 
and increased Firmicutes in obese vs. lean individuals (159). Faecalibacterium prausnitzii 
has been associated with reduced inflammation and increased numbers of this bacteria are 
thought to play a protective role in IBD and diabetes (351) while Akkermansia muciniphila 
has been associated with weight reduction (352). 
4.2.3 Gut bacterial metabolic activity in relation to diet 
Changes in the diversity of gut microbiota may occur with change in energy intake, 
nutrient load, or nutrient composition which highlights diet as an important factor that 
interacts with gut microbiota (265). Gut microbiota and their capability to produce SCFA 
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are thought to co-evolve as an adaptive response to the change in dietary intake which 
varies with geography (155). Differences or change in dietary patterns might cause a 
dramatic transient change in the gut microbiota population at species and group level 
(217). However, these changes are not consistent between different studies possibly due to 
differences in experimental settings, dietary substrates used, and biological variation 
between individuals. A study by Kim et al. showed a reduction in faecal SCFA, reduction 
in Firmicutes, increase in Bacteroidetes, and reduction in Firmicutes: Bacteroidetes ratio 
in six overweight and obese adults who were kept on a strict vegetarian diet for 28 days 
(170). Lastly, Belobrajdic et al. (2012) showed a significant increase in the faecal output 
and total SCFA pool in the caecum of Sprague-Dawley rats independent of obesity 
phenotype with the introduction of at least 8% dietary resistant starch (174). 
4.2.4 Factors contributing to the variation in the gut bacterial 
metabolites and diversity 
Several factors have been proposed to help explain the higher faecal short chain fatty acid 
levels in obese populations. These include; increased production by ―obesogenic‖ gut 
microbiota, altered symbiotic relationships for the utilization of nutrients in the gut lumen 
between different groups of gut microbiota, decreased mucosal absorption, and increased 
transit time (260). However, generally, it is recognised that changes in gut microbiota are 
associated with changes in the SCFA profile of the faecal samples (166). Anatomical 
changes in the gut may also influence the variation in the gut microbial diversity and 
metabolic activity. This is exemplified by gastric bypass surgery in individuals who show a 
sustained post-surgical weight loss (353). The change in gut physiology might be due to 
the reduction in the amount of dietary substrate intake, changes in bile circulation, 
anatomical changes to the normal passage of the food and acids, and changes in 
parasympathetic innervation. However, some authors suggest that gut microbiota play their 
role in causing weight loss by ways independent of these effects (354). 
4.2.5 Controversies in the relationship of gut microbiota metabolites 
with obesity 
Whereas the  studies discussed above point towards the gut microbiota as a factor in 
obesity pathogenesis, several studies have contradicted this notion by showing no 
compositional differences or changes in gut microbiota with dietary intervention between 
lean and obese individuals (95) and that such changes in the gut microbiota are not always 
associated with obesity (260). Some studies have found significantly higher proportion of 
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Firmicutes and higher Firmicutes to Bacteroidetes ratio in lean rather than obese 
individuals (350). Additionally, a compositional shift in gut microbiota induced by 
intervention with supposedly beneficial gut microbiota such as Lactobacillus salivarius-
ls33 (171) or with high fat diet (222) may not be associated with the change in 
functionality or markers of increased energy harvest by the resident gut microbiota. As 
opposed to findings of the pioneering study by Backhed and colleagues (162), some studies 
found significantly higher weight gain in germ-free mice than conventionally raised mice 
on high fat diet which suggested that other mechanisms might be involved in weight gain 
induced by high fat diet independent of gut microbiota (165). Some authors have suggested 
a reciprocal relationship between caloric density and gut microbiota because on one hand 
gut microbiota are modulated by increased caloric density while on the other hand they 
extract energy from the diet and increase energy salvage in the form of SCFA. The balance 
of this relationship is affected by a variety of genetic factors influencing the expression of 
certain genes that may be peculiar to obese and lean individuals. 
This discussion leads us to the debate as to whether changes in gut bacteria are a 
cause or an effect in obesity genesis and the role of diet in this interplay. Studies done on 
experimental animals are not always reciprocated in humans due to anatomical and 
physiological differences and differences in diet and lifestyle of animals and human 
subjects. Several controversial data on the gut microbiota diversity in lean vs. obese 
population suggest that the functionality, and not the actual structural organisation, of the 
gut microbiota might be more important (199). Although the core gut microbiome remains 
relatively stable throughout the life of an individual, shifts in the gut luminal environment 
due to changes in the availability of substrate for fermentation may cause shifts in the 
relative abundance and proportions of gut microbiota (263).  
No study has thus far been able to prove a causal relationship between the gut 
microbiota and obesity. We have therefore used a unique model to look at this relationship 
by comparing a group of obese children and young adults who are prone to develop obesity 
either because of a genetic disorder (e.g. Prader-Willi Syndrome) or a tumour that erodes 
the hypothalamic satiety centre (e.g. craniopharyngioma) and compare their gut bacterial 
diversity and metabolic activity with a group of children who have obesity of 
undetermined cause and healthy lean controls. We have attempted to account for the 
dietary intake by recording the 24 hour food diary and we also explored alterations with 
weight change. A causative role of gut microbiota would be expected to reveal  significant 
differences in microbial metabolic activity between the ―bacterial induced‖ simple obesity 
and hypothalamic or ―pathological‖ obesity caused by hyperphagia (66). 
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4.3 Purpose of this chapter 
 To compare gut bacterial metabolic activity by measuring the concentration of 
faecal SCFA, hydrogen sulphide, lactate, and ammonia profile between simple and 
hypothalamic obese groups at the time of recruitment and at follow-up after 2-3 
months.  
 To assess changes in gut bacterial metabolites between and within the groups with 
weight change over a period of 2-3 months and explore relationships with weight 
change. 
 To assess the association of demographic, anthropometric, and dietary predictor 
variables with gut bacterial metabolites using univariate and multivariate analysis. 
4.4 Patients and Methods 
A detailed description of participants and the methods used is given in chapter 2. Briefly, 
simple obese (n=16), hypothalamic obese (n=10), and hypothalamic lean (n=12) were 
recruited from the endocrine and dietetic clinics at Royal Hospital for Sick Children 
Glasgow. Healthy lean (n=27) participants were recruited from the community. Two faecal 
samples along with body composition data and 24 h food diary were collected from each 
participant at an interval of 2-3 months as described in section 2.2.3. 
Laboratory methods 
All faecal samples were processed for the measurement of SCFA using gas 
chromatography (section 2.3.6). Hydrogen sulphide (free, total, bound) was measured with 
a colorimetric assay according to the methylene blue reaction (section 2.3.7), ammonia 
using automated ammonia analyser (HANNAH Electrical HI93715) (section 2.3.4), pH 
using a benchtop pH meter (section 2.3.3), and lactate (D, L, and total isomers) with an 
enzymatic assay (section 2.3.8). Values for SCFAs and BCFA in freeze dried faecal 
material were expressed as µg/g dry or wet faeces. Free, bound, and total sulphide were 
expressed as µmol/g dry or wet faeces. Faecal NH3 and lactate were expressed as mg/g dry 
or wet faeces. 
Dietary assessment 
All participants or their parents on behalf of the participant were handed over a form to 
complete a 24 h food diary. They were encouraged to complete the diary prospectively; 
however, some participants filled it in retrospect. The diaries were analysed using 
Windiet® 2005 software (Robert Gordon University Aberdeen UK). All foods entered into 
the software were analysed for total caloric intake and major macronutrient intake per day. 
The amounts of macronutrients (fats, carbohydrates, and proteins) were then expressed as 
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percentage proportion of total caloric intake. The proportion of recommended estimated 
average energy requirements (%EAR) and dietary fibre intake as percent recommendations 
(%DF) by the UK Scientific Advisory Committee on Nutrition (SACN) 2011 report (303) 
while the recommended nutritional intake of proteins (%RNI) was calculated from the 
Department of Health 1991 recommendation (COMA 1991). Portion sizes for all 
unspecified foods were estimated from the information based on published data from 
National Diet and Nutrition Survey (NDNS) (355). Foods not mentioned in the software 
were added as per 100 grams dietary values to the software from the information given by 
the major supermarket chains such as Tesco and ASDA stores in the UK. A total of 99 new 
foods were added to the database. 
4.5 Statistics 
Anderson Darling test of normality showed non-normal distribution of the data, therefore 
non-parametric analysis was applied. All values are expressed as median and inter-quartile 
range unless otherwise stated. Due to the difference in the nature of the groups, differences 
between two primary outcome variables were determined by Mann-Whitney U test. 
Correlation between variables was measured with Spearman Rank correlation. No 
adjustment for multiple testing or false discovery rates was done for these tests. All 
significant p-values in the results section should therefore be considered as nominally 
significant. 
Univariate regression analysis for all faecal SCFA, BCFA, hydrogen sulphide (free, 
total, & bound), lactate (D & L), and ammonia at the time of recruitment and at after 2-3 
months were individually assessed for demographic, anthropometric, and dietary predictors 
(Table 4.1). All associations with p≤0.1 were then analysed in a stepwise regression 
analysis with and without adjustment for pathology (i.e. presence or absence of Prader-
Willi Syndrome and craniopharyngioma). 
Associations of change (Δ = after 2-3 months – at recruitment) in SCFA, BCFA, 
hydrogen sulphide, lactate, and ammonia with the time elapsed between assessments and 
changes in the above mentioned anthropometric, body composition, and dietary predictors 
(in table 4.1) between the two time points. In a similar way; the association of change in 
these parameters on the response variables at 2-3 months were also assessed. All 
associations with p≤0.1 were then analysed in a stepwise regression analysis with and 
without adjustment for pathology. 
All data was first compiled on Excel spreadsheets, and then analysed using statistical 




Table 4.1: Demographic, anthropometric, and dietary predictors used in regression analysis 
Age (years) 
Gender 
SIMD rank and quintiles 
Time elapsed between assessments 
BMI SDS 
ΔBMI SDS/month 
% Body fat 
Body fat mass (kg) 
Fat free mass (kg) 
Carbohydrates (g) 
Fat intake (g) 
Protein (%) 
Carbohydrates (%) 
Fat intake (%) 
% Recommended dietary fibre intake (%) 
% Recommended intake of proteins (%RNI) 
% Estimated average requirements (%EAR) 
Faecal pH 
Percentage faecal water (%H2O) 
 
4.6 Results 
4.6.1 Differences in faecal SCFA between groups 
4.6.1.1 Differences in faecal SCFA between obese subjects of different aetiology 
No significant differences in the absolute concentration as well as the proportion of  
individual SCFA and BCFA were observed between simple and hypothalamic obese 
participants at recruitment and after 2-3 months except for the proportion of acetate 
(hypoth. vs. simple Obese, median (IQR) C2%; (65.57(10.83) vs. 60.57(6.25), p=0.022) 
and iso-butyrate (simple vs. hypoth. obese median (IQR) iC4%= 3.45(1.88) vs. 1.86(1.7), 
p=0.010) only at recruitment (table 4.2). A trend towards higher proportion of iC5 
(p=0.051) and C5 (p=0.083) in simple obese patients was observed only at recruitment 
(Table 4.2, Table 4.3). 
Molar ratios of different SCFA (particularly acetate/butyrate and lactate/butyrate) 
may indicate the predominance of peculiar pathways of substrate utilisation and transfer 
between different groups of gut microbes in order to maintain symbiotic relationship. At 
recruitment, there was a trend towards a higher molar ratio of acetate to butyrate (C2/C4) 
in hypothalamic obese than simple obese group [median (IQR) C2/C4= 5.18(3.02) vs. 
4.14(3.03), p=0.06] (Table 4.4). However, this trend was reversed at follow-up as the ratio 
of acetate to butyrate was significantly lower for hypothalamic obese than simple obese 




4.6.1.2 Differences in faecal SCFA between lean subjects 
The absolute concentration of total and individual SCFA did not differ between healthy 
lean and hypothalamic lean participants at both presentation and at follow up (Table 4.2, 
Table 4.3) except for the proportion of propionate (C3%) at presentation which was 
significantly higher in healthy lean than the hypothalamic lean group [healthy lean vs. 
hypoth. lean, median (IQR) C3%=13.6(2.92) vs. 10.8(2.17), p=0.04] (Table 4.2).  
Molar ratios of acetate/propionate were significantly higher in hypothalamic lean 
than healthy lean group in both dry (p=0.03, Table 4.2) and wet faeces (p=0.02, Table 4.3) 
at presentation while only trend was observed after 2-3 months (p=0.09, Table 4.3). 
Hypothalamic lean group also had a significantly higher lactate/butyrate ratio in dry faeces 
(p=0.05, Table 4.4) and a trend in acetate/butyrate ratio (p=0.06) only after 2-3 months. 
4.6.1.3 Differences in faecal SCFA between non-pathological groups (healthy lean 
and simple obese) 
Significant differences in the proportion of propionate were found between the two groups 
only for the second sample. The simple obese group had a significantly higher proportion 
of propionate than the healthy lean in dry (median (IQR) %C3; Simple obese 17.1(5.89), 
Healthy lean 13.3(3.32), p=0.01) as well as wet faecal sample (median (IQR) %C3; Simple 
obese 16.6(6.03), healthy lean 13.3(3.32), p=0.03) (Table 4.3). Acetate/propionate ratio 
was significantly higher (p=0.04) while the propionate/butyrate ratio was significantly 
lower (p=0.04) in healthy lean than simple obese group only for dry faeces (Table 4.4). 
4.6.1.4 Differences in faecal SCFA between pathological groups (Hypothalamic lean 
vs. hypothalamic obese)   
At the time of recruitment, the total SCFA concentration in dried faecal sample was 
significantly higher in the hypothalamic obese group in both dry (median (IQR); 
681.6(395) vs. 406.6(280.1) µmol/g dry faeces, p=0.037) and wet faeces (median (IQR); 
543.7(298.5) vs. 277.4(257.8) µmol/g wet faeces, p=0.01).  
For the individual SCFA, the hypothalamic obese group showed a consistent and 
significantly higher concentration of propionate than the hypothalamic lean group at 
recruitment in both dry faeces [median (IQR); hypoth. obese 84.2(62.7) vs. hypoth. Lean 
45.2(37.69) µmol/g dry faeces, p=0.015] and wet faeces [median (IQR); hypoth. obese 
68.28(53), hypoth. Lean 29.68(25.26) µmol/g wet faeces, p=0.01]. Similar results were 
observed in faecal samples after 2-3 months in dry [median (IQR) C3; hypoth. Obese 
86.03(72.4), hypoth. Lean 47.56(29.78) µmol/g dry faeces, p=0.018) and wet faeces 
(median (IQR) C3; hypoth. obese 58.6(52.8), hypoth. Lean 33.90(20.48) µmol/g wet 
faeces p=0.04) (Table 4.2, Table 4.3). The proportion of propionate was also significantly 
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higher in hypothalamic obese than lean group but only after 2-3 months in both dry 
(p=0.004, table 4.2) and wet faeces (p=0.004, Table 4.3). 
Concentration of butyrate was significantly higher in hypothalamic obese than lean 
group only in wet faecal sample [median (IQR); hypoth. obese 74.09(58.30) vs. hypoth. 
lean 29.5(38.5) µmol/g, p<0.01] (Table 4.3). Amongst medium chain fatty acids, only the 
proportion of octanoic acid (C8%) was significantly higher in hypothalamic lean than 
obese group at recruitment both in dry [median (IQR) hypoth. Lean 1.26(1.33) vs. hypoth. 
obese 0.57(0.80), p=0.01] and wet faecal samples [median (IQR) 1.22(1.33) vs. 0.58(0.80), 
p=0.01] (table 4.3).The concentration of BCFA, isobutyric acid was significantly higher in 
hypothalamic obese group (p=0.04, Table 4.3) only in wet faecal sample. 
Consistent with a higher concentration of propionate in hypothalamic obese group, 
the ratio of acetate/propionate was significantly lower (p=0.04, Table 4.4) while that of 
propionate/butyrate was significantly higher (p=0.002, Table 4.4) in hypothalamic obese 
than lean group (both in dry and wet faecal samples) at the time of recruitment (Table 4.4). 
4.6.2 Total and major individual SCFA concentrations according to lean 
(healthy lean and hypothalamic lean) and obese (simple and 
hypothalamic obese) phenotype 
A tendency in the concentration of total and major individual SCFA was seen in the two 
obese groups compared to the two lean groups. Therefore, participants were grouped 
according to their phenotype into lean (healthy lean and hypothalamic lean) and obese 
(simple and hypothalamic obese) groups. Obese phenotype showed significantly higher 
concentration of total SCFA (p=0.028), acetate (p=0.028), and propionate (p=0.011) at 
recruitment (Figure 4.1). Concentration of propionate remained significantly higher in 
obese phenotype than lean phenotype even after 2-3 months (p=0.010) (Figure 4.1).  
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Figure 4.1: Boxplot showing concentration of total SCFA, acetate (C2), propionate (C3), and butyrate 
(C4) (expressed as µmol/g dry faeces) according to lean (healthy lean and hypothalamic lean) and 
obese (simple and hypothalamic obese) phenotype, at the time of recruitment and after 2-3 months. 
 
Blank circles indicate outliers, * indicate p<0.05, ** indicate p=0.01 
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Table 4.2: Concentration (µmol/g) and proportion (%) of total and individual short chain fatty acids and branched-chain fatty acids (freeze dried) at the time of recruitment 
(A) and after 2-3 months (B). 
Parameter Hypoth Lean (n=12) Hypoth Obese(n=10) Healthy Lean(n=27) Simple Obese(n=16) 
Sample No. A B A B A B A B 
Concentration  (µmol/g dry faeces) median (IQR) 
Acetate (C2) 256.3(241.2) 292.5(108.9) 427.3(241.9) 380.8(125.3) 246.6(146.4) 290.1(190.7) 327.1(198.9) 290.4(149.6) 
Propionate (C3) 45.21(37.69)† 47.56(29.8)† 84.2(62.7)† 86.0(72.4)† 49.88(28.50) 65.60(40.68) 63.0(52.6) 82.9(48.3) 
Iso-butyrate (iC4) 12.29(5.45) 13.98(4.95) 11.52(8.88) 11.29(7.39) 13.47(6.12) 14.55(6.46) 14.34(4.40) 11.71(7.94) 
Butyrate (C4) 44.1(41.4) 55.68(35.02) 95.3(73.3) 59.16(31.90) 59.91(71.46) 61.1(79.7) 75.1(71.4) 58.0(46.6) 
Iso-valerate (iC5) 13.31(7.06) 15.69(6.56) 12.52(9.52) 11.38(7.05) 14.50(6.53) 15.96(8.52) 16.82(7.42) 11.53(9.64) 
Valerate (C5) 10.66(11.51) 14.59(8.74) 10.24(10.2) 14.85(11.08) 12.85(6.50) 15.03(8.55) 15.04(6.53) 12.61(11.71) 
Iso-caproic acid (iC6) 0.00 (0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 
Caproic acid (C6) 0.00(8.62) 0.00(8.16) 1.40(4.68) 0.87(4.98) 3.40(7.51) 3.13(9.22) 3.21(9.13) 2.48(7.82) 
Heptanoic acid (C7) 0.000(1.85) 0.00(3.85) 0.00(1.568) 0.00(0.000) 0.00(2.88) 0.00(0.60) 0.00(0.87) 0.00(0.63) 
Octanoic acid (C8) 5.660(3.140) 4.66(4.63) 3.88(5.47) 3.30(1.98) 4.23(4.72) 4.56(4.63) 3.08(5.05) 3.32(4.03) 
Total SCFA 406.6(280.1)† 448.0(152.9) 681.6(395.0)† 590.6(244.9) 413.9(224.5) 479.7(333.7) 494.0(309.7) 487.9(247) 
Proportion (%)median(IQR) 
Acetate (C2%) 64.93(7.41) 64.44(6.29) 65.6 (10.83)‡ 64.48(6.86) 60.93(9.09) 60.18(8.65) 60.57(6.25)‡ 61.45(6.57) 
Propionate (C3%) 10.8(2.17)¥ 11.88(3.48)† 14.57(7.17) 14.81(5.69)† 13.64(3.12)¥ 13.31(3.32) 12.59(2.40) 17.09(5.89) 
Iso-butyrate (iC4%) 2.83(2.74) 3.26(1.85) 1.86(1.74)* 2.54(1.645) 2.72(2.27) 3.23(2.42) 3.45(1.88)* 2.03(2.370) 
Butyrate (C4%) 10.28(5.96) 13.0(3.97) 12.62(5.66) 10.57(2.59) 13.82(4.19) 14.1(6.77) 14.77(7.75) 11.65(3.99) 
Iso-valerate (iC5%) 3.21(3.31) 3.435(2.35) 1.85(1.44)‡ 2.54(1.865) 3.26(2.87) 3.71(2.94) 2.99(3.31)‡ 2.41(3.29) 
Valerate (C5%) 2.98(3.49) 3.10(2.23) 1.73(2.41) 2.53(1.16) 2.86(1.98) 2.69(2.32) 2.98(1.70) 2.80(3.00) 
Iso-caproic (iC6%) 0.00( 0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 
Caproic acid (C6%) 0.00(2.39) 0.00(1.80) 0.21(0.62) 0.22(0.81) 0.97(1.70) 0.66(1.38) 0.72(1.69) 0.42(1.07) 
Heptanoic acid (C7%) 0.00(0.54) 0.00(0.66) 0.00(0.248) 0.00(0.00) 0.00(0.53) 0.00(0.15) 0.00(0.12) 0.00(0.13) 
Octanoic acid (C8%) 1.26(1.33)† 0.93(0.94) 0.57(0.80)† 0.47(0.66) 0.81(1.02) 0.67(0.82) 0.74(1.30) 0.54(0.87) 
The values are expressed as median and interquartile range. A; at recruitment, B; after 2-3 months, n; number of participants in each group. 
† indicate significant differences between hypoth. lean and hypoth. obese, * indicate significant differences between healthy lean and simple obese  
‡ indicate significant differences between hypoth obese and simple obese, ¥ indicate significant differences between hypoth lean and healthy lean 
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Table 4.3: Concentration (µmol/g) and proportion (%) of total and individual short chain fatty acids and branched-chain fatty acids (wet faeces) at the time of 
recruitment (A) and after 2-3 months (B). 
Parameter Hypoth Lean (n=12) Hypoth Obese(n=10) Healthy Lean(n=27) Simple Obese(n=16) 
Sample No. A  B A B A B A B 
Concentration (µmol/g wet faeces)median(IQR) 
Acetate (C2) 191.3(228.5) 200.1(132.6) 340.8(198.0) 243.8(119.1) 162.8(131.0) 197.4(147.9) 210.9(178.5) 216.4(174.4) 
Propionate (C3) 29.68(25.26)† 33.92(20.48) 68.3(53.0)† 58.7(52.8) 32.88(24.45) 47.91(31.99) 44.84(39.13) 61.6(51.3) 
Iso-butyrate (iC4) 9.08(2.56) 9.73(3.56) 9.06(7.21) 7.26(4.81) 9.05(4.48) 10.07(4.30) 9.91(3.96) 8.57(5.38) 
Butyrate (C4) 29.5(38.5)† 34.64(35.59) 74.09(58.30)† 38.79(22.77) 37.17(56.60) 43.70(60.27) 56.0(61.7) 38.5(53.1) 
Iso-valerate (iC5) 9.91(3.04) 10.09(3.04) 9.61(7.21) 7.26(4.46) 9.83(4.22) 10.87(4.14) 10.95(3.80) 8.48(5.50) 
Valerate (C5) 7.63(7.43) 9.74(5.56) 8.66(7.90) 9.38(9.32) 8.75(4.69) 10.12(5.91) 10.40(5.64) 8.25(8.23) 
Iso-caproic acid (iC6) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 
Caproic acid (C6) 0.00(5.54) 0.00(4.52) 1.08(3.60) 0.67(3.39) 2.99(5.48) 2.06(6.63) 2.09(6.78) 1.02(5.50) 
Heptanoic acid (C7) 0.00(1.19) 0.00(2.38) 0.00(1.22) 0.00(0.00) 0.00(1.98) 0.00(0.48) 0.00(0.59) 0.00(0.35) 
Octanoic acid (C8) 4.05(2.37) 2.89(2.08) 3.05(4.15) 2.57(1.37) 2.86(3.20) 3.30(3.14) 2.04(2.87) 1.98(3.33) 
Total SCFA 277.4(257.8)† 309.6(186.9) 543.7(298.5)† 379.4(214.8) 271.2(205.4) 312.4(251.8) 334.5(271.4) 334.1(264.9) 
Proportion (%)median(IQR) 
Acetate (C2%) 64.94(7.48) 64.48(6.28) 65.60(10.83) 64.49(6.89) 60.63(9.12) 60.17(8.41) 60.44(4.02) 61.96(5.07) 
Propionate (C3%) 10.80(2.17) 11.88(3.49) 14.57(7.17) 14.79(5.69) 13.64(2.92) 13.31(3.32) 12.59(1.88)* 16.66(6.03)* 
Iso-butyrate (iC4%) 2.82(2.74) 3.26(1.86) 1.855(1.748) 2.54(1.65) 3.16(2.20) 3.23(2.45) 3.51(2.14) 2.04(2.58) 
Butyrate (C4%) 9.97(5.96) 12.99(3.97) 12.60(5.66) 10.57(2.59) 14.21(5.11) 14.08(6.77) 15.07(7.03) 12.04(4.53) 
Iso-valerate (iC5%) 3.21(3.31) 3.43(2.35) 1.84(1.44) 2.53(1.86) 3.69(3.07) 3.69(2.98) 3.25(3.54) 2.70(3.56) 
Valerate (C5%) 2.69(3.49) 3.09(2.23) 1.73(2.42) 2.52(1.18) 2.86(1.88) 2.69(2.32) 3.10(1.41) 2.75(2.49) 
Iso-caproic (iC6%) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 
Caproic acid (C6%) 0.00(2.39) 0.00(1.79) 0.20(0.63) 0.22(0.80) 1.02(1.70) 0.69(1.37) 0.87(1.72) 0.19(1.03) 
Heptanoic acid (C7%) 0.00(0.54) 0.00(0.66) 0.00(0.24) 0.00(0.00) 0.00(0.54) 0.00(0.13) 0.00(0.15) 0.00(0.07) 
Octanoic acid (C8%) 1.22(1.33)† 0.93(0.94) 0.57(0.80)† 0.47(0.62) 0.87(1.15) 0.66(0.81) 0.79(1.30) 0.51(1.01) 
The values are expressed as median and interquartile range. A; at recruitment, B; after 2-3 months, n; number of participants in each group. † indicate significant 
differences between hypoth. lean and hypoth. obese  
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Table 4.4: Molar ratios of different SCFA in freeze dried faeces (dry faeces) and faecal samples (wet faeces) of all participants at recruitment and after 2-3 
months. 
Parameter Hypoth lean (n=12) Hypoth obese(n=10) Healthy lean(n=27) Simple obese(n=16) 
Sample No. A B A B A B A B 
Dry faeces         
Lactate:C4 0.08(0.09) 0.08(0.09)* 0.05(0.04) 0.06(0.04) 0.07(0.05) 0.05(0.05)* 0.06(0.06) 0.06(0.05) 
C2:C3 6.01(2.74)¥ 5.425(2.15) 4.32(3.55) 4.43(1.70) 4.42(1.26)¥ 4.74(1.74)* 4.840(1.03) 3.89(1.12)* 
C2:C4 6.17(3.37) 4.86(1.58) 5.185(3.02) 6.35(1.82)‡ 4.38(1.92) 4.11(2.34) 4.14(3.03) 4.74(1.61)‡ 
C3:C4 1.03(0.62) 0.90(0.48) 1.205(1.07) 1.47(0.22) 0.94(0.362) 0.82(0.56) 0.90( 0.70) 1.35(1.13) 
Wet faeces 
Lactate:C4 0.03(0.05) 0.05(0.052) 0.01(0.011) 0.02(0.03) 0.03(0.04) 0.03(0.03) 0.03(0.05) 0.03(0.04) 
C2:C3 6.01(2.74)¥ 5.42(2.15) 4.32(3.55) 4.43(1.71) 4.34(1.19)¥ 4.74(1.74) 4.85(1.23) 4.06(0.97) 
C2:C4 6.17(3.37) 4.86(1.58) 5.18(3.02) 6.35(1.83) 4.21(1.89) 4.11(2.34) 4.05(1.97) 4.67(1.75) 
C3:C4 1.03(0.62) 0.90(0.48) 1.20(1.07) 1.47(0.23) 0.94(0.39) 0.82(0.56) 0.87(0.48) 1.17(0.87) 
The values are expressed as median and interquartile range. A; at recruitment, B; after 2-3 month, n; number of participants in each group. 
* indicate significant differences between healthy lean and simple obese  
‡ indicate significant differences between hypoth. obese and simple obese  
¥ indicate significant differences between hypoth. lean and healthy lean
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4.6.3 Percentage faecal water 
At the time of recruitment, hypothalamic obese group had a significantly higher percentage 
water content than simple obese [median (IQR): %H2O= hypoth.  Obese 78.6 (7.23), 
simple obese 70.3 (12.73), p=0.04] and hypothalamic lean groups [median (IQR): %H2O= 
hypoth. obese 78.6(7.23) vs. hypoth. Lean 73.12(12.24), p=0.02] (Figure 4.1, table 4.5). 
However, no significant differences were found between any of the groups after 2-3 
months (Table 4.5, Figure 4.2).  
4.6.4 Faecal Ammonia in dry and wet faeces 
At recruitment, healthy lean participants showed a significantly higher faecal ammonia 
levels than simple obese [median (IQR): healthy lean 3.6(1.79) simple obese 2.1(1.91), 
p=0.02] and hypothalamic lean group [median (IQR): healthy lean 3.6(1.79), hypoth. Lean 
2.37(1.60), p=0.04] (Table 4.5, Figure 4.3). 
After 2-3 months, faecal ammonia was only marginally-significantly lower in 
hypothalamic obese group than the hypothalamic lean group in wet faeces (Hypoth. obese 
vs. lean; median (IQR): 0.48(0.29) vs. 0.82(0.54) µg/ml, p=0.05) (Figure 4.3, Table 4.5).  
4.6.5 Faecal D, L, and total lactate 
No significant differences were observed for D, L, and total lactate at the time of 
recruitment and after 2-3 months between any of the groups apart from hypothalamic lean 
group which had a significantly higher D-lactate than hypothalamic obese group (dry 
faeces; p=0.03 and wet faeces; p=0.01, Table 4.5) and total lactate (wet faeces; p=0.01, 
Table 4.5) at the time of recruitment. 
4.6.6 Faecal pH and faecal hydrogen sulphide 
There was no significant difference in the faecal pH (Figure 4.4, Table 4.5) and hydrogen 
sulphide (free, bound, and total) between any of the groups at the time of recruitment and 




Figure 4.2: Boxplot of faecal water (%) content in faecal samples of all 4 groups at recruitment and 
after 2-3 months. 
 
* indicate p<0.05, Hypoth.; hypothalamic (lean or obese) 
Figure 4.3: Boxplot of faecal ammonia concentration (per freeze dried faecal material) at recruitment 
and after 2-3 months for all 4 groups. 
 
Blank circles represent outliers, * indicate p<0.05. The top most outlier in ―after2-3 months‖ panel belongs to 














Table 4.5: Concentration of hydrogen sulphide (free, total, bound), lactate (D, L, and total), ammonia, faecal pH, and % water content in the dry and wet faecal 
samples of all participants at recruitment and at after 2-3 months. 
 
The values are expressed as median and interquartile range. A; sample at recruitment, B; sample after 2-3 months.H2O; water, NH3; ammonia, H2S; Hydrogen sulphide, D/L; ratio 
of D and L lactate. † indicate significant differences between hypoth. lean and hypoth. obese, * indicate significant differences between healthy lean and simple obese, ‡ indicate 
significant differences between hypoth obese and simple obese, ¥ indicate significant differences between hypoth lean and healthy lean 
Parameter HYPOTH LEAN HYPOTH OBESE HEALTHY LEAN SIMPLE OBESE 
Sample No. A B A B A B A B 
Faecal pH 6.86(0.96) 6.65(0.81) 6.58(1.22) 6.87(1.73) 6.51(0.65) 6.62(0.78) 6.69(1.09) 7.15(0.93) 
Median H20% 73.12(12.24) 70.46(17.77) 78.65(7.23)‡ 77.01(20.19) 69.38(9.39) 71.18(9.25) 70.31(12.73)‡ 72.75(15.25) 
Dry Faeces                 
NH3 (µg/ml) 2.37(1.60)¥ 2.91(0.93) 3.22(1.33) 2.41(1.94) 3.66(1.79)*¥ 3.54(1.73) 2.12(1.91)* 3.25(1.01) 
Free H2S (μmol/g) 0.01(0.03) 0.02(0.06) 0.02(0.04) 0.01(0.019) 0.02(0.054) 0.04(0.03) 0.03(0.02) 0.03(0.04) 
Total  H2S  (μmol/g) 0.13(0.24) 0.19(0.10) 0.09(0.23) 0.12(0.24) 0.16(0.17) 0.15(0.24) 0.25(0.32) 0.20(0.22) 
Bound  H2S  (μmol/g) 0.18(0.18) 0.15(0.09) 0.08(0.18) 0.11(0.25) 0.13(0.18) 0.11(0.22) 0.20(0.29) 0.17(0.20) 
D-lactate (mg/g) 2.59(1.01)† 2.64(1.36) 1.98(0.86)† 1.86(0.24) 2.16(0.63) 1.91(0.39) 1.9(1.09) 1.84(1.08) 
L-lactate (mg/g) 2.24(1.49) 2.05(1.23) 1.83(1.22) 1.78(0.57) 2.01(0.61) 1.82(0.33) 1.7(0.85) 1.79(1.03) 
Total Lactate (mg/g) 4.78(2.07) 4.79(2.54) 3.80(1.80) 3.66(0.79) 4.15(0.94) 3.77(0.63) 3.81(1.71) 3.67(2.09) 
D/L ratio 1.05(0.24) 1.07(0.14) 1.03(0.11) 0.98(0.11) 1.04(0.06) 1.04(0.06) 1.07(0.14) 1.04(0.09) 
Wet Faeces                 
NH3 (µg/ml) 0.78(0.46)† 0.82(0.54) 0.56(0.38)† 0.48(0.288) 1.02(0.56) 0.91(0.54) 0.71(1.06) 0.93(0.66) 
Free  H2S  (μmol/g) 0.05(0.07) 0.11(0.18) 0.077(0.15) 0.05(0.13) 0.07(0.10) 0.12(0.12) 0.07(0.08) 0.07(0.12) 
Total  H2S  (μmol/g) 0.54(0.76) 0.73(0.75) 0.41(0.92) 0.67(0.65) 0.54(0.52) 0.63(0.59) 0.79(1.00) 0.72(0.86) 
Bound  H2S  (μmol/g) 0.66(0.57) 0.61(0.79) 0.38(0.79) 0.56(0.61) 0.47(0.52) 0.42(0.54) 0.70(0.99) 0.66(0.72) 
D-lactate (mg/g) 0.68(0.41)† 0.79(0.64) 0.47(0.14)† 0.64(0.27) 0.69(0.33) 0.56(0.18) 0.58(0.48) 0.41(0.44) 
L-lactate (mg/g) 0.50(0.49) 0.61(0.55) 0.40(0.22) 0.62(0.23) 0.58(0.28) 0.48(0.23) 0.47(0.49) 0.41(0.43) 
Total Lactate (mg/g) 1.15(0.86)† 1.42(1.17) 0.84(0.29)† 1.28(0.50) 1.24(0.53) 1.06(0.36) 1.11(0.94) 0.82(0.88) 
D/L ratio 1.05(0.24) 1.07(0.14) 1.03(0.11) 0.98(0.11) 1.04(0.06) 1.04(0.06) 1.07(0.14) 1.04(0.09) 
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4.6.7 Changes in gut microbiota metabolic parameters within individual 
groups over the period of follow-up 
No significant differences in the median concentration and proportion of the total and 
individual SCFA (Table 4.2, Table 4.3), hydrogen sulphide (free, bound, and total), lactate 
(D, L, and D/L ratio), ammonia, faecal pH, and % faecal H2O content were observed over 
the period of follow-up within each group (Table 4.5). 
4.6.8 Correlation of SCFA and BCFA with BMI SDS according to their 
pathology (healthy vs. pathological) 
Whether the various faecal metabolites correlated with BMI SDS was tested in the 
pathological (hypothalamic lean and obese) and healthy group (healthy lean and simple 
obese) of participants. 
Participants grouped as a pathological group showed consistently significant 
positive correlation BMI SDS with concentration and proportion of propionate both at 
recruitment and after 2-3 months (figure 4.5 and figure 4.6), while healthy group showed a 
significant positive correlation with the proportion of propionate only after 2-3 months 
(Figure 4.6 and Table 4.6). Additionally, the pathological group also showed a strong 
negative correlation of BMI SDS with proportion of octanoic acid at recruitment  and 




Figure 4.5: Correlation of BMI SDS with concentration and proportion of propionate (µmol/g) between Healthy 
(healthy lean + simple obese) and pathological groups (hypothalamic lean + hypothalamic obese) at recruitment. 
 
 
C3; propionate concentration or proportion in freeze dried faeces 
 
Figure 4.6: Correlation of BMI SDS with concentration of propionate (µmol/g) between Healthy (healthy lean + 
simple obese) and pathological groups (hypothalamic lean + hypothalamic obese) after 2-3 months. 
 
 




Table 4.6: Spearman-Rank Correlations of all SCFA and BCFA with BMI SDS according to pathology 
(healthy with no pathology and patients with pathology). 
 Healthy 
(Healthy Lean + Simple Obese) 
Pathological 
(Hypoth. Lean + Hypoth. Obese) 
SCFA (µmol/ml and %)       R p-value          R p-value 
Correlations of BMI SDS with SCFA and BCFA at recruitment 
Acetate (C2) 0.239 0.132 0.364 0.115 
Propionate (C3) 0.215 0.178 0.572 0.008* 
Iso-butyrate (iC4) 0.160 0.317 0.289 0.217 
Butyrate (C4) 0.106 0.510 0.052 0.827 
Iso-valerate (iC5) 0.103 0.524 0.085 0.722 
Valerate (C5) 0.191 0.232 0.128 0.591 
Iso-caproic acid (iC6) -0.060 0.709 -0.021 0.930 
Caproic acid (C6) -0.185 0.247 0.155 0.515 
Heptanoic acid (C7) -0.069 0.669 -0.328 0.158 
Acetate (C2%) -0.001 0.995 -0.167 0.482 
Propionate (C3%) -0.042 0.793 0.523 0.018* 
Iso-butyrate (iC4%) 0.052 0.747 0.042 0.862 
Butyrate (C4%) -0.062 0.702 -0.363 0.116 
Iso-valerate (iC5%) -0.117 0.465 -0.343 0.139 
Valerate (C5%) 0.037 0.820 -0.028 0.908 
Caproic acid (C6%) -0.120 0.454 -0.181 0.445 
Heptanoic acid (C7%) -0.193 0.227 0.153 0.519 
Octanoic acid (C8%) -0.051 0.750 -0.536 0.015* 
Total SCFA 0.222 0.164 0.446 0.049* 
Correlations of BMI SDS with SCFA and BCFA after 2-3 months 
Acetate (C2) 0.055 0.755 0.454 0.059 
Propionate (C3) 0.277 0.107 0.636 0.005* 
Iso-butyrate (iC4) -0.052 0.765 0.224 0.371 
Butyrate (C4) -0.285 0.097 -0.427 0.077 
Iso-valerate (iC5) -0.204 0.240 -0.436 0.071 
Valerate (C5) -0.174 0.319 0.275 0.270 
Iso-caproic acid (iC6) -0.092 0.601 0.099 0.696 
Caproic acid (C6) -0.075 0.667 -0.125 0.622 
Heptanoic acid (C7) -0.126 0.471 -0.207 0.411 
Acetate (C2%) 0.061 0.726 -0.307 0.215 
Propionate (C3%) 0.491 0.003* 0.705 0.001* 
Iso-butyrate (iC4%) -0.319 0.062 -0.264 0.291 
Butyrate (C4%) -0.222 0.200 -0.585 0.011* 
Iso-valerate (iC5%) -0.173 0.319 -0.548 0.019* 
Valerate (C5%) -0.138 0.431 -0.105 0.677 
Caproic acid (C6%) -0.116 0.507 0.103 0.685 
Heptanoic acid (C7%) -0.067 0.704 -0.125 0.622 
Octanoic acid (C8%) -0.101 0.565 -0.363 0.139 
Total SCFA 0.058 0.739 0.448 0.062 





4.6.9 Univariate and multivariate analysis of dietary, demographic and 
anthropometric factors as predictors of gut bacterial metabolites 
4.6.9.1 Univariate analysis of dietary, demographic and anthropometric factors as 
predictors of gut bacterial metabolites 
Determinants of faecal bacterial metabolites (SCFA, BCFA, sulphide (free, bound, & 
total), D- & L-lactate, and ammonia) and pH were explored. These included demographic 
characteristics, dietary, and anthropometric variables tested in a univariate linear regression 
analysis (Table 4.1). Various significant associations were seen at recruitment as well as 
after 2-3 months (Table 4.7, Table 4.8, Table 4.9, Table 4.10).  
Of particular note, concentration of total SCFA, acetate, propionate, and butyrate 
were significantly negatively associated with faecal pH and % faecal water both at the time 
of recruitment (Table 4.7) and after 2-3 months (Table 4.9). Moreover, concentration of 
propionate was significantly positively associated with fat mass (kg) and fat free mass (kg) 
at the time of recruitment (Table 4.7).  
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Table 4.7: Univariate analysis of demographic, dietary, and anthropometric variables at the time of recruitment as predictors of gut bacterial metabolites. 
Predictors  Total 
SCFA 
(dry) 
C2 (dry) C3 (dry) iC4 (dry) C4 (dry) iC5 (dry) C5 (dry) C6 (dry) C7 (dry) C8 (dry) 
Age (years) β-coef.  -0.008     0.492 0.197   
 p-value  0.08     0.002 0.047   
 R
2
-adj  3.40%     13.30% 4.90%   
SIMD Quintiles β-coef.         0.411  
 p-value         0.02  
 R
2
-adj         7.10%  
Time elapsed (h) β-coef.          0.316 
p-value          0.092 
R
2
-adj          3.10% 
BMI SDS β-coef.  0.003 0.018        
 p-value  0.054 0.005        
 R
2
-adj  4.60% 11.20%        
% body fat β-coef.       0.092    
 p-value       0.088    
 R
2
-adj       5.24%    
Body fat mass (kg) β-coef.       0.09    
p-value       0.068    
R
2
-adj       6.20%    
% actual energy  
consumed 
β-coef.       -0.01    
p-value       <0.001    
R
2
-adj       17.00%    
Energy intake (kcal)  β-coef.    21.45  0.004     
p-value    0.09  0.015     
R
2




Predictors  Total SCFA  C2 (dry) C3 (dry) iC4 (dry) C4 (dry) iC5 (dry) C5 (dry) C6 (dry) C7 (dry) C8 (dry) 
Fat intake (g) β-coef.    1.4  0.112 0.095 0.047   
p-value    0.034  0.002 0.032 0.069   
R
2
-adj    7.10%  16.9% 7.3% 4.80%   
Protein intake (g) β-coef.    1.355  0.126     
 p-value    0.027  0.002     
 R
2
-adj    7.90%  16.7%     
Fat intake (%) β-coef.    0.358  0.286 0.202    
 p-value    0.105  0.01 0.106    
 R
2
-adj    3.40%  11.40% 3.40%    
Carbohydrate intake 
(%) 
β-coef.    -0.49  -0.288     
p-value    0.058  0.002     
R
2
-adj    5.40%  17.20%     
DF % recommended 
intake 
β-coef.         0.016  
p-value         0.033  
R
2
-adj         7.20%  
% estimated average 
req (% EAR) 
β-coef.       -0.06    
p-value       0.1    
R
2
-adj       3.50%    
Faecal pH β-coef. -145.22 -0.002 -0.007 0.025 -40.3 4.49   -0.986  
 p-value <0.001 0.002 0.004 0.095 <0.001 0.001   0.014  
 R
2
-adj 20.30% 14.60% 11.90% 3.10% 35.74% 17.50%   8.50%  
Faecal % H2O β-coef. 10.03 0.022  -0.34  -0.368     
 p-value 0.001 0.002  0.098  <0.001     
 R
2
-adj 16.20% 14.30%  3.10%  21.80%     
Predictors which had a significant association or a tendency for association (p<0.1) are shown only.β-coef.; beta coefficient, SIMD; Scottish Index of multiple deprivation, time elapsed; 
time elapsed between sample production and processing in the lab, Protein% RNI; percentage recommended nutritional intake of proteins (%RNI), %EAR; percentage of estimated 
average requirements of calories for UK population, C2; acetate, C3; propionate, iC4; iso-butyrate, C4; butyrate, iC5; iso-valerate, C5; valerate, iC6; iso-caproic acid, C6; Caproic acid, 
C7; heptanoic acid, C8; Octanoic acid  
Table 4.7 continued 
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Table 4.8: Univariate analysis of demographic, dietary, and anthropometric variables as predictors of other gut bacterial metabolites at the time of recruitment. 








Age (Years) β-coef.  -0.1706 0.199  0.099 -0.0022 -0.012 -0.013    
 p-value  0.034 0.05  0.007 0.061 0.073 0.077    
 R
2
-adj  5.70% 4.70%  11% 4.70% 4.30% 4.10%    
Time elapsed (h) β-coef. 0.006   0.04 -1.932    0.064  0.115 
p-value 0.025   0.097 0.052    0.047  0.066 
R
2
-adj 7.30%   2.90% 5.10%    5.40%  4.40% 
BMI SDS β-coef.     -0.218    -0.066   
 p-value     0.07    0.087   
 R
2
-adj     4.20%    3.6   
% body fat β-coef.         -0.01   
 p-value         0.065   
 R
2
-adj         6.80%   
Body fat mass 
(kg)  
β-coef.         -0.011 -0.009 -0.021 
p-value         0.018 0.092 0.036 
R
2
-adj         12.50% 5.30% 9.50% 
Fat free mass 
(kg) 
β-coef.      -0.0005      
p-value      0.01      
R
2
-adj      15.70%      
% actual energy 
intake  
β-coef.  0.004 0.004 0.0006   0.0006 0.0007    
p-value  0.09 <0.001 0.052   0.001 0.001    
R
2














β-coef.  -0.002   0.001       
p-value  0.089   0.014       
R
2
-adj  3.90%   11.3%       
Fat intake (g) β-coef.  -0.044   0.017  0.002 0.002    
 p-value  0.044   0.08  0.084 0.08    
 R
2
-adj  6.20%   4.70%  4.90% 5%    
Protein intake (g) β-coef. 0.0004    0.019    0.006 0.006  
p-value 0.098    0.059    0.07 0.09  
R
2
-adj 4.20%    5.90%    5.40% 4.40%  
Carbohydrate 
intake (g) 
β-coef.     0.008      0.012 
p-value     0.014      0.056 
R
2
-adj     11.20%      6.20% 
Dietary fibre 
intake (g) 
β-coef.     0.09       
p-value     0.012       
R
2
-adj     11.90%       
Fat intake (%) β-coef.  -0.131          
 p-value  0.05          
 R
2
-adj  5.90%          
Protein intake 
(%) 
β-coef. 0.004  0.125         
p-value 0.017  0.039         
R
2
-adj 10.70%  6.70%         
  
Table 4.8 continued 
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β-coef.  0.098  -0.013        
p-value  0.08  0.088        
R
2




β-coef.     0.015       
p-value     0.018       
R
2
-adj     10.30%       
Protein % RNI β-coef.   0.006   0.0001 0.001 0.001    
 p-value   0.012   0.031 <0.001 <0.001    
 R
2




β-coef.      0.0003 0.005 0.005    
p-value      0.021 <0.001 <0.001    
R
2
-adj      10.00% 28.70% 28.80%    
Faecal pH β-coef. 0.041  1.389 0.187        
 p-value <0.001  <0.001 0.087        
 R
2
-adj 30.30%  19.80% 3.40%        
Faecal %H2O β-coef. -0.002     -0.001 -0.006 -0.008    
 p-value 0.015     <0.001 0.017 0.003    
 R
2
-adj 9.20%     27.10% 9.50% 14.70%    
Predictors which had a significant association or a tendency for association (p<0.1) are shown only. β-coef.; beta coefficient, SIMD; Scottish Index of multiple deprivation, time 
elapsed; time elapsed between sample production and processing in the lab, Protein% RNI; percentage recommended nutritional intake of proteins (%RNI), %EAR; percentage of 
estimated average requirements of calories for UK population, NH3; ammonia,  lactate:C4; lactate to butyrate ratio, C2:C3; acetate to propionate ratio, C2:C4; acetate to butyrate ratio, 
C3:C4; propionate to butyrate ratio 
  
Table 4.8 continued 
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Table 4.9: Univariate analysis of demographic, dietary, and anthropometric variables as predictors of gut bacterial metabolites after 2-3 months. 
Predicators  Total SCFA 
(dry) 
















Age (Years) β-coef.       NS 0.297   
 p-value        0.004   
 R
2
-adj        13.20%   
BMI SDS β-coef.    -0.77  -0.783     
 p-value    0.018  0.052     
 R
2
-adj    8.70%  5.40%     
% body fat β-coef.    -0.094  -0.123     
 p-value    0.037  0.03     
 R
2
-adj    9.40%  10.00%     
Body fat mass (kg) β-coef. 3.679  1.933 -0.079  -0.11     
p-value 0.053  <0.001 0.019  0.014     
R
2
-adj 7.70%  34.20% 12.40%  13.50%     
Fat free mass (kg) β-coef.   2.185        
p-value   0.001        
R
2
-adj   24.60%        
% actual energy 
consumed 
β-coef.          -0.003 
p-value          0.055 
R
2
-adj          5.60% 
Energy intake 
(kcal) 
β-coef.    0.002  0.004     
p-value    0.089  0.011     
R
2
-adj    4%  10.80%     
Fat intake (g) β-coef.   0.442  0.371 0.057  0.038  0.022 
 p-value   0.1  0.101 0.022  0.087  0.047 
 R
2
-adj   3.40%  3.50% 8.60%  4%  6% 
Carbohydrate 
intake  (g) 
β-coef.    0.015  0.025     
p-value    0.078  0.021     
R
2
-adj    4.40%  8.80%     
Dietary fibre (g)            
            
Dietary Fat (%) β-coef. 8 4.284 1.925  1.285     0.084 
 p-value 0.019 0.046 0.028  0.08     0.017 
 R
2





Predicators  Total SCFA 
(dry) 
















Protein intake % β-coef.    -0.314  -0.331     
p-value    0.007  0.023     
R
2
-adj    12.40%  8.40%     
Carbohydrate 
intake (%) 
β-coef. -6.75  -1.957       -0.060 
p-value 0.046  0.024       0.086 
R
2




β-coef.      0.055     
p-value      0.024     
R
2
-adj      8.30%     
Faecal pH β-coef. -222.8 -128.3 -41.88  -48.79 1.775  -1.74 -0.56  
 p-value <0.001 <0.001 <0.001  <0.001 0.098  0.072 0.051  
 R
2
-adj 44.70% 35.80% 24.50%  45.30% 3.90%  5% 6.20%  
Faecal %H2O β-coef. 12.98 8.791 2.562 -0.172 2.178 -0.266    -0.067 
p-value <0.001 <0.001 0.001 0.008 0.002 0.001    0.064 
R
2
-adj 27.20% 30.30% 16.70% 11.10% 15.40% 18.80%    4.60% 
Predictors which had a significant association or a tendency for association (p<0.1) are shown only. β-coef.; beta coefficient, SIMD; Scottish Index of multiple deprivation, time 
elapsed; time elapsed between sample production and processing in the lab, Protein% RNI; percentage recommended nutritional intake of proteins (%RNI), %EAR; percentage of 
estimated average requirements of calories for UK population, C2; acetate, C3; propionate, iC4; iso-butyrate, C4; butyrate, iC5; iso-valerate, C5; valerate, iC6; iso-caproic acid, C6; 
Caproic acid, C7; heptanoic acid, C8; Octanoic acid 
  
Table 4.9 continued 
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Table 4.10: Univariate analysis of demographic, dietary, and anthropometric factors as predictors of other gut bacterial metabolites after 2-3 months. 
Predicators  Lactate:C4 C2: C3 C2: C4 C3: C4 NH3 Free-H2S Bound-H2S Total-H2S D-Lactate L-lactate Total Lactate 
Time 
elapsed (h) 
β-coef.    0.094        
p-value    0.035        
R
2
-adj    6.40%        
BMI SDS β-coef.  -0.306 0.286 0.195  -0.004      
 p-value  0.003 0.015 <0.001  0.08      
 R
2
-adj  14.80% 9.20% 25.20%  4.90%      
% body fat β-coef.  -0.037  0.023        
 p-value  0.015  0.006        
 R
2
-adj  13.30%  17.10%        
Body fat 
mass (kg) 
β-coef.  -0.036  0.025  -.0004      
p-value  0.002  <0.001  0.08      
R
2
-adj  22.70%  39.70%  6.90%      
Fat free 
mass (kg) 
β-coef.  -0.041  0.029        
p-value  0.008  <0.001        
R
2
-adj  16.10%  30.70%        
Dietary fibre 
intake (g) 
β-coef.   -0.065 -0.031        
p-value   0.098 0.084        
R
2
-adj   3.60% 4.10%        
Fat intake 
(%) 
β-coef.  -0.04          
p-value  0.075          
R
2
-adj  4.50%          
CHO% β-coef.  0.037          
 p-value  0.095          
 R
2




β-coef.    -0.006        
p-value    0.07        
R
2
-adj    4.70%        
Faecal pH β-coef. 0.034  1.195  1.34       
 p-value <0.001  <0.001  0.038       
 R
2
-adj 25.90%  23.60%  9.17%       
Faecal 
%H2O 
β-coef. -0.002     -0.001 -0.008 -0.009    
p-value 0.001     0.026 <0.001 <0.001    
R
2
-adj 21.80%     9.10% 23.90% 24.20%    
Predictors which had a significant association or a tendency for association (p<0.1) are shown only. β-coef.; beta coefficient, SIMD; Scottish Index of multiple deprivation, 
time elapsed; time elapsed between sample production and processing in the lab, Protein% RNI; percentage recommended nutritional intake of proteins (%RNI), %EAR; 
percentage of estimated average requirements of calories for UK population, H2S; hydrogen sulphide, NH3; ammonia, lactate:C4; lactate to butyrate ratio, C2:C3; acetate to 
propionate ratio, C2:C4; acetate to butyrate ratio, C3:C4; propionate to butyrate ratio. 
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4.6.9.2 Independent predictors of gut bacterial metabolites at the time of 
recruitment (multivariate analysis) 
All associations at the time of recruitment that were either significant (p<0.05) or showed a 
tendency (p ≤ 0.1) on univariate analysis were entered together in a step-wise multiple 
linear regression analysis with and without adjustment for pathology. 
4.6.9.2.1 Association of faecal SCFA at the time of recruitment 
Total SCFA at the time of recruitment were significantly negatively associated with pH 
and positively with % faecal H2O on unadjusted (for pathology) multivariate step-wise 
regression analysis (pH; p=0.005, β= -111 and %H2O p=0.04, β= 5.9, R
2
=29.6%) (Table 
4.11). Acetate was significantly negatively associated with pH; p=0.02, β=-60, BMI SDS; 
p=0.05, β=18, and % faecal water; p=0.04, β=5.9, R2-Adj=33%). Propionate was 
negatively associated with pH and positively with BMI SDS (pH; p=0.007, β=-17.9, 
%H2O; p=0.004, β= 6.6, R
2
-Adj=22.53%) while butyrate was only significantly associated 
with faecal pH (p<0.0001, β=-40.3, R2-Adj=35.37%) (Table 4.11). 
When adjusted for pathology, the association of % faecal water with total SCFA 
and that of BMI SDS with acetate was no longer significant (Table 4.11). 
4.6.9.2.2 Association of faecal ammonia, sulphide and lactate 
Faecal NH3 was significantly associated with age and dietary fibre intake in grams in 
unadjusted multiple step-wise regression analysis (age; p=0.004, β=0.125, DF in g; p=0.03, 
β=0.072, R2-adj=29.18%)(Table 4.12).Faecal free, bound, and total sulphide were 
significantly negatively associated with %H2O content [p=0.02, β=-0.001 (R
2
-
adj=25.40%), p=0.005, β=-0.001 (R2-adj=16.07%), and p=0.001, β=-0.007 (R2-
adj=21.40%) respectively] (Table 4.12). Similarly, faecal D and total lactate were 
significantly negatively associated with body fat mass in kg and positively associated with 
dietary intake of protein in grams (R
2
-adj=35%.25 for D lactate, R
2
-adj=35%.04 for total 
lactate) (Table 4.12). 
However, on adjustment for pathology in multiple regression analysis, the 
significant association of D lactate with fat mass and that of total lactate with protein 
intake in grams was no more observed (p=0.218 for D lactate with fat mass & p=0.060 for 
protein intake in grams). In contrast, the association of acetate: butyrate ratio with 
proportion (%) of protein intake significantly increased when adjusted for pathology 
compared to unadjusted association (p=0.02, R
2




Table 4.11: Multivariate regression analysis for the association of dietary, anthropometric and demographic factors with gut bacterial metabolites at the time of recruitment. 






























Β p β p β p β p Β p β p β p β p 
Total SCFA 
  
26.96                         -111 0.005 5.9 0.039 
26.36                         -115.8 0.004 5.161 0.09 
C2 
  
27.94         18 0.049             -60 0.028     
26.33         15.83 0.086             -68.9 0.014     
C3 
  
22.53         6.6 0.004             -17.9 0.007     
21.26         6.41 0.007             -17.9 <0.001     
iC4 
  
9.78                         2.4 0.03     
9.38                         2.222 0.219     
C4 
  
35.7                         -40.3 <0.001     
34.8                         -40.25 <0.001     
iC5 
  
38.69             0.118 0.001             -0.37 <0.001 
43.71             0.146 0.29             -0.34 0.009 
C5 
  
16.17                 0.34 0.02             
12.99                 0.86 0.016             
C6 
  
8.41 0.25 0.023                             
8.42 0.19 0.106                             
C7 
  
26.1     0.46 0.006             0.013 0.038 -0.85 0.023     
26.47     0.49 0.004             0.015 0.023 -0.92 0.016     
C8 
  
NS                                 
NS                                 
β ; beta coefficient, p; p-value, R2 Unadj/adj for pathology; R2 value (%) unadjusted and adjusted for pathology (hypothalamic lean and hypothalamic obese vs. healthy lean and simple 
obese), SIMD; Scottish Index of multiple deprivation, time elapsed; time elapsed between sample production and processing in the lab, DF; dietary fibre, C2; acetate, C3; propionate, 








































β p Β p β P β p β p Β p β p β p β p β p 
Lactate:C4 
  
41.51     0.005 0.049                     0.004 0.024     -0.001 0.08 
36.51     0.006 0.029                     4E-04 0.092     -0.001 0.153 
C2: C3 
  
11.02             0.004 0.065 -0.046 0.033                     
12.91             0.003 0.32 0.211 0.171                     
C2: C4* 
  
40.4             0.003 0.002             0.1 0.56 0.88 0.029     
38.1             0.004 0.002             0.127 0.02 0.97 0.014     
C3: C4 
  
20.12     0.06 0.067     0.001 0.001                         
18.61     0.482 0.086     2.714 0.01                         
NH3 
  
29.18 0.125 0.004                     0.072 0.028             
23.25 0.023 0.816                      NS                
Free-H2S 
  
25.4                                     -.001 0.023 
25.99                                     -9E-04 0.086 
Bound H2S 
  
16.07                                     -0.007 0.005 
11.65                                     -0.009 0.007 
Total- H2S 
  
21.42                                     -0.01 0.001 
11.65                                     -0.009 0.007 
D-Lactate 
  
35.25         -0.169 0.001         0.008 0.03                 
41.74         -0.013 0.218         0.008 0.026                 
L-lactate 
  
9.18         -0.011 0.07                             
12.59         -0.01 0.102                             
Total 
Lactate 
35.04     0.153 0.024 -0.305 0.003         0.015 0.03                 
29.35     0.094 0.019 -0.012 0.035         0.008 0.059                 
Analysis is presented both with and without adjustment for pathology (hypothalamic disorder) Predictors which had a significant association are shown only.β; beta coefficient, p; p-
value, R
2
 Unadj/adj for pathology; R
2 
value (%) unadjusted and adjusted for pathology, time elapsed; time elapsed in h between sample production and processing in the lab, NH3; 
ammonia,  lactate:C4; lactate to butyrate ratio, C2:C3; acetate to propionate ratio, C2:C4; acetate to butyrate ratio, C3:C4; propionate to butyrate ratio, NS; non-significant.* p<0.05 
after adjustment for pathology
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4.6.9.3 Independent predictors of faecal bacterial metabolites after 2-3 months 
Each selected demographic, anthropometric, and dietary predictor were individually 
analysed by univariate regression analysis (Table 4.9, Table 4.10). All significant variables 
with p<0.05 and those showing tendency (p<0.1) were included in multiple stepwise 
regression analysis with and without adjustment for pathology, to explore their 
independent association. 
4.6.9.3.1 Association of SCFA after 2-3 months 
Unadjusted step-wise regression analysis showed a significant negative association of total 
SCFAs with pH and %H2O (pH; p<0.0001, β= -191, %H2O; p=0.007, β=9.2 R
2
-
Adj=67.07%). Acetate was significantly negatively associated with faecal pH and 
positively with %H2O (pH; p<0.0001, β=-103, %H2O; p=0.002, β=5.8, R
2
-adj. = 61.4%) 
(Table 4.13). Propionate was significantly associated with body fat mass and negatively 
with faecal pH (fat mass in kg; p<0.0001, β=1.81, pH; p<0.0001, β= -47, R2-Adj=59.58%) 
while butyrate was only significantly negatively associated with pH (p<0.0001, β= -39.6% 
R
2
-Adj=48.62%) (Table 4.13). Multiple regression analysis adjusted for pathology didn’t 
affect these associations except in branched chain fatty acids (isobutyric and isovaleric 
acids) where the unadjusted association of energy intake was no more significant after 
adjustment for pathology (Table 4.13).   
4.6.9.3.2 Association of faecal ammonia, sulphide, and lactate after 2-3 months 
Faecal (dry) bound and total sulphide were significantly negatively associated with %H2O 
(p<0.0001, β= -0.008 R2-adj=23.9% for bound sulphide and p<0.0001, β= -0.009 R2-
adj=24.2% for total sulphide) in unadjusted multiple step-wise regression analysis. Faecal 
ammonia was associated with pH (p=0.04, β=1.34, R2-Adj=9.2%) while faecal lactate (D, 
L and total lactate) after 2-3 months were not significantly associated with any predictor on 
multivariate analysis (Table 4.14). 
Adjustment for pathology in multiple regression analysis only affected the 
association of free sulphide with body fat in kg (p=0.27 after adjustment compared to 




Table 4.13: Multivariate step-wise regression analyses of anthropometric, dietary, and demographic factors with molar SCFA ratios, Ammonia, sulphide, lactate after 2-3 



















Faecal H2O (%) 
 
  
β p β p β p Β p β p β p 
Total 
SCFA 
67.07             5.6 0.06 -191 <0.001 9.2 0.007 
63.73             6.827 0.171 -185.01 <0.001 9.49 0.02 
C2 
  
56.13             0.053 0.053 -103 <0.001 5.8 0.002 
54.96             3.387 0.062 -103.2 <0.001 5.817 0.002 
C3 
  
59.89 1.81 <0.001             -47 <0.001     
55.5 1.212 0.183             -39.02 0.008     
iC4 
  
21.09         0.003 0.005         -0.27 0.001 
39.79         0.002 0.342         -0.244 0.008 
C4* 
  
48.62                 -39.6 <0.001 1.23 0.06 
54.58                 -45.75 <0.001 0.908 0.153 
iC5 
  
52.63         0.006 <0.001         -0.291 0.002 
46.29         0.004 0.115         -0.303 0.008 
C5 
  
NS                         
NS                         
C6 
  
14.75                 -2.1 0.037     
12.38                 -2.07 0.052     
C7 
  
6.2                 -0.56 0.051     
5.52                 -0.56 0.051     
C8 
  
24.31     -0.003 0.022             -0.09 0.01 
19.35     -0.004 0.024             -0.087 0.015 
β ; beta coefficient, p; p-value, R2 Unadj/adj for pathology; R2 value (%) unadjusted and adjusted for pathology,  C2; acetate, C3; propionate, iC4; iso-butyrate, C4; butyrate, iC5; 
iso-valerate, C5; valerate, iC6; iso-Caproic acid, C6; Caproic acid, C7; heptanoic acid, C8; Octanoic acid, * indicate p=0.04 after adjustment for pathology 
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Table 4.14: Multivariate step-wise regression analyses of anthropometric, dietary, and demographic factors with molar SCFA ratios, Ammonia, sulphide, lactate after 2-3 

















% faecal H2O 
 
  
β p Β p β p Β p β p β p 
Lactate:C4 
  
33.42                 0.024 0.014 -0.002 0.026 
33.42                 0.024 0.014 -0.002 0.026 
C2: C3 
  
NS                         
NS                         
C2: C4* 
  
27.02     0.27 0.028         1.00 0.003     
34.59     0.165 0.2         0.978 0.003     
C3: C4** 
  
49.6 0.1 0.031     -0.024 0.063 0.038 <0.001         
52.73 0.082 0.074     -0.037 0.068 0.038 0.028         
NH3 
  
9.25                 1.34 0.038     
9.25                 1.3 0.045     
Free-H2S 
  
14.26             -0.001 0.027         
0.53             -0.0002 0.624         
Bound H2S 
  
23.9                     -0.008 <0.001 
22.79                     -0.008 0.001 
Total- H2S 
  
24                     -0.009 <0.001 
22.79                     -0.009 0.001 
D-Lactate 
  
 NS                         
NS                         
L-lactate 
  
NS                         
NS                         
Total 
Lactate 
NS                         
NS                         
β; beta coefficient, p; p-value, R2 Unadj/adj for pathology; R2 value (%) unadjusted and adjusted for pathology, time elapsed; time elapsed between sample production and 
processing in the lab, NH3; ammonia,  lactate:C4; lactate to butyrate ratio, C2:C3; acetate to propionate ratio, C2:C4; acetate to butyrate ratio, C3:C4; propionate to butyrate ratio, 





4.6.9.4 Association of gut bacterial metabolites after 2-3 months with change in 
demographic, anthropometric, and dietary predictors (i.e. response at 2-3 
months vs. change in predictors between recruitment and after 2-3 months) 
Whether change in demographic, anthropometric, and dietary predictors determines the 
concentration of gut bacterial metabolites in the faecal samples at the time of follow-up, 
was studied by univariate analysis. All significant associations in univariate analysis were 
then analysed by multiple regression analysis.  
Univariate analysis 
Higher SCFA at follow-up were associated negatively with change in pH while branched 
chain fatty acids at follow-up were associated with changes in the intake of dietary 
components particularly carbohydrates and proteins (Table 4.15).  
Multivariate analysis 
Change in pH (Δ pH) predicted the concentration of follow-up total SCFA (p=0.004, β= -
153, R
2
-Adj=27.28%), acetate (p=0.01, β= -76, R2-Adj=23.2%), propionate (p=0.01, β= -
35.06, R
2
-Adj=11.35), and butyrate (p=0.004,β= -33.3 R2-Adj=18.06%) in adjusted & 
unadjusted multivariate analysis (table 21) while faecal sulphide and lactates at follow-up 
were not significantly associated with change in any of the predictor (Table 4.16).
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Table 4.15: Univariate analysis of demographic, dietary, and anthropometric variables as predictors of other gut bacterial metabolites after 2-3 months with change in 





C2 C3 iC4 C4 iC5 C5 C6 C7 Lact:C4 C2: C4 
Δ BMI SDS β-coef.        4.09   
 p-value        0.088   
 R
2
-adj        3.80%   
Δ BMI SDS/month β-coef.        4.05   
p-value        0.09   
R
2
-adj        1.97%   
Δ Energy  intake 
(Kcal) 
β-coef.   0.002  0.003      
p-value   0.064  0.026      
R
2
-adj   6%  9.50%      
Δ Fat intake (g) β-coef.   0.036  0.044      
p-value   0.09  0.098      
R
2
-adj   4.80%  4.40%      
Δ Carbohydrates  
intake (g) 
β-coef.   0.017  0.026      
p-value   0.041  0.012      
R
2
-adj   7.80%  12.50%      
Δ Dietary fibre 
intake (g) 
β-coef.       -0.241    
p-value       0.027    
R
2
-adj       9.40%    
Δ Protein intake 
(%) 
β-coef.   -0.196  -0.214      
p-value   0.013  0.036      
R
2
-adj   12.30%  8.30%      
Δ Carbohydrates 
intake (%) 
β-coef.        -0.055   
p-value        0.02   
R
2
-adj        10.60%   
DF% recommended 
intake 
β-coef. -1.02      -0.046    
p-value 0.06      0.026    
R
2
-adj 6.30%      9.50%    
Faecal pH β-coef. -73.5 -35.6  -33.29  -5.409 -2.96  0.023 0.96 
 p-value 0.029 0.014  0.004  0.001 0.006  0.047 0.021 
 R
2
-adj 8.60% 11.3  15.70%  21.90% 14.30%  7.80% 9.70% 
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Table 4.16; Univariate analysis of demographic, dietary, and anthropometric variables as predictors of other gut bacterial metabolites after 2-3 months with change in 








(%) Δ  BMI SDS 
Δ  Carbohydrate 
(g) 
Δ  Dietary fibre 
intake (g) 




Δ Dietary Fibre 
(%) Δ  faecal pH 
  
β p Β p β p Β p β p β p β P 
Total SCFA 
  
27.28                         -153 0.004 
15.16                         -156.1 0.004 
C2 
  
23.19                     -1.03 0.05 -76 0.01 
22.64                     -1.134 0.041 -78.16 0.012 
C3 
  
11.3                         -35.6 0.01 
9.24                         -35.63 0.015 
iC4 
  
12.27             -0.2 0.01             
5.8             -0.107 0.614             
C4** 
  
15.7                         -33.3 0.004 
24.17                         -35.32 0.002 
iC5 
  
12.5     0.03 0.01                     
7.65     0.003 0.969                     
C5 
  
21.9                         -5.41 0.001 
21.31                         -5.308 0.001 
C6** 
  
25.33         -0.19 0.04             -2.77 0.007 
37.07         -0.069 0.261             -2.707 0.006 
C7 
  
20.58 5.1 0.03             -0.06 0.01         
18.43 5.05 0.033             -0.055 0.012         
Lactate:C4* 
  
7.8                         0.023 0.047 
18.99                         0.021 0.047 
C2: C4** 
  
9.7                          0.964 0.021 
25.92                         1.06 0.006 
β; beta coefficient, p; p-value, R2 Unadj/adj for pathology; R2 value (%) unadjusted and adjusted for pathology, Δ; measurement at follow-up – measurement at presentation. CHO; 
carbohydrates, DF; dietary fibre. Delta BMISDS/month was not significantly associated with any metabolite in multivariate regression analysis and is therefore not presented in the 
table, * indicate p<0.05 and ** indicate p<0.01 after adjustment for pathology
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4.6.10 Differences in gut bacterial metabolites between the groups with 
weight loss or weight gain 
Weight loss over the period of follow-up was calculated as change in BMI SDS per month 
(Δ BMI SDS/month) for all the groups 
Differences in gut bacterial metabolites between the groups with weight loss or weight 
gain 
Changes in the concentration of total SCFA and major individual SCFA (acetate, 
propionate, and butyrate) were not significantly different between the groups with weight 
loss or weight gain. 
Association of gut bacterial metabolites with weight loss or weight gain 
To determine whether change in weight expressed as Δ BMI SDS/month is associated with 
change in gut bacterial metabolites (Δ) between two time points over the period of 2-3 
months; regression analysis was done using Δ SCFA, Δ H2S, Δ lactate, and Δ NH3 as 
response or dependent variables and Δ BMI SDS/month as predictor or outcome variable . 
Change in none of the gut bacterial metabolite was significantly associated with change in 
weight (weight loss or weight gain) when adjusted for pathology. The only exception was 
the significant negative association of lactate: butyrate ratio with pathology-adjusted Δ 




To assess whether gut bacterial metabolites at follow-up (i.e. time point B) are 
determined by Δ BMI SDS/month; regression analysis was done for total and individual 
SCFA, H2S, lactate, and NH3 at follow-up. None of the metabolite, except heptanoic acid, 
had a tendency of positive association with change in BMI SDS/month when adjusted for 
pathology (R
2









Several animal and human studies (164, 177, 217) have looked at the relationship of gut 
microbial metabolites in relation to obesity. However, the results are controversial and 
there is no definite conclusion regarding the cause or effect relationship in the role of gut 
microbiota in obesity onset and pathogenesis. To test whether gut microbiota play a 
causative role in the aetiology of obesity by producing excess SCFAs, the current study 
compared the gut bacterial metabolic activity between children /young adults with known 
and unknown cause of obesity. 
Our results suggest that apart from differences in faecal water, proportion of acetate 
and iso-butyric acid at recruitment, there was no significant difference in the gut bacterial 
metabolites (total SCFA, H2S, ammonia, and D &L lactate) between the simple and 
hypothalamic obesity. No difference in metabolic activity between simple and 
hypothalamic obese groups suggests that metabolic activity of the gut microbiota is not 
different between obesity of different aetiology which contradicts the causative role of gut 
microbiota in the aetiology of obesity. Moreover, higher SCFA concentration in obese 
(simple & hypothalamic obese) than lean (healthy & hypothalamic lean) phenotype in our 
study indicate that previously observed differences in the concentration of SCFA are the 
result of differences in dietary intake. In our study the absence of difference between 
obesity of different aetiology indicates that simple and hypothalamic obese people might 
share the same dietary pattern distinct from lean people resulting in the increased 
metabolic potential of gut microbiota in obesity.  
Published data suggest that availability and/or changes in the type and amount of 
substrate in the gut lumen determine the concentration and pattern of SCFA in obese 
individuals (166, 217). Furthermore, high fat diet has been shown to have a pronounced 
but similar effect on the gut microbiota in obese and non-obese groups of Sprague Dawley 
rats, supporting the role of dietary substrate on the gut microbiota and their metabolic 
potential (199). However, changes in gut microbiota due to different pattern of diets in 
obese individuals, irrespective of the cause of obesity, might then acquire the capacity to 
harvest energy from the available substrates in the gut lumen as suggested by Turnbaugh et 
al.(2006) from mouse models(159) and Ley et al.(2006) in human studies (164). However, 
this will not be implicated in the primary onset but possibly in the propagation of adiposity 
and increase in cardiovascular risk.  
It can be argued that SCFA in faecal samples are the result of a net difference in 
production in the gut lumen and absorption in the colon and therefore might not be good 
indicators of energy harvesting capability of the gut microbiota. This question will be 
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addressed by in-vitro batch culture fermentation in the next chapter which suggested no 
difference in the energy harvesting capability of gut microbiota of the two obese groups 
(chapter 5). Whether differences in dietary patterns between obese and lean phenotype 
determine the SCFA production capability of the gut microbiota in our study, was explored 
but the interpretation of the results are limited by dietary underreporting on behalf of our 
participants and the validity of method of dietary assessment used (chapter 3). 
In contrast to our expectation, median percentage faecal water was significantly 
higher in the hypothalamic obese than simple obese group at recruitment. Reduced gastric 
emptying and prolonged gastrointestinal transit time due to hormonal disturbances 
(particularly reduced PYY and persistently increased ghrelin) in Prader Willi syndrome has 
been linked to constipation (356, 357). Additionally, studies have reported gastric wall 
necrosis and rupture due to severely reduced gastric emptying in PWS patients (358). 
Although, a questionnaire-based study have reported soft (but not watery) stools in 49.2% 
patients compared to 7.9% hard stools in Prader-Willi syndrome (359),this evidence is 
subjective, as it was based on mailed questionnaires filled by the parents compared to an 
objective measurement of gastrointestinal transit time by Kuhlmann et al.(2014) (356). 
Despite this evidence, increased water content in hypothalamic obese patients in our study 
could be attributed to a shorter transit time (as opposed to the reported prolonged transit 
time) leading to a state of malabsorption in children with hypothalamic obesity, the 
mechanism for which is however unknown to us, but it may be associated with the 
muscular hypotonia observed in this population. Moreover, hypothalamic obese group 
might have higher food and fibre intake which might be holding more water in the gut 
lumen compared to other groups. This is however not suggested by the dietary data but it is 
impossible to rule out this possibility as under-reporting was large in our cohort. Lastly, 
this effect could be due to high inter-individual variations (as suggested by a wide IQR) 
within hypothalamic obese group and lack of statistical power and hence suggest more 
study participants to account for this variation. 
In addition to the percentage water content, hypothalamic obese group also had a 
significantly higher proportion of acetate compared to simple obese group at recruitment. 
Furthermore, proportion of acetate had a tendency (p=0.062) towards positive association 
with percentage faecal water in hypothalamic obese group in general regression analysis 
suggesting that higher proportion of acetate was predicted by higher percentage of faecal 
water. With decrease in faecal water by 4% after 2-3 months, the proportion of acetate was 
no more significant. Moreover, increased proportion of acetate at recruitment could also be 
due to the preferential utilisation of lactate to generate butyrate by lactate-utilising 
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butyrate-producing bacteria such as E. halii and Anaerostipes caccae, thus sparing the 
utilization of acetate (292).  
The proportion of BCFA, iso-butyric acid, was significantly higher (p=0.010) in the 
simple obese group compared to hypothalamic obese group at the time of recruitment. 
These results are in line with a crossectional study by Payne et al. (2012), who found a 
higher concentration of iso-butyric acid in simple obese Swiss children as compared to 
lean children (95). Although, these results may not be comparable with the two obese 
groups of our study, the results of this study at least in part indicate differences between 
obese and lean groups. However, their study did not give an indication of the relationship 
of BCFA in obese children with diet as dietary data was not recorded. The concentration 
and proportion of BCFA are generally increased when fermentable carbohydrate is limited 
in the colon and also from endogenous sources of proteins in the form of sloughed cells. In 
accordance with this, we found a significant negative association of proportional intake of 
carbohydrates with BCFA (isobutyric and iso-valeric acid) at the time of recruitment. This 
was further supported by the finding that the proportion of both iso-butyric and iso-valeric 
acids were significantly negatively correlated with BMI SDS in healthy as well as 
pathological group. 
BCFAs, iso-butyric acid and iso-valeric acid, are produced as a result of protein 
fermentation particularly branched amino acids such as  valine and leucine from exogenous 
protein sources of proteins (114) or from endogenous sloughed colonic epithelium (360). A 
study on faecal samples of 4 different species (humans, horses, rats, and pegs) has shown a 
consistently strong correlation between percentage of iso-butyric and iso-valeric acid in 
these species fed on different diets, irrespective of the amount of SCFA, age, diet, and 
living conditions (114). Although the proportional intake of proteins was significantly 
higher in simple obese vs. healthy lean group after 2-3 months, none of the BCFAs was 
significantly associated with the amount or proportion of protein intake in multivariate 
regression analysis. We therefore suggest the use of stronger and more reliable methods of 
dietary assessment such as multiple days weighed food diaries with food frequency 
questionnaires to elucidate difference in dietary intake of carbohydrates and proteins as our 
dietary assessment method (24 h food diaries) might have failed to show these differences. 
Octanoic acid or caprylic acid, an eight carbon medium chain saturated fatty acid, 
is naturally found in the milk of mammals (such as goats) and in minor concentrations in 
coconut and palm oil. Caprylic acid has been shown to inhibit the activity of several 
pathogenic bacteria such as E. coli (O157: H7 strain) (361), Salmonella enterica (362), 
Clostridium difficile(363), Listeria monocytogenes (364), Furthermore, the active acylated 
form of ghrelin requires n-octanoic acid at serine residue on its chain and studies in fish 
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(barfin flounder) (365)and mouse models (366)have shown that ingested fatty acids (such 
as octanoic acid)increased the acylated form of ghrelin and hence are substrates for ghrelin 
acylation(365). Very little is known about the source and microbial producers of caprylic 
acid in the gut. Previous studies in this department reported lower faecal levels of caprylic 
acid in Crohn’s disease patients compared to healthy children(126). Recent unpublished 
data from this department have shown that caprylic acid is produced by the degradation of 
medium chain triglycerides (MCTs) in a formula feed (Modulen®). No study to date has 
reported faecal caprylic acid in obese children and young adults. Negative correlation of 
the proportion of caprylic acid with BMI SDS in PWS patients might suggest a lower 
intake of MCTs and hence lower production of caprylic acid in this group. However, we 
have no dietary record of the intake of MCTs from our food diaries. MCTs are absorbed 
via passive diffusion from the gut into portal circulation and do not require bile salts for 
absorption unlike long-chain fatty acids. They are therefore used in malabsorption states as 
a source of energy. Whether negative correlation of caprylic acid with BMI SDS in PWS 
patients represents increasing malabsorption and faster transit time with increasing BMI, 
need to be investigated in future studies. 
 
Propionate was consistently and significantly higher and significantly correlated with 
BMI SDS in the two obese groups 
Our results showed consistently higher faecal propionate in simple and hypothalamic obese 
groups. Moreover, both the concentration and proportion of faecal propionate was 
significantly positively correlated with BMI SDS in the pathological group (hypothalamic 
lean and obese) but not in the healthy (healthy lean and simple obese) groups.  
Obesity is generally associated with metabolic dysfunction. Furthermore, higher 
levels of propionate have been associated with hypocholesterolemia (96), reverse 
cholesterol transport, anti-lipogenesis, improved satiety through hormone PYY, decreased 
meal size by increased leptin (which induces suppression of food intake through receptors 
expressed in central nervous system) (97), and antiproliferative effect on colonic cancer 
cells (98). However, this paradoxical increase in ―beneficial propionate‖ in our obese 
groups has also been reported by other studies (95, 172, 176, 350). Propionate is primarily 
produced by Bacteroidetes. Members of Bacteroidetes such as B. thetaiotaomicron have 
the ability to respond to the diverse environmental fluctuation by producing a range of 
glycosyl hydrolases that can redirect its energy harvesting capability to degrade mucin in 
the presence of a low dietary fibre intake (367). Upon exposure to diet containing simple 
sugars, caeca of gnotobiotic mice with B. thetaiotaomicron express genes that encode 
enzymes for degrading only the host glycans (367). This makes them better suited to the 
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situation of ―increased energy but less fibre intake‖. It may therefore be more important to 
look into the substrate source of increased propionate in these groups rather than just the 
increased propionate itself. Population based studies in humans have reported a reduced 
intake of dietary fibre and higher amounts of the readily available sources of dietary 
carbohydrates in the diets of obese people (343). This might explain the abundance of 
Bacteroidetes and the consequently higher concentration of propionate reported in obese 
people. An apparent increase in the ―beneficial‖ propionate might be an indication  of a 
higher carbohydrate but less dietary fibre-rich food (172).  
Moreover increased propionate in our obese groups might suggest increased 
propionate-induced hepatic gluconeogenesis which plays its part in causing insulin 
resistance (368). Insulin resistance is one of the hallmarks of diabetes, to which obese 
people are generally prone. However, a recent study have suggested that propionate exert 
beneficial metabolic actions by stimulating intestinal gluconeogenesis to which propionate 
is a substrate (348). Glucose from intestinal gluconeogenesis is sensed by the portal vein 
glucose sensors which transmits signals to the brain to promote beneficial effects on the 
food intake and energy metabolism (348). 
SCFA especially propionate also act as a ligand for G protein coupled receptor 
GPR41 (also called FFAR3). These receptors are expressed in adipose tissue, pancreas, 
spleen, liver, enteroendocrine L cells, and mononuclear cells. These receptors have been 
shown to improve insulin sensitivity and secretion via stimulation of GLP-1 from L-cells 
(99). The results are however controversial as other studies have found a reduction in 
insulin sensitivity with activation of GPR41 which indicate other mechanisms involved 
which are poorly known (99). Propionate and acetate added to a culture medium containing 
adipocytes and pre-adipocytes reduced lipolysis by 50% and the same effect was seen in 
C57BL/6 mice fed with propionate and acetate preparations (100).This anti-lipolytic effect 
was abolished when GPR41deficient knock-out mice were used, implicating that 
propionate and acetate exert this effect through GPR41 (100). 
Faecal ammonia is associated with dietary fibre intake, pH and age 
We found significantly higher faecal ammonia in dry faecal sample of healthy lean group 
than the simple obese and hypothalamic lean groups at the time of recruitment. To our 
knowledge, we are reporting differences in faecal ammonia between lean and obese 
children for the first time as no study has thus far studied faecal ammonia in relation to 
obesity.  
In the colon, faecal pH and carbohydrate availability are the major negative 
determinants of peptides and amino acid fermentation in the large intestine; carbohydrate 
availability being stronger factor than faecal pH (135). Our dietary data showed a lower 
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amount and percentage intake of dietary carbohydrates in healthy lean group as compared 
to the hypothalamic lean group which might indicate that host mucins and dead bacteria 
are used for the production of ammonia. However, this was not the case for simple obese 
group which may be due to a significant effect of under-reporting. The levels of faecal 
ammonia increased with a significant change in the percentage intake of proteins in simple 
obese group as reported in the data after 2-3 months; which conforms with another study in 
which increase in the intake of meat protein was associated with a significant increase in 
the production of SCFA and ammonia fed to human volunteers (73). Birkett et al.(1996) 
showed a reduction in the faecal ammonia and phenols with increase in the intake of 
resistant starch although there was no change in the urinary ammonia, phenol, urea, and 
total nitrogen (136). Russell et al.(2011) showed similar faecal ammonia concentration in 
obese human volunteers on high protein medium carbohydrate, high protein low 
carbohydrate, and weight maintenance diets for 8 weeks (137).However, faecal ammonia 
in our study was significantly positively associated with intake of dietary fibre and age at 
presentation and with pH after 2-3 months and not with protein intake. 
Faecal sulphide were not significantly different between the two obese and lean 
groups  
We found no significant difference in the faecal concentration of free, bound, and total 
sulphide between any of the four groups. To our knowledge this is the first study to report 
faecal hydrogen sulphide in children with simple and hypothalamic obesity. Although 
extensively studied in relation to inflammatory bowel disease (126); faecal hydrogen 
sulphide in obese human beings including children has not been studied. Similar levels of 
hydrogen sulphide in all our groups might suggest similar relative abundance of SRBs, 
similar gut luminal conditions in terms of transit time and pH, and similar capability of 
maintaining the redox potential in the gut lumen.  
Whereas physiological concentrations of hydrogen sulphide has beneficial effects 
on gut health (124), a number of potentially adverse effects of excess hydrogen sulphide 
have been suggested (119) as discussed in chapter 1 section 1.2.2.6.  
We found significant negative association of faecal sulphide with % faecal water 
content at recruitment and after 2-3 months irrespective of the study group in a multivariate 
regression analysis. Chassard et al.(2012) reported a significantly lower faecal sulphide, 
molecular hydrogen, and significantly higher methane in healthy lean women as compared 
to women with constipated irritable bowel syndrome (IBS) (128). This was coupled with 
significantly higher lactate utilising bacteria and methanogenic archaea, and significantly 
lower sulphate reducing bacteria in healthy lean women as compared to constipated IBS 
women. Although total SCFA, acetate and propionate were similar between the two 
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groups; levels of butyrate were significantly lower in the constipated IBS group signifying 
the fact that hydrogen sulphide inhibited oxidation of butyrate (128). 
Interestingly, the change in faecal sulphide (Δ) in our study was determined by the 
proportion of fat and carbohydrate intake in grams (for bound sulphide) in addition to % 
water content (for total sulphide).This result should be considered with caution as our 
obese group might have underreported their diet but other studies have also found changes 
in faecal sulphide with changes in faecal consistency and dietary intervention (121, 129, 
369). A recent study on gnotobiotic mouse model showed an increase in caecal sulphides, 
increase in a prominent SRB; Desulfovibrio piger, and a decrease in acetate and propionate 
on high fat and low complex polysaccharide diet. This was in addition to increased gene 
expression  of sulfatase; a mucosal peptidoglycan degrading enzyme sulfatase produced by 
Bacteroides (121). De Preter et al.(2010) showed a significant reduction of sulphide in 
faecal samples incubated with oligofructose-inulin by in vitro fermentation (129). In 
another study, volunteers who had SRBs in their faeces, showed a reduction in faecal 
sulphide with oligofructose along with increase in the total SCFA although the population 
of SRBs did not change with intervention(130). However, this is controversial as some 
studies have shown higher sulphate reducing bacteria in African population consuming 
high fibre diet than in African-Americans consuming low fibre diet (131). 
Systemic hydrogen sulphide is a gasotransmitter vasodilator and has several 
beneficial cardiovascular and anti-obesity effects (120, 124). Shen et al.(2013) have shown 
that gut microbiota play a key role in regulating the bioavailability of hydrogen sulphide in 
the systemic circulation (132). They found significantly lower tissue and intestinal free 
H2S in germ free vs. conventionally housed animals. In contrast, a study by Flannigan et 
al. (2011) on Swiss Webster mice showed no difference in faecal H2S between germ free 
and conventional mice (120). The difference may be attributed to different mouse models, 
experimental conditions and sample size between the two studies. Our study did not look 
into the systemic levels of hydrogen sulphide to compare the faecal sulphide with that in 
systemic circulation. It will be interesting to correlate gut luminal H2S which is being 
considered as harmful metabolite with H2S in systemic circulation with its aforementioned 
beneficial actions and whether gut microbiota or obesity plays any role in determining this 
balance. Furthermore, based on the available data, the source and mechanisms of faecal 
sulphide production is not known in our group of patients. We also cannot comment on the 
proportion of faecal sulphide contributed by the microbial production from the available 
luminal substrates (prokaryotic contribution) and that contributed by the host mucin 





Overall; there was no significant difference in the concentration of faecal D, L and total 
lactate and D/L ratio between simple and hypothalamic obese groups. Generally, healthy 
lean and hypothalamic lean groups had a tendency towards higher faecal lactate as 
compared to the two obese groups. However, this was only significantly higher in 
hypothalamic lean than hypothalamic obese group in wet faecal samples at presentation but 
not in the freeze dried samples and at follow-up. Since lactate is a metabolic intermediate 
during the production of butyrate, propionate, and acetate; its presence in lower quantities 
in obese might indicate active utilisation of lactate in obese group. This in turn might have 
resulted in the relatively higher total and major individual SCFA in the two obese groups 
as compared to the lean groups. This finding also conforms with findings from other 
studies in children where higher faecal lactate was found in lean children as compared to 
obese children (95).Higher levels of lactate in our lean groups might indicate a higher 
lactate producing Bifidobacterium spp. and studies have shown a positive association of 
lactate producing Bifidobacteria with leanness and that a higher Bifidobacteria in early 
infancy may predict normal weight in later childhood (258). In contrast, lower levels of 
lactate  in plasma has been associated with presence of increased Bifidobacteria in the gut 
(370). 
Concentration of faecal bacterial metabolites may be explained by increased 
production in vivo and is not affected by the presence or absence of pathology.  
Extensive multivariate regression analysis of faecal bacterial metabolites with dietary, 
anthropometric, and demographic predictors suggested that faecal SCFA and the changes 
in faecal SCFA over the period of study were strongly negatively associated with the 
change in pH of the faeces both at the time of recruitment and after 2-3 months. This is 
expected, as the production of SCFA in the gut lumen reduces the pH in the gut lumen and 
the pH rises as the rate of SCFA production decrease along the distal end of the gut. 
Colonic pH decreases to ~5.5 at the caecum and proximal part of the ascending colon due 
to SCFA production (70-140 mol/kg) and rises to ~6.5-6.8 in the descending colon and 
rectum where the production of SCFA is lower (~20-70 mmol/kg) compared to the 
proximal part. Interestingly this association remained unchanged even after adjustment for 
the presence of pathology which suggested that any possible differences in gut physiology 
due to Prader- Willi syndrome or craniopharyngioma may not be affecting the metabolic 
potential of the gut microbiota and that the availability of substrate might be a more 
important determinant of this association. However, none of the gut bacterial metabolites 
was significantly associated with the dietary macronutrients or energy intake. Branched 
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chain fatty acids were significantly associated with energy intake at follow-up only, but 
were no more significant when the analysis was adjusted for pathology. 
Nevertheless, the significant association of propionate both with and without 
pathology was striking. This was discussed above. Additionally, presence of a disease 
seems to alter the molar ratios of butyrate with acetate, propionate, and lactate which might 
be driven by the utilization of more lactate than acetate to generate butyrate in our 
hypothalamic obese group. 
Weight loss or weight gain (expressed as Δ BMI SDS/month) was not associated with 
changes in bacterial metabolites. 
Differences in weight loss and weight gain between the groups were not significantly 
different and were discussed in chapter 3. We explored the association of weight change (Δ 
BMI SDS/month) with changes in gut bacterial metabolites and we found no significant 
differences in the concentration of faecal gut bacterial metabolites between obesity of 
different aetiology (simple vs. hypothalamic obese), between the two lean groups (healthy 
lean vs. hypothalamic lean), and between obese (simple and hypothalamic obese) and lean 
(healthy lean and hypothalamic lean) phenotypes. None of the predictors was associated 
with any of the metabolites at follow-up or with the change in metabolites between the two 
time points even after adjustment for pathology.  Studies have reported changes in the gut 
microbial diversity and metabolic activity with changes in weight; weight loss being 
associated with an increase in Bacteroidetes, total SCFA, and major individual SCFA such 
as acetate (163, 164). However, weight change is also associated with change in dietary 
pattern which is also reported to alter the gut microbial communities, at least transiently, if 
not permanently (216). Furthermore, weight loss or weight gain is associated with changes 
in the endocrine and neuronal pathways of food intake (371, 372), which may also 
contribute to the change in metabolism of gut microbial metabolites.  No significant 
differences in gut bacterial metabolites in our study might therefore suggest functional 
resilience of the gut microbiota diversity and metabolic activity in our participants which 
does not vary significantly with obesity or pathology, at least within a period of 2-3 
months. It is however difficult to implicate whether differences in weight gain/loss over an 
extended period of follow-up would bring up differences in metabolism and diversity of 
gut microbiota in our cohort. This will need a long term close follow-up of these 
participants.  
4.8 Conclusion 
Data presented in this chapter indicate no major differences in the gut bacterial metabolic 
activity between simple and hypothalamic obesity suggesting that obesity and not the cause 
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of obesity determine differences in the metabolic potential and that other factors such as 
diet and lifestyle might be more important in the cause of obesity than gut microbiota. 
In subsequent chapters this potential is further explored by in-vitro batch culture 
fermentation of gut microbiota to see whether fermentation capacity or energy harvesting 
capability of gut microbiota is different between simple and hypothalamic obese groups 
under similarly mimicked gastrointestinal conditions.  
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 Chapter 5: In Vitro Fermentation Capacity of Gut 
Microbiota from Children with Simple and 
Hypothalamic Obesity 
5.1 Chapter Outlines 
This chapter investigated the energy harvesting capacity of gut microbiota between 
children with obesity of different aetiology through in vitro batch culture fermentation 
studies using a range of fermentable carbohydrates (apple pectin, raw-potato starch, wheat 
bran, raftilose, and maize starch). Furthermore, changes in fermentation capacity with 
dietary management in simple and hypothalamic obese groups were assessed. 
5.2 Introduction 
The on-going pandemic of obesity in adults and children is a major public health issue and 
an economic burden in both the developed and developing world due to its association with 
cardiovascular diseases, diabetes and hypertension (chapter 1, section 1.3)(19). Obesity is 
generally regarded as a state of positive energy balance resulting from the availability of 
excess energy in the body related to lower energy expenditure. This has been linked to low 
levels of  physical activity(373), increased energy intake(374, 375), genetic 
predisposition(376), inflammation(377), and hormonal disturbances(378).  
As discussed in the previous chapter, the gut microbiota may play a key role in 
deriving energy from the diet as they degrade fermentable carbohydrates into short chain 
fatty acids, the amount of which varies with the amount of dietary fibre intake. Chronic 
excess production of 200 extra kcal/day energy by this route would result in increased 
energy availability and hence increase in weight by 1kg in a year and 10 kg over 10 years 
(169). Compositional differences and changes in the gut microbiota with dietary 
intervention in obese animal and human studies suggested increased efficiency in energy 
harvesting capability of the ―obese‖ gut microbiome. The obese microbiome is associated 
with lower bacterial richness and diversity, increased relative abundance of Firmicutes, and 
reduced Bacteroidetes (162). In study of 12 lean and 9 obese adults on diet containing 
either 2400 kcal/day or 3400 kcal/day, Jumpertz et al. (2011) reported that on the same 
diet, a 20% increase in Firmicutes was associated with faecal energy loss of approximately 
150 Kcal collected over 3 days in lean individuals but not in obese (265). However, this 
evidence was limited by the fact that the calculations of the difference in faecal energy 
were based on the assumption that all the subjects had equal nutrient digestion and 
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absorption statuses. Furthermore, despite similar reported gut transit time, no significant 
differences were seen in the energy loss in faeces in obese subjects on weight maintenance, 
2400 kcal/day, or 3400 kcal/day diets. The differences seen in the gut microbial population 
between obese and lean subjects may not be related to the results for faecal energy loss as 
the samples for estimating gut microbiota composition were spot faecal samples taken at 
two different times than those for the faecal energy studies which were 3 day stool 
collections. In contrast, studies in genetically obese ob/ob mice on low fat diet and wild-
type mice on high fat Western diet showed a progressive increase in Firmicutes over 15 
weeks in the obese but not in the lean mice. Additionally, changes in energy harvesting 
capability were not associated with changes in the gut microbiota (such as increase in 
relative abundance of Firmicutes) (220). Another study found similar gut microbiota in 
RELMβ knock-out mice (resistant to obesity) and wild-type mice on high fat diet 
independent of the genetic or lean/obese phenotype (224). Differences observed between 
these studies may have been due to differences in the source of samples (faecal vs. caecal 
sample), in experimental settings, methods of DNA extraction, use of different animal 
models, and different macronutrients and fibre proportion of the diets. A convincing 
conclusion is therefore still awaited to explain the association of gut microbiota with 
energy harvest.   
In the previous chapter, we reported no significant differences in the faecal SCFA 
and other bacterial metabolic products between simple and hypothalamic obese groups and 
that the two obese groups had a tendency towards a higher total faecal SCFA than the two 
lean groups. In particular, the concentration and proportion of propionate was consistently 
significantly higher in hypothalamic obese than lean groups both at recruitment 
(concentration; p=0.015 & proportion; p=0.004) and after 2-3 months (concentration; 
p=0.018 & proportion; p=0.004) (chapter 4, section 4.6.1.4) and was significantly 
positively correlated with BMI SDS. Similarly, the proportion of propionate was 
significantly higher in simple obese vs. healthy group (p=0.01). However, the amount of 
faecal SCFA is the result of a difference in the production and absorption of SCFA as the 
material moves from proximal colon to the rectum. Whether increased SCFA in the faecal 
samples are due to increased production or is an effect of malabsorption is not known.  
Thus it is important to measure production rates to understand these results. 
Several factors have been identified that affect the production of SCFA in the gut 
such as; the availability of substrate in the form of fermentable carbohydrates and gut 
transit time (379, 380). Sampling from the caecum of experimental animals gives a more 
accurate estimation of SCFA concentration in the lumen of the gut after dietary fibre 
intervention than that measured in faeces (381). However, this approach is not practical in 
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human studies, although measurement of intestinal SCFA have been reported in studies on 
sudden death victims (382, 383). Cummings and colleagues in their study analysed SCFA 
in jejunal, ileal, and colonic content and portal, hepatic, and peripheral femoral blood in 
victims of sudden death in 1987 (n=6, age range: 16-89 years, mean age: 57 years) (382). 
The authors observed a progressive rise in pH from 5.6 in the caecum to 6.7 in the 
descending colon with an inverse trend in the SCFA concentration falling from 131 ± 0.9 
mmol/kg content in the caecum to 80 ± 17 mmol/kg colonic content in the descending 
colon. SCFA concentration rose by 10 fold between ileum and caecum (382). Molar ratios 
of acetate: propionate: butyrate was 57:22:21 in the whole colonic content, not varying 
between the segments (382). The results were important given that it was the first study to 
give an indication of the colonic concentration of SCFA in humans, however there were 
several confounders that could potentially limit the interpretation of these results. There 
was no history of diet or the gastrointestinal health or other conditions that could 
potentially affect fermentation capability. Additionally, the age range was very wide given 
the differences in the fermentation capability varying with age and the inter-individual 
variation in the given data was very high due to small numbers. Furthermore, the cause of 
their death might also have affected the levels of the SCFA in the gut as well as portal, 
hepatic, and peripheral blood due to sudden metabolic stress and shock (gunshot, road 
traffic accident) or due to chronic compromised blood supply (coronary heart disease). 
McFarlane and Gibson in their study on two sudden death victims reported results similar 
to Cummings et al.(383). In addition, these authors reported that the in vitro batch culture 
fermentation of the colonic content without any added substrate showed higher 
concentration of SCFA in the proximal colon than distal colon. In contrast, the production 
of branched chain fatty acids iso-butyrate and iso-valerate were significantly higher in 
distal than proximal colon. Furthermore, the authors found higher methane and 
methanogenic archaea in distal colonic content of one person while higher sulphide and 
sulphate reducing bacteria in the colonic content of the other, suggesting differences in the 
gut microbial composition and physiology with substrate availability and anatomy of the 
large intestine (383).  This study was also limited by number of participants making the 
results less representative.  
Further to this evidence, variation in fermentability of the dietary fibre (such as 
non-starch polysaccharides) may differentially affect faecal and caecal SCFA, in which 
case caecal SCFA might underestimate the true picture of colonic fermentation for some 
fibres. In a study by Edwards and Eastwood (1995), male Wister rats (n=60) were housed 
for four weeks on basal diet containing 45 g/kg non-starch polysaccharide followed by 
supplementation with 50g/kg either of guar gum, xanthan, tragacanth, karaya, gellen, or 
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ispaghula for further four weeks (384). Guar gum was shown to increase caecal SCFA due 
to rapid fermentation, while another group of NSP (tragacanth, xanthan, and karaya) 
increased faecal SCFA and faecal water but not caecal SCFA suggesting that the 
fermentability of dietary fibre is related to the site of SCFA accumulation (384). Campbell 
and colleagues conducted a study in 50 male Sprague-Dawley rats fed with control diet 
with or without cellulose, fructo-oligosaccharide, xylo-oligosaccharide, or raftilose for 13 
days. After 13 days intervention, the authors did not find significant correlation of faecal 
SCFA with caecal SCFA concentration despite strong correlation of the faecal microbiota 
with caecal microbiota composition (346). This suggests rapid absorption of SCFA in the 
large bowel shortly after being produced and hence demonstrates the fact that fibres 
degraded in the proximal large bowel may not be comparable to those fermented partially 
while the faecal microbiota composition is still reproducibly comparable between caecum 
and faeces. 
In-vivo fermentation studies, where the dietary fibre fermentation actually takes 
place, is the ideal approach to assess the energy harvesting capability of gut microbiota 
from dietary fibre. However, this is very difficult to achieve in humans. Bellieret al.(1995) 
measured in-vivo caecal fermentation capacity in 12 adult and post-weaning rabbits by 
caecal cannulation. They found significantly lower total SCFA, lower molar proportion of 
butyrate, and higher ammonia in the caecum of post-weaned rabbits but not in adult 
rabbits. Changes in the pattern of fermentation products were observed according to the 
circadian rhythm only in post weaned rabbits (385). James (1972) measured the digestion 
and absorption of orally ingested lactose and sucrose in 8 malnourished children by jejunal 
perfusion with a multi-lumen tube and found that apparently well absorbed sugars may not 
always be coupled with good tolerance of lactose (386). Florent et al.(1985) attempted to 
assess in vivo caecal and ileal lactic and volatile fatty acids (VFA) concentration by triple 
lumen tube intubation upon administration of 20 g twice daily lactulose for eight days in 
eight volunteers (387). They observed a reduction in caecal pH and increase in lactate, 
acetate, and total VFA after eight days intervention. Interestingly, no changes in faecal pH, 
lactate and VFA were observed with intervention suggesting a reliable and early detection 
of changes in metabolic activity of the caecal gut microbiota (387). Moreover, in-vivo ileal 
(388) and colonic perfusion studies (389) have been conducted to study availability of 
Bifidobacteria in the ileum or the absorption of salt and water with colonic SCFA 
perfusion respectively. Translation of these studies to routine and clinical studies involving 
humans is still a major issue to address when considering in vivo studies. Furthermore, the 
inaccessibility of the colon, limitations in reproducibility, inability to account for the 
complex interaction of food with enzymes and hormones in the gut, and the ethical issues 
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involved in in vivo studies make them difficult to achieve in humans. This makes the less 
powerful  in vitro batch or continuous culture fermentation studies, conducted in controlled 
environment mimicking gastrointestinal tract, a more likely and convenient choice to study 
the fermentation capacity of gut microbiota. These methods have been shown to be 
reproducible, repeatable, and well controlled (273, 274). 
With regard to obesity, there is very limited evidence from animal models studying 
the fermentation capacity of gut microbiota in relation to obesity. Recently, Condezo-
Hoyos et al. (2014) conducted in-vitro batch culture fermentation of faecal samples of 
obese (n=3) and lean (n=3) mice incubated with apple pectin derived from a special variety 
of apple, Granny Smith. Obese mice were fed with high fat diet while lean mice were fed 
standard normal diet. After 12 h of incubation in batch cultures, relative abundance of 
Bacteroidetes significantly decreased in lean control cultures compared to obese control 
cultures. However, in obese cultures incubated with apple pectin as a substrate, relative 
abundance of Bacteroidetes also decreased significantly. SCFA analysis revealed that only 
acetate was significantly reduced in the cultures of obese mice incubated with apple pectin 
compared to obese control cultures (390). The conclusions from this study should however 
be interpreted with caution as the authors used a different diet regimen for each group for 
un-explained reasons (high fat diet for obese and standard diet for lean), used a composite 
of faecal samples from all members of the same group (which might have masked the 
pattern of SCFA and bacterial diversity from individual mice), and was also limited by few 
numbers (n=3). 
In humans, several studies have investigated the effect of dietary fibre interventions 
on gut bacterial metabolic parameters in obese (391, 392) and lean humans (393, 394). 
However, only three human studies have investigated the differences in metabolic potential 
of gut microbiota by in-vitro fermentation in simple obese and healthy lean people (95, 
172, 395).   
Payne et al. (2012) in their in-vitro continuous culture fermentation study involving 
one lean and one obese child showed a similar ―butyrogenic effect‖ of high and normal 
energy nutrient load with no effect on propionate. This was coupled with increased 
butyrogenic bacteria from phylum Firmicutes (Roseburia/E.rectale in the obese child and 
E.halii in the lean child under high energy Western diet and the reverse was found on 
normal energy load) (95). The results of this study are interesting but less convincing as 
there was only one lean and one obese child in the study and the differences observed may 
be a subject of inter-individual variation and not attributable to the obesity phenotype.  
Yang et al. ( 2013b) showed an increase in the molar propionate to total SCFA ratio and a 
lower proportional acetate in faeces from obese than lean adults through in-vitro batch 
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culture fermentation, and a significant positive correlation of propionate with BMI (kg/m
2
) 
of participants (172). This study was limited because the authors used faecal samples that 
were stored for more than 24 h and then processed which may have affected the balance of 
aerobic and anaerobic gut bacterial population. Sarbini et al.(2013) investigated the effect 
of α-gluco-oligosaccharides (GOS) using in-vitro batch cultures and reported no significant 
difference in the production of SCFA between lean and obese adults (395). Although the 
production rates of acetate and propionate were observed to be similar in both lean and 
obese adults, the ratio of acetate to propionate was significantly lower in the obese than the 
lean subjects. Changes in gut microbiota with GOS and inulin were similar in lean and 
obese. Levels of Bifidobacteria increased with GOS compared to control (with no GOS), 
Bacteroides/Prevotella increased with both GOS and inulin, while Faecalibacterium 
prausnitzii decreased with both GOS and inulin (395). Although this study had pH 
controlled in-vitro conditions, the numbers were again very small (n=4) and are limited to 
provide conclusive evidence for differences in fermentation capacity between lean and 
obese phenotypes.  
In the presence of limited and inconclusive evidence, it remains to be determined 
whether the obese phenotype differs from the lean phenotype in terms of fermentation 
capacity. Furthermore, is any difference in fermentation capacity between lean and obese 
phenotype determined by the gut microbiota populations. In an attempt to rule out this 
reverse causality, we conducted in-vitro batch culture fermentation studies on fresh faecal 
samples from a larger group of children and young adults with obesity of different 
aetiology and healthy lean children to give a better indication of the fermentation capacity 
of gut microbiota (i.e. production and rate of production of SCFA). Our main aim was to 
investigate the cause or effect relationship of gut microbiota with obesity, for which reason 
we conducted this study to assess whether the fermentation capacity of gut microbiota was 
any different between obesity of different aetiology.  
We used a range of different commonly consumed dietary fibres as substrates to 
assess if the response of gut microbiota to individual fibres was ―general‖ (i.e. fermenting 
all fibres uniformly; as a proxy for a general increase in the capacity) or whether any 
differences in microbiota were ―substrate-selective‖ (i.e. more specific based on the 
predominant components of the diet of the participants). Published studies have shown a 
selective pattern of both gut microbiota and SCFA production by different dietary 
substrates used in-vitro (Table 5.1).  
 218 
 
Table 5.1:  Predominant SCFA produced by fermentation of selected fibres for this study and the 
predominant gut microbiota involved in their production. 





Apple Pectin Butyrate Bifidobacteria, Lactobacilli, 
Bacteroides fragilis, Enterococci 
(396, 397) 
Raw Potato Starch Propionate, acetate Bifidobacteria, Lactobacilli, 
Enterobacteria, Streptococci 
(398) 
Raftilose Acetate Bifidobacteria, Lactobacilli (392, 399) 
Wheat bran Butyrate Bifidobacteria, lactobacilli, 
Eubacteria 
(394) 
Maize starch Butyrate, propionate Ruminococcus 
bromii and Eubacterium rectale 
(400, 401) 
In our study; raftilose & raw potato starch produced the most acetate, wheat bran & raw potato starch 
produced the most propionate, and raw potato starch & maize starch produced the most butyrate 
 
The fermentability of dietary fibre by the gut microbiota depends on its water-solubility, 
chemical structure, particle size, lignification, and other ingested food components (402). 
The pattern of short chain fatty acids production depends on the type of fibre and gut 
microbiota residing in the colon (403). Excess SCFA particularly acetate is regarded as 
more obesogenic, while butyrate and propionate are regarded beneficial for colonic and 
general health (98, 404). Choosing a range of dietary fibres with a predominant pattern of 
SCFA production is therefore advisable to elucidate the differences in pattern of SCFA 
between lean and obese people.  
To the best of our knowledge, this is the first study looking at the differences in the 
fermentation capacity of gut microbiota between obese children/young adults of different 
aetiology (hypothalamic obesity vs. simple obesity) and between the obese and lean 
phenotypes through in vitro batch culture fermentation studies. 
5.3 Subjects and Methods 
5.3.1 Patients and methods 
Detailed information about the subjects and their recruitment is given in chapter 2. Briefly, 
each participant giving written informed consent was asked to give two faecal samples at 
an interval of 2-3 months with dietary and body composition data. Faecal samples were 
collected and transported in an anaerobic environment to the laboratory within 4 h after 
being produced. Each sample was processed for in vitro batch culture fermentation (Figure 
5.1). Detailed explanation of the in-vitro batch culture fermentation is given in chapter 2, 
section 2.3.5. Fermentation supernatant obtained from the incubated sample at 0 h, 4 h, and 
24 h of incubation was used to measure pH (using a benchtop pH meter) and short chain 
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fatty acids (using gas chromatography (chapter 2, section 2.3.6). Approximately, 4,500 
samples were analysed for SCFAs over a period of 8 months. 
Note: Obtaining two faecal samples, body composition measurements, and the 
comparisons done between the two time points were primarily aimed at the assessment of 
changes in fermentation capacity with weight management. Changes in anthropometric and 
body composition measurement are explored in detail in chapter 3.  




Pectin derived from apple source (cat. No.76282) and raw potato starch (containing 10% 
resistant starch) (Cat no. S2004) were both obtained from Sigma Aldrich. Raftilose (Orafti 
P95®), a short chain inulin fructo-oligosaccharide [degree of polymerization (DP) = 3-5] 
extracted from chicory root (cichoriumintybus) was kindly provided by BeneoOrafti 
(Tienen Belgium).  This oligofructose has 95% raftilose and 5% other sugars such as 
glucose, lactose, and sucrose. Un-treated non-pre-digested wheat bran was obtained from 
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Infinity foods co. UK. Maize starch Hi-Maize® TM 260 (Cat. no. KK10283) was kindly 
provided by National Food Innovation Manchester. HI MAIZE® has high amylose content 
from corn and is a type 2 resistant starch containing 60% resistant starch and 40% slowly 
digestible starch. 
5.4 Data sorting 
Sorting and analysing of the data obtained from 24 h in-vitro batch culture fermentation 
was a complex task. Participants were in four groups; each participant had two faecal 
samples incubated for 24 h, using 5 substrates and a blank (with faecal inoculum but no 
substrate), and each substrate incubated in duplicate. Furthermore, samples in duplicate 
were taken from the incubated fermentation vessels for SCFA analysis at three time points 
(0h, 4h, and 24 h). Total of 151 samples were collected from all the recruited participants 
and their parents whenever they agreed to take part (n=30). This generated about 4500 
faecal samples for SCFA extraction and analysis with GC-FID. 
All data in the form of area under the curve obtained from GC-FID software was first 
converted into molar concentrations using a formula (explained in chapter 2, section 2.3.6). 
Each sample analysis was transferred to a single sheet and then screened for mismatch 
(high %CV) between the duplicates. Any erroneous and abnormal samples were 
scrutinised and the samples re-extracted. The duplicates were averaged, data was first 
organised in a single sheet containing all participants, with all dietary substrates and the 
blank, all time points taken at 0h, 4h and 24h incubation, and both samples taken at 
interval of 2-3 months.  This sheet was used to generate descriptive statistics in Minitab® 
16. All data could not be analysed in a single worksheet therefore this main sheet was 
further split into sub-sheets of time points (0 h, 4 h, and 24 h) for each sample (at 
recruitment and after 2-3 months). Sheet with 24 h data was used for statistics related to 
fermentation end point (24 h) while sheets for 0h and 4 h were combined to calculate the 
rate of SCFA production between 0-4 h incubation. Anthropometric data was incorporated 
into each sheet to correlate SCFA production or the rate of SCFA production with BMI 
SDS. Each sheet was also sub-divided based on the dietary substrate to find differences 
between the groups based on dietary substrates. Within each sheet and sub-sheet, data had 
to be unstacked several times for the purpose of analysis.  
5.5 Statistics 
Non-parametric statistics were used for analysis due to the non-normal distribution of the 
data based on Anderson-Darling test of normality. Median and interquartile range were 
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used for calculations and statistics. Mann-Whitney U test was used to compare two groups 
for different variables. P-values of less than 0.05 were considered significant. Due to the 
difference in the nature of the groups, comparisons were done using Mann-Whitney U test 
between hypothalamic obese vs. simple obese, hypothalamic obese vs. hypothalamic lean, 
healthy lean vs. simple obese, and healthy lean vs. hypothalamic lean. No adjustment for 
multiple testing or false discovery rates was done for these tests. All significant p-values 
should therefore be considered as nominally significant. 
Change in total and individual SCFA (Δ) between samples at recruitment and 
samples after 2-3 months was measured as a difference of measurement at follow-up minus 
measurement at presentation.  Spearman rank correlations were used to find correlations 
between BMI SDS and SCFA production on ranked data. General regression analysis was 
used to find associations between total SCFA and time elapsed in processing the samples 
for in-vitro fermentation.  
 
5.6 Results 
5.6.1 Differences in pH of incubated faecal samples after 24 h at 
recruitment and after 2-3 months 
At the time of recruitment, there was no significant difference in culture pH after 24 h 
incubation between those seeded with faeces of children with obesity of different 
aetiology, between the two lean groups, and between lean and obese groups for any of the 
substrate and the blank (Table 5.2, Figure 5.2).  
However, after 2-3 months follow up, the cultures from the simple obese group 
tended to have a lower pH than all other groups but this was significantly lower only 
compared with the hypothalamic obese (p=0.04) and healthy lean groups (p=0.02) in 
cultures containing raw potato starch (Table 5.2, Figure 5.3). 
Table 5.2: pH of the faecal samples after 24 h incubation period at the time of recruitment and after 2-
3 months. 
Substrate Healthy Lean  Hypoth. lean  Hypoth. Obese Simple Obese 
 
Median IQR Median IQR Median IQR Median IQR 
Sample A  n=27   n=12  n=10   n=15 
Apple Pectin 4.47 0.32 4.68 0.56 4.54 0.49 4.61 0.45 
Blank 7.20 0.25 7.36 0.34 7.26 0.29 7.30 0.39 
Maize Starch 4.93 0.75 5.17 0.55 4.98 0.72 5.06 0.59 
Raftilose 4.17 0.48 4.18 0.31 4.28 0.24 4.18 0.51 
Raw Potato Starch 4.81 0.61 5.23 1.47 4.93 0.63 5.06 0.75 




Sample B                               n=24                            n=10                          n=9                           n=13 
Apple Pectin 4.50 0.47 4.43 0.40 4.56 0.93 4.35 0.72 
Blank 7.11 0.35 7.12 0.41 7.37 0.26 7.15 0.49 
Maize Starch 4.98 0.31 4.93 0.50 4.97 0.73 4.83 0.47 
Raftilose 4.02¥ 0.23 4.21¥ 0.22 4.27 0.61 4.02 0.78 
Raw Potato Starch 4.76* 0.51 5.10 0.53 4.91‡ 1.28 4.54*‡ 0.30 
Wheat bran 5.65 0.34 5.71 0.70 5.95 0.58 5.59 0.56 
≦ indicate significant differences between hypothalamic lean and healthy lean, ‡ indicate significant 
differences between hypothalamic obese and simple obese, * indicate significant differences between healthy 
lean and simple obese 
 
Figure 5.2: Culture pH of the 24 h incubated sample at the time of recruitment 
 
Blank circles represent outliers. HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, 
SO; simple obese. 
Figure 5.3: Culture pH of the 24 h incubated sample after 2-3 months of recruitment 
 
Blank circles represent outliers. HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, 




5.6.2 Differences in the production of total and major SCFA after 24 h 
incubation 
Differences in total SCFA at recruitment and after 2-3 months 
There was no significant difference in the concentration of total SCFA between any of the 
groups at the time of recruitment (Table 5.3, Figure 5.4&Figure 5.6) and after 2-3 months 
(Table 5.4, Figure 5.5&Figure 5.7), although the two obese groups (hypothalamic and 
simple obese) had a tendency to produce higher SCFA than the two lean groups. 
Differences in individual SCFA at recruitment 
With regard to individual SCFA, no significant differences were observed between simple 
and hypothalamic obese groups except the concentration of acetate which was significantly 
higher in simple obese than hypothalamic obese participants in cultures containing maize 
starch [median (IQR) µmol/ml: simple obese; 51.09(20.40) vs. Hypoth. obese; 
40.06(21.60), p=0.04]. 
Although, tendencies towards higher individual SCFA concentration and 
proportions (acetate, propionate, and butyrate) were observed in the two obese groups than 
the two lean groups, only few reached statistical significance due to large variation in the 
data particularly in the obese. Only, the proportion of acetate was significantly higher in 
hypothalamic obese than hypothalamic lean group in cultures containing wheat bran 
[median (IQR) %; hypoth. obese; 65.14 (16.10) vs. hypoth. Lean; 57.89 (8.41), p<0.05] 
(Table 5.3). Additionally, proportion of butyrate was marginally significantly higher in 
hypothalamic obese than hypothalamic lean group only for cultures containing wheat bran 
(p=0.052, Table 5.3).   
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Table 5.3: Concentration and proportion of total and major individual SCFA after 24 h incubation of 
faecal samples with substrates and the blank culture at the time of recruitment. 
 Healthy Lean 
(n=27) 






 Median IQR Median IQR Median IQR Median IQR 
Blank 
Total SCFA 20.57 4.49 18.03 6.66 20.45 9.39 21.21 7.04 
C2 11.83 2.66 11.39 3.39 11.46 2.53 11.81 4.68 
C3 3.11 1.03 2.32 1.08 3.39 2.66 3.56 1.86 
C4 2.24 1.08 2.07 0.73 2.77 3.95 1.84 0.83 
C2% 56.12 9.21 61.27 7.20 52.72 16.57 58.01 11.32 
C3% 14.97 6.12 13.11 2.37 15.30 7.44 15.39 4.92 
C4% 12.00 3.85 9.73 2.94 11.81 12.69 9.21 4.62 
Apple Pectin 
Total SCFA 77.55 38.05 62.76 45.62 66.89 41.41 80.83 42.88 
C2 54.68 24.99 45.54 28.14 49.11 20.22 50.90 14.21 
C3 7.71 4.62 6.62 8.44 7.66 9.72 8.44 7.13 
C4 14.30 14.47 10.36 10.07 9.03 11.30 8.95 17.61 
C2% 71.91 7.59 74.76 12.77 73.42 14.04 75.63 14.89 
C3% 9.31 5.61 8.70 9.32 12.08 10.99 11.77 8.63 
C4% 14.66 12.03 15.66 11.07 12.24 11.93 10.32 14.16 
Maize Starch 
Total SCFA 68.38 20.59 65.63 26.03 69.22 29.00 79.55 21.12 
C2 42.32 17.84 43.29 18.08 40.06‡ 21.60 51.09‡ 20.40 
C3 6.61 5.91 6.17 6.31 7.51 13.88 6.70 6.18 
C4 8.29 17.48 8.53 11.02 9.66 17.33 6.39 17.75 
C2% 68.40 13.93 68.69 20.78 57.98 27.77 68.00 20.26 
C3% 9.92 7.50 11.24 10.48 10.06 13.81 9.99 9.35 
C4% 11.91 14.04 13.49 23.55 13.96 21.42 14.33 17.22 
Raftilose 
Total SCFA 87.8 25.3 79.6 14.0 95.3 33.4 93.4 21.5 
C2 69.9 25.5 69.3 24.1 74.6 21.2 82.4 25.4 
C3 5.9 7.2 2.1 2.3 10.0 12.8 5.9 9.2 
C4 4.2 7.1 3.9 10.9 8.6 14.5 2.0 3.5 
C2% 87.3 18.9 89.5 13.4 74.7 26.4 88.8 22.1 
C3% 6.4 7.2 2.7 2.6 10.0 14.6 6.1 10.8 
C4% 4.7 7.6 5.8 13.5 8.7 11.4 2.1 5.0 
 225 
 
         Table 5.3 continued 
 Healthy Lean 
(n=27) 






 Median IQR Median IQR Median IQR Median IQR 
Raw Potato Starch 
Total SCFA 82.22 25.73 70.45 24.92 77.71 21.75 85.44 50.39 
C2 51.59 20.92 46.00 24.16 52.41 18.75 61.85 36.94 
C3 7.89 4.85 6.18 4.27 9.20 4.89 8.72 6.30 
C4 10.01 15.79 8.12 13.11 16.28 8.93 14.09 14.66 
C2% 67.85 16.14 66.83 18.75 61.30 10.71 68.87 14.85 
C3% 9.82 5.49 10.10 6.74 11.06 8.43 10.38 6.35 
C4% 13.62 13.92 12.45 16.33 20.21 11.57 16.83 16.64 
Wheat bran 
Total SCFA 72.62 17.53 68.42 18.02 70.53 12.66 74.12 17.74 
C2 45.12 10.51 46.82 16.28 39.14 11.21 47.31 13.62 
C3 9.87 4.01 9.24 5.62 10.78 7.99 10.86 6.45 
C4 11.74 8.08 9.61 6.08 15.15 11.02 9.41 6.38 
C2% 65.00 5.79 65.14† 16.10 57.89† 7.41 67.11 8.57 
C3% 13.03 5.13 12.35 8.82 15.20 7.93 14.66 6.38 
C4% 14.99 11.15 12.68† 8.84 18.56† 13.55 13.14 4.61 
C2; acetate, C3; propionate, C4; butyrate, concentration are expressed as µmol/ml while proportions are 
expressed as %, † indicate significant differences between hypoth. lean and hypoth. obese, ‡ indicate 




Figure 5.4: Concentration of total SCFA at the time of recruitment in all the groups after 24 h 
incubations. 
 
Blank circles represent outliers. HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, 
SO; simple obese. 
 
Figure 5.5: Concentration of total SCFA after 2-3 months in all the groups after 24 h incubations. 
 
Blank circles represent outliers. HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, 
SO; simple obese 
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Differences in the concentration and proportion of individual SCFA after 2-3 
months 
No peculiar pattern of higher or lower concentration and proportion of acetate and butyrate 
were seen in the any of the groups and in any substrate. However, consistent with samples 
at recruitment, tendencies towards higher concentration and proportion of propionate was 
observed in obese (simple and hypothalamic) than lean groups (hypoth. lean and healthy 
lean). Only the proportion of propionate was significantly higher in simple obese vs. 
healthy lean in apple pectin (median (IQR) C3%: simple obese; 12.02(12.96) vs. healthy 
lean: 8.56(3.06), p=0.02) (Table 5.4, Figure 5.8). Overall, there was a large variation in the 
simple and hypothalamic obese groups than hypothalamic lean and healthy lean groups in 
all substrates.  
Table 5.4: Concentration and proportion of total and major individual SCFA after 24 h incubation of 
faecal samples with different fibres and the blank after 2-3 months. 








Variable Median IQR Median IQR Median IQR Median IQR 
Blank 
Total SCFA 20.31 4.62 21.24 6.93 22.90 11.47 19.35 5.45 
C2 10.59 2.59 11.78 3.09 13.05 3.53 11.09 4.32 
C3 3.12 0.96 2.56 1.49 3.51 3.70 3.02 1.37 
C4 2.30 0.88 2.19 0.88 2.42 5.09 1.97 0.63 
C2% 54.09 6.43 61.96 12.20 56.40 21.79 57.31 10.00 
C3% 15.11 3.18 12.52 4.90 15.40 7.36 15.87 6.10 
C4% 11.94 3.29 10.51 1.71 10.83 7.57 10.18 3.00 
Apple Pectin 
Total SCFA 78.39 33.93 60.64 55.91 75.40 55.20 63.73 57.10 
C2 52.75 21.42 42.79 42.64 49.55 42.67 42.07 28.43 
C3 6.45 4.37 8.06 9.16 8.19 12.98 7.51 13.47 
C4 13.83 14.15 12.33 9.31 12.60 9.37 9.46 13.04 
C2% 71.35 8.41 70.57 9.16 67.64 16.90 70.92 23.87 
C3% 8.56* 3.06 7.26 11.90 13.93 14.17 12.02* 12.96 
C4% 18.04 9.84 18.16 12.07 17.20 5.04 11.23 22.24 
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         Table 5.4 continued 








Variable Median IQR Median IQR Median IQR Median IQR 
Maize Starch 
Total SCFA 69.35 18.03 68.88 28.74 64.20 59.30 73.76 28.82 
C2 41.60 15.27 39.26 24.34 36.11 34.24 47.67 28.94 
C3 6.09 2.54 6.36 4.65 8.50 18.62 8.58 14.00 
C4 15.62 7.81 14.02 11.26 14.43 14.52 13.10 10.80 
C2% 61.38 9.92 62.71 19.69 65.99 31.78 64.08 18.46 
C3% 9.13 3.23 9.38 6.76 9.38 25.44 12.43 11.75 
C4% 21.89 10.94 24.29 21.12 15.68 10.49 19.48 17.18 
Raftilose 
Total SCFA 89.09 23.75 81.97 31.67 94.19 39.31 82.06 24.99 
C2 76.73 21.93 53.11 35.97 73.50 47.08 70.65 35.50 
C3 4.41 4.13 2.48 7.60 7.60 25.91 6.39 11.01 
C4 4.25 5.02 8.64 19.45 6.61 9.91 2.57 4.52 
C2% 88.29 8.43 82.69 35.36 84.66 27.22 87.26 14.32 
C3% 6.06 4.75 3.86 7.49 6.54 24.64 9.14 11.75 
C4% 4.99 6.42 13.45 24.74 9.09 9.65 2.91 5.28 
Raw Potato Starch 
Total SCFA 79.98 25.89 71.48 32.83 73.40 47.10 89.36 37.72 
C2 47.22 18.69 43.78 19.85 49.02 41.62 58.18 24.35 
C3 5.75 5.00 5.09 6.54 11.05 9.55 6.88 8.45 
C4 17.06 9.35 10.57 10.72 15.34 12.26 11.99 14.17 
C2% 65.67 11.36 64.32 13.61 64.92 16.18 72.22 15.85 
C3% 9.07 4.97 8.59 7.08 14.92 10.71 10.93 8.70 
C4% 22.29 10.30 17.76 16.94 17.97 7.77 17.64 12.96 
Wheat bran 
Total SCFA 70.49 12.72 71.87 20.54 73.70 19.90 64.61 19.79 
C2 43.57 9.31 40.34 14.68 44.42 19.29 41.90 13.02 
C3 9.97 2.57 8.21 6.00 11.65 10.37 12.14 8.61 
C4 13.81 5.67 11.22 4.97 13.04 7.16 9.80 3.60 
C2% 61.22 7.32 61.79 10.42 60.24 15.55 59.90 14.32 
C3% 12.93 3.13 11.21 5.56 14.15 15.07 17.06 7.87 
C4% 18.24 6.31 17.80 10.50 17.18 7.42 15.64 9.16 
C2; acetate, C3; propionate, C4; butyrate, concentrations are expressed as µmol/ml. Proportions are 




Figure 5.8: Concentration of Propionate in 24 h incubated culture in all groups after 2-3 months. 
a) 
 
Blank circles represent outliers, * indicate significant differences. HC; healthy lean control, HL; 
hypothalamic lean, HO; hypothalamic obese, SO; simple obese. Note the huge variation in concentration and 
proportion of propionate in hypothalamic obese group. 
 
Figure 5.8b:Proportion of Propionate in 24 h incubated cultures in all groups for 
different fibres after 2-3 months. 
 
Blank circles represent outliers, * indicate significant differences. HC; healthy lean control, HL; 
hypothalamic lean, HO; hypothalamic obese, SO; simple obese. Note the huge variation in concentration and 




5.6.3 Change in pH and the production of SCFA between 0 h and 4 h of 
incubation 
It is likely that the rate of fermentation tends to slow down or plateau towards maximum at 
24 h. SCFA at the end point of fermentation (i.e. at 24 h) indicate only the total 
fermentation capability of the gut microbiota. However, it poorly indicates the rate or 
speed of fermentation and the rate at which this plateau or maximum levels are reached. 
Therefore, we measured the change in pH and change in total and individual SCFA 
between 0h and 4 h of incubation to estimate the rate of SCFA production.  This was 
assessed by calculating the difference between measurements at 4 h and 0h of incubation. 
Change in pH between 0-4 h at recruitment and after 2-3 months 
 No significant difference was seen in the change in pH between any of the groups in all 
substrates and the blank cultures both at recruitment and after 2-3 months (Table 5.5). 
Table 5.5: change in pH (ΔpH= pH at 4 h – pH at 0 h) for all substrates between 0 h and 4 h of 
incubation at recruitment and after 2-3 months. 
  Healthy Lean Hypoth. Lean Hypoth. Obese Simple Obese 
Variable Median IQR Median IQR Median IQR Median IQR 
Δ pH between 0 & 4 h at recruitment 
Apple Pectin -1.81 0.51 -1.77 0.35 -1.81 0.47 -1.93 0.39 
Blank 0.04 0.14 0.11 0.11 0.02 0.11 0.03 0.11 
Maize Starch -0.62 1.08 -0.7 1.42 -0.59 0.49 -0.58 0.68 
Raftilose -2.56 0.65 -2.32 0.61 -2.59 0.78 -2.44 0.73 
Raw Potato Starch -0.44 0.52 -0.23 0.53 -0.28 0.51 -0.34 0.95 
Wheat Bran -0.70 0.38 -0.58 0.24 -0.53 0.39 -0.65 0.45 
Δ pH between 0 & 4 h after 2-3 months 
Apple Pectin -1.75 0.74 -1.87 0.67 -1.98 0.61 -2.16 0.69 
Blank 0.04 0.10 0.06 0.44 0.04 0.31 0.04 0.22 
Maize Starch -0.69 0.62 -0.59 1.10 -0.99 1.69 -0.98 1.64 
Raftilose -2.46 0.44 -2.34 0.95 -2.57 0.60 -2.82 0.88 
Raw Potato Starch -0.43 0.50 -0.25 0.63 -0.66 1.04 -0.42 0.72 
Wheat Bran -0.62 0.26 -0.47 0.37 -0.69 0.47 -0.74 0.32 
 
Change in total and individual SCFA between 0-4 h at recruitment 
 Overall, no significant difference was observed in the change in total SCFA concentration 
between simple and hypothalamic obese groups. However, the two obese groups (simple 
obese in particular) showed an increased change in the concentration of total SCFA in all 
substrates than the two lean groups which was only significant in cultures containing wheat 
bran between hypothalamic obese and hypothalamic lean participants (p=0.02, Figure 5.9, 
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Table 5.6). As a general trend, hypothalamic obese group showed a tendency towards 
higher change in concentration and proportion of propionate and butyrate.  
Change in the concentration of propionate between zero and 4 h incubation was 
significantly higher in hypothalamic obese than hypothalamic lean group in the blank 
cultures (p=0.02), cultures containing maize starch (p=0.008), raftilose (p=0.02), and 
wheat bran (p=0.006) (Table 5.6, Figure 5.10). Similarly, hypothalamic obese group also 
showed a significantly higher change in the concentration of butyrate than simple obese 
(p=0.04, Table 5.6) and hypothalamic lean group (p=0.04, Table 5.6) only in the blank 
culture. 
 
Figure 5.9: Δ total SCFA expressed as μmol/ml between 0 h and 4 h incubation at recruitment. 
 
HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, SO; simple obese.*indicate 




Table 5.6: change in total and major individual SCFA between 0 h and 4 h of incubation at 
recruitment. 
 Healthy Lean Hypoth. Lean Hypoth. Obese Simple Obese 
Variable Median IQR Median IQR Median IQR Median IQR 
Apple Pectin 
Δ Total SCFA 33.69 14.76 26.83 11.06 31.47 9.84 37.77 21.26 
Δ C2 28.96 10.89 23.31 9.62 25.28 8.22 30.53 7.67 
Δ C3 3.05 3.38 1.74 1.65 4.14 3.54 2.33 7.72 
Δ C4 1.08 1.43 1.95 2.29 1.85 3.77 0.98 2.66 
Δ C2% 0.01 5.95 -2.70 13.56 -1.30 12.06 3.90 19.87 
Δ C3% 2.53 5.59 0.00 5.40 0.98 5.24 -1.22 13.30 
Δ C4% -2.41 8.70 1.00 7.47 1.67 7.63 -4.18 5.90 
Blank 
Δ Total SCFA 5.16 3.89 6.87 3.75 8.53 11.20 8.19 5.97 
Δ C2 3.62 1.77 4.54 1.99 5.35 6.95 5.02 3.31 
Δ C3 1.23 0.63 0.85† 0.38 1.45† 2.35 1.40 0.94 
Δ C4 0.51 0.83 0.58† 0.88 1.11†‡ 0.82 0.74‡ 0.74 
Δ C2% -9.60 11.04 -8.02 6.64 -11.48 11.40 -6.72 12.56 
Δ C3% 8.35 9.25 3.18 4.81 2.57 6.46 3.41 7.26 
Δ C4% -1.50 5.67 0.09 7.71 3.03 5.82 -1.84 6.55 
Maize Starch 
Δ Total SCFA 15.70 12.04 22.47 20.33 26.71 14.80 28.67 12.89 
Δ C2 11.41 10.28 17.39 16.92 17.56 9.07 18.39 13.53 
Δ C3 2.40 1.71 1.67† 1.16 4.4† 3.82 2.96 4.24 
Δ C4 1.29 1.19 1.46 2.31 2.85 2.53 1.38 2.01 
Δ C2% -4.34 14.26 -0.10 17.57 -4.61 11.48 0.93 16.58 
Δ C3% 3.91 6.28 -1.32 6.83 3.41 9.04 0.94 9.88 
Δ C4% -0.11 8.17 0.43 8.52 2.57 6.40 -2.89 5.37 
Raftilose 
Δ Total SCFA 47.29 22.94 38.23 11.27 44.31 17.22 51.18 33.64 
Δ C2 39.21 15.51 35.87 12.23 32.22 17.39 41.44 18.31 
Δ C3 2.57 4.40 1.31† 1.19 4.19† 5.69 1.96 6.75 
Δ C4 1.55 2.11 2.26 3.04 3.00 5.42 1.29 2.54 
Δ C2% 2.08 10.38 -1.24† 11.09 -9.95‡† 14.09 4.38‡ 14.62 
Δ C3% 1.16 4.51 -0.45 5.80 2.01 5.07 -1.50 12.14 
Δ C4% -2.96 7.64 0.88 6.88 0.39 11.26 -3.47 5.73 
Raw Potato Starch 
Δ Total SCFA 14.31 11.89 11.47 8.47 15.31 10.61 15.32 28.78 
Δ C2 8.57 8.96 8.64 5.63 9.25 8.82 11.77 23.06 
Δ C3 1.96 1.57 1.38 0.61 2.80 4.49 2.27 4.24 
Δ C4 0.91 1.18 1.09 1.43 2.05 2.22 1.13 1.85 
Δ C2% -4.26 8.16 -1.45 10.04 -12.57‡ 11.80 1.74‡ 16.59 
Δ C3% 4.48 6.60 1.91 6.20 6.26 7.48 0.36 11.43 
Δ C4% -1.38 7.09 -0.09 7.46 2.05 6.27 -4.47 5.85 
Wheat bran 
Δ Total SCFA 26.47 12.54 23.52† 5.15 31.65† 22.68 26.31 22.19 
Δ C2 17.70 9.72 18.14 4.60 21.65 12.80 19.86 14.69 
Δ C3 3.49 3.00 2.19† 0.76 5.04† 4.55 3.82 5.53 
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Δ C4 1.76 2.19 2.18 2.84 3.44 4.01 1.53 2.51 
Δ C2% -6.68 11.09 -4.39 12.57 -9.26 8.33 2.64 15.80 
Δ C3% 4.77 6.09 -0.07 3.67 4.89 5.92 1.44 10.45 
Δ C4% -0.55 9.92 2.14 10.02 3.17 6.97 -2.32 6.85 
C2; acetate, C3; propionate, C4; butyrate, Δ indicate change between 0 and 4 h (4 h- 0h), † indicate 
significant differences between hypothalamic lean and hypothalamic obese, ‡ indicate significant differences 
between hypothalamic obese and simple obese, (Mann Whitney U test). Concentrations are expressed as 
µmol/ml and proportion as %. 
 
Figure 5.10: Change in propionate (Δ) expressed as μmol/ml between 0 h and 4 h incubation at 
recruitment. 
 
HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, SO; simple obese. Blank circles 
represent outliers. * indicate p<0.05, ** indicate p<0.01 on Mann Whitney U test 
 
Change in total and individual SCFA production between 0 & 4 h incubation 
after 2-3 months 
Consistent with the results at recruitment, no significant differences were observed 
between simple and hypothalamic obese groups in the change in production of total SCFA 
between 0 h and 4 h incubation after 2-3 months. As a general trend, simple and 
hypothalamic obese groups, particularly the latter, had a higher change in the SCFA 
production than the two lean groups. Hypothalamic obese group showed a significantly 
higher change in total SCFA than hypothalamic lean group in cultures containing raw 
potato starch (p=0.04) and wheat bran (p=0.04) (Figure 5.11, Table 5.7) 
In terms of the concentration and proportion of individual SCFA, no significant 
difference was observed between simple and hypothalamic obese groups and between the 
two obese and the two lean groups in any of the substrates and the blank except that the 
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proportion of propionate was significantly lower in hypothalamic obese groups than 
hypothalamic lean group in the blank culture (p<0.05) (Table 5.7).  
Figure 5.11: Δ total SCFA expressed as μmol/ml between 0 h and 4 h incubation after 2-3 months. 
 
HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, SO; simple obese. 
* indicate p<0.05 on Mann Whitney U test 
 
Table 5.7: change in total and major individual SCFA between 0 h and 4 h of incubation after 2-3 
months. 
Delta B Healthy Lean Hypoth. Lean Hypoth. Obese Simple Obese 
Variable Median IQR Median IQR Median IQR Median IQR 
Apple Pectin 
Δ Total SCFA 30.62 13.78 31.20 11.08 31.27 24.36 31.35 11.81 
Δ C2 25.61 10.36 23.86 11.16 20.85 12.27 27.12 8.02 
Δ C3 2.54 1.87 1.15 3.31 2.69 7.94 2.86 5.10 
Δ C4 2.30 2.80 1.63 2.63 2.69 3.01 2.23 4.86 
Δ C2% 3.67 7.98 -1.03 12.46 -1.21 8.16 -2.00 8.49 
Δ C3% 0.22 3.61 0.18 3.15 0.43 9.68 0.20 4.21 
Δ C4% -2.64 6.76 -1.87 7.21 1.78 7.43 0.87 5.05 
Blank 
Δ Total SCFA 7.22 2.98 5.35 6.61 10.37 10.22 6.84 6.55 
Δ C2 4.17 2.11 4.11 3.77 6.94 6.38 4.31 3.89 
Δ C3 1.40 0.59 0.65 1.13 1.23 2.67 1.30 0.95 
Δ C4 0.86 0.72 0.72 0.98 1.17 1.11 0.90 1.15 
Δ C2% -9.43 10.10 -7.56 13.78 -4.89 23.14 -5.56 9.96 
Δ C3% 5.03 5.82 2.59† 5.11 0.44† 5.69 2.77 7.73 
Δ C4% -1.28 5.84 1.41 4.96 1.47 4.80 0.34 6.52 
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         Table 5.7 continued 
Delta B Healthy Lean Hypoth. Lean Hypoth. Obese Simple Obese 
Variable Median IQR Median IQR Median IQR Median IQR 
Maize Starch 
Δ Total SCFA 24.04 14.74 24.59 9.06 28.05 17.26 27.56 23.34 
Δ C2 16.45 10.16 17.58 9.73 19.72 11.43 16.50 17.87 
Δ C3 2.40 1.43 1.49 1.65 3.29 7.34 3.19 4.35 
Δ C4 2.61 2.05 2.10 3.21 3.45 1.65 2.73 4.45 
Δ C2% -1.58 13.77 -4.13 19.87 -5.26 15.15 -3.87 21.02 
Δ C3% 1.77 4.89 1.37 7.46 -1.25 10.89 0.20 6.38 
Δ C4% -2.26 6.60 0.57 8.63 2.74 6.77 1.54 6.96 
Raftilose 
Δ Total SCFA 48.48 21.89 37.94 24.28 41.22 29.19 49.49 22.44 
Δ C2 41.89 14.56 25.44 18.40 27.73 27.15 36.40 14.50 
Δ C3 2.36 3.93 1.00 2.34 2.78 13.28 3.23 9.74 
Δ C4 2.58 2.73 2.07 4.85 3.82 1.23 2.39 2.83 
Δ C2% 1.98 12.15 0.92 17.35 -2.41 19.56 1.34 15.46 
Δ C3% 0.20 8.17 -1.06 7.89 1.79 23.74 -0.30 9.09 
Δ C4% -2.14 7.10 -0.14 9.77 2.77 9.86 -1.24 7.84 
Raw Potato Starch 
Δ Total SCFA 16.33 10.24 10.68† 7.23 18.57† 11.64 21.61 16.48 
Δ C2 10.79 8.23 7.50 3.30 13.76 13.63 13.92 10.00 
Δ C3 2.14 0.94 1.36 2.04 2.19 4.07 3.05 3.01 
Δ C4 1.92 1.54 1.31 2.26 2.33 0.92 2.01 3.20 
Δ C2% -3.40 8.57 -11.14 22.34 -8.59 11.72 -2.55 14.87 
Δ C3% 2.21 6.28 3.59 7.66 2.22 13.03 0.42 8.55 
Δ C4% -2.26 6.30 3.07 10.02 3.58 4.46 0.00 7.73 
Wheat bran 
Δ Total SCFA 25.87 9.86 22.96 13.25 31.99 21.46 30.21 18.54 
Δ C2 18.55 6.41 16.48 6.97 19.68 12.44 19.40 7.01 
Δ C3 3.25 2.31 1.70 2.42 4.51 7.44 4.44 5.18 
Δ C4 3.08 2.54 2.52 3.28 3.76 3.92 3.14 4.85 
Δ C2% -4.51 12.89 -11.10 14.01 -7.17 7.58 -6.49 13.97 
Δ C3% 2.65 7.62 4.46 6.25 2.22 10.11 2.46 9.06 
Δ C4% -0.22 7.01 1.14 6.91 4.34 10.44 2.72 6.94 
C2; acetate, C3; propionate, C4; butyrate, Δ indicate change between 0 and 4 h (4 h- 0h), concentrations are 
expressed as µmol/ml and proportion as %, † indicate p<0.05 between hypoth. lean and hypoth. obese(Mann 
Whitney U test). 
 
5.6.4 Changes in pH and production of total and major individual SCFA 
at 24 h incubation over the period of follow-up 
Change (increase or decrease) in pH and total and major individual SCFA after 24 h 
incubation over the period of follow up was calculated by the difference of measurements 




Changes in pH after 24 h incubation over the period of follow-up 
No significant difference in the change in pH was observed between any of the groups 
except in wheat bran where the change was significantly higher in hypothalamic lean as 
compared to healthy lean participants (p=0.006, Table 5.8). 
Table 5.8: change in pH for all substrates at 24 h incubation between samples at recruitment and after 
2-3 months (change in pH= pH after 2-3 months– pH at recruitment). 
 Healthy Lean Hypoth lean Hypoth Obese Simple Obese 
Substrate Median IQR Median IQR Median IQR Median IQR 
Apple Pectin -0.01 0.63 -0.12 0.78 0.03 1.26 -0.39 0.88 
Blank -0.15 0.41 -0.25 0.49 0.06 0.52 -0.14 0.50 
Maize Starch -0.12 0.65 -0.22 0.80 -0.09 0.93 -0.36 0.29 
Raftilose -0.05 0.59 0.08 0.30 -0.05 0.50 -0.19 0.69 
Raw Potato Starch -0.02 0.42 -0.05 0.91 -0.23 1.60 -0.49 0.91 
Wheat Bran -0.26¥ 0.64 0.35¥ 0.66 0.02 0.92 -0.47 0.57 
¥ indicate p=0.006 between healthy lean and hypothalamic lean (Mann Whitney U test).IQR; Inter-quartile 
range 
 
Changes in total and major individual SCFA after 24 h incubation over the 
period of follow-up 
No significant difference in the change in concentration of 24 h total and major individual 
SCFA (acetate, propionate, and butyrate) were observed between samples incubated at 
recruitment versus those incubated after 2-3 months between any of the group and in any 
substrate (Table 5.9, Figure 5.12).  
The proportion of major individual SCFA (acetate, propionate, and butyrate) were 
not significantly different between any of the groups for most of the substrates. However, 
significantly higher change in the proportion of acetate was observed in healthy lean vs. 
hypothalamic lean in cultures containing apple pectin (p=0.032) (Table 5.9). Change in the 
proportion of propionate was significantly higher in hypothalamic lean vs. hypothalamic 
obese in cultures containing wheat bran [median (IQR) µmol/ml: hypoth. lean; 5.32(10.01) 
vs. hypoth. obese; -2.02(10.84), p=0.038] (Table 5.9) while change in the proportion of 
butyrate was significantly higher in cultures containing raw potato starch [median (IQR) 
µmol/ml: hypoth. lean; 6.45(11.51) vs. hypoth. obese; -3.88(17.15), p=0.042] (Table 5.9). 
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Figure 5.12: change in total SCFA after 24 h of incubation between the time of recruitment and after 
2-3 months (change in total SCFA= total SCFA after 2-3 months – total SCFA at recruitment). 
 
HC; healthy lean control, HL; hypothalamic lean, HO; hypothalamic obese, SO; simple obese. Dotted line 
indicates no change. Blank circles represent outliers 
 
Table 5.9: change in total and major individual SCFA after 24 h of incubation between recruitment 
and after 2-3 months (change in total SCFA= total SCFA after 2-3 months – total SCFA at 
recruitment). 
  Healthy Lean Hypoth lean Hypoth Obese Simple Obese 
Variable Median IQR Median IQR Median IQR Median IQR 
Apple Pectin 
Change in Total 
SCFA 
-14.28 43.81 0.59 47.14 2.10 64.60 -23.70 77.80 
Change in C2 -6.17 29.10 -1.43 33.91 2.41 39.23 -18.76 41.28 
Change in C3 -1.15 6.24 0.11 6.68 2.37 11.73 -0.08 12.74 
Change in C4 -1.54 9.64 2.37 10.98 3.37 17.35 -1.30 12.79 
Change in C2% -1.40¥ 8.35 -5.31¥ 12.42 -9.62 18.58 -4.53 25.57 
Change in C3% -0.09 5.70 1.38 11.39 2.00 10.08 -1.52 15.77 
Change in C4% -0.11 9.10 5.40 7.32 1.29 13.08 0.76 10.22 
Blank 
Change in Total 
SCFA 
-1.21 7.53 0.75 12.94 1.78 15.97 -0.39 8.42 
Change in C2 -0.23 2.55 0.13 8.56 1.96 7.10 1.00 5.21 
Change in C3 0.10 1.49 0.71 1.97 -0.12 4.04 -0.38 1.71 
Change in C4 -0.02 1.02 -0.26 1.27 -0.18 5.72 -0.03 1.12 
Change in C2% -0.08 8.97 0.39 7.57 1.03 25.17 -0.07 10.80 
Change in C3% 1.10 4.90 1.55 7.90 -1.14 3.95 -0.59 5.51 
Change in C4% 0.88 3.03 0.64 3.67 -1.03 13.41 1.05 4.31 
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         Table 5.9 continued 
  Healthy Lean Hypoth lean Hypoth Obese Simple Obese 
Variable Median IQR Median IQR Median IQR Median IQR 
Maize Starch 
Change in Total 
SCFA 
-5.45 24.88 5.92 26.22 8.97 42.65 4.75 32.49 
Change in C2 -4.43 12.58 -3.94 27.63 4.36 37.01 -8.71 22.88 
Change in C3 -0.59 6.07 0.67 6.86 0.63 17.50 0.84 10.72 
Change in C4 5.04 12.63 5.61 9.51 0.16 23.70 1.83 8.11 
Change in C2% -6.49 16.92 -10.38 25.36 -0.20 55.30 -0.47 14.66 
Change in C3% -1.25 8.40 1.09 12.21 -0.23 20.54 0.31 10.23 
Change in C4% 9.91 15.82 16.22 18.53 1.61 33.94 4.20 7.40 
Raftilose 
Change in Total 
SCFA 
-7.85 39.23 9.92 24.33 -3.00 27.10 -4.20 44.87 
Change in C2 -4.54 29.89 -2.99 24.25 1.77 35.30 -5.49 35.04 
Change in C3 -0.74 3.63 1.60 5.69 0.25 25.02 -0.53 8.41 
Change in C4 0.65 8.36 0.73 18.58 0.06 14.22 -0.27 2.53 
Change in C2% -0.73 19.15 -6.12 21.45 3.04 32.76 -0.98 16.14 
Change in C3% -0.24 7.10 2.99 6.12 -0.67 17.96 -1.35 8.12 
Change in C4% 0.77 8.68 0.09 20.57 1.89 9.66 0.21 1.79 
Raw Potato Starch 
Change in Total 
SCFA 
-3.42 23.32 0.08 34.20 -6.70 25.70 -4.13 34.77 
Change in C2 -7.40 28.91 -3.66 26.37 -3.20 42.50 -4.02 23.83 
Change in C3 -0.85 6.37 0.25 8.86 0.28 11.27 0.98 6.21 
Change in C4 4.25 10.06 4.32 5.19 2.06 22.37 1.76 13.56 
Change in C2% -9.65 16.89 -9.30 16.29 1.97 27.22 -4.54 20.57 
Change in C3% -1.40 5.96 0.34 7.80 3.68 6.61 0.30 4.26 
Change in C4% 7.27 12.22 6.45† 11.51 -3.88† 17.15 2.02 12.31 
Wheat bran 
Change in Total 
SCFA 
-3.73 23.73 -3.60 27.19 3.20 22.30 -5.60 46.80 
Change in C2 -3.30 8.42 -6.24 27.01 1.90 21.08 -6.74 17.25 
Change in C3 -0.76 5.07 2.58 7.85 -0.87 12.21 1.53 7.91 
Change in C4 1.27 11.33 2.32 6.17 -1.39 10.00 0.44 8.16 
Change in C2% -3.94 10.14 -7.32 18.05 1.31 18.64 -2.59 14.00 
Change in C3% 0.14 6.27 5.32† 10.06 -2.02† 10.84 1.24 6.71 
Change in C4% 3.87 13.43 6.68 11.86 -1.30 12.77 1.91 5.80 
C2; acetate, C3; propionate, C4; butyrate, † indicate significant differences between hypoth. lean and hypoth. 
obese, ¥ indicate significant differences between hypothalamic lean and healthy lean (Mann Whitney U test). 
Concentrations are expressed as µmol/ml and proportion as %. 
 
5.6.5 Changes in the rate of production (between 0-4 h incubation) of 
total and individual SCFA over the period of follow-up 
To assess the changes in the rate of production of total and major individual SCFA 
between incubated samples over the period of follow-up, the rate of production after 2-3 
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months was subtracted from the rate of production at recruitment for participants in all the 
groups.  
Change in the rate of production of SCFA= rate of production (between 0-4 h) after 2-3 
months – rate of production (between 0-4 h) at recruitment 
The change in the rate within each individual group (intra-group differences) and between 
different groups (inter-group differences) was then compared. 
Within the groups, only simple obese group showed a significant increase in the change in 
proportion of butyrate (Δ C4%) between samples at recruitment versus samples after 2-3 
months in cultures containing apple pectin [median(IQR)%: -4.18(5.89) vs. 0.87(5.05), 
p=0.004], maize starch [median(IQR)%: -2.88(5.37) vs. 1.54(6.96), p=0.02], raw potato 
starch [median(IQR)%: -4.46(5.86) vs. 0.00(7.71), p=0.036], and wheat bran 
[median(IQR)%: -2.32(6.86) vs. 2.72(6.94), p=0.02] (Figure 5.13).  
Figure 5.13: Change in the proportion of butyrate (ΔC4%) in simple obese group between 0 h and 4 h 
incubation between samples incubated at recruitment versus those incubated after 2-3 months. 
 
A; samples at recruitment, B; samples after 2-3 months. Blank circles represent outliers. * indicate p<0.05 




5.6.6 Differences in the rate of total and individual SCFA production 
between 0-4 h according to obese or lean phenotype and according 
to the presence or absence of pathology 
When participants were grouped together based on their lean (healthy lean and 
hypothalamic lean) or obese (simple and hypothalamic obese) phenotype, no significant 
differences were found in the 0-4 h rate of production of total and major individual SCFA 
both at the time of recruitment (Figure 5.13) and after 2-3 months (Figure 5.14). However, 
obese phenotype had a characteristically uniform and consistent tendency towards higher 
rate of total SCFA, acetate, propionate, and butyrate production than the lean phenotype 
both at the time of recruitment (Figure 5.13) and after 2-3 months (Figure 5.14).   
With regard to the proportion of individual SCFA, no significant difference was 
observed in the rate of change in the proportion of 0-4 h acetate, propionate, and butyrate 
both at recruitment and after 2-3 months. There was no peculiar pattern for the distribution 
of proportion of acetate and propionate both at recruitment and after 2-3 months. However, 
the proportion of butyrate at 2-3 months showed a consistent tendency to be non-
significantly higher in the obese phenotype than lean phenotype (Figure 5.16).  
When participants were grouped into pathological group (hypothalamic lean and 
obese) and healthy group (simple obese and healthy lean) based on the presence or absence 
of pathology, no significant difference or peculiar pattern of SCFA production was seen 
between the two groups. 
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Figure 5.14: : Boxplots showing the rate of change in the concentration of total and individual SCFA between 0-4 h according to obese and lean phenotype at recruitment 
 





Figure 5.15:  Boxplots showing the rate of change in the concentration of total and individual SCFA between 0-4 h according to obese and lean phenotype after 2-3 months 
 





Figure 5.16: Boxplots showing the rate of change in proportion of butyrate between 0-4 h according to 
obese and lean phenotype after 2-3 months. 
 
Blank circles represent outliers, C4; butyrate, Lean; healthy lean and hypothalamic lean, obese; hypothalamic 
obese and simple obese 
 
 
5.6.7 Correlation of BMI SDS with total SCFA production and the rate 
of SCFA production between 0-4 hour incubation at recruitment 
and after 2-3 months 
Spearman rank correlations were done to assess the correlation of BMI SDS with total 
SCFA production and the rate of SCFA production between 0-4 hour incubation at the time 
of recruitment and after 2-3 months.  
Correlation of BMI SDS with the total SCFA after 24 h incubation 
No significant correlations were found between BMI SDS and the total SCFA production 
after 24 h incubation at the time of recruitment in any of the groups for all the substrates. 
However, after 2-3 months, the healthy lean group showed significant negative correlations 
in cultures containing maize starch (R=-0.510, p=0.015), Raftilose (R=-0.468, p=0.028), 
and the blank cultures (R=-0.418, p=0.047) (Table 5.10). Similarly, hypothalamic obese 
showed significant negative correlations in cultures containing raftilose (R=-0.717, 
p=0.045) while hypothalamic lean group showed significant positive correlation in blank 
cultures (R=0.678, p=0.045) and (Table 5.10).  
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Correlation of BMI SDS with the rate of SCFA production between 0-4 h 
Consistent with total SCFA production after 24 h incubation at recruitment, no significant 
differences were seen in the rate of total SCFA production between 0-4 h incubation at the 
time of recruitment (Table 5.10). After 2-3 months, healthy lean group showed a 
significant negative correlation of BMI SDS with the rate of total SCFA production in 
cultures containing apple pectin (R=-0.452, p=0.039) and raftilose (R=-0.455, p=0.038). In 
contrast, BMI SDS in Simple obese group had a tendency towards positive correlation with 
the rate of SCFA production which was only significant in raw potato starch (R=0.612, 
p=0.026) (Table 5.10).    
Correlation of BMI SDS with the production of 24 h SCFA and the rate of 
SCFA production according to phenotype (lean or obese) and pathology 
(healthy or pathological) 
To assess the correlation of BMI SDS with SCFA production and rate of SCFA production 
based on their phenotype or the presence or absence of pathology, participants were 
grouped into lean and obese phenotype (based on phenotype) or healthy and pathological 
groups (based on pathology) (Table 5.11).  
No significant correlations were found in the 24 h total SCFA production at the 
time of recruitment and after 2-3 months in any of the groups (lean/obese or 
healthy/pathological) except for a positive correlation in cultures containing apple pectin in 
obese phenotype only at recruitment (R=0.469, p=0.021) (Table 5.11).  
Rate of SCFA production was significantly negatively correlated with BMI SDS 
with lean phenotype at recruitment only in cultures containing raftilose (R=-0.421, 






Table 5.10: Correlation of BMI SDS with total SCFA production after 24 h incubation and the rate of SCFA production between 0-4 h incubation at the time of recruitment and 
after 2-3 months in all the study groups. 
 Healthy Lean Control Hypothalamic Lean Hypothalamic Obese Simple Obese 
  At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months 
Variable R p  R p  R p  R p  R p  R p  R p  R p  
Total SCFA after 24 h incubation  
Apple Pectin -0.052 0.795 -0.355 0.105 -0.226 0.503 0.262 0.495 -0.578 0.062 -0.390 0.340 0.412 0.143 0.126 0.767 
Blank 0.062 0.765 -0.428 0.047* -0.280 0.404 0.678 0.045* 0.029 0.931 -0.380 0.353 0.528 0.052 0.204 0.661 
Maize Starch -0.263 0.185 -0.510 0.015* -0.281 0.402 -0.068 0.862 -0.279 0.406 -0.156 0.712 0.490 0.151 0.222 0.597 
Raftilose 0.141 0.483 -0.468 0.028* -0.047 0.890 0.234 0.545 -0.364 0.271 -0.717 0.045* 0.534 0.112 -0.032 0.940 
Raw Potato Starch 0.066 0.745 -0.247 0.267 -0.466 0.149 -0.167 0.651 0.315 0.346 -0.254 0.544 0.003 0.994 0.196 0.641 
Wheat Bran 0.014 0.945 -0.396 0.068 -0.405 0.217 0.265 0.776 -0.360 0.277 0.165 0.697 0.281 0.432 0.243 0.562 
Rate of SCFA production between 0-4 h     
Apple Pectin -0.058 0.788 -0.452 0.039* -0.203 0.550 -0.752 0.051† -0.279 0.435 -0.259 0.501 0.513 0.088 0.266 0.379 
Blank -0.247 0.233 -0.232 0.326 -0.108 0.753 -0.510 0.242 0.353 0.317 0.085 0.841 0.514 0.087 0.377 0.204 
Maize Starch 0.169 0.408 0.006 0.981 0.425 0.255 0.675 0.096 -0.217 0.548 0.215 0.578 0.258 0.419 0.304 0.313 
Raftilose 0.087 0.673 -0.455 0.038* 0.060 0.861 -0.679 0.094 -0.639 0.047 -0.319 0.403 0.319 0.313 0.391 0.187 
Raw Potato Starch 0.016 0.939 -0.056 0.808 0.219 0.517 -0.076 0.871 0.151 0.676 0.147 0.707 0.214 0.504 0.612 0.026* 
Wheat Bran 0.112 0.585 -0.257 0.260 -0.086 0.801 0.052 0.923 -0.038 0.916 0.265 0.492 0.610 0.412 0.473 0.102 




Table 5.11: Correlation of BMI SDS with total SCFA production after 24 h incubation and the rate of SCFA production between 0-4 h incubation at the time of recruitment and 
after 2-3 months according to their phenotype (lean or obese) and pathology (pathology and healthy). 
 Lean 
(Healthy & Hypoth. lean) 
Obese 
(Simple & Hypoth. obese) 
Healthy 
(Healthy lean & Simple obese) 
Pathology 
(Hypoth. Lean & Hypoth. obese) 
  At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months 
Variable R p R p R P R p R P R p R p R p 
Total SCFA after 24 h incubation      
Apple Pectin -0.249 0.131 -0.346 0.061 0.469 0.021* -0.180 0.422 0.014 0.928 -0.187 0.281 0.285 0.251 0.113 0.665 
Blank -0.064 0.709 -0.335 0.071 0.210 0.324 -0.138 0.550 0.202 0.194 -0.113 0.516 0.068 0.790 0.352 0.181 
Maize Starch 0.164 0.282 -0.281 0.132 0.038 0.881 -0.104 0.644 -0.263 0.111 0.091 0.605 0.246 0.236 -0.058 0.605 
Raftilose -0.077 0.648 -0.513 0.004 -0.024 0.910 -0.356 0.104 0.193 0.208 -0.294 0.087 0.225 0.369 -0.090 0.731 
Raw Potato Starch -0.086 0.609 -0.339 0.067 0.148 0.489 -0.175 0.437 0.147 0.339 0.067 0.701 0.319 0.197 0.015 0.955 
Wheat Bran -0.137 0.414 -0.224 0.235 0.325 0.121 -0.249 0.263 0.129 0.406 -0.177 0.309 0.113 0.657 0.055 0.833 
Rate of SCFA production between 0-4 h     
Apple Pectin -0.206 0.235 -0.326 0.091 0.237 0.288 0.063 0.779 0.146 0.375 0.048 0.788 0.220 0.381 -0.285 0.285 
Blank -0.272 0.108 -0.186 0.353 0.325 0.140 0.128 0.580 0.134 0.411 0.124 0.490 0.473 0.047* 0.236 0.398 
Maize Starch 0.180 0.286 0.090 0.655 0.210 0.925 0.204 0.363 0.318 0.043 0.281 0.113 0.205 0.414 0.455 0.077 
Raftilose 0.017 0.923 -0.421 0.026* -0.012 0.958 0.131 0.560 0.220 0.167 -0.046 0.794 0.186 0.459 -0.141 0.602 
Raw Potato Starch -0.046 0.787 -0.154 0.435 0.232 0.299 0.371 0.089 0.256 0.107 0.271 0.121 0.234 0.349 0.389 0.137 
Wheat Bran -0.041 0.808 -0.155 0.441 0.093 0.680 0.287 0.195 0.241 0.129 0.217 0.218 0.363 0.139 0.389 0.152 
R; Spearman Rank correlations, p; p-value, *indicate significant correlations (p<0.05), † indicate p=0.052 (Spearman Rank) 
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5.6.8 Correlation of BMI SDS with production of acetate, propionate, 
and butyrate after 24 h incubation at recruitment and after 2-3 
months 
Spearman rank correlations were done to assess the correlation of BMI SDS with acetate, 
propionate, and butyrate production after 24 hour incubation at the time of recruitment and 
after 2-3 months in individual groups.  
Correlation of BMI SDS with acetate in individual groups 
Significant negative correlations were observed between BMI SDS and acetate in cultures 
containing apple pectin in hypothalamic lean (R=-0.616, p=0.044) and raftilose in 
hypothalamic obese group (R=-0.680, p=0.031) only at the time of recruitment (Table 
5.12). 
Correlation of BMI SDS with propionate in individual groups 
A general tendency towards positive correlation of BMI SDS with propionate was 
observed in the two obese groups which was statistically significant only in the blank 
cultures with no substrates (R=0.583, p=0.029) and cultures containing apple pectin 
(R=0.676, p=0.008) only at the time of recruitment (Table 5.12). In contrast, healthy lean 
participants showed significant negative correlation of BMI SDS with propionate in 
cultures containing maize starch (R=-0.563, p=0.006) and a tendency in apple pectin 
(p=0.052), raftilose (p=0.072), and wheat bran (p=0.072) (Table 5.12). 
Correlation of BMI SDS with butyrate in individual groups 
Simple obese participants showed a tendency towards a positive correlation of BMI SDS 
with butyrate which was significant for raw potato starch (R=0.718, p=0.004) and wheat 
bran at recruitment and maize starch (R=0.627, p=0.022) after 2-3 months (Table 5.12). In 
contrast, healthy lean participants showed a tendency towards negative correlation of BMI 
SDS with butyrate which was statistically significant for apple pectin (R=-0.444, p=0.038), 
maize starch (R=-0.678, p=0.001), and raw potato starch (R=-0.538, p=0.010) after 2-3 
months (Table 5.12).  
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Table 5.12: Correlation of BMI SDS with acetate, propionate, and butyrate after 24 h incubation at recruitment and after 2-3 months. 
  Healthy Lean Control Hypothalamic Lean  Hypothalamic Obese  Simple Obese 
  At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months 
Variable R p  R p  R p  R p R p  R p  R p  R p  
Acetate production after 24 h incubation   
Apple Pectin 0.009 0.964 -0.415 0.055 -0.616 0.044* -0.290 0.485 0.372 0.290 -0.041 0.916 0.148 0.613 -0.404 0.171 
Blank culture 0.123 0.550 -0.256 0.251 0.226 0.503 -0.351 0.393 -0.500 0.141 0.593 0.121 0.104 0.723 -0.358 0.230 
Maize Starch -0.044 0.829 -0.020 0.928 -0.422 0.196 -0.022 0.959 -0.094 0.795 -0.269 0.484 0.147 0.601 -0.504 0.079 
Raftilose 0.028 0.890 -0.342 0.119 -0.156 0.648 -0.609 0.109 -0.680 0.031* -0.553 0.123 -0.226 0.437 -0.276 0.361 
Raw Potato Starch 0.058 0.772 0.088 0.698 0.041 0.904 -0.047 0.912 -0.102 0.780 -0.384 0.307 -0.008 0.977 -0.469 -0.106 
Wheat Bran 0.135 0.503 -0.173 0.441 -0.241 0.475 0.279 0.504 0.002 0.995 -0.363 0.337 0.008 0.977 -0.500 0.082 
Propionate production after 24 h incubation   
Apple Pectin -0.076 0.708 -0.419 0.052† -0.296 0.376 -0.039 0.928 0.509 0.133 0.038 0.923 0.676 0.008* 0.004 0.989 
Blank culture -0.003 0.989 -0.336 0.126 -0.033 0.922 -0.390 0.339 -0.171 0.637 0.326 0.430 0.583 0.029* 0.357 0.231 
Maize Starch -0.227 0.255 -0.563 0.006* -0.213 0.529 0.465 0.245 0.199 0.581 -0.058 0.882 0.384 0.158 0.005 0.987 
Raftilose -0.212 0.287 -0.388 0.075 -0.330 0.322 -0.053 0.900 0.346 0.328 0.109 0.780 0.617 0.019 0.271 0.371 
Raw Potato Starch -0.038 0.849 -0.298 0.178 0.247 0.463 0.050 0.907 0.153 0.673 0.109 0.780 0.309 0.282 0.049 0.875 
Wheat Bran 0.095 0.637 -0.391 0.072 -0.096 0.778 -0.109 0.798 0.229 0.524 -0.253 0.511 0.437 0.118 0.196 0.521 
Butyrate production after 24 h incubation   
Apple Pectin -0.186 0.354 -0.444 0.038* -0.194 0.567 -0.354 0.390 0.365 0.300 -0.149 0.701 0.455 0.111 0.520 0.069 
Blank culture -0.010 0.959 -0.285 0.199 0.237 0.483 -0.505 0.202 -0.323 0.362 -0.060 0.888 0.418 0.137 0.433 0.139 
Maize Starch -0.406 0.036 -0.678 0.001* 0.403 0.219 -0.162 0.701 -0.428 0.217 -0.107 0.784 0.422 0.117 0.627 0.022* 
Raftilose 0.063 0.753 -0.324 0.141 -0.048 0.899 -0.013 0.976 -0.113 0.755 0.054 0.899 0.422 0.133 -0.556 0.049* 
Raw Potato Starch -0.101 0.617 -0.538 0.010* 0.673 0.023 -0.453 0.260 -0.385 0.272 -0.143 0.713 0.526 0.053† 0.320 0.287 
Wheat Bran 0.029 0.885 -0.205 0.360 0.025 0.942 0.260 0.534 -0.487 0.153 -0.137 0.725 0.718 0.004* 0.551 0.051† 
* indicate p<0.05, † indicate p=0.05, R; Spearman Rank correlations, p; p-value, 
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Correlation of BMI SDS with the production of acetate, propionate, and 
butyrate 24 hour incubation according phenotype (lean or obese) and 
pathology (healthy or pathological) 
To assess the correlation of BMI SDS with acetate, propionate, and butyrate according to 
lean/obese phenotype or presence/absence of pathology, participants were grouped into 
lean (healthy and hypothalamic lean) and obese (simple and hypothalamic obese) 
phenotype or into pathological (hypothalamic lean and obese) and healthy (healthy lean 
and simple obese) groups.  
Correlations of BMI SDS with acetate, propionate, and butyrate according to 
phenotype 
Lean phenotype showed significant negative correlations of BMI SDS with acetate, 
propionate, and butyrate in most dietary substrates and the blank cultures particularly in 
samples collected after 2-3 months (Table 5.13). In contrast, obese phenotype showed a 
consistent tendency towards positive correlations of BMI SDS particularly with propionate 
and butyrate (Table 5.13).  
Acetate was significantly negatively correlated with BMI SDS in lean phenotype after 2-3 
months in cultures containing apple pectin (R=-0.384, p=0.036) and raftilose (R=-0.450, 
p=0.013) (Table 5.13). Obese phenotype only showed a significant negative correlation of 
BMI SDS with acetate only in cultures containing wheat bran in samples collected after 2-
3 months (R=-0.464, p=0.030). 
Propionate in obese phenotype was significantly positively correlated with BMI 
SDS in cultures containing apple pectin (R=0.592, p=0.002) at recruitment while lean 
phenotype showed significant negative correlations with raftilose (R=-0.350, p=0.031) at 
recruitment and in blank cultures (R=-0.374, p=0.042) after 2-3 months (Table 5.13). 
Butyrate showed strong negative correlations with BMI SDS in the lean phenotype 
for cultures containing apple pectin (R= -0.399, p=0.029), maize starch (R=-0.448, 
p=0.013), raw potato starch (R=-0.555, p=0.002), and the blank cultures (R=-0.466, 
p=0.013) after 2-3 months (Table 5.13). In contrast, no significant correlations between 
BMI SDS and butyrate were observed in the obese phenotype at recruitment as well as 




Correlations of BMI SDS with acetate, propionate, and butyrate according to 
pathology 
When participants were grouped according to the presence or absence of pathology, no 
significant correlations were found between BMI SDS and acetate, propionate, and 
butyrate at the time of recruitment or after 2-3 months, except a significant negative 
correlation of butyrate in healthy group in blank cultures after 2-3 months (R= -0.407, 
p=0.015). This was suggestive of negligible effect of pathology on the correlations of BMI 
SDS with individual SCFAs.  
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Table 5.13: Correlation of BMI SDS with acetate, propionate, and butyrate production after 24 h incubation according to phenotype (lean or obese) and presence or absence 
of pathology (pathological or healthy), at the time of recruitment and after 2-3 months.  
 Lean 
(Healthy & Hypoth. lean) 
Obese 
(Simple & Hypoth. obese) 
Healthy 
(Healthy lean & Simple obese) 
Pathology 
(Hypoth. Lean & Hypoth. Obese) 
  At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months At recruitment At 2-3 months 
 R p  R p  R p  R p  R p  R p  R p  R p  
Acetate production after 24 h incubation 
Apple Pectin -0.233 0.179 -0.384 0.036* 0.292 0.166 -0.288 0.193 -0.003 0.987 -0.284 0.098 0.227 0.364 0.075 0.775 
Blank culture 0.104 0.538 -0.099 0.604 -0.240 0.259 -0.155 0.503 0.021 0.893 0.012 0.945 -0.147 0.561 0.343 0.194 
Maize Starch -0.096 0.566 0.004 0.984 0.173 0.408 -0.312 0.157 0.188 0.217 0.177 0.309 -0.243 0.331 -0.050 0.850 
Raftilose -0.050 0.764 -0.450 0.013* -0.382 0.066 -0.348 0.113 0.119 0.441 -0.265 0.124 -0.137 0.588 -0.261 0.312 
Raw Potato Starch -0.083 0.619 -0.108 0.571 0.034 0.876 -0.282 0.204 0.161 0.296 0.218 0.208 0.243 0.331 0.027 0.917 
Wheat Bran 0.124 0.458 -0.012 0.950 0.096 0.657 -0.464 0.030* -0.316 0.201 -0.193 0.268 0.091 0.558 0.006 0.982 
Propionate production after 24 h incubation   
Apple Pectin -0.207 0.213 -0.209 0.268 0.592 0.002* -0.001 0.998 0.101 0.512 0.083 0.637 0.322 0.192 0.129 0.621 
Blank culture -0.171 0.311 -0.374 0.042* 0.320 0.127 0.156 0.499 0.175 0.262 0.012 0.944 0.285 0.251 0.412 0.113 
Maize Starch -0.213 0.199 -0.297 0.110 0.282 0.173 0.016 0.943 0.058 0.704 0.102 0.561 0.098 0.699 0.178 0.495 
Raftilose -0.350 0.031* -0.332 0.073 0.406 0.049 0.179 0.425 0.027 0.860 0.124 0.479 0.461 0.054† 0.279 0.278 
Raw Potato Starch -0.095 0.569 -0.204 0.280 0.212 0.321 0.023 0.919 0.084 0.586 0.102 0.561 0.321 0.194 0.320 0.210 
Wheat Bran -0.144 0.388 -0.326 0.078 0.347 0.097 0.030 0.894 0.179 0.244 0.110 0.529 0.380 0.120 -0.022 0.933 
Butyrate production after 24 h incubation   
Apple Pectin -0.228 0.169 -0.399 0.029* 0.395 0.056 0.142 0.528 -0.061 0.694 -0.269 0.119 0.181 0.471 0.082 0.752 
Blank culture -0.140 0.409 -0.460 0.011* -0.163 0.448 -0.065 0.779 -0.141 0.367 -0.407 0.015* 0.254 0.310 0.281 0.291 
Maize Starch -0.221 0.181 -0.448 0.013* 0.054 0.796 0.337 0.125 -0.100 0.513 -0.233 0.179 -0.060 0.814 -0.334 0.191 
Raftilose -0.023 0.893 -0.119 0.532 0.040 0.852 0.136 0.548 -0.100 0.517 -0.268 0.120 0.141 0.576 -0.019 0.942 
Raw Potato Starch -0.084 0.617 -0.550 0.002* 0.133 0.534 0.109 0.628 0.047 0.761 -0.334 0.050† 0.410 0.091 -0.113 0.666 
Wheat Bran -0.147 0.379 -0.160 0.399 0.147 0.492 0.160 0.477 -0.034 0.828 -0.215 0.215 0.242 0.333 0.083 0.752 
* indicate p<0.05, † indicate p=0.05, R; Spearman Rank correlations, p; p-value, 
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5.6.9 Differences in sample collection and processing time (in h) between 
the groups and its effect on SCFA production capability 
At the start of the study, the aim was to process all faecal samples in the laboratory within 
4 h after being produced. However, for reasons explained earlier, 40/151 samples (n=23 at 
recruitment and n=17 after 2-3 months) were processed more than 4h after they were 
produced. The median processing time was significantly higher in hypothalamic lean group 
than healthy lean group [median (IQR) h: hypoth. lean; 5.1(3.7) vs. healthy lean; 3.7(1.1)] 
(table 5.14, figure 5.17). 
Table 5.14: Comparison of sample processing times (time elapsed) between different groups at 
recruitment after 2-3 months 
Group Processing time at recruitment (h) Processing time at 2-3 months (h) 
  Median IQR Min Max Median IQR Min Max 
Healthy Lean  3.7† 1.1 2.7 9.0 3.6 1.6 1.6 9.0 
Hypoth. Lean 5.1† 3.7 4.0 13.6 4.5 3.6 2.5 8.0 
Hypoth. obese 4.0 1.5 3.1 7.0 3.5 2.3 3.0 10.0 
Simple Obese 3.7 3.5 2.5 10.0 3.5 1.7 2.0 12.7 
† indicate significant difference between healthy lean and hypothalamic lean at recruitment (Mann-Whitney 
U test). Min; minimum, max; maximum time elapsed in h, IQR; interquartile range. 
 
Figure 5.17: Individual value plot showing distribution of sample processing times in all the groups at 
recruitment (A, in black colour) and after 2-3 months (B, in red colour). 
 
A; sample processing time at recruitment, B; sample processing time after 2-3 months. Each dot represent a 




Whether SCFA production after 24 h incubations were affected by the difference in sample 
processing time was assessed by Spearman rank correlations. Hypothalamic lean group 
showed a consistent and strong negative correlation of SCFA production in apple pectin 
with sample processing time at recruitment (R= -82.8, p=0.001) and after 2-3 months (R= -
85.0, p=0.004) (table 5.15, figure 5.18, figure 5.19). Healthy lean group also showed a 
negative correlation of SCFA with sample processing time in cultures containing apple 
pectin at recruitment (R= -51.9, p=0.006) (Table 5.15, Figure 5.17) and in cultures 
containing maize starch (R= -0.432, p=0.040), raftilose (R= -0.440, p=0.036), and blank 
cultures (R= -49.4, p=0.017) after 2-3 months (Table 5.15, Figure 5.18). 
Table 5.15: Correlation of SCFA production at 24 h incubation with sample processing times 
(Spearman rank correlations) 







 R P R P R p R p  
Correlation of time elapsed with24 h total SCFA at recruitment 
Apple Pectin -0.519 0.006† -0.828 0.001† -0.603 0.065 -0.208 0.476 
Blank -0.318 0.113 0.138 0.670 0.306 0.389 -0.360 0.206 
Maize Starch -0.270 0.173 0.132 0.684 -0.155 0.668 -0.261 0.347 
Raftilose -0.363 0.063 -0.278 0.382 -0.057 0.876 -0.107 0.715 
Raw Potato Starch -0.122 0.546 0.190 0.554 -0.257 0.474 -0.036 0.902 
Wheat Bran 0.027 0.895 -0.448 0.144 -0.226 0.530 -0.440 0.116 
Correlation of time elapsed with24 h total SCFA after 2-3 months 
Apple Pectin -0.290 0.179 -0.851 0.004† -0.125 0.748 -0.147 0.632 
Blank -0.494 0.017* -0.637 0.065 -0.057 0.893 0.120 0.696 
Maize Starch -0.432 0.040* -0.369 0.329 -0.016 0.967 -0.100 0.746 
Raftilose -0.440 0.036* -0.717 0.030* -0.309 0.418 0.337 0.260 
Raw Potato Starch -0.302 0.161 -0.462 0.211 -0.189 0.626 -0.045 0.883 
Wheat Bran -0.276 0.203 -0.201 0.604 0.051 0.896 0.142 0.642 
*indicate p<0.05, † indicate p<0.01, R; Spearman rank correlation, p; p-value 
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Figure 5.18: Scatter plot showing correlation/association of 24 h SCFA with sample processing time (in 
h) for different dietary substrates at recruitment 
 
Figure 5.19: Scatter plot showing correlation/association of 24 h SCFA with sample processing time (in 
h) for different dietary substrates after 2-3 months 
 
Black dots; healthy lean, Red dots; hypothalamic obese, Purple dots; hypothalamic lean, Blue dots; simple 
obese 
Correlations analysis showed strong negative correlations of hypothalamic lean and 
healthy lean group with the sample processing times across different substrates. However, 
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general regression analysis adjusted for participants’ group (used as an interaction term) 
showed significant negative associations of 24 h total SCFA production with sample 
processing time independent of the participants group both at the time of recruitment and 
after 2-3 months. General regression analysis (adjusted for participant groups) showed 
significant negative associations between sample processing time (in h) and the production 
of total SCFA after 24 h incubation in cultures containing apple pectin, both at recruitment 
(β= -6.274, R2-adj=16.46%, p=0.001) and after 2-3 months (β= -4.597, R2-adj=10.01%, 
p=0.010). Furthermore, significant negative associations between sample processing time 
and total SCFA production in samples after 2-3 months were also seen in cultures 
containing maize starch(β= -2.954, R2-adj= 10.37%, p=0.016), raftilose (β= -3.425, R2-
adj=7.59%, p=0.007), and blank cultures (β= -0.6900, R2-adj=12.02%, p=0.041). 
Marginally significant effect (p=0.048) of hypothalamic obese group was seen only in 
cultures containing maize starch after 2-3 months.  
5.7 Discussion 
Despite an exceptional diversity of complex dietary carbohydrates in human diets, our 
metagenome encodes only few enzymes for the digestion of oligo- and polysaccharides. 
The majority of these complex non-digestible, fermentable carbohydrates are degraded by 
a wide array of enzymes secreted by up to 1000 known species of gut microbiota into short 
chain fatty acids which contribute up to 10% towards our daily energy needs (75). Whether 
this energy generating capability depends on the resident gut microbiota in obese people or 
whether the nature of diet modulates the efficiency of gut microbiota in these people is 
controversial.  
To the best of our knowledge this is the first study to address the cause or effect 
relationship between gut microbiota and obesity by comparing obese groups of known and 
unknown aetiology. Our results suggest no major difference in the fermentation capacity of 
gut microbiota between simple and hypothalamic obese patients which indicates that the 
increased energy harvesting capability of gut microbiota reported in other studies may not 
be causally attributed to obesity. Differences in diet and energy intake, physical activity, 
genetic propensity towards obesity, or other environmental factors between lean and obese 
populations may cause changes in the gut microbiota that in turn determine the changes in 
energy extraction capability from the diet. Moreover, non-significant differences in the 
production of total SCFA after 24 h incubation between the lean and obese groups also 
suggest a similar but slightly increased energy harvesting capability in obese than lean 
group which may indicate that increased harvesting capacity in obese individuals follows 
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obesity onset. With lower than anticipated study participants and several comparisons 
necessary to explore differences between the groups using a Mann-Whitney U test might 
have resulted in false discovery and over-interpretation of some significant results. Results 
from differences in p-value greater than 0.01 but less than 0.05 should therefore be 
interpreted with caution. Furthermore, very high interquartile range in our study 
participants particularly in our obese group reduced the chances of observing significant 
results.  
These results are in accordance with findings from Sarbini et al.(2011) (405) who 
found no significant difference in the fermentation capacity of gut microbiota between lean 
and obese adults incubated with galacto-oligosaccharides or inulin. Similarly, in the study 
by Yang et al. (2013) (172), no significant difference was observed in total SCFA 
production after 24 h incubation. Additionally, Payne et al. (2012) (95) observed a similar 
response of normal and high energy nutrient load on the production of SCFA in continuous 
cultures of faecal bacteria between lean and obese children. Whereas these results agree 
with our findings, these studies are limited by fewer study numbers, methodological issues, 
and fewer dietary substrates tested. Our study had a larger cohort and we included a control 
group. Most of the samples (111/151, ~73% samples) were analysed within 4 h after being 
produced and were maintained with an anaerobic and cold environment. Furthermore, we 
analysed the fermentation capacity with a range of dietary fibres producing different 
pattern of SCFA to test our hypothesis compared to less substrates in previous studies.  
Reduction in pH in the gut lumen implicates changes in the gut luminal milieu and 
increased SCFA production particularly due to the formation of SCFA particularly acetate, 
which in vivo, enhances the absorption of sodium and water from the lumen (406). Lower 
pH in the incubated samples of our simple obese patients compared to lean group after 2-3 
months was suggestive of increased SCFA production particularly acetate. However, in 
contrast to our expectations, there was a net decrease in the proportion of acetate after 2-3 
months which might indicate active utilization of acetate into butyrate or less likely, 
propionate. As shown in figure 5.12, the rate of change in the proportion of butyrate in 
simple obese group increased by approximately 5% in the second sample after 2-3 months 
compared to samples at recruitment which might indicate utilisation of acetate to butyrate 
by acetate-utilising butyrate-producing bacteria. However, butyrate can also be produced in 
the gut by conversion of lactate to butyrate by lactate-utilizing butyrate-producing bacteria 
such as E. halii and Anaerostipes caccae strains which have been shown to convert lactate 
to butyrate when pH of the gut lumen decreases (86). However, we did not measure lactate 
levels in our incubated samples that could give an indication of any activity of this cross-
feeding pathway. Moreover, in-vitro conditions with only one dietary fibre substrate per 
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culture unlike diverse food components in the gut in vivo may not be the ideal environment 
to allow and establish these cross feeding pathways and matrix interactions in the 
fermentation vessels. 
Measuring total and individual SCFAs give an idea about the total production but 
the rate at which these SCFA are produced tend to reduce over the period of incubation due 
to substrate exhaustion and end product inhibition in the in-vitro batch cultures. So we 
estimated the rate of production by calculating the difference of total and individual SCFA 
between 0 and 4 h incubation. Consistent with the total amounts after 24 h, the rate of 
production of total SCFA and acetate production was similar between the two obese 
groups. Simple and hypothalamic obese groups had a tendency towards a higher rate of 
change in SCFA production than the two lean groups particularly propionate and butyrate 
which suggested that gut microbiota of obese participants are efficient in energy extraction 
compared to the lean. In support of this, the rate of SCFA production between 0-4 h 
incubation was positively correlated with BMI SDS in obese phenotype but not in lean 
phenotype.  
A significantly higher rate of propionate production between 0-4 h incubation and 
tendency towards higher concentration and proportion of propionate after 24 h in obese 
(simple and hypothalamic obese) compared to lean groups (healthy lean and hypothalamic 
lean) suggested increased propionate producing capability of the gut microbiota in obese 
phenotype irrespective of the aetiology of obesity. Furthermore, production of propionate 
was positively correlated with BMI SDS within the obese phenotype. These findings 
further re-confirmed our results from the faecal samples where we observed increased 
concentration and proportion of propionate in obese (simple and hypothalamic obese) than 
lean groups (healthy lean and hypothalamic lean). Similar results were also shown by other 
studies in the form of lower acetate to propionate ratio (405) and increased concentration 
and proportion of propionate (172) in obese adults compared to lean. 
As discussed in chapter 4 section 4.7, higher levels of propionate have been 
associated with hypocholesterolemia, reverse cholesterol transport (96), improved satiety 
through hormone PYY, and decreased meal size via increased leptin (97). Furthermore, it 
has been shown to exert antiproliferative action on colon cancer cells in experimental cell 
models (98). The capability of gut microbiota of obese participants to produce this 
beneficial propionate consistently across different dietary substrates suggests higher 
propionate-producing bacteria residing in the colon of obese patients. Several studies have 
found higher faecal propionate in obese versus lean children and adults along with higher 
relative abundance of propionate producing Bacteroidetes (95, 172, 176, 350). 
Bacteroidetes express a diverse range of glycosyl-hydrolases capable of degrading a 
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variety of exogenous dietary and endogenous host glycans allowing this group of bacteria 
to survive in diverse ecological systems, not only in the gut. As reported in our study in 
chapter 3, section 3.6.7, and also in a population based study (340), obese people consume 
significantly lower amounts and proportions of dietary fibre and higher amount of readily 
available carbohydrates such as simple sugars (which are absorbed from the small 
intestine) compared to lean population. This suggests that endogenous source of host 
glycans might be an important and predominant source due to low fibre intake and hence 
might indicate a ―stress situation‖ of low fibre intake. The capability of obese groups to 
ferment dietary substrate to produce propionate at a much higher rate than lean groups 
might therefore be an indication of the ability of obese gut ecosystem to be well-equipped 
for the low-fibre stress. This might also indicate that the gut microbiota re-shape 
themselves according to the type of substrate available for utilisation in the gut. 
Tendency to produce higher butyrate across most of the dietary fibres was observed 
in the hypothalamic obese group at recruitment.  Furthermore, BMI SDS was significantly 
positively correlated with butyrate production in the obese phenotype but not in lean 
phenotype. This could either be due to increased production of butyrate by butyrate 
producing bacteria or increased production of butyrate by conversion of acetate or lactate 
to butyrate by acetate- and lactate-utilising bacteria such as Roseburia spp. /E. rectale 
group (166). As discussed in previous chapter, section 4.7 and also given that the amount 
of dietary substrate and faecal slurry added to the batch cultures were the same, this trend 
of increased butyrate was also seen in the spot faecal samples of the same group which 
strengthens our assumption that higher butyrate in this group might be due to a higher rate 
of conversion of acetate or lactate to butyrate. This trend towards higher butyrate and 
lower acetate reversed at follow up in hypothalamic obese group accompanied by an 
increased pH, indicating that the increased butyrate in the samples at presentation might 
have been mainly due to the utilization of acetate or lactate into butyrate (166).  
Children and young adults attending Yorkhill endocrine and dietetic clinic are 
monitored for changes in weight and general growth while they are following a prescribed 
healthy diet and physical activity. However, during the course of the recruitment, a very 
high rate of non-attendance to the clinic appointments was observed by the researcher 
suggesting low compliance. No significant changes in dietary macronutrients intake were 
observed within the groups except for a significant increase in percentage intake of daily 
protein in simple obese group and in percentage intake of recommended dietary fibre in 
healthy lean group (chapter 3, section 3.5.9.1). Despite this, a non-significant decrease in 
median BMI SDS (↓ΔBMI SDS) was observed in all the groups over the period of 2-3 
months (chapter 3, Table 3.5). Accordingly, the fermentation capacity of gut microbiota 
 261 
 
decreased in the two obese groups for most of the fibres after 2-3 months. Although 
changes in the concentration of total and major individual SCFA were not significantly 
different between and within the groups, significant changes in the proportion of SCFA 
within the groups (such as increase in the rate of change in butyrate in simple obese) 
suggested that dietetic weight management might beneficially affect the pattern of SCFA 
production although the total SCFA concentration remains unchanged. Simple obese 
groups showed significantly higher proportion of butyrate at follow up than at presentation 
in all fibres except raftilose. This indicates that shifts in the metabolic priorities of gut 
microbiota towards beneficial SCFA with weight management might be more important 
than the actual change in total energy production. Whether this response is an effect of 
altered dietary behaviour or it was an effect of a changed pattern of gut microbiota with 
dietetic weight management was further assessed by the estimation of dietary intake by 24 
h food diary and next generation sequencing of the faecal gut microbiota. Analysis of 24 h 
food diary showed a significant increase only in the percentage intake of proteins in simple 
obese group. This might be expected to increase the fermentation of proteins to branched 
chain fatty acids rather than butyrate depending on the amount of the available fibre and 
composition of gut microbiota. Alternatively, pathways of butyrate production might have 
been activated in simple obese group by butyrate producing bacteria such as 
Roseburia/E.rectale group. Although faecal gut microbiota profile showed increased 
butyrogenic Roseburia species belonging to the phylum Firmicutes in obese groups, this is 
yet to be confirmed in the samples obtained from in-vitro fermentation studies as we did 
not study the gut microbiota in faecal samples obtained via in-vitro fermentation. Lastly, 
this discrepancy between the changes in dietary intake in obese participants and changes in 
rate of SCFA production in simple obese group may be due to lack of compliance and 
significant under-reporting of the diet in this group.  
The human gut ecosystem is a symbiotic association of aerobic and anaerobic 
(obligate and facultative) microbiota, the association being outweighed by the anaerobes. 
The overall fermentation capability and the pattern of SCFA production might be affected 
by the relative abundance of gut microbiota in vivo. In our study, there was a significant 
impact of the sample processing time on the production of SCFA in cultures containing 
apple pectin, maize starch, raftilose and the blank cultures both at the time of recruitment 
and after 2-3 months independent of the study group.  
Evidence regarding the effect of sample storage at room temperature, cold (0 
o
C or 4 
o
C) or freezing conditions (-20 
o
C or -80 
o
C) on the relative abundance of the gut microbial 







C, and -80 
o
C) and various storage conditions for 3 or 14 days on the soil (n=2), 
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skin, and faecal gut microbial communities analysed by high throughput 16S rRNA 
sequencing (298). Clustering of the gut microbiota communities was observed based on the 
individual sample community and not based on the temperature and storage conditions. 







C, and -80 
o
C (298). Similar results were also found in study by Roesch et 
al.(2009) in faecal samples from 4 study subjects after 72 h storage of faecal sample at 
room temperature (407). Carroll et al. (2012) in their study on two healthy and two IBS 
patients found no significant difference in the relative abundance of Firmicutes, 
Bacteroidetes, Proteobacteria, and Actinobacteria after storage for 24 h at room 
temperature and another subset of samples for 6 months at -80 
o
C (297). Although overall 
phylogenetic diversity of gut microbiota remained stable, these studies did observe changes 
at lower (family) level taxa [such as significant increase in Lachnospiraceae at -20
o
C 
storage, reduction in Bacteroideaceae at -80 
o
C in study by Lauber et al. (2010) and non-
significant increase in Actinobacteria over 24 h in study by Carrol et al. (2012)]. Lower 
taxonomic level changes in gut microbiota might influence the fermentation capacity of the 
specific dietary substrates in in-vitro batch cultures such as that of apple pectin by 
members of Bacteroideaceae.  Furthermore, the sample size of these studies was too small 
to account for inter-individual variations. Study by Hervais et al. (2005) found no effect of 
storage of sample at 0 
o
C for 3 or 6 h or freezing at -18 
o
C for 24 h on the cellulose and 
starch degradation and gas production by ruminal microbiota (408). McBurney and 
Thompson observed similar substrate fermentibility rankings with oat bran, wheat bran, 
kidney beans, and guar gum for all 6 faecal sample donors despite the difference in the 24 
h SCFA and gas production (381). SCFA and gas production were affected by the source 
of inoculum, the substrate, and the interaction of the inoculum with the substrate (381). 
This suggests that the differences seen in our study may not be solely attributable to the 
processing time of the sample analysis but other factors related to the study participants 
and the nature of the dietary substrate might also be playing a role in determining 
differences in fermentation capacity of gut microbiota. In this context, differences in the 
functionality of gut microbiota (SCFA production) in our study with time might represent 
natural variation in the study subjects and not the effect of difference in sample processing 
time. However, the effect on the composition of microbiota on this difference in 
functionality is not known to us in this study and will be an interesting future aspect to 
investigate.  
Total SCFA production in apple pectin showed a consistent negative correlation with 
the processing time of the sample in our study. Apple pectin is fermented by 
Bifidobacteria, Lactobacilli, Bacteroides fragilis, and Enterococci (397). Although 
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significant reduction in the ratio of Firmicutes to Bacteroides have been reported due to 
long term storage (>50 days) in -80 
o
C, a non-significant reduction in Bacteroideaceae was 
also observed by Lauber et al. (2010) in short term (up to 24 h) storage as mentioned above 
(298). Therefore a reduction in the population of Bacteroidetes might have reduced the 
extent of SCFA production from fermentation of apple pectin in our study. However, study 
conducted by Hoyos et al. (2014) on faecal sample incubated with apple pectin in obese 
and lean rats found that the obese rats faecal cultures incubated with apple pectin as a 
substrate resulted in significant reduction in the relative abundance of Bacteroidetes 
compared to obese cultures without apple pectin (390). The relationship of apple pectin 
with Bacteroidetes is therefore controversial and needs further investigation. 
5.8 Conclusion 
In conclusion, our results from in-vitro batch culture fermentation studies suggest that 
fermentation capacity of the gut microbiota do not differ between obesity of different 
aetiology implicating that factors other than gut microbiota energy harvesting capability 
may be causally related to the aetiology of obesity. Differences between lean and obese 
phenotypes are blunted by inter-individual variations particularly in the obese groups. 
Significantly higher rate of propionate production in obese vs. lean groups is in 
confirmation with our findings from faecal samples. Furthermore, processing time of the 
samples negatively affects the production of SCFAs independent of phenotype and 
pathology. 
Whether no difference in functionality extends to the composition of gut microbiota has 
been explored in subsequent chapter.
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 Chapter 6: Preliminary Analysis of the Gut Microbiota 
Composition in Simple and Hypothalamic Obesity 
6.1 Outline 
We explored gut bacterial metabolic activity in previous sections to see any difference 
between simple and hypothalamic obese groups. No differences were observed in the 
faecal metabolites, so the energy harvesting capability of the gut microbiota was further 
explored by in-vitro fermentation studies which confirmed findings from spot faecal 
samples. Whether changes exist in gut microbiota composition between the different 
aetiology of obesity and against lean controls was further studied by applying next 
generation sequencing of the 16S rRNA gene. This chapter outlines preliminary results of 
this analysis. 
Note: Although in the original plan of this PhD we wanted to study selected gut bacteria 
through quantitative polymerase chain reaction (qPCR), the continuous decreasing cost of 
high throughput sequencing and emerging collaborations with world leading 
bioinformaticians within the team allowed us to explore the global faecal 
microenvironment with these state-of-the-art techniques in all samples from our 
participants.   
6.2 Introduction 
The continuous increase in prevalence of obesity worldwide is attributed to several factors 
such as consumption of energy dense foods, sedentary lifestyle, and familial predisposition 
but none of these fully explain the aetiology of obesity (15). Obesity is a polygenic 
disorder but only a small proportion (up to 10%) of obesity is attributed solely to the 
mutations in the expression of obesogenic traits (such as leptin gene) in obese population 
(14).  
Gut microbiota residing primarily in the proximal colon; carry a whole 
metagenome which out-numbers human metagenome by 100 times.  Since this ―microbial 
organ‖ has close ties with the physiology of the host and outer environment at the same 
time, several biochemical functions such as energy harvest from complex polysaccharides 
to produce SCFA, production of vitamins such as B6 and B12 and other hormonal effects 
are established in the human host through this relationship with gut microbiota. 
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6.2.1 Gut microbiota as a cause of obesity 
Recently, gut microbiota have been suggested as one of the environmental factors that 
might affect host energy storage and homeostasis (162). Gut microbiota transplanted into 
the germ-free mice resulted in ~60% increase in body fat and plasma insulin despite 
reduced chow intake. Gut microbiota were shown to stimulate hepatic de novo lipogenesis 
by the expression of carbohydrate response element binding proteins and sterol response 
element binding protein 1, stimulation of hepatic triglyceride storage by supressing fasting 
induced adipocyte factor, and decrease hepatic and muscle fatty acid oxidation (89). 
Further to this, evidence also suggested increased energy harvesting capability in the form 
of SCFA in obese than lean animals (159) and humans (164). Gut microbiota were also 
shown to play a key role in chronic low-grade inflammation commonly found in obesity 
(168).  These aspects were discussed in detail in preceding chapters of this thesis. 
Phylum-wide differences in gut microbiota composition with higher relative 
abundance of Firmicutes and lower Bacteroidetes were shown in obese than lean 
phenotype(162). This finding was supported by several other studies from genetic animal 
models of obesity (203) and  diet-induced animal models of obesity (211). However, data 
from human subjects suggested species and genus level differences between lean and obese 
such as Lactobacillus reuteri (237), E. coli (170), and Staphylococcus aureus(239) (chapter 
1, table 1.5 & 1.6).  The mere presence of the gut microbiota in conventionally raised mice 
compared to amicrobiotic environment in germ-free mice was enough to show higher 
levels of energy metabolites such as pyruvic acid, citric, fumaric, and malic acid, and 
higher rate of clearance of cholesterol and triglycerides (213).  
The association of changes in markers of aberrant metabolism with gut microbiota 
supported the causative role of gut microbiota composition in metabolic syndrome. 
Reversal of metabolic abnormalities with weight loss were shown to be associated with 
reversal of Firmicutes to Bacteroidetes ratio suggesting that changes in glucose and lipid 
metabolism in an individual might be influenced by changes in gut microbial composition. 
Furthermore, the manipulation of the gut microbiota such as introduction of Bifidobacteria 
have been shown to improve diabetes and endotoxemia (184). Colonic fermentation pattern 
determine the energy harvesting capability from the diet and a higher Firmicutes to 
Bacteroidetes ratio in obese than lean people have been shown to be positively correlated 
with the production of SCFA in the colon (176). Additionally, the anti-obesity effect of 
conjugated linoleic and linolenic acid derived from polyunsaturated fatty acid in obese 
women were shown to be produced by the action of Bifidobacteria, F. prausnitzii, and 
Lactobacilli. Both linoleic and linolenic acid stimulate PPARα and PPARγ receptor to 
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exert anti-inflammatory effects and also improve lipid and glucose metabolism (increase 
HDL, reduce LDL cholesterol, increased insulin sensitivity). The production of these 
compounds from dietary PUFA is unaffected by intervention with prebiotic which suggest 
that indigenous gut microbiota might be determining this potential (242). Gut microbiota 
relative abundance at various taxonomic levels in obese versus lean people and their 
relationship with pattern of faecal or caecal SCFA has been shown to differ between 
different studies as discussed in chapter 1 (Table 1.6, Table 1.10).    
Evidence regarding this causative role was further supported by human mono- and 
dizygotic twin studies which showed that obese related twins and their mothers had had 
lower microbial diversity, shared community structure (higher Firmicutes and lower 
Bacteroidetes in obese than lean) and metabolic pathways (Firmicutes enriched with 
transport system genes and Bacteroidetes enriched with carbohydrate metabolism genes) 
for the degradation of dietary substrate compared to lean (409). Developments in the field 
of metagenomics revealed differences in the functionality of gut microbiota i.e. the 
expression of genes related to distinct metabolic pathways in lean versus obese. Microbiota 
of obese animals and humans were shown to have low gene counts related to metabolic 
functions (410) and expressed genes involved in detoxification, stress response, and 
biosynthesis of cobalamin, essential and non-essential amino acids, and gluconeogenic 
pathways (212, 214, 409, 410). On the other hand, lean animals and humans exhibited 
genes capable of synthesizing vitamin B6, fermenting plant polysaccharides, butyrate, and 
propionate (212, 214, 409, 410). Furthermore, the transmissibility of compositional and 
functional characteristics from obese to lean animals (159) and vice versa (212) in 
experimental studies strengthened the causative role of gut microbiota in determining host 
energy homeostasis.  
The above mentioned evidence suggested a causative role of gut microbiota in the 
aetiology of obesity. However, data from both animal and human studies hint towards 
certain limitations in these studies that need to be taken into account when interpreting 
these results.  For example, germ-free animals with ―amicrobiotic environment‖ were 
suggested to be resistant to obesity by Backhed et al.(162); however, study by Fleissner et 
al. (2010) contradicted this finding as GF mice in their study developed 2-3 fold more 
weight than CONV mice on a high fat diet and the phylum wide differences in gut 
microbiota were driven by a single class of Erysipelotrichaceae in Firmicutes (165). 
Moreover, evidence also suggested that structural differences between lean and obese may 
not be consistent and may not be important from functional prospects as some studies 
found high Firmicutes to Bacteroidetes ratio in lean than obese subjects but these 
differences were unrelated to the metabolic differences in the two groups (220, 224). Yet 
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others found no differences in the gut microbiota community and metabolic activity 
between lean and obese adults (260). Some gut microbes such as L. reuteri associated with 
obesity are used as probiotics supplements which have been shown to reduce the 
absorption of non-cholesterol sterols from the gut through deconjugation of intraluminal 
bile acids, reduce low-density lipoproteins and apolipoprotein B compared to placebo 
(411).  
Furthermore, differences in the anatomy and physiology of animal models from 
that of humans is documented and extrapolation of findings in experimental studies may 
therefore need careful revision. Additionally, differences in the metabolome and 
microbiome has been observed even between different strains of the same animal models 
(such as C57BL/6J vs. C57BL/6N) (228). Some differences might also be attributed to the 
gender of the experimental animals as suggested by Won et al. (2013) (214).This, in 
addition to other methodological, host, and environmental differences in experimental 
conditions add to the complexity of the relationship. The exact mechanism of how these 
changes might affect obesity phenotype is still not known. 
6.2.2 Gut microbiota as a consequence of obesity 
Although differences in gut microbiota between lean and obese phenotype were observed 
in studies but the effect of diet in determining this capacity was outlined as a primary 
driver than the gut microbiota themselves (217). Differences in dietary patterns between 
lean and obese create a peculiar environment that suits both gut microbiota and host to 
maintain this symbiotic relationship albeit at a new threshold that may result in increased 
energy harvest and obesity (166). Changes in gut microbiota have been observed with 
changes in dietary habits such as anorexia nervosa (236). Patients with this dietary 
behaviour have been shown to have higher methanogens than lean and obese (236). Some 
interventional studies reported changes in gut microbiota with change in proportion of 
macronutrients in isocaloric diets (223), while others reported changes in energy harvest 
with changes in the nutrient load (95, 265) or caloric restriction coupled with exercise 
(263). Change in the nature of the diet such as a switch over to a strictly vegetarian diet 
was shown to improve markers of the metabolic syndrome (170). Using diet, dietary 
supplementation with prebiotics, or diet with live cultures of gut microbiota (probiotics) as 
therapeutic alternative for the treatment of obesity has therefore been attempted to treat 
diet-induced obesity-related increase in metabolic alteration (193, 412).  However, the gut 
microbiota restructure or develop ―resistance‖ to the intervention over the period of weeks 
to months to blunt the effect of pre-, pro- or antibiotics (413). Faecal transplantation 
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studies attempted in human studies reported changes in the gut microbial community and 
improvement in the insulin sensitivity and markers of inflammation at least until the period 
of follow-up (414). However, the authors observed a gradual decrease in response and 
restructuring of gut microbiota over the period of 4 weeks. The fact that germ free animals 
were able to develop the obese phenotype upon transplantation of gut microbiota from lean 
or obese donors might have been due to the lack of immunogenic response that develops 
after birth and after exposure to environmental antigens (415). Additionally, these animals 
develop alternative preferential metabolic pathways to meet the body energy requirements 
such as reduced energy expenditure compared to CONV mice and the ability to absorb 
more glucose compared to conventionalised animals (165). This highlights the importance 
of innate immune and genetic factors of the host that could potentially affect the 
colonisation of certain preferred set of gut microbiota in early infancy and hence the 
metabolic phenotype.  
Pattern of colonisation of gut microbiota in early infancy and childhood may 
influence the immune status and community structure of the gut microbiota in later life. 
Children born through normal vaginal delivery harbour gut microbiota communities 
broadly similar to their parents (138, 147, 150) while those born via caesarean section 
harbour gut microbiota unrelated to maternal gut microbial community. Additionally, the 
presence of certain species and genera (such as Staphylococcus aureus) in early childhood 
are correlated with obesity while others with leanness (such as Bifidobacteria) in later life 
(229). Population based studies suggest that children exposed to antibiotics within 6 
months of their life are prone to develop obesity in later childhood  (251) which indicate 
the role of antibiotics in modulation of gut microbiota and hence energy balance. 
Furthermore, children exposed to the commonly used antibiotic amoxicillin  had lower 
Bifidobacteria and Bacteroides compared to children not exposed to antibiotics (150). 
Although obesity in childhood potentially contributed by gut microbiota is associated with 
obesity in adulthood in 50-70% of cases, only 20% of obese adults are reported to be obese 
during their childhood (20). The link between obesity in childhood and obesity in 
adulthood is therefore missing and the role of gut microbiota in this missing link is still 
poorly understood. 
6.2.3 Conclusion and aim of this chapter 
On the balance of evidence, the debate remains to determine whether gut microbiota cause 
obesity or they are a consequence of a changed dietary pattern in obese population to 
harvest increased energy from the diet. We attempted to prove this ―reverse causality‖ by a 
human observational study; comparing two groups of obese children/young adults, one 
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with a known of cause of obesity (such as Prader Willi Syndrome or craniopharyngioma) 
and another with no known cause of obesity (commonly referred to as simple obesity or 
classical obesity). Our hypothesis was based on the assumption that if gut microbiota were 
to be implicated as a cause of obesity, we would expect to see differences in the gut 
microbiota between obesity of different aetiology and vice-versa if they were an effect of 
diet. Bacterial metagenome was sequenced by high throughput next generation sequencing 
to address this hypothesis. 
This is an on-going research project. 16S rRNA gene amplification using barcoded fusion 
primers was done initially to sequence bacterial metagenome of all our participants which 
is still under statistical bio-informatics analysis. Furthermore, metagenomic libraries were 
created for 96 samples from participants in all our groups to look into the differences in 
functional representation of genes in obesity of different aetiology. However, due to time 
restraints for the timely completion of this PhD, we have only been able to present the 
preliminary analysis of the data from 16S rRNA gene sequencing while data for microbial 
metagenomics is not included in this thesis and will be published as soon as it is analysed. 
6.3 Patients and methods 
6.3.1 Patients 
Detailed description of participants and the methods used is given in chapter 2. Briefly, 
simple obese (n=16), hypothalamic obese (n=10), and hypothalamic lean (n=12) 
participants were recruited from the endocrine and dietetic clinics at Royal Hospital for 
Sick Children Glasgow. Healthy lean (n=27) participants were recruited from the 
community. Two faecal samples along with body composition data and 24 h food diary 
were collected from each participant at an interval of 2-3 months as described in chapter 2, 
section 2.2.4. 
6.3.2 Laboratory methods (details in chapter 2, section 2.3.10) 
Preparation of the amplicon pool 
Genomic bacterial DNA was extracted from all faecal samples using chaotropic method 
discussed in detail in chapter 2, section 2.3.9). 16S rRNA gene of the double stranded 
DNA was amplified by polymerase chain reaction targeting V4 region of the 16S rRNA 
gene using barcoded fusion reverse primers (Golay barcoded primers) (chapter 2, section 
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2.3.10.1). Each amplified sample was subjected to agarose gel electrophoresis (1% agarose 
gel in 1X TAE buffer) followed by extraction of DNA bands under UV light (chapter 2, 
section 2.3.10.2). Each DNA band was purified using QIAquick gel extraction kit (Cat. no. 
28705 QIAGEN® Germany) (chapter 2, section 2.3.10.3). The concentration of resultant 
purified DNA was measured by Qubit® 2.0 flourometer (life® technologies, USA) 
(chapter 2, section 2.3.10.4).    
Emulsion PCR and sequencing 
Emulsion PCR followed by sequencing was done on illumina® Miseq platform 
(illumina®, USA) with 2 x 250 bp reads. This was done in Bioscience laboratory, 
University of Birmingham as we did not have these facilities within the University of 
Glasgow at the time of this study. The principle of this procedure is given in chapter 2, 
section 2.3.10. 
6.4 Bioinformatics and Statistics 
For the gut microbiota analysis, sequence reads from illumina Miseq® were filtered for 
quality to reduce ubiquitous artefacts. They were further followed by trimming to a fixed 
length, overlapped and consensus determined, chimeras were removed and operational 
taxonomic units (OTUs) constructed with UPARSE at 3% sequence difference (416). 
OTUs are groups of sequences that are intended to correspond to taxonomic clades or 
monophyletic groups. UPARSE is a recently devised pipeline (software) for the 
construction of OTUs by Edger (416). The reads were also taxonomically classified using 
the RDP stand-alone classifier. After filtering, only samples with more than 10,000 reads 
were used in the following analysis. To determine the impact of obesity, pathology and the 
result of dietary intervention on community structure, two-way nested permutational 
multivariate analyses of variances were performed using genera frequencies or UParse 3% 
OTU frequencies. Bray-Curtis distances were used following normalisation of relative 
frequencies. 
Values for the relative abundance of gut microbiota were expressed as median 
percentage relative abundance and the frequency was expressed as log10 logarithmic scale. 
Kruskal-Wallis non-parametric ANOVA was used to calculate differences (significant at p-
value <0.05) between the groups. To account for false positive or false negative significant 
differences due to multiple comparisons, Benjamini-Hochberg false discovery rate test 
(expressed as pa) was used and pa value <0.1 was considered significant. Non-metric 
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multidimensional scale (NMDS) plots were used to show the position of the bacterial 
community structure in relation to obese or lean phenotype. The NMDS scale is expressed 
as rank order of the bacterial community (and not the absolute or relative abundance). To 
group the similar communities, Bray-Curtis distances using matrix of dissimilarities were 
used. 
All bioinformatics analysis and statistics discussed below was performed by Dr 
Christopher Quince and Dr Umar Ijaz from the School of Engineering, University of 
Glasgow. 
6.5 Results 
Two way nested permutational multivariate analysis of variance showed no significant 
differences in community genera composition between the  sample at recruitment and after 
2-3 months)  (R
2
=0.00364, Pr (>F) =0.9298) and OTU composition (R
2
=0.00333, Pr (>F) 
=0.9974). Hence, all subsequent analysis was done combining all the samples at both time 
points (samples at recruitment + samples after 2-3 months) considering them as biological 
replicates of each other. 
6.5.1 Relative abundance of gut microbiota composition 
6.5.1.1 Phylum level differences in relative abundance between the groups 
Relative abundance of majority of the phyla detected in the participants were contributed 
by Firmicutes (66.8%) and Bacteroidetes (16%), followed by Actinobacteria (11.9%) 
(Table 6.1, Figure 6.1). No significant differences in the relative abundance of major phyla 
were observed between simple and hypothalamic obese groups except Proteobacteria 
which was significantly higher in hypothalamic obese group compared to simple obese 
group (hypoth. obese; 4.3% vs. simple obese; 1.5%, p<0.05). Additionally, healthy lean 
group had a significantly higher relative abundance of Verrucomicrobia compared to 
simple obese group (healthy lean; 4.1% vs. simple obese; 0.70%, p<0.01) (Table 6.1, 
Figure 6.1). Phylum Archaea, consisting of methanogens, were not detected in simple 
obese group in contrast to the healthy lean participants.  
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Figure 6.1: Percentage relative abundance of different phyla in all the groups (samples at the time of 
recruitment are combined with samples after 2-3 months) 
 
Different colours in the bars represent specific phyla given on the right.* indicate significant difference of 
Proteobacteria in hypothalamic obese group from simple obese. ** indicate significant difference of 
Verrucomicrobia in healthy lean from the simple obese group 
 
Table 6.1: Relative abundance of phylum level gut microbial composition in all the groups 
Phylum level 
taxonomy 









Firmicutes 66.80 65.70 67.50 68.60 67.50 
Bacteroidetes 16.00 14.40 12.70 12.00 14.10 
Actinobacteria 11.90 13.30 13.80 13.20 16.00 
Verrucomicrobia 2.80 4.10 2.20 1.60 0.70 
Proteobacteria 2.30 2.10 3.30 4.30 1.50 
Euryarchaeota 0.10 0.30 0.20 0.10 0.00 
Synergistetes 0.00 0.00 0.20 0.00 0.00 
Cyanobacteria 0.00 0.10 0.00 0.00 0.10 
Tenericutes 0.00 0.10 0.00 0.00 0.00 
Fusobacteria 0.00 0.00 0.00 0.10 0.00 
Acidobacteria 0.00 0.00 0.00 0.00 0.00 
Gemmatimonadetes 0.00 0.00 0.00 0.00 0.00 
Lentisphaerae 0.00 0.00 0.00 0.00 0.00 
Spirochaetes 0.00 0.00 0.00 0.00 0.00 
TM7 0.00 0.00 0.00 0.00 0.00 
Figures in bold indicate significant differences between the groups 
6.5.1.2 Class level differences in relative abundance between the groups 
Differences in relative abundance at phylum level extended to the class level taxonomy. 
The difference between hypothalamic obese and simple obese in phylum Proteobacteria 












































simple obese; 0.40%, p<0.01) (Table 6.2, Figure 6.2). However, despite no differences in 
Firmicutes at phylum level, the relative abundance of Bacilli, belonging to Firmicutes, was 
significantly different between the hypothalamic obese group and simple obese group 
(hypoth. obese; 3.20% vs. simple obese;1.00%,  p<0.01)  (Table 6.2, Figure 6.2). This 
indicates that differences at higher taxonomic level may not be sufficient to reveal 
differences at lower taxonomic levels which can impact the metabolism of the gut 
microbiota within and between the groups.   
Figure 6.2: Percentage relative abundance of different classes in all the groups (samples at the time of 
recruitment are combined with samples after 2-3 months) 
 
Different colours in the bars represent specific classes given on the right.* indicate significant difference of 
Bacilli in hypothalamic obese group from all other groups. ** indicate significant difference of 
Gammaproteobacteria in hypothalamic obese from the simple obese group, *** indicate significant 


















































Table 6.2:  Relative abundance of Class level gut microbial composition in all the groups 
 
*indicate significant differences between the two highlighted groups in a given row 
 
Phylum Class Total (%) Healthy Lean (%) Hypoth. Lean (%) Hypoth. Obese 
(%) 
Simple Obese (%) 
Firmicutes Bacilli 1.30 0.90 1.00 3.20* 1.00* 
 Clostridia 64.80 64.30 66.10 64.60 66.10 
 Erysipelotrichia 0.70 0.40 0.40 0.70 0.40 
 CK-1C4-19 0.00 0.00 0.00 0.00 0.00 
 RF3 0.00 0.00 0.00 0.10 0.00 
Bacteroidetes Bacteroidia 16.00 14.40 12.70 12.00 14.10 
 Flavobacteria 0.00 0.00 0.00 0.00 0.00 
 Sphingobacteria 0.00 0.00 0.00 0.00 0.00 
Actinobacteria Actinobacteria 11.90 13.30 13.80 13.20 16.00 
Verrucomicrobia Verrucomicrobia 2.80 4.10* 2.20 1.60 0.70* 
Proteobacteria Alphaproteobacteria 0.10 0.00 0.70 0.00 0.10 
 Betaproteobacteria 0.70 0.70 1.10 0.70 0.70 
 Deltaproteobacteria 0.40 0.50 0.30 0.30 0.40 
 Epsilonproteobacteria 0.00 0.00 0.00 0.00 0.00 
 Gammaproteobacteria 1.10 0.90 1.20 3.30* 0.40* 
Euryarchaeota Methanobacteria 0.10 0.30 0.20 0.10 0.00 
 Thermoplasmata 0.00 0.00 0.00 0.00 0.00 
Synergistetes Synergistia 0.00 0.00 0.20 0.00 0.00 
Tenericutes Mollicutes 0.00 0.10 0.00 0.00 0.00 
Cyanobacteria 4C0d-2 0.00 0.10 0.00 0.00 0.10 
 Chloroplast 0.00 0.00 0.00 0.00 0.00 
Fusobacteria Fusobacteria 0.00 0.00 0.00 0.10 0.00 
Gemmatimonadetes Gemm-5 0.00 0.00 0.00 0.00 0.00 
Lentisphaerae Lentisphaeria 0.00 0.00 0.00 0.00 0.00 
Spirochaetes Spirochaetes 0.00 0.00 0.00 0.00 0.00 
 Brachyspirae 0.00 0.00 0.00 0.00 0.00 
TM7 TM7-3 0.00 0.00 0.00 0.00 0.00 
Acidobacteria Acidobacteria-2 0.00 0.00 0.00 0.00 0.00 
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6.5.1.3 Order level differences in relative abundance between the groups 
At order level taxonomy, hypothalamic obese group had significantly higher relative 
abundance of Aeromonodales and Enterobacteriales in class Gammaproteobacteria than 
simple obese group (Aeromonodales: hypoth. obese; 0.80% vs. simple obese; 0.00%, 
p<0.01 and Enterobacteriales: hypothalamic obese; 1.60% vs. simple obese; 0.30%, 
p<0.01) (Table 6.3). 
6.5.1.4 Family level differences 
Differences in Aeromonodaceae and Enterobacteriaceae belonging the phylum Firmicutes 
were also observed at family level (Aeromonodaceae: hypoth. obese; 0.80% vs. simple 
obese; 0.00%, p<0.01 and Enterobacteriaceae: hypothalamic obese; 1.60% vs. simple 
obese; 0.30%, p<0.01) (Table 6.4). In addition, differences observed in Bacilli at class 
level between hypothalamic obese and simple obese were more pronounced in family 
Lactobacillaceae (Lactobacillaceae: hypoth. obese; 1.20% vs. simple obese; 0.50%, 





Table 6.3: Relative abundance of Order level gut microbial composition in all the groups 








Euryarchaeota Methanobacteriales 0.10 0.30 0.20 0.10 0.00 
 E2 0.00 0.00 0.00 0.00 0.00 
Firmicutes Bacillales 0.00 0.00 0.00 0.00 0.00 
 Gemellales 0.00 0.00 0.00 0.00 0.00 
 Lactobacillales 1.20 0.80 1.00 3.10* 0.90* 
 Turicibacterales 0.10 0.10 0.00 0.10 0.10 
   3.00 3.00 2.80 3.20 2.80 
 Clostridiales 51.60 51.90 57.50 49.40 52.50 
 Coriobacteriales 10.20 9.30 5.90 12.00 10.90 
 Desulfitobacterales 0.00 0.00 0.00 0.00 0.00 
 SHA-98 0.00 0.00 0.00 0.00 0.00 
 Erysipelotrichales 0.70 0.40 0.40 0.70 0.40 
Fusobacteria Fusobacteriales 0.00 0.00 0.00 0.10 0.00 
Bacteroidetes Bacteroidales 16.00 14.40 12.70 12.00 14.10 
 Flavobacteriales 0.00 0.00 0.00 0.00 0.00 
 Sphingobacteriales 0.00 0.00 0.00 0.00 0.00 
Actinobacteria Actinomycetales 0.10 0.10 0.20 0.20 0.10 
 Bifidobacteriales 11.80 13.10 13.60 13.00 15.90 
Verrucomicrobia Verrucomicrobiales 2.80 4.10* 2.20 1.60 0.70* 
Cyanobacteria YS2 0.00 0.10 0.00 0.00 0.10 
 Streptophyta 0.00 0.00 0.00 0.00 0.00 
Proteobacteria Caulobacterales 0.00 0.00 0.00 0.00 0.00 
 RF32 0.10 0.00 0.70 0.00 0.10 
 Rhizobiales 0.00 0.00 0.00 0.00 0.00 
 Rickettsiales 0.00 0.00 0.00 0.00 0.00 
 Sphingomonadales 0.00 0.00 0.00 0.00 0.00 
 Burkholderiales 0.70 0.60 1.10 0.70 0.70 
 Neisseriales 0.00 0.00 0.00 0.00 0.00 
 Desulfovibrionales 0.40 0.50 0.30 0.30 0.40 
 Campylobacterales 0.00 0.00 0.00 0.00 0.00 
 Aeromonadales 0.20 0.20 0.00 1.50* 0.00* 
 Enterobacteriales 0.70 0.60 1.00 1.60* 0.30* 
 Oceanospirillales 0.00 0.00 0.00 0.00 0.00 
 Pasteurellales 0.10 0.10 0.10 0.10 0.00 
 Pseudomonadales 0.10 0.10 0.10 0.10 0.00 
 Xanthomonadales 0.00 0.00 0.00 0.00 0.00 
Synergistetes Synergistales 0.00 0.00 0.20 0.00 0.00 
TM7   0.00 0.00 0.00 0.00 0.00 
Tenericutes Anaeroplasmatales 0.00 0.00 0.00 0.00 0.00 
 RF39 0.00 0.10 0.00 0.00 0.00 
   0.00 0.00 0.00 0.00 0.00 
Gemmatimonadetes Victivallales 0.00 0.00 0.00 0.00 0.00 
Lentisphaerae Spirochaetales 0.00 0.00 0.00 0.00 0.00 
Spirochaetes Brachyspirales 0.00 0.00 0.00 0.00 0.00 
   0.00 0.00 0.00 0.00 0.00 
Acidobacteria  0.00 0.00 0.00 0.00 0.00 
*indicate significant differences between the two highlighted groups in a given row. 
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Table 6.4: Relative abundance of family level gut microbial composition in all the groups 












Euryarchaeota  Methanobacteriaceae 0.10 0.30 0.20 0.10 0.00 
Acidobacteria   0.00 0.00 0.00 0.00 0.00 
Actinobacteria Actinomycetaceae 0.10 0.10 0.20 0.20 0.10 
  Un-named 1.10 1.50 0.70 1.10 1.80 
 Bifidobacteriaceae 10.6 11.6 12.9 11.9 14.1 
Bacteroidetes Bacteroidaceae 4.70 4.80 7.90 4.40 4.20 
 Porphyromonadaceae 0.40 0.60 0.50 0.80 0.40 
 Prevotellaceae 9.10 5.10 2.30 6.10 8.30 
 Rikenellaceae 0.70 1.50 1.10 0.30 0.40 
 S24-7 0.30 0.70 0.00 0.10 0.10 
 Barnesiellaceae 0.40 0.80 0.60 0.20 0.30 
 Odoribacteraceae 0.10 0.20 0.20 0.10 0.10 
 Paraprevotellaceae 0.30 0.70 0.20 0.10 0.40 
Cyanobacteria   0.00 0.10 0.00 0.00 0.10 
Firmicutes Lactobacillaceae 0.40 0.00 0.10 1.20* 0.50* 
 Streptococcaceae 0.80 0.80 0.90 1.90* 0.40* 
 Turicibacteraceae 0.10 0.10 0.00 0.10 0.10 
  Un-named 3.00 3.00 2.80 3.20 2.80 
  Un-named 1.30 2.30 1.10 1.70 0.70 
 Catabacteriaceae 0.10 0.20 0.10 0.00 0.10 
 Christensenellaceae 0.00 0.10 0.00 0.00 0.10 
 Clostridiaceae 0.40 0.40 0.50 0.40 0.30 
 Lachnospiraceae 24.4 23.2 27.1 26.8 23.5 
 Peptococcaceae 0.10 0.00 0.00 0.00 0.00 
 Peptostreptococcaceae 1.00 1.10 1.00 1.80 1.20 
 Ruminococcaceae 16.5 19.4 18.6 11.8 18.3 
 Veillonellaceae 7.80 5.20 8.90 6.90 8.20 
   2.80 3.10 2.50 2.30 3.00 
 Coriobacteriaceae 7.40 6.30 3.40 9.70 7.90 
 Desulfitobacteraceae 0.00 0.00 0.00 0.00 0.00 
 Erysipelotrichaceae 0.30 0.10 0.10 0.40 0.10 
 Coprobacillaceae 0.30 0.30 0.30 0.40 0.20 
Fusobacteria Fusobacteriaceae 0.00 0.00 0.00 0.10 0.00 
Lentisphaerae Victivallaceae 0.00 0.00 0.00 0.00 0.00 
Proteobacteria Desulfovibrionaceae 0.40 0.50 0.30 0.30 0.40 
  Un-named 0.10 0.00 0.70 0.00 0.10 
 Alcaligenaceae 0.70 0.60 1.10 0.70 0.60 
 Burkholderiaceae 0.00 0.00 0.00 0.00 0.00 
 Oxalobacteraceae 0.00 0.00 0.00 0.00 0.00 
 Neisseriaceae 0.00 0.00 0.00 0.00 0.00 
 Campylobacteraceae 0.00 0.00 0.00 0.00 0.00 
  Un-named 0.10 0.10 0.00 0.70 0.00 
 Aeromonadaceae 0.10 0.10 0.00 0.80* 0.00* 
 Enterobacteriaceae 0.70 0.60 1.00 1.60* 0.30* 
 Pasteurellaceae 0.10 0.10 0.10 0.10 0.00 
 Moraxellaceae 0.10 0.10 0.10 0.10 0.00 
Spirochaetes Spirochaetaceae 0.00 0.00 0.00 0.00 0.00 
 Brachyspiraceae 0.00 0.00 0.00 0.00 0.00 
Synergistetes Dethiosulfovibrionaceae 0.00 0.00 0.00 0.00 0.00 
 Synergistaceae 0.00 0.00 0.20 0.00 0.00 
TM7  Un-named 0.00 0.00 0.00 0.00 0.00 
Tenericutes Anaeroplasmataceae 0.00 0.00 0.00 0.00 0.00 
  Un-named 0.00 0.10 0.00 0.00 0.00 
Verrucomicrobia Verrucomicrobiaceae 2.80 4.10* 2.20 1.60 0.70* 
*indicate significant differences between the two highlighted groups in a given row. 
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6.5.2 Richness of Operational taxonomic units (OTU) in all groups 
There was a significant relationship (p-value = 0.0227) between group and rarefied OTU 
richness. However, both obese groups (simple and hypothalamic obese) had a lower 
diversity relative to Lean groups (healthy and hypothalamic lean) (Figure 6.3). 
Figure 6.3: Boxplots of rarefied OTU richness in all groups. 
 
Colour coding for the groups is given on the right of the figure. Individual dot represent each participant. 
OTU; operational taxonomic unit based on 97% similarity 
6.5.3 Impact of obesity and pathology on the community genera 
composition 
To determine the impact of obesity, pathology and the result of dietary intervention on 
genus level and OTU level community structure, two nested permutational multivariate 
analysis of variances were performed. The first used genera frequencies from Ribosomal 
Database Project (RDP) and the second the UPARSE 3% OTU frequencies. In both cases, 
Bray-Curtis distances were used following normalisation of relative frequencies. The 
results were similar, indicating a highly significant effect of obesity on community 
structure both at genera (R
2
=0.0326, Pr (>F) =0.0005) and OTUs level (R
2
=0.0287, Pr 
(>F) =9.99E-05) and a mildly significant impact of pathology at genus level (R
2
=0.0166, 
Pr (>F) =0.0422) and OTU level (R
2
=0.0157, Pr (>F) =0.0125) (Figure 6.4a, b). However, 




Figure 6.4: Non-metric multidimensional scale (NMDS) plot of genus level (a) and OTU level (b) 
community compositions using Bray-Curtis distances. 
a. NMDs plot of genus level community composition 
 
b. NMDS plot of OTU level community composition 
 
NMDS1 and NMDS2 Scale is the rank-order of the bacterial community in a two dimensional space. Colour 
of the dot represent group of the participant; magenta dots-simple obese, red dots-hypothalamic obese, black 
dots-healthy lean, and green dots-hypothalamic lean. Each dot represents a participant. The line from each 
dot converges to a centre based on similarity of genera community to a central point. In Figure 6.4b, 
hypothalamic obese group is hidden behind simple obese group while hypothalamic lean group is hidden 




6.5.4 Community composition of genera in relation to obesity and 
pathology 
In the presence of no significant difference in the community genus and OTU level 
composition and subsequent clustering based on phenotype and not pathology, the analysis 
of OTU level and genus level composition was performed by grouping  obese (simple + 
hypothalamic obese) and lean (healthy lean + hypothalamic lean) participants. 
6.5.4.1 Community genera composition in relation to obesity 
Of more than 200 genera identified, relative abundance of only 11 genera shown in table 
6.5 were found to be significantly different between the lean and obese groups. All genera 
with a false discovery rate of less than 10% are shown. Relative abundance of Dorea, 
Collinsella, Lactobacillus, Megamonas, and Gemmiger were significantly higher in obese 
while Veillonella, Pasteurellaceae, Alistipes, Oscillibacter, Clostridium cluster XVIII, and 
Rothia were significantly higher in lean than obese group (Table 6.5). The most significant 
effects included a higher frequency of Dorea (Figure 6.5) and Collinsella in Obese 
participants and a lower frequency of Veillonella and Alistipes in lean participants (Table 
6.5, Figure 6.5). 
Table 6.5: Relative abundance (mean percentage abundance) of genera differing significantly between 
lean and obese groups. 
Genera Lean (%) Obese (%) p pa 
Dorea 1.26 2.57 3.66E-06 0.000235 
Veillonella 1.95 0.266 6.09E-06 0.000235 
Collinsella 3.04 6.27 1.66E-04 0.00427 
Lactobacillus 0.0618 0.245 7.51E-04 0.0144 
Unclassified Pasteurellaceae 0.0572 0.00696 1.56E-03 0.0213 
Alistipes 0.522 0.182 1.66E-03 0.0213 
Megamonas 0.253 2.17 2.10E-03 0.022 
Oscillibacter 0.544 0.195 2.28E-03 0.022 
Clostridium cluster XVIII 0.0251 0.00358 3.17E-03 0.0271 
Rothia 0.00284 0.000559 6.80E-03 0.0524 
Gemmiger 1.21 2.07 8.51E-03 0.0596 
The mean %age abundances in the two groups are given along with the p-value from a Kruskal-Wallis non-
parametric ANOVA (p) and the Benjamini-Hochberg false discovery rate (pa) to account for multiple 
comparisons. All genera with pa < 0.1 were judged significant. 
6.5.4.2 Community genera composition in relation to pathology 
In contrast to the much higher differences in the genera based on obese or lean phenotype, 
only four genera (Coprococcus, Eggerthella, Collinsella, and Flavonifractor) differed 
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significantly in abundance between healthy and pathological children (Table 6.6). 
Coprococcus and Collinsella were significantly higher in healthy vs. pathological group 
(p=0.00031 & p=0.00164) while Eggerthella and Flavonifractor were significantly higher 
in pathological vs. healthy group (p=0.00039 & p=0.00248).  
Table 6.6: Relative abundance (mean percentage abundance) of genera differing significantly between 
healthy (lean healthy + simple obese) and pathological (hypothalamic lean + obese) groups. 
Genera Healthy (%) Pathology 
(%) 
P pa 
Coprococcus 1.220 0.683 3.10E-04 0.0151 
Eggerthella 0.156 0.196 3.92E-04 0.0151 
Collinsella 4.150 3.140 1.64E-03 0.0422 
Flavonifractor 0.077 0.267 2.48E-03 0.0478 
Healthy; healthy lean + simple obese, pathology; hypothalamic lean + hypothalamic obese. The mean %age 
abundances in the two groups are given along with the p-value from a Kruskal-Wallis non-parametric 
ANOVA (p) and the Benjamini-Hochberg false discovery rate (pa) to account for multiple comparisons. 
Genera with pa < 0.1 were judged significant. 
 
Figure 6.5:Boxplot of frequency (log10) of Dorea (a) and Veillonella (b) in lean and obese groups. 
 
Dots represent individual participant 
6.5.5 Community composition of OTU in relation to obesity and 
pathology 
6.5.5.1 Community OTU composition in relation to obesity 
Differences in OTU composition between lean and obese groups mirrored the genera level 
differences, with the two most significant OTUs corresponding to Dorea elevated in obese 
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(2.22% in obese vs. 0.958% in lean, p=2.79e-06) and Veillonella elevated in lean (1.99% 
in lean vs. 0.267% in obese, p=3.15e-06). In total, 17 OTUs differed significantly between 
lean and obese groups (Table 6.7). 
Table 6.7: Relative abundance (mean percentage abundance) of OTUs differing significantly between 
lean and obese groups. 
OTU Assignment Lean (%) Obese (%) p pa 
OTU17 Dorea sp. 0.9580 2.2200 2.79E-06 0.0005 
OTU21 Veillonella sp. 1.9900 0.2670 3.15E-06 0.0005 
OTU908 Bifidobacteria sp. 0.0128 0.0325 1.83E-05 0.0021 
OTU58 _ 0.1480 0.4380 1.08E-04 0.0091 
OTU241 _ 0.0916 0.0105 2.54E-04 0.0171 
OTU798 _ 0.0990 0.2220 5.19E-04 0.0262 
OTU52 _ 0.1980 0.0493 5.44E-04 0.0262 
OTU657 _ 0.5370 1.2600 8.41E-04 0.0344 
OTU123 _ 0.0589 0.0069 9.20E-04 0.0344 
OTU71 _ 0.3360 0.1020 1.70E-03 0.0572 
OTU22 _ 0.9380 1.6900 2.19E-03 0.0585 
OTU883 _ 6.5000 10.600 2.23E-03 0.0585 
OTU247 _ 0.0152 0.0006 2.28E-03 0.0585 
OTU129 _ 0.0942 0.0400 2.43E-03 0.0585 
OTU240 _ 0.0126 0.0009 3.24E-03 0.0724 
OTU181 _ 0.0125 0.0018 3.44E-03 0.0724 
OTU26 _ 0.3610 0.0484 4.45E-03 0.0883 
Healthy; healthy lean and simple obese, Pathology; hypothalamic lean and hypothalamic obese. The mean 
%age abundances in the two groups are given along with the p-value from a Kruskal-Wallis non-parametric 
ANOVA (p) and the Benjamini-Hochberg false discovery rate (pa) to account for multiple comparisons. All 
OTUs with pa < 0.1 were judged significant. 
 
6.5.5.2 Community OTU composition in relation to pathology 
Remarkably, eighteen OTUs differed significantly in abundance between the healthy 
(healthy lean + simple obese) and pathological (hypothalamic lean + hypothalamic obese) 
groups (Table 6.8). The majority of these correspond to assorted Firmicutes that are more 
abundant in healthy group than pathological group. The most significantly different OTU 
between healthy and pathology group was OTU210 which is derived from the order 
Clostridiales (Figure 6.6). OTU908 assigned to Bifidobacterium spp. from Actinobacteria 
is also significantly higher in healthy group, and this is largely contributed by the simple 
obese group as the relative abundance of Actinobacteria is significantly higher in simple 
obese (16% in simple obese vs. 13.3% in healthy lean, p<0.05).   
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Table 6.8: Relative abundance (mean percentage abundance) of OTUs differing significantly between 
healthy and pathological groups. 
OTU Taxonomic assignment Healthy (%) Pathology (%) p pa 
OTU210 Clostridiales order 0.0207 0.0051 3.96E-06 0.0008 
OTU65 Lachnospiraceae family 0.2310 0.1850 4.65E-06 0.0008 
OTU908 Bifidobacteria sp. 0.0233 0.0063 6.53E-05 0.0056 
OTU26 Coprococcus comes 0.4550 0.2660 8.26E-05 0.0056 
OTU61 Eggerthella sp. 0.1420 0.1890 8.26E-05 0.0056 
OTU740 Blautia sp. 0.0211 0.0034 1.79E-04 0.0101 
OTU34 Ruminococcaceae family 0.8600 0.2770 2.19E-04 0.0105 
OTU66 Firmicutes phylum 0.1720 0.0909 1.30E-03 0.0507 
OTU223 Clostridiales order 0.0052 0.0187 1.35E-03 0.0507 
OTU246 Lachnospiraceae family 0.0176 0.0101 1.84E-03 0.0598 
OTU86 - 0.1760 0.0511 2.18E-03 0.0598 
OTU170 - 0.0245 0.0509 2.22E-03 0.0598 
OTU622 - 0.0316 0.2030 2.31E-03 0.0598 
OTU74 - 0.1090 0.0186 3.77E-03 0.0908 
OTU841 - 0.0091 0.0349 4.27E-03 0.0936 
OTU97 - 0.1840 0.1010 4.50E-03 0.0936 
OTU382 - 0.0204 0.0164 4.83E-03 0.0936 
OTU542 - 0.0504 0.0083 5.00E-03 0.0936 
Healthy; healthy lean + simple obese, pathology; hypothalamic lean + hypothalamic obese. The mean %age 
abundances in the two groups are given along with the p-value from a Kruskal-Wallis non-parametric 
ANOVA (p) and the Benjamini-Hochberg false discovery rate (pa) to account for multiple comparisons. All 
OTUs with pa < 0.1 were judged significant. 
Figure 6.6: Relative abundance of OTU210 in Control and Pathological children. Log relative 
frequency of OTU210 assigned to order Clostridiales in healthy and Pathological individuals. 
 





In previous chapters we observed no significant differences in the gut microbial metabolic 
activity and fermentation capacity between obesity of different aetiology which hinted 
towards structural and/or functional similarity between the two obese groups. Preliminary 
analysis of the whole bacterial metagenome by high throughput next-generation 
sequencing complemented this work and offered insight into differences in gut bacterial 
compositional differences between hypothalamic obese and simple obese groups.  
Taken as a whole, no significant differences were observed in gut microbial 
diversity between obesity of different aetiology at phylum, class, order, and family level 
except for phylum Proteobacteria which extended to the lower order taxonomy (class 
Gammaproteobacteria, order Enterobacteriales and Aeromonodales, family 
Enterobacteriaceae and Aeromonodaceae). Furthermore, hypothalamic obese group had a 
higher level of class Bacilli (including Bacillus sp., Lactobacilli and Mollicutes).  
No significant differences in the major phyla i.e. Firmicutes and Bacteroidetes 
between the simple and hypothalamic obese groups contradict the causal relationship of 
gut microbiota with obesity. Our study is the first line of evidence to explore this 
relationship in a human study. Furthermore, no significant difference in the relative 
abundance of these two major phyla between the lean (healthy lean and hypothalamic lean) 
and obese (simple obese and hypothalamic obese) groups contradicts previous major 
studies (162, 217). On the contrary, our study supports evidence which suggested no 
differences in Bacteroidetes and Firmicutes between lean and obese subjects (95, 260). 
Hypothalamic obese group had significantly higher relative abundance of 
Proteobacteria than simple obese group and Bacilli (from phylum Firmicutes). 
Enterobacteriaceae, commonly known as ―Enterobacteria‖ is the most important family of 
the phylum Proteobacteria. They are Gram negative facultative anaerobes and include 
many important pathogenic microorganisms such as E.coli, Salmonella, Yersinia pestis, 
Klebsiella, Shigella, Proteus, Citrobacter, and Enterobacter apart from other harmless 
symbionts (417). Gut microbiota in this group perform mixed acid fermentation producing 
lactate, acetate, succinate, ethanol, 2, 3-butanediol and formate in varying amounts.  
Additionally, members of Proteobacteria produce endotoxin (such as Shigella and 
E. coli) which is released when cellular apoptosis and cell wall disintegration occurs. This 
may cause systemic inflammatory response when released into the systemic circulation 
through a compromised gut barrier (168). Higher levels of Proteobacteria have been 
 285 
 
correlated with chronic low-grade inflammation in obesity in Sprague Dawley rats (199) 
and human adults (167), type 2 diabetes (262), and late-onset necrotising enterocolitis in 
premature infants with compromised gut barrier function (418).  
Studies have shown the presence of chronic low grade inflammation in children and adults 
with PWS compared to obese non-PWS controls such as raised post-prandial CRP, 
complement component 3, and pro-inflammatory IL-18 (419),  and raised IL-6 and 
markers of neutrophil activation (CD66b & CD11b) (420). Interestingly, the inflammatory 
status in these studies was not related to BMI or BMI SDS and the relationship with insulin 
resistance was controversial suggesting other mechanisms for chronic low grade 
inflammation unrelated to adiposity and insulin sensitivity. Thus far, no study has 
investigated whether chronic low-grade inflammation in PWS is related to endotoxin-
producing pro-inflammatory gut microbiota. Our study might be the first evidence linking 
chronic low-grade inflammation in PWS patients to the presence of increased endotoxin 
producing gut microbiota, independent of BMI. Increased capability of Enterobacteria to 
adhere to the colonic epithelium with the help of type 1 fimbriae might help in facilitating 
disruption of gut barrier and translocation of endotoxin into the systemic circulation. 
Patients with PWS have been reported to have higher incidence of non-alcoholic fatty liver 
disease related to chronic low grade inflammatory status (421). Furthermore, obese non-
PWS adults with non-alcoholic fatty liver disease have been shown to have higher relative 
abundance of Gammaproteobacteria in addition to Lactobacilli and members of 
Lachnospiraceae (422). Therefore, a higher relative abundance of Gammaproteobacteria in 
hypothalamic obese group in our study might link with increased incidence of NAFLD in 
PWS through endotoxin-induced chronic low-grade inflammation. However, we did not 
have data regarding the systemic inflammatory markers and hepatic health status that could 
prove this explanation and is therefore a potential new area for us to investigate in near 
future (Figure 6.7).  
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Figure 6.7: Proposed mechanism for the relationship of increased Enterobacteria with chronic low 
grade inflammation in hypothalamic obese children/young adults in our study 
 
Increased endotoxin production and the capability of these bacteria to adhere to the epithelium may result in 
altered gut barrier through altered expression of tight junction proteins allowing the release of endotoxin into 
the systemic portal circulation, chronic low grade inflammation, insulin resistance, and non-alcoholic fatty 
liver diseases. Additionally, increase endotoxin release into the gut epithelium may cause enterocolitis.   
 
Hypothalamic obese group also had a higher relative abundance of Bacilli; which amongst 
other Bacillus species also includes Lactobacilli. Lactobacilli mainly produce lactate as a 
product of their fermentation which is either utilised in the synthesis of butyrate, 
propionate, or acetate. Heterofermentative Lactobacilli (such as Leuonoctoc, Oenococcus, 
and Weissella) also produce ethanol and carbon dioxide via pentose phosphate pathway. 
Butyrate, but not propionate is the primary route of utilisation of lactate. Although strains 
belonging to the genus Lactobacillus (such as L. reuteri) are correlated with obesity, other 
Lactobacilli (such as L. plantarum, L. casei, L. paracasei) are positively associated with 
leanness (236). Probiotics, which selectively stimulate groups of gut microbiota to 
beneficially affect the human gastrointestinal tract are mostly composed of different strains 
from the genus Lactobacillus and are shown to reduce obesity associated metabolic 
inflammatory markers (412, 423). Additionally, Bifidobacteria and Lactobacilli in 
mother’s milk are crucial for the colonisation of non-pathogenic symbionts in the infant’s 
gut (149). Therefore, genomic variability within Lactobacillus group demands a strain 
level analysis, rather than a more general approach, to assess any association with obesity.  
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Lower methanogenic bacteria and higher sulphate-reducing bacteria (Deufovibrio 
sp.) in obese than lean 
Excess production of SCFA in the gut results in accumulation of hydrogen and reduced 
SCFA which can inhibit further fermentation due to the accumulation of reducing 
equivalents (NADH and NADPH) as a result of oxidation-reduction reaction. Removal of 
molecular hydrogen from these reducing equivalents is necessary for the acceptance of 
further electrons in glycolysis and Krebs’s cycle. In the gut, homoacetogenic bacteria, 
sulphate reducing bacteria and methanogenic archaeacompete for the acceptance of 
hydrogen to generate acetate via Wood-Ljundahl pathway, hydrogen sulphide or methane 
respectively (121). Complete absence of  methanogens in the simple obese or presence in 
reduced numbers in hypothalamic obese participants compared to lean participants suggest 
that sulphate reducing bacteria (SRBs) outcompete methanogens in accepting hydrogen to 
generate hydrogen sulphide. Published data suggest that higher SRBs level is associated 
with a negligible or extremely lower methanogens in the distal gut (122). Presence of 
methanogenic archaea has been associated with leanness (236, 237) and in anorexia 
nervosa (240). However, a study by Zhang et al. (2009) showed higher gene copies of 
methanogens in obese and association of hydrogen producing Prevotellaceae with 
hydrogen consuming Methanobacteriales in obese adults but not in lean and post-gastric 
bypass patients  (167). In our study, although methanogens were absent or reduced in the 
two obese groups, there was no significant difference in the relative abundance of 
Desulfovibrionaceae and Prevotellaceae between lean and obese groups. This suggests that 
the association of methanogenic archaea with leanness or obesity is dependent on the 
interaction of gut microbial communities that varies between individuals and may be 
dependent on the dietary pattern of individual. 
Verrucomicrobia (represented by Akkermansia muciniphila) were higher in lean 
than obese 
We found significantly higher Verrucomicrobia at phylum, class, and family level in 
healthy lean group compared to simple obese group (4.1% in healthy lean vs. 0.70% in 
simple obese).  Verrucomicrobia, primarily represented by Akkermansia muciniphila are 
mucin degrading bacteria residing in the mucus layer of the colonic epithelium (424). They 
represent up to 3-5% of the total bacterial population in healthy subjects, however the 
relative abundance may vary between individuals (424, 425). Higher levels of 
Verrucomicrobia have been observed in normal weight (254) and gastric bypass patients 
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(167) compared to obese subjects. Moreover, higher levels of Akkermansia muciniphila 
have been shown to be inversely associated with adiposity and measure of adiposity, 
metabolic endotoxemia, and markers of metabolic syndrome (247, 248). Our finding is 
therefore in accordance with these studies. Whether higher levels of A. muciniphila are a 
marker of good health or disease is controversial.  A recent study by Everard et al.(2013) 
in animal models have shown reduced level of Akkermansia muciniphila in both genetic 
model of leptin deficient ob/ob mice (3,300 fold lower than lean) and high fat fed mice 
(100 fold lower than lean) (231). Supplementation with viable, but not heat-killed 
Akkermansia muciniphila was shown to improve metabolic disorder and diabetes by 
enhancing the markers of adipocyte differentiation, lipid oxidation (such as carnitine 
palmitoyltransferase 1), and glucose homeostasis (by improving fasting hyperglycaemia by 
40% reduction in gluconeogenic enzyme glucose-6-phosphatase) (231). Interestingly, these 
effects were independent of changes in dietary intake by the experimental animals. In 
contrast, supplementation with prebiotic oligofructose was shown to recover the population 
of Akkermansia muciniphila. Whether this was a direct effect of the oligofructose on the 
selective growth of this species or it was due to the presence of other cross-feeding 
pathways that favoured increase in A. muciniphila was not shown. Earlier study by Collado 
et al. (2008) and Santacruz et al. (2010) showed higher levels of Akkermansia muciniphila 




 trimester of pregnancy 
compared to those who gained excessive weight during that period (247, 248). 
In contrast, the mucus-degrading capability of Akkermansia in human health is 
controversial as degradation of mucus is associated with reduction in thickness of mucus 
layer and exacerbation of inflammatory bowel disease. Furthermore, the effect of 
prebiotics fibre on the levels of A. muciniphila is controversial as Jakobsdottir et al. (2013) 
found  positive association of fibre-free diet with A. muciniphila (226).  
 
Obese phenotype is associated with lower OTU richness compared to lean phenotype 
Regardless of the aetiology of obesity, we found a significantly lower OTU richness in 
obese than lean phenotype. A discussed in chapter 1, evidence regarding compositional 
differences in the relative proportion of gut microbiota at various taxonomic levels from 
phyla to species level is controversial both in experimental and human studies in obese vs. 
lean (159, 164, 222, 260, 350, 410). However, in these studies, there is a general agreement 
on a reduced diversity and richness of gut microbiome in obese vs. lean animals and 
humans. Our finding is novel, as to our knowledge, this is the first evidence from human 
studies to suggest that lower gut microbiota richness is independent of the type of obesity 
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(simple or hypothalamic obesity). This evidence further implicates that factors other than 
obesity such as dietary, environmental, and lifestyle factors may be much stronger 
determinants of the colonisation of gut microbial communities.  
A recent study by Le Chatelier et al.(2013) showed a bimodal distribution of 292 
individuals based on their low or high gene counts (more than 480,000 genes or less than 
480,000 genes respectively). Obese adults (40% of study subjects) with lower gene count 
had higher counts of Proteobacteria and Bacteroidetes at phylum level, higher genomic 
potential to produce potentially harmful metabolites such as genes for β glucoronide and 
aromatic amino acids degradation, and had increased markers of metabolic syndrome and 
diabetes in contrast to high-gene count adults (410). Body mass index and body weight 
were the only significantly negatively associated parameters with gene counts amongst 
biochemical (insulin, HOMA IR, adiponectin, leptin, triglycerides, ALT, free fatty acids, 
hsCRP, fiaf,) and anthropometric (BMI, body weight, and body fat %) parameters.  
In our study, differences in gut microbiota between lean and obese phenotypes 
were driven mostly by genera and OTUs belonging to the phylum Firmicutes, obese 
subjects showing higher relative abundance of Dorea, Collinsella, Lactobacilli, 
Megamonas, and Gemmiger while lean subjects had a higher relative abundance of  genera 
Veillonella, Pasteurellaceae, Alistipes, Oscillibacter, Clostridial cluster XVIII, and Rothia. 
Taxonomic richness of Firmicutes in obese subjects have been shown to be linked to a 
lower functional diversity and expression of genes for metabolic pathways (409).  On the 
contrary, some authors suggest that the functional representation of gut microbiota such as 
Bacteroidetes is equal to that of Firmicutes although the relative abundance is low and the 
disturbance of this equilibrium is a hallmark of obese phenotype (252). A recent study by 
Cottilard et al. (2013) has shown reduced bacterial richness and diversity, higher dys-
metabolism and low-grade inflammation in obese vs. lean humans. Although dietary 
intervention improved gene richness and metabolism in obese, it is less efficient to 
improve the low grade inflammation (252). 
Reduction in the OTU richness might suggest functional redundancy in the 
metabolic cross-feeding pathways due to a ―monotonous diet‖ usually rich in fat and 
depleted in fermentable carbohydrates. Presence of fermentable carbohydrates allows the 
development of symbiotic associations between various taxonomic clades and enzyme 
system containing complex glycosylhydrolases for the generation of metabolic end 
products necessary for survival of gut microbiota (64, 426). These associations fail to 
develop when diet with abundant simple sugars is used(86). High fat diet containing higher 
amounts of saturated fat (such as palm oil) are also absorbed in the small intestine and are 
shown to reduce the diversity of gut microbiota and stimulate distal gut signalling 
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pathways to increase the expression of lipid metabolism-related genes in the distal colonic 
epithelium  (223).  This evidence is further supported by interventional studies highlighting 
the influence of introduction of probiotics on the gut microbiota richness and diversity at 
least transiently if not permanently (427). In their study, Wang et al. (2014) showed that 
introduction of three candidate probiotics each containing Lactobacillus paracasei, L. 
rhamnosus, and Bifidobacterium animalis to high-fat fed mice for 12 weeks significantly 
attenuated the gut microbiota OTU composition of obese metabolic phenotype. Of 83 
OTUs altered by probiotics, 26 OTUs which were positively associated with metabolic 
syndrome were reduced and 13 OTUs that were negatively correlated with metabolic 
syndrome were promoted as a result of probiotics feeding. This was coupled with increase 
in caecal acetate and reduction in hepatic and adipose tissue TNFα expression (427).  
Furthermore, introduction of high fibre diet (such as inulin type fructans) in obese women 
has been shown to reverse the relative abundance of the predominant gut microbial 
communities (such as Firmicutes and Bacteroidetes), stimulation of previously suppressed 
microbes (such as Bifidobacterium and F. prausnitzii), and development of new cross-
feeding pathways evidenced by the changes in the levels of metabolic end products (such 
as SCFA and lactate) (428). These changes in turn had a positive influence on improving 
anthropometric parameters, metabolic endotoxemia, and fasting glycaemia.  
 
Bacterial genera and OTUs composition clustered based on their phenotype, and not 
pathology 
Despite subtle differences in the gut microbiota composition between simple and 
hypothalamic obese groups, genus level and OTU level composition in obese phenotype 
clustered together and distinctly from lean phenotype (healthy lean and hypothalamic 
lean). Clustering of gut microbiota of obese phenotype distinct from the lean phenotype 
have been shown both in experimental animal (217) and human studies(410). However, 
our study indicates that adiposity and measures of adiposity are more closely related to the 
structure of gut microbiota than the cause of adiposity and, as mentioned above, it further 
implicates that gut microbiota are not causally related to the aetiology of obesity. However, 
microbial species which are different between the two types of obesity might be important 
for adiposity and cardiovascular risk.  
Despite inter-individual differences, evidence suggests similarity of gut microbial 
community and their metabolic activity between members of the same community and 
between mother and off-springs distinct from unrelated individuals (248, 409). Obese 
related twins and their mothers had had lower microbial diversity, shared community 
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structure (higher Firmicutes and lower Bacteroidetes in obese than lean) and metabolic 
pathways (Firmicutes enriched with transport system genes and Bacteroidetes enriched 
with carbohydrate metabolism genes) for the degradation of dietary substrate compared to 
lean (409). Clustering of the gut microbiota of obese unrelated individuals with different 
aetiology therefore suggest common ―exposure‖ factors such as diet, environment, and 
lifestyle that make them similar to each other in gut microbiota diversity at genera level, 
independent of obese phenotype. Although the core microbiome colonising the infant gut 
is determined by several factors discussed in detail in chapter 1, exposure to environmental 
factors play an important role in modifying gut microbiota. For example, study by De 
Fillipo et al. (2010) showed clustering of gut microbiota from African and European 
children in early days of life which then became grossly distinct over the period of months 
to years after exposure to different diets (African diet rich in plant fibre vs. European diet 
rich in fat and low in fibre) (155). Similarly, studies in centenarian population (≥100 years 
age) also indicate distinct clustering of the gut microbiota based on their community 
dwelling (hospitalization, day-care centres, and community dwelling)(429). Additionally, 
diet was a separate factor that produced sub-clusters within the same group. These findings  
further support the role of environmental factors in clustering individuals together 
distinctly from others (429).   
Distinct clustering based on OTUs in our study might also suggest distinct 
grouping of gut microbiome in symbiotic relationship in obese vs. lean phenotypes. In the 
recent study by Ridaura et al.(2013), animals with obese transplanted microbiota exhibited 
higher expression of genes involved in detoxification and stress response, biosynthesis of 
cobalamin, essential and non-essential amino acids and gluconeogenic pathways. In 
contrast, animals with lean- transplanted microbiota exhibited genes capable of  fermenting 
plant polysaccharides, butyrate, and propionate (212). Similarly, Won et al. (2013) found 
48 distinct metabolic products in urine of obese subjects to be significantly up-regulated 
compared to the lean subjects (214). In this context, several discriminating gut microbial 
metabolic products have also been identified in the urine of obese vs. lean people, some of 
which include higher levels of hippuric acid, trigonelline, 2-hydroxybutyrate and xanthine 
(241).  
In summary, obesity and not the cause of obesity classify participants into separate 
clusters and this might be attributed to the distinct dietary, lifestyle, and environmental 
factors to which the obese and lean phenotypes are exposed. However, our dietary data did 
not show any effect of diet on the community composition possibly due to under-reporting, 
limitation related to the method of dietary assessment, and other unknown host-related 




In conclusion, simple and hypothalamic obese group are not different in terms of relative 
abundance of the major phyla such as Firmicutes and Bacteroidetes, although differences 
in Proteobacteria were observed. Obesity and not the cause of obesity explain variations in 
the gut microbial diversity. The presence of similar metabolic profile in hypothalamic vs. 
simple obese as seen in previous chapters is not fully translated into their structural 
diversity at all taxonomic levels which suggest that composition of the gut microbiota may 
not be related to the similarity in functional diversity and the absence of compositional 
differences at phylum level may not indicate absence of lower taxonomic level differences. 
Similar metabolic function may suggest identical or comparable dietary patterns in obese 
people regardless of the aetiology of obesity. 
Analysis of gut microbiota composition in our participants has generated important 
research questions: 
 Whether gut microbiota composition and their metabolic products (SCFA, lactate, 
ammonia, and H2S) in our cohort are related to the expression of functional genes in 
metabolic pathways? Whether the gut metabolome in obesity of different aetiology is 
distinct from metabolome in lean groups? And whether the metabolome of the obese and 
lean participants is related to their diet?  
These are future steps for us to investigate. This has encouraged us to prepare 
metagenomic libraries for the analysis of 96 samples from our participants, although their 




 Chapter 7: General Discussion and Conclusions 
Obesity has nearly doubled in the past 30 years and is growing in pandemic proportions 
worldwide. It is the leading cause of many preventable causes of death such as type 2 
diabetes, coronary heart disease, hypertension, osteoarthritis, and cancer (19). Amongst 
several other factors related to the aetiology of obesity such as diet, lifestyle, environment, 
and genetic makeup; the gut microbiota has been implicated in the aetiology of obesity by 
increasing energy harvest from the diet (via SCFA production), altering gut barrier 
function, releasing certain hormones that positively affect host hepatic and adipose tissue 
lipogenesis (Table 1.7, chapter 1). However, in contrast, other studies suggested that diet 
might be the principal factor driving these changes in gut microbiota and hence increased 
energy harvest. The evidence largely remains controversial and there is a need to determine 
the ―cause or effect‖ relationship between gut microbiota and obesity. 
Work done towards the completion of this PhD aimed at addressing the potential 
reverse causality by studying gut microbiota diversity and metabolic activity in children 
and young adults with obesity of known (Prader-Willi syndrome & Craniopharyngioma) 
and unknown aetiology (simple or classical obesity). If the gut microbiota were the cause 
of obesity, we could expect to see differences in gut microbiota diversity and metabolic 
activity between obesity of known versus unknown causes. Similarity in gut microbiota 
diversity and metabolic activity would implicate that altered gut microbiota reported in 
previous studies are a consequence of altered dietary, environmental, lifestyle, and other 
factors.  
The main aim of the study in this PhD was ―to compare gut microbial metabolic 
activity (in the form of SCFA, hydrogen sulphide, D & L lactate, and ammonia), 
fermentation capacity and microbiota composition between obesity of different aetiology 
and their relationship with diet and weight loss‖.  
The research content of this thesis was divided into the following four main sections: 
1. Subject characteristics including demographic, anthropometric, and dietary analysis 
2. Differences in gut microbial metabolites (SCFA, BCFA, H2S, D & L-lactate, and 
NH3) in simple and hypothalamic obesity 
3. In vitro fermentation capacity of gut microbiota from children with simple and 
hypothalamic obesity  
4. Gut microbiota diversity in simple and hypothalamic obesity 
Due to the difference in the nature of the groups, the analysis for determining the 
difference between the groups was done using Mann-Whitney U test (comparing only two 
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groups at a time) instead of Kruskal-Wallis test followed by Bonferroni post-hoc test or 
any other corrections for multiple comparison. Using Mann-Whitney U test for testing 
multiple hypotheses might have resulted in nominally significant differences which may 
not have remained significant after multiple testing adjustment or using other tests for false 
discovery rate. 
7.1 Subject characteristics: differences in body composition and 
dietary intake 
In accordance with published data, this study described lower height for age in the 
hypothalamic obese versus simple obese group. Height SDS of participants with pathology 
(hypothalamic lean and hypothalamic obese group) was significantly lower than those with 
no pathology(healthy lean and simple obese group). Patients with Prader Willi syndrome 
are genetically prone to growth hormone deficiency while patients with craniopharyngioma 
develop growth hormone deficiency due to the invasion and destruction of anterior 
pituitary gland and hypothalamus by the tumour. Owing to hyperphagia, we would expect 
a higher weight SDS in hypothalamic obese patients, however in contrast, weight SDS of 
hypothalamic obese children was significantly lower than the simple obese patients and 
interestingly these differences did not translate into the BMI SDS which suggests that PWS 
and simple obese participants were proportionate or equally obese for their height.  
Although not all children with Prader Willi syndrome in our study were obese, the 
median BMI SDS of PWS children in lean category was higher (median BMI SDS ˃1 
SDS) compared to healthy lean control (median BMI SDS <0 SDS). Whether this 
represents the transitional phase between already-started metabolic changes (i.e. reduced 
energy expenditure and increased fat mass) and hyperphagia towards an obese status is a 
possible subject for future investigation and warrants a long term follow-up of these 
participants. It would also be interesting to explore changes in weight/BMI gain/velocity 
with a longer follow up. This also suggests that the clinician should focus not only on 
weight management in the obese hypothalamic but also ―prevention‖ of weight gain in the 
lean hypothalamic group as they might likely progress to become overweight and obese in 
future. This was partially indicated by the higher weight velocity in hypothalamic obese 
and hypothalamic lean group compared to the healthy lean and simple obese group. 
Sustained increase in weight velocity despite weight management suggest that, weight 
velocity of the simple obese group is reduced but the hypothalamic obese and lean group 
continue to have an increased weight gain under the effect of the pathology. 
Measurement of body composition was based on foot-to-foot bioelectrical 
impedance analysis. Although this has been validated for use in children and adults, 
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several studies have found that it can over estimate fat-free mass and underestimate 
percentage body fat (319, 320). Moreover, large variation between measurements has been 
reported that vary with gender (321). Body composition could not be measured in all 
participants due to the young age of some and hence the results of the TANITA® need to 
be interpreted with caution. However this is a simple, cheap bedside approach and might 
be useful to explore sequential changes where more precise and accurate methods are 
limited. 
Analysis of the dietary data in our study showed that the proportional intake of 
dietary fat and proteins was higher while that of carbohydrate was lower in the obese 
group, particularly the simple obese group. Our data suggest a clear downward trend in the 
percentage recommended intake of dietary fibre from the lean phenotype towards an obese 
phenotype. The lower percentage of average recommended intake of energy in the 
hypothalamic lean, hypothalamic obese and simple obese groups could be attributed to 
either reduced energy requirements, reduced energy expenditure, or to the effect of dietetic 
management, or it may represent under-reporting of dietary habits. A trend of decreasing 
energy intake with increasing BMI SDS suggests major underreporting in our obese group. 
It still remains to be determined how far this reported lower intake of energy in 
hypothalamic obese group is attributable to the lower energy expenditure. Physical activity 
and health related quality of life measurements are therefore recommended to correlate 
reported energy intake with body composition.  
Our method of dietary assessment (24 h food diary) has some limitations(430). It 
was not a weighed diary, therefore potential variation due to the perception of portion sizes 
by parents or the participants may have contributed to the differences recorded in energy 
intake. Moreover, a single day diary may not represent the typical diet of participants on 
other days not recorded in the diary. Parents completing the food diary on behalf of a 
young child may have missed foods taken at school. Furthermore, the food diary does not 
give an indication of the frequency of the type of foods consumed and should therefore be 
supported by a food frequency questionnaire (431). We tried to minimise these potential 
variables by explaining the food diary in detail to the participant and/or the parent and 
asking them to preferentially choose a weekday to fill the diary. Food frequency 
questionnaires (FFQs) were included as part of the dietary assessment for all participants, 
but unfortunately, certain cereals taken as part of the daily breakfast were missed and not 
included in the FFQs, which made the extrapolation of any conclusion from that data 
biased and incomplete. These are therefore not included in the thesis.  Multiple pass food 
diaries are designed to address issues related to memory bias and under-reporting by 
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participants (339), and thus may give a more accurate measure of food intake in future 
studies involving overweight and obese groups.  
 
7.2 Differences in gut microbial metabolites (SCFA, BCFA, 
H2S, D & L Lactate, and NH3) in faeces of children with 
simple and hypothalamic obesity 
Several animal and human studies have investigated the relationship of faecal gut 
microbial metabolites in obese versus lean animals and humans (table 1.7, chapter 1). 
However, there is no good data to rule out reverse causality i.e. whether gut microbiota are 
a cause or they are a consequence of obesity.  
To the best of our knowledge, this is the first human study attempting to prove 
reverse causality by comparing gut microbial metabolic activity and diversity between two 
obese groups; one with a known cause of obesity (hypothalamic obesity - due to a genetic 
disorder or a tumour), and another with an unknown cause of obesity (simple or classical 
obesity). 
Overall, there was no difference in the faecal metabolites including SCFA, BCFA, 
H2S (free, bound, and total), lactate (D &L), and ammonia between simple and 
hypothalamic obesity and thus our results did not support the pioneering studies by Jeffry 
Gordon’s group suggesting a causative role of the gut microbiota in the aetiology of 
obesity. All previous human studies have attempted to address the cause or effect 
relationship of gut microbiota with obesity by focusing only on simple obese children and 
adults compared with healthy lean populations. However, we have controlled for the most 
important variable, ―obesity‖ and then compared the gut microbial diversity and metabolic 
activity between simple and hypothalamic obese group. Furthermore, we also included 
hypothalamic lean group which acted as a control group for the hypothalamic obese group.  
Thus, we were able to control both for obesity and cause of obesity (pathology) in our 
analysis enabling us to draw more confident conclusions with a reasonable number of 
participants given the rarity of hypothalamic obesity.  
Inconsistent differences in the proportion of acetate and the percentage of faecal 
water between simple and hypothalamic obese groups were seen only at recruitment, 
which suggested different cross-feeding pathways in individual bacterial groups to harvest 
energy from the diet while maintaining a functional symbiotic relationship. A higher 
proportion of acetate in the hypothalamic obese group suggested preferential utilization of 
lactate as a substrate for butyrate production. This was supported by the lower lactate to 
butyrate ratio and significantly higher rate of change in D and total lactate over the period 
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of study in hypothalamic obese than all other groups suggesting higher lactate production. 
Higher production of lactate was also supported by the presence of significantly higher 
relative abundance of class Bacilli which amongst other Bacillus sp. also include 
Lactobacilli. Further metagenomic analysis of genes involved in bacterial metabolic cross-
feeding pathways is suggested to confirm and establish this finding with larger number of 
participants.   
Reduced gastric emptying and prolonged intestinal transit time due to hormonal 
disturbances has been reported to cause constipation in PWS patients (356, 357). However, 
in contrast, we observed a significantly higher percentage of faecal water in the 
hypothalamic obese group which may suggest that increased water content was a 
consequence of higher SCFA production and absorption, which drives bicarbonate ions to 
the gut lumen in exchange. Although we do not have data on the gut transit time of our 
patients, increased faecal water could be due to a reduced transit time leading to lesser 
absorption of water and salts from the gut lumen. 
In our study, the obese groups (simple and hypoth. obese) had a higher faecal 
SCFA concentration than the lean (healthy and hypoth. lean) groups. Published data 
suggest that availability and/or changes in the type and amount of substrate in the gut 
lumen determine the concentration and pattern of SCFA in obese individuals (166, 217). 
However, changes in the gut microbiota due to different pattern of diets in obese 
individuals, irrespective of the cause of obesity, might then acquire the capacity to harvest 
energy from the available substrates in the gut lumen as suggested in mice (159) and 
human(164)studies. However, this will not be implicated in the primary onset but possibly 
in the propagation of adiposity and increase in cardiovascular risk. SCFA in faeces are a 
net difference of what is being produced and what is being absorbed. Whether higher 
faecal SCFA in the obese group represents higher SCFA production or is due to a state of 
malabsorption in the gut is unknown. This question was addressed by in-vitro batch culture 
fermentation the results of which suggested no difference in the energy harvesting 
capability of gut microbiota of the two obese groups. 
One interesting finding was the paradoxically higher faecal propionate in the obese 
phenotype compared to the lean phenotype which was consistent between the two time 
points and in batch cultures. As discussed in chapter 4, higher levels of propionate have 
been associated with many beneficial effects on host metabolism whereas obesity is 
generally thought to be associated with metabolic dysfunction such as 
hypercholesterolemia and hepatic and adipose tissue lipogenesis. Propionate is a potential 
anti-obesity agent but our results are opposite to this notion. This paradoxical increase in 
―beneficial‖ propionate in our obese groups, which ameliorates these metabolic 
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abnormalities, has also been reported by other studies (95, 172, 176, 350). Bacteroidetes 
producing propionate express a wide variety of glycosyl hydrolases capable of degrading 
host mucus glycans during situation of low-fibre intake. Population based studies in obese 
humans have reported a reduced intake of dietary fibre and higher amounts of the readily 
available sources of digestible carbohydrates (327). In accordance with this, the simple 
obese participants in our study had a significantly lower fibre intake and the intake of 
dietary fibre was significantly negatively correlated with BMI SDS. This might explain the 
abundance of Bacteroidetes and the consequently higher concentration of propionate 
reported in obese people. An increase in ―beneficial‖ propionate might be an indication of 
a high intake of digestible carbohydrate but less dietary fibre-rich food (172). A high 
propionate should therefore be seen in the context of its source and not just its increased 
level in faeces. A comparative study of simple and hypothalamic obese population with 
higher intake of fibre with that of patients with low fibre intake would help further increase 
our understanding of this propionate paradox in obesity. 
Although studies have suggested alteration in the gut microbial diversity and 
metabolic activity with changes in weight, changes in weight were not significantly 
different between any of the groups in our study and were not associated with changes in 
gut bacterial metabolites. This suggests functional resilience of the gut microbiota diversity 
and metabolic activity in our participants which does not vary significantly with obesity or 
pathology, at least within a period of 2-3 months. It is however very hard to determine 
whether differences in weight gain/loss over an extended period of follow-up would cause 
differences in metabolism and diversity of gut microbiota in our cohort. This would require 
long term close follow-up of these participants and measurable changes in weight.  
Furthermore, future research is suggested to determine if the changes with weight loss or 
weight gain are due to changes in gut microbiota or due to changes in diet that usually 
happen with weight management, or due to changes in the endocrine and neuronal 
pathways of metabolism. 
Finally, the lack of association of dietary intake with major gut microbial 
metabolites in multivariate analysis with and without adjustment for pathology indicate 
that other factors might be playing more important role in determining the metabolic 
potential of the gut microbiota such as lifestyle and environment, host genetic makeup. 
However, analysis of the dietary data from our participant strongly suggest under-reporting 
and call for a more robust dietary assessment method in combination with FFQ as 
suggested above.  
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7.3 In vitro fermentation capacity of gut microbiota from 
children with simple and hypothalamic obesity 
SCFA measured in faecal samples represent only the difference of what is produced and 
what is absorbed into the gut epithelium. The fermentation capacity of the gut microbiota 
represent their capability to degrade complex polysaccharides and proteins to SCFA and 
BCFA and is a true representation of the energy harvesting capability of the gut microbiota 
from the diet.  
In vitro fermentation studies conducted on faecal samples of our participants 
confirmed our findings from faecal bacterial metabolites. No significant differences were 
observed in energy harvesting capability of gut microbiota between obesity of different 
aetiology contradicting the causal relationship of gut microbiota in the aetiology of obesity. 
On the other hand, significant differences in the rate of production of SCFA between obese 
(simple and hypothalamic obese) and lean groups (healthy lean and hypothalamic lean) 
indicated that obesity, and not the aetiology of obesity, determine differences between lean 
and obese population. 
Thus far, only three human studies have investigated the differences in 
fermentation capacity between obese vs. lean human subjects (95, 172, 395). This is the 
first in vitro batch culture fermentation study conducted for the measurement of the energy 
harvesting capability to investigate the cause or effect relationship of gut microbiota 
fermentation capacity in obesity of different aetiology. Furthermore, we used a range of 
different commonly consumed dietary fibres as substrates to assess if the response of gut 
microbiota to individual fibres was ―general‖ (i.e. fermenting all fibres uniformly; as a 
proxy for a general increase in the capacity) or whether any differences in microbiota were 
―substrate-selective‖ (i.e. specific to predominant components of the diet of the 
participants). Moreover, in contrast to other studies (172), we worked hard to preserve the 
colonic relative abundance of faecal gut microbiota by keeping those in anaerobic media, 
by keeping the sample cold at approximately 4
o
C, and processing majority of the samples 
within 4 h after being produced. This was achieved for majority of the samples. 
Additionally, the number of participants is this study was higher than previous human 
studies. 
Several findings in this chapter correlated very well with findings from previous 
chapters. Of particular note was the high inter individual variation in fermentation 
capacity, across all dietary substrates and at both time points, particularly in the two obese 
groups.  High inter-individual variations only in the obese group may indicate higher inter-
individual variations in the gut microbiota communities in obese but not in lean hosts. 
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Furthermore it also indicated that a much larger cohort of participants is needed to bring up 
or establish a significant difference that is otherwise blunted due to small sample size. 
Similar to changes in faecal SCFA in chapter 4, the fermentation capacity of gut 
microbiota did not significantly change with weight management. Although there was no 
significant weight loss and the concentration of SCFA did not change significantly with 
weight management, significant changes in the proportion of SCFA within the groups over 
the period of study suggested that weight management might beneficially affect the pattern 
of SCFA production (such as propionate and butyrate). 
One of the important findings was the significantly higher rate of production of 
propionate in obese (simple and hypoth. obese) compared to lean (healthy and hypoth. 
lean) phenotype which was consistent across most of the dietary fibres. This consistent 
response in the obese group once again indicates adaptation of the obese participants’ 
microbiota to low fermentable carbohydrate availability in the colon. This may have 
allowed Bacteroidetes to produce more propionate with the help of their abundant 
glycosyl-hydrolases. Relative abundance of the phylum Bacteroidetes was however not 
significantly different between the obese and lean groups as discussed in chapter 6. This 
prompts us to investigate whether or not these differences in the rate of propionate 
production are due to the differences in the expression of functional genes in Bacteroidetes 
in obese vs. lean groups. This can be tested by metagenomic sequencing of the bacterial 
DNA extracted from the fermentation supernatant.  
Presence of trends but lack of significant differences between the lean and obese 
might be due to limitations related to the in-vitro batch culture fermentation studies. 
Accessing the colon in ideal conditions by conducting in-vivo studies or obtaining caecal 
samples could reduce variations related to the in-vitro procedures. However, both of these 
procedures carry practical and ethical issues making it difficult to put in practice. Another 
suggestion could be to use in-vitro continuous culture fermentation which allows the 
fermentation products to be removed from the system while maintaining the pH. Although 
this facility was available in the department, it was not chosen for practical reasons: a) due 
to multiple samples collected at a given time which would require more than one 
continuous culture set-up, b) the time sample was produced by the patient, which varied 
between 7am till 8pm, and c) it was labour intensive, given the time constraints to carry 
processing of faecal sample for other analyses and the total number of samples to be 
incubated (n=151). In-vitrobatch culture studies were therefore chosen for their 
convenience, proven reproducibility, repeatability, and inter- and intra-laboratory validity 
in many centres across different countries.  
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Another possible reason for the presence of trends but lack of significant results 
could be related to the small study numbers, particularly in the obese groups. Post hoc 
power analysis based on our results suggested that recruitment of at least 20 participants in 
each group would give sufficient power to see a significant difference between the groups. 
However, having mentioned these issues, the numbers of participants in our study are still 
far greater than the number of participants in previous studies. We used five different 
dietary substrates which were also expected to provide the element of consistency to any 
significant difference found between the two obese groups or between the obese and lean 
phenotypes. Moreover, despite meticulous sample collection process, rigorous in-vitro 
incubation, and sample analysis; inter-individual variation might be an idiosyncratic 
response of the participants’ microbiota. This has been a feature of most in-vitro 
fermentation studies.   
7.4 Gut microbiota diversity in simple and hypothalamic 
obesity 
Our study did not support a causal relationship of the gut microbiota composition with 
obesity as we did not find any significant difference in the relative abundance of the major 
bacterial phyla i.e. Firmicutes and Bacteroidetes, between obesity of different aetiology 
and also between obese (simple & hypoth. obese) and lean (healthy & hypoth. lean) 
phenotypes.   
The hypothalamic obese group showed two significant differences from the simple 
obese group; significantly higher relative abundance of a) phylum Proteobacteria and b) 
class Bacilli. This suggests that the similarity in metabolic potential may not fully translate 
into the composition of gut microbiota at all taxonomic levels. Therefore, analysis of 
composition should be accompanied with the analysis of metabolic function to better 
elucidate this relationship. 
Members of phylum Proteobacteria, particularly Gammaproteobacteria (dominated 
by family Enterobacteriaceae) produce endotoxin which might contribute to the chronic 
low-grade inflammation and metabolic endotoxemia. Children with PWS have been shown 
to have higher prevalence of non-alcoholic fatty liver disease (NAFLD) and inflammation 
compared to simple obese patients (419, 420). However, the link between gut microbiota, 
chronic low grade inflammation, and NAFLD has not been studied. Here we proposed for 
the first time that higher relative abundance of Gammaproteobacteria in hypothalamic 
obese group might link with increased incidence of NAFLD in PWS through endotoxin-
induced chronic low-grade inflammation (figure 6.7, chapter 6). Gathering data on the 
systemic inflammatory markers and hepatic health status could prove this explanation and 
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is therefore a potential new area for us to investigate in near future. Furthermore, studying 
systemic chronic low-grade inflammation and development of NAFLD in a genetic germ-
free animal model of PWS colonised with Enterobacteria could be another future study to 
establish this link. Moreover, higher levels of Enterobacteria (containing pathogenic strains 
such as Shigella, Klebsiella, Salmonella, E.coli, Enterobacter, and Citrobacter) have been 
associated with frequent hospitalisation and repeated infections(432). Establishing a link 
between Enterobacteria, inflammation, and NAFLD in PWS would potentially enable 
researchers in future to introduce strategies to prevent factors related to the colonisation of 
pathogenic strains of Enterobacteria as a step to prevent the development of NAFLD and 
cardiovascular disease. 
Several taxonomic features were found to be distinct between the lean and obese 
phenotype and were mildly influenced by the presence of pathology. Genus level and OTU 
level composition in obese phenotype clustered together and distinctly from lean 
phenotype. Although this was shown in previous studies (409, 410), our study gives a 
novel insight indicating that adiposity, but not the cause of adiposity, is more closely 
related to the structure of gut microbiota which further strengthens our assumption that gut 
microbiota may not be causally related to the aetiology of obesity. Similarly, the obese 
phenotype had significantly lower richness of operational taxonomic units than the lean 
phenotype as suggested by previous studies. However, to the best of our knowledge, this is 
the first evidence from human studies to suggest that lower gut microbiota richness is 
independent of the cause of obesity and most likely is the effect rather than the result of the 
latter. These findings implicate that factors other than gut microbiota such as dietary, 
environmental, lifestyle, and genetic factors may be much stronger determinants of the 
energy harvesting capability of gut microbiota and should therefore be considered while 
studying gut microbiota in relation to obesity. 
Differences between the obese (simple & hypoth. obese) and lean (healthy & 
hypoth. lean) phenotype were also seen at different taxonomic levels. Of particular 
importance was the absence of methanogenic archaea and reduced relative abundance of 
Verrucomicrobia in obese compared to lean phenotype. The presence of methanogenic 
archaea has been paradoxically associated both with leanness (236, 237, 241) and obesity 
(167). Additionally, levels of methanogens have been inversely associated with the levels 
of sulphate reducing bacteria (SRBs). Complete absence of methanogens in the simple 
obese or reduced numbers in hypothalamic obese compared to healthy lean individual 
therefore suggests that SRBs may have out-competed methanogens to generate hydrogen 
sulphide. On the other hand, the presence of methanogens in the lean group suggest that 
methanogens might have accepted molecular hydrogen produced by members of 
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Prevotellaceae, Ruminococci, Dorea, and Enterobacteriaceae. Relative abundance of the 
members of Prevotellaceae have been positively correlated with methanogenic archaea in 
previous studies (167). However, in contrast to our expectation, an inverse relationship of 
methanogens with SRBs and a positive correlation with Prevotellaceae was not found in 
our study as there was no significant difference in the relative abundance of 
Desulfovibrionaceae and family Prevotellaceae between lean and obese phenotype. This 
suggests that the association of methanogenic archaea with SRBs, members of family 
Prevotellaceae, or with leanness and obesity is dependent on the interaction of gut 
microbial communities with each other that varies between individuals and may be 
dependent on the dietary pattern of individual.  
Higher levels of Verrucomicrobia (Akkermansia muciniphila) in lean participants in 
our study agreed with previous studies (247, 248). However, gathering data regarding 
inflammation and markers of metabolic syndrome that are associated with reduced levels 
of Verrucomicrobia would further help in establishing whether this group of bacteria are 
actively playing a protective role in the gut.  
Our dietary data did not show any effect on the community composition, however, 
under-reporting in the obese groups and a small sample size may have limited our ability to 
identify any link that may exist in this group. Other unknown environmental or genetic 
host-related factors might also contribute to community composition making it difficult to 
identify links with diet. 
Measurement of the gut microbiota composition using high throughput sequencing 
is efficient and informative. However, it measures relative abundance of species and a 
quantitative shift in the population of one species may result in a change in the relative 
abundance of another related species resulting in a ―secondary effect‖ of change in another 
species. Similarly, quantitative changes in two groups may not translate into changes in 
their relative abundance.  
7.5 Challenges in recruitment of the participants 
Although the overall prevalence of obesity has reached up to ~64% in men and women of 
all ages in Scotland, the dietetic and weight management clinic in this tertiary care hospital 
receives children/young adults referred from general practitioners surgeries or community 
weight management programs. Recruiting from these clinics was a challenge for the 
researcher for several reasons. In addition to the management of simple obese patients, this 
clinic also manages obese and overweight children associated with other disease states. 
Despite weekly clinics, only 2-4 attendants in the list were usually eligible to be informed 
about the study and asked for participation. Simple obese patients often have a low level of 
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motivation and can be resistant to changes in behaviour by weight loss programmes. More 
importantly, among those patients who were potential for recruitment, they had a very low 
rate of attending their appointments. Moreover, one third of patients who gave their signed 
informed consent for the study did not give any faecal sample or refused after an informed 
consent. Another difficulty in recruitment was in our hypothalamic obese and lean group 
where the number of eligible participants for the study was limited by several factors 
including severe co-morbidities due to the disease, age of the patient (>25 years), 
resistance of the child to provide a sample, and distance of the hospital (recruitment centre) 
from the patient’s residence. Another challenge was demographically matching our control 
group with our two obese groups as patients attending the endocrine and dietetic clinics 
were referred from whole of West of Scotland and some patients from Northern England.  
Despite these challenges, the researcher successfully organised travel efficiently to 
recruit as many participants by visiting homes (at participants’ convenience), covering 
distances up to 120 miles, collecting samples at evenings and weekends, and travel 
efficiently to bring the samples to the lab and process them within 4 h after being 
produced. The end result of travelling for more than 2000 miles and working out of hours 
in the lab on a regular basis greatly increased the researcher’s ability to collect a good 
sample size despite these difficulties. The period of recruitment was limited to 16 months 
due to the set funding and time constraints of the study.  
7.6 Aspirations for future study 
Keeping in view the high inter-individual variability, particularly in the two obese 
groups, it is strongly recommended to conduct studies with larger numbers of subjects and 
under better controlled conditions in terms of dietary intake and weight loss management. 
Due to small number of participants in this ―pilot‖ study, the results obtained should be 
considered exploratory. This study however provides a base for designing a future study 
that address only specific primary outcomes to avoid testing multiple hypotheses. 
Moreover, testing each outcome should be appropriately adjusted for multiple comparisons 
or false discovery rates. As mentioned earlier, post hoc power analysis for future study 
would need at least 20 participants in each group. Sufficient power coupled with 
appropriate adjustment for multiple testing would enable the researcher finding statistically 
significant differences between the groups. 
Two years since the recruitment of the first participant for this study, follow-up 
anthropometric data and faecal samples are also recommended to assess changes in gut 
microbiota in relation to weight loss or weight gain. Additionally, hypothalamic lean 
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patients, who had median BMI SDS scores >1SDS at the time of recruitment, may 
represent a transition from lean towards obese status as suggested in the literature. Their 
follow-up is therefore of particular interest to study the changes in gut microbiota 
composition and function from leanness towards obesity.    
Results from our study have encouraged us to investigate the link of gut 
microbiome of our participants further by sequencing their gut microbial metagenome to 
explore if similar metabolic profile and microbial communities in simple and hypothalamic 
obese groups translate into the functional genes. This is another exciting aspect to this 
study and we have sent 96 genomic bacterial DNA samples (hypoth. obese n=10, hypoth. 
lean, n=12, simple obese, n=13, healthy lean, n=13 each for recruitment and after 2-3 
months)for shotgun illumina Hiseq® sequencing. However, this will not constitute a part 
of this PhD.  
We also suggest further studies into gut microbial metabolic activity, gut 
microbiome, and gut microbial metagenome by transplantation of gut microbiota of our 
obese groups into germ free animals to explore if characteristics associated with obesity 
are transmissible in terms of microbial composition and functionality.  
Furthermore, characterisation of microbial community composition and expression 
of microbial genes with different dietary substrates in in vitro fermentation studies is also 
suggested to explore how gut microbiota of simple and hypothalamic obese patients 
respond to dietary fibre challenge over a period of 24 h. This will help in identifying 
potential prebiotics that could beneficially affect gut microbiota that produce beneficial 
metabolites (such as butyrate) and express functional genes related to metabolic health 
(such as genes related to SCFA production). As a first step to achieve this aim, we have 
modified and established our genomic bacterial DNA extraction method for the 
fermentation samples. This was deemed essential, as these incubated faecal samples are a 
diluted mixture of fermentation medium (containing phosphate and carbonate buffer, 
trypton, and microminerals), reducing solution (sodium sulphide, cysteine hydrochloride, 
and NaOH), one of the five dietary fibre substrates, and sodium hydroxide. 
Since our simple obese group had a higher proportional intake of proteins, the 
measurement of faecal phenol and cresol, which are potentially harmful degradation 
products of dietary and endogenous proteins, would also give an indication of the risk to 
gut health in the two obese groups. Initial attempts by a Masters (MRes) research student 
were not successful in optimising a simple and quick colorimetric assay for the 
determination of total faecal phenol. Therefore a more sensitive and specific method based 




Whether obese participants share similarities in gut microbiota composition and 
metabolic activity with their parents is another interesting subject for us to investigate. 
Since we also collected anthropometric data and faecal samples from parents (n= 30) who 
agreed to take part, analysis of their faecal samples for bacterial metabolic activity, 
fermentation capacity, and microbial diversity would further help in establishing the 
influence of parents on the gut microbiota of their offspring’s in determining their lean or 
obese phenotype.    
7.7 Conclusion 
In the final analysis, this PhD provided several novel insights into the ―cause or effect‖ 
relationship of the gut microbiota with obesity (Figure 7.1). We explored the relationship 
of gut microbiota with obesity by studying three dimensions: a) gut microbial metabolic 
activity, b) energy harvesting capability, and c) gut microbial diversity. Based on our 
results we conclude that gut microbiota are not causally related to the aetiology of obesity 
as there was no difference in the metabolic activity, energy harvesting capability, and 
microbial diversity between obesity of different aetiology. Furthermore, obesity, and not 
the cause of obesity was explaining differences in metabolites and microbial diversity 
between the groups. 
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Figure 7.1: Schematic flow-chart of this PhD 
Chapter 1: Introduction 
The gut microbiota has been implicated in the aetiology of obesity. However, the evidence is inconclusive as to whether differences between lean and obese people are a cause of obesity or it is 
an effect of different dietary patterns between lean and obese individuals. We explored the possibility of reverse causality by comparing gut microbial composition and bacterial metabolic 
activity in children with obesity of different aetiology 
Aim 2 (chapter 5): Differences in energy harvesting capability between 
simple and hypothalamic obesity 
What these data add to the literature? Fermentation capacity is 
determined by the amount of fermentable carbohydrates and not obese or 
lean phenotype 
Future directions: Large sample size required due to high inter-
individual variations. Analysis of microbial diversity in fermentation 
samples after 24 h incubation to correlate changes in metabolites with 
changes in bacterial diversity 
Chapter 2: Subjects and methods 
Subjects: Simple obese (n=16), hypothalamic obese (n=10), hypothalamic lean (n=12), and healthy lean 
(n=27) 





lactate, illumina Miseq® pyrosequencing 
Chapter 4  
Faecal gut microbial 
metabolic activity 







between simple and 
hypoth. obese. 
Propionate higher in 
obese vs. lean phenotype 
No difference in 
fermentation capacity 
between simple and 
hypoth. obese  
Rate of propionate 
production high in obese 
vs. lean phenotype 
Higher Proteobacteria 
and Bacilli in simple vs. 
hypoth. obese. 
OTUs and genera cluster 
based on BMI, not 
pathology. Low OTUs 
richness in obese vs. lean 
Chapter 7: Discussion & conclusion 
Gut microbiota are not causally related to the aetiology of obesity. Other factors such as diet, lifestyle, host 
genetics, and environment may be more important. Interventions should be aimed at preventing or treating 
obesity in these lines. Further studies are suggested to investigate gut microbiome and metagenome in a 
large cohort.  
Chapter 5  
Fermentation capacity 
(energy harvest) 
Chapter 6  
Gut microbiota diversity 
Aim 1 (chapter 4): Differences in faecal gut microbial metabolites 
(SCFA, BCFA, H
2
S, D & L Lactate, and NH
3
) between simple and 
hypothalamic obesity 
What these data add to the literature? Obesity and not the cause of 
obesity determine faecal bacterial metabolites. High propionate might 
indicate low fibre stress. 
Future directions:  Larger cohorts and longer follow-up required, 
Metagenomics to correlate functional genes with these faecal metabolites, 
robust dietary assessment methods needed 
 
Aim 3 (chapter 6): Differences in microbial diversity between simple and 
hypothalamic obesity 
What do these data add to the literature? Factors other than gut 
microbiota are causatively related to obesity. Interventions should be   
aimed at targeting diet, lifestyle, and environmental factors. 
Future directions: Microbial diversity need to be correlated with 
functionality. Faecal transplantation studies need to explore the same 
effect in germ free mice. 
Chapter 3: Subject characteristics 
Wt. & Ht. SDS lower in hypoth. obese vs. simple obese but no difference in BMI SDS. Obese group have 
lower % fibre intake and higher % proteins and fats. Lower % energy intake in obese suggest under-
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Appendix 2: List of information sheets and consent forms developed for this study  
 
 
List of information sheets developed for this study 
 
1. Information sheet for children younger than 7 years; healthy normal weight children 
2. Information sheet for children younger than 7 years attending Yorkhill endocrine/weight 
management clinic 
3. Information sheet for children 8-13 years; healthy normal weight children 
4. Information sheet for children 8-13 years; attending the Yorkhill outpatient endocrine/weight 
management clinic 
5. Information sheet for children/young adults older than 13 years; healthy children/young adults  
6. Information sheet for children older than 13 years children/young adults attending the Yorkhill 
outpatient endocrine/weight management clinic  
7. Information sheet for the carers of healthy children  
8. Information sheet for the carers of children/young adults attending Yorkhill outpatient 
endocrine/weight management clinic  
 
List of consent forms developed for the study 
 
1. Assent form for children (To be completed by the child and their parent/guardian):  Do the bugs 
inside the bellies of different kinds of children with increased weight, act differently? 
1. Consent form (young persons and adults): Do the bugs (bacteria) normally present in 
human guts affect body weight?  
2. Consent form (carer/parent of participant): Diet, gut microbiota and energy from 
colonic fermentation of carbohydrates in children with simple and pathological obesity, 
cause or effect?   
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Appendix 3: List of Golay bar-coded reverse fusion primers used for amplification of 16S 





Name RC of Illumina 3' Adapter Golay Barcode 
PWS001 3.02 806rcbc302 CAAGCAGAAGACGGCATACGAGAT TGTATCTTCACC 
PWS002 2.96 806rcbc198 CAAGCAGAAGACGGCATACGAGAT CGAGCTGTTACC 
PWS003 2.52 806rcbc328 CAAGCAGAAGACGGCATACGAGAT ACTTTGCTTTGC 
PWS004 4.98 806rcbc235 CAAGCAGAAGACGGCATACGAGAT AGGTGAGTTCTA 
PWS005 2.86 806rcbc300 CAAGCAGAAGACGGCATACGAGAT TCCAACTGCAGA 
PWS006 4.40 806rcbc220 CAAGCAGAAGACGGCATACGAGAT GTCGTCCAAATG 
PWS007 5.04 806rcbc248 CAAGCAGAAGACGGCATACGAGAT ACCGTGCTCACA 
PWS008 6.68 806rcbc245 CAAGCAGAAGACGGCATACGAGAT TATCACCGGCAC 
PWS009 6.12 806rcbc291 CAAGCAGAAGACGGCATACGAGAT GATCCTCATGCG 
PWS010 4.74 806rcbc331 CAAGCAGAAGACGGCATACGAGAT GAGGACCAGCAA 
PWS011 14.3 806rcbc301 CAAGCAGAAGACGGCATACGAGAT TAAAGACCCGTA 
PWS012 31.2 806rcbc259 CAAGCAGAAGACGGCATACGAGAT GAACGGGACGTA 
PWS013 7.32 806rcbc304 CAAGCAGAAGACGGCATACGAGAT TCGTGGATAGCT 
PWS014 9.54 806rcbc242 CAAGCAGAAGACGGCATACGAGAT GCAGATTTCCAG 
PWS015 17.9 806rcbc266 CAAGCAGAAGACGGCATACGAGAT TGGCTTTCTATC 
PWS016 4.10 806rcbc268 CAAGCAGAAGACGGCATACGAGAT GAGCGTATCCAT 
PWS017 26.4 806rcbc241 CAAGCAGAAGACGGCATACGAGAT GCCGTAAACTTG 
PWS018 4.96 806rcbc238 CAAGCAGAAGACGGCATACGAGAT AGACAGTAGGAG 
PWS019 3.14 806rcbc314 CAAGCAGAAGACGGCATACGAGAT AGGCACAGTAGG 
PWS020 20.8 806rcbc316 CAAGCAGAAGACGGCATACGAGAT CTCTTCTGATCA 
PWS021 7.26 806rcbc300 CAAGCAGAAGACGGCATACGAGAT TCCAACTGCAGA 
PWS022 3.32 806rcbc327 CAAGCAGAAGACGGCATACGAGAT ACGGCGTTATGT 
PWS023 13.3 806rcbc303 CAAGCAGAAGACGGCATACGAGAT GACTGACTCGTC 
PWS025 3.76 806rcbc360 CAAGCAGAAGACGGCATACGAGAT AACCGATGTACC 
PWS026 6.42 806rcbc366 CAAGCAGAAGACGGCATACGAGAT CGCCACGTGTAT 
PWS027 8.96 806rcbc274 CAAGCAGAAGACGGCATACGAGAT TAACGCTGTGTG 
PWS028 3.84 806rcbc302 CAAGCAGAAGACGGCATACGAGAT TGTATCTTCACC 
PWS029 5.52 806rcbc319 CAAGCAGAAGACGGCATACGAGAT TATCCAAGCGCA 
PWS030 20.2 806rcbc348 CAAGCAGAAGACGGCATACGAGAT CTTGACGAGGTT 
PWS031 2.78 806rcbc261 CAAGCAGAAGACGGCATACGAGAT GGTCTCCTACAG 
PWS032 3.74 806rcbc204 CAAGCAGAAGACGGCATACGAGAT AGGGTGACTTTA 
PWS033 5.24 806rcbc303 CAAGCAGAAGACGGCATACGAGAT GACTGACTCGTC 
PWS034 2.90 806rcbc244 CAAGCAGAAGACGGCATACGAGAT GAGACGTGTTCT 
PWS035 6.32 806rcbc322 CAAGCAGAAGACGGCATACGAGAT AACTGCGATATG 
PWS036 3.92 806rcbc315 CAAGCAGAAGACGGCATACGAGAT CTACTTACATCC 
PWS037 10.8 806rcbc236 CAAGCAGAAGACGGCATACGAGAT CCTGTCCTATCT 
PWS038 4.38 806rcbc304 CAAGCAGAAGACGGCATACGAGAT TCGTGGATAGCT 
PWS039 15.8 806rcbc311 CAAGCAGAAGACGGCATACGAGAT CTACGAAAGCCT 
PWS040 3.32 806rcbc251 CAAGCAGAAGACGGCATACGAGAT CCTTGACCGATG 
PWS041 24.0 806rcbc249 CAAGCAGAAGACGGCATACGAGAT CTCCCTTTGTGT 
PWS042  15.3 806rcbc305 CAAGCAGAAGACGGCATACGAGAT GACGCACTAACT 
PWS043 19.2 806rcbc306 CAAGCAGAAGACGGCATACGAGAT GGCGATTTACGT 
PWS044 3.00 806rcbc269 CAAGCAGAAGACGGCATACGAGAT ATGGGCGAATGG 
PWS045 8.28 806rcbc364 CAAGCAGAAGACGGCATACGAGAT CACACAAAGTCA 
PWS046 4.50 806rcbc240 CAAGCAGAAGACGGCATACGAGAT ATTGTTCCTACC 
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PWS047 8.82 806rcbc307 CAAGCAGAAGACGGCATACGAGAT TAAGGCATCGCT 
PWS048 4.84 806rcbc258 CAAGCAGAAGACGGCATACGAGAT GAGAGTCCACTT 
PWS049 21.0 806rcbc332 CAAGCAGAAGACGGCATACGAGAT AATAGCATGTCG 
PWS050 14.5 806rcbc308 CAAGCAGAAGACGGCATACGAGAT ACCCATACAGCC 
PWS051 7.44 806rcbc268 CAAGCAGAAGACGGCATACGAGAT GAGCGTATCCAT 
PWS052 14.8 806rcbc336 CAAGCAGAAGACGGCATACGAGAT ATAGGCTGTAGT 
PWS053 6.82 806rcbc309 CAAGCAGAAGACGGCATACGAGAT CGCACTACGCAT 
PWS054 6.60 806rcbc289 CAAGCAGAAGACGGCATACGAGAT GATCATTCTCTC 
PWS055 4.14 806rcbc358 CAAGCAGAAGACGGCATACGAGAT TTGGTAAAGTGC 
PWS056 66.0 806rcbc239 CAAGCAGAAGACGGCATACGAGAT GCCACGACTTAC 
PWS057 20.2 806rcbc275 CAAGCAGAAGACGGCATACGAGAT AACCAAACTCGA 
PWS058 18.70 806rcbc370 CAAGCAGAAGACGGCATACGAGAT ACCTGTCCTTTC 
PWS059 3.12 806rcbc246 CAAGCAGAAGACGGCATACGAGAT TATGCCAGAGAT 
PWS060 7.34 806rcbc333 CAAGCAGAAGACGGCATACGAGAT CGGAGTAATCCT 
PWS061 21.2 806rcbc368 CAAGCAGAAGACGGCATACGAGAT CATGTGCTTAGG 
PWS062 4.14 806rcbc273 CAAGCAGAAGACGGCATACGAGAT ATAGCGAACTCA 
PWS063 4.54 806rcbc342 CAAGCAGAAGACGGCATACGAGAT TATGAACGTCCG 
PWS064 2.78 806rcbc295 CAAGCAGAAGACGGCATACGAGAT TCCATCGACGTG 
PWS065 9.78 806rcbc363 CAAGCAGAAGACGGCATACGAGAT TTGGGCCACATA 
PWS066 10.3 806rcbc317 CAAGCAGAAGACGGCATACGAGAT ATGCTAACCACG 
PWS067 27.6 806rcbc227 CAAGCAGAAGACGGCATACGAGAT CACCCGATGGTT 
PWS068 3.16 806rcbc260 CAAGCAGAAGACGGCATACGAGAT ACGTGTAGGCTT 
PWS069 5.89 806rcbc221 CAAGCAGAAGACGGCATACGAGAT CAACGTGCTCCA 
PWS070 5.66 806rcbc340 CAAGCAGAAGACGGCATACGAGAT AGGAACCAGACG 
PWS071 9.14 806rcbc347 CAAGCAGAAGACGGCATACGAGAT CTAGCTATGGAC 
PWS072 4.8 806rcbc225 CAAGCAGAAGACGGCATACGAGAT GTCGCCGTACAT 
PWS073 4.22 806rcbc270 CAAGCAGAAGACGGCATACGAGAT GATCTCTGGGTA 
PWS074 13.4 806rcbc230 CAAGCAGAAGACGGCATACGAGAT GGTTCCATTAGG 
PWS075 3.18 806rcbc323 CAAGCAGAAGACGGCATACGAGAT CTTCCAACTCAT 
PWS076 11.4 806rcbc310 CAAGCAGAAGACGGCATACGAGAT CAGTCGTTAAGA 
PWS077 24.2 806rcbc350 CAAGCAGAAGACGGCATACGAGAT CTCTGCCTAATT 
PWS078 2.86 806rcbc283 CAAGCAGAAGACGGCATACGAGAT CGCATTTGGATG 
PWS079 7.00 806rcbc260 CAAGCAGAAGACGGCATACGAGAT ACGTGTAGGCTT 
PWS080 15.1 806rcbc358 CAAGCAGAAGACGGCATACGAGAT TTGGTAAAGTGC 
PWS081 4.58 806rcbc301 CAAGCAGAAGACGGCATACGAGAT TAAAGACCCGTA 
PWS082 9.94 806rcbc207 CAAGCAGAAGACGGCATACGAGAT ACTGATGGCCTC 
PWS083 3.60 806rcbc307 CAAGCAGAAGACGGCATACGAGAT TAAGGCATCGCT 
PWS084 6.22 806rcbc309 CAAGCAGAAGACGGCATACGAGAT CGCACTACGCAT 
PWS085 4.12 806rcbc362 CAAGCAGAAGACGGCATACGAGAT GCATTACTGGAC 
PWS086 8.52(1/20 
dilution) 
806rcbc319 CAAGCAGAAGACGGCATACGAGAT TATCCAAGCGCA 
PWS087 4.90 806rcbc252 CAAGCAGAAGACGGCATACGAGAT CTATCATCCTCA 
PWS088 55.8 806rcbc367 CAAGCAGAAGACGGCATACGAGAT GCAACCGATTGT 
PWS089 5.24 806rcbc290 CAAGCAGAAGACGGCATACGAGAT AGACATACCGTA 
PWS090 3.30 806rcbc321 CAAGCAGAAGACGGCATACGAGAT TCGCCGTGTACA 
PWS091 10.5 806rcbc330 CAAGCAGAAGACGGCATACGAGAT CGAAACTACGTA 
PWS092 3.22 806rcbc312 CAAGCAGAAGACGGCATACGAGAT ATAATTGCCGAG 
PWS093 102 806rcbc322 CAAGCAGAAGACGGCATACGAGAT AACTGCGATATG 
PWS094 17.7 806rcbc212 CAAGCAGAAGACGGCATACGAGAT GTTCGGTGTCCA 
 344 
 
PWS095 23.0 806rcbc357 CAAGCAGAAGACGGCATACGAGAT GGCTGCATACTC 
PWS096 4.44 806rcbc294 CAAGCAGAAGACGGCATACGAGAT AGCTCTAGAAAC 
PWS097 9.04 806rcbc282 CAAGCAGAAGACGGCATACGAGAT GTAGGTGCTTAC 
PWS098 3.22 806rcbc271 CAAGCAGAAGACGGCATACGAGAT CATCATACGGGT 
PWS099 5.78 806rcbc325 CAAGCAGAAGACGGCATACGAGAT TGTACATCGCCG 
PWS100 4.60 806rcbc343 CAAGCAGAAGACGGCATACGAGAT CCACATTGGGTC 
PWS101 8.10 806rcbc196 CAAGCAGAAGACGGCATACGAGAT CGCTCACAGAAT 
PWS102 9.56 806rcbc272 CAAGCAGAAGACGGCATACGAGAT TACGGATTATGG 
PWS103 5.48 806rcbc263 CAAGCAGAAGACGGCATACGAGAT GATGCTGCCGTT 
PWS104 5.34 806rcbc325 CAAGCAGAAGACGGCATACGAGAT TGTACATCGCCG 
PWS105 2.50 806rcbc296 CAAGCAGAAGACGGCATACGAGAT CGATGTGTGGTT 
PWS106 20.4 806rcbc365 CAAGCAGAAGACGGCATACGAGAT GCCAAGGATAGG 
PWS107 13.6 806rcbc326 CAAGCAGAAGACGGCATACGAGAT TGTTAAGCAGCA 
PWS108 6.48 806rcbc327 CAAGCAGAAGACGGCATACGAGAT ACGGCGTTATGT 
PWS109 14.4 806rcbc329 CAAGCAGAAGACGGCATACGAGAT CAAAGCGGTATT 
PWS110 2.50 806rcbc334 CAAGCAGAAGACGGCATACGAGAT CTGTGTCCATGG 
PWS111 10.9 806rcbc284 CAAGCAGAAGACGGCATACGAGAT ATAACATGTGCG 
PWS112 3.60 806rcbc318 CAAGCAGAAGACGGCATACGAGAT ACCAATCTCGGC 
PWS113 15.7 806rcbc235 CAAGCAGAAGACGGCATACGAGAT AGGTGAGTTCTA 
PWS114 4.92 806rcbc199 CAAGCAGAAGACGGCATACGAGAT CAACACATGCTG 
PWS115 3.96 806rcbc256 CAAGCAGAAGACGGCATACGAGAT CTTAGGCATGTG 
PWS116 3.44 806rcbc217 CAAGCAGAAGACGGCATACGAGAT ATTTAGGACGAC 
PWS117 4.34 806rcbc219 CAAGCAGAAGACGGCATACGAGAT TGGTTGGTTACG 
PWS118 9.36 806rcbc208 CAAGCAGAAGACGGCATACGAGAT TTCGATGCCGCA 
PWS119 19.5 806rcbc361 CAAGCAGAAGACGGCATACGAGAT TCGATTGGCCGT 
PWS120 5.12(1/20 
dilution) 
806rcbc328 CAAGCAGAAGACGGCATACGAGAT ACTTTGCTTTGC 
PWS120 22.2 806rcbc208 CAAGCAGAAGACGGCATACGAGAT TTCGATGCCGCA 
PWS121 15.2 806rcbc336 CAAGCAGAAGACGGCATACGAGAT ATAGGCTGTAGT 
PWS122 5.46 806rcbc277 CAAGCAGAAGACGGCATACGAGAT CTGGGTATCTCG 
PWS123 10.3 806rcbc265 CAAGCAGAAGACGGCATACGAGAT ATTAAGCCTGGA 
PWS124 2.52 806rcbc251 CAAGCAGAAGACGGCATACGAGAT CCTTGACCGATG 
PWS125 42.6 806rcbc285 CAAGCAGAAGACGGCATACGAGAT CTTGAGAAATCG 
PWS126 3.20 806rcbc313 CAAGCAGAAGACGGCATACGAGAT GGCATGTTATCG 
PWS127 8.70 806rcbc337 CAAGCAGAAGACGGCATACGAGAT TGTGTAGCCATG 
PWS128 9.82 806rcbc350 CAAGCAGAAGACGGCATACGAGAT CTCTGCCTAATT 
PWS129 84.4 806rcbc337 CAAGCAGAAGACGGCATACGAGAT TGTGTAGCCATG 
PWS130 9.86 806rcbc338 CAAGCAGAAGACGGCATACGAGAT AAGGGCGCTGAA 
PWS131 4.32 806rcbc339 CAAGCAGAAGACGGCATACGAGAT GTTTCCGTGGTG 
PWS132 5.04 806rcbc341 CAAGCAGAAGACGGCATACGAGAT TAATGCCCAGGT 
PWS133 4.44 806rcbc243 CAAGCAGAAGACGGCATACGAGAT AGATGATCAGTC 
PWS134 22.80 806rcbc245 CAAGCAGAAGACGGCATACGAGAT TATCACCGGCAC 
PWS135 18.8 806rcbc218 CAAGCAGAAGACGGCATACGAGAT GGATAGCCAAGG 
PWS136 3.30 806rcbc310 CAAGCAGAAGACGGCATACGAGAT CAGTCGTTAAGA 
PWS137 11.9 806rcbc308 CAAGCAGAAGACGGCATACGAGAT ACCCATACAGCC 
PWS138 3.06 806rcbc338 CAAGCAGAAGACGGCATACGAGAT AAGGGCGCTGAA 
PWS139 4.98 806rcbc342 CAAGCAGAAGACGGCATACGAGAT TATGAACGTCCG 
PWS140 5.44 806rcbc233 CAAGCAGAAGACGGCATACGAGAT AGCGTAATTAGC 
PWS140 3.18 806rcbc324 CAAGCAGAAGACGGCATACGAGAT GAGATCGCCTAT 
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PWS141 16.1 806rcbc306 CAAGCAGAAGACGGCATACGAGAT GGCGATTTACGT 
PWS142 3.90 806rcbc343 CAAGCAGAAGACGGCATACGAGAT CCACATTGGGTC 
PWS143 11.6 806rcbc209 CAAGCAGAAGACGGCATACGAGAT TGTGGCTCGTGT 
PWS144 14.9 806rcbc267 CAAGCAGAAGACGGCATACGAGAT ACAGCTCAAACA 
PWS145 10.4 806rcbc351 CAAGCAGAAGACGGCATACGAGAT ATATGACCCAGC 
PWS146 6.84 806rcbc347 CAAGCAGAAGACGGCATACGAGAT CTAGCTATGGAC 
PWS147 18.3 806rcbc262 CAAGCAGAAGACGGCATACGAGAT ACTGACTTAAGG 
PWS148 5.00 806rcbc353 CAAGCAGAAGACGGCATACGAGAT ATTGAGTGAGTC 
PWS149 5.04 806rcbc210 CAAGCAGAAGACGGCATACGAGAT AACTTTCAGGAG 
PWS150 4.16 806rcbc263 CAAGCAGAAGACGGCATACGAGAT GATGCTGCCGTT 
PWS151 2.50 806rcbc266 CAAGCAGAAGACGGCATACGAGAT TGGCTTTCTATC 
 
